| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000001 (PRS77_BC) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Breast cancer | breast carcinoma | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000001/ScoringFiles/PGS000001.txt.gz |
| PGS000002 (PRS77_ERpos) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000002/ScoringFiles/PGS000002.txt.gz |
| PGS000003 (PRS77_ERneg) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000003/ScoringFiles/PGS000003.txt.gz |
| PGS000004 (PRS313_BC) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Breast cancer | breast carcinoma | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000004/ScoringFiles/PGS000004.txt.gz | |
| PGS000005 (PRS313_ERpos) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000005/ScoringFiles/PGS000005.txt.gz | |
| PGS000006 (PRS313_ERneg) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000006/ScoringFiles/PGS000006.txt.gz | |
| PGS000007 (PRS3820_BC) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Breast cancer | breast carcinoma | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000007/ScoringFiles/PGS000007.txt.gz | |
| PGS000008 (PRS3820_ERpos) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000008/ScoringFiles/PGS000008.txt.gz | |
| PGS000009 (PRS3820_ERneg) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000009/ScoringFiles/PGS000009.txt.gz | |
| PGS000015 (GPS_BC) |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Breast cancer | breast carcinoma | 5,218 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000015/ScoringFiles/PGS000015.txt.gz | |
| PGS000028 (PRS) |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Breast cancer | breast carcinoma | 83 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000028/ScoringFiles/PGS000028.txt.gz |
| PGS000029 (PRS_AS) |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Breast cancer | breast carcinoma | 76 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000029/ScoringFiles/PGS000029.txt.gz |
| PGS000030 (PrCa) |
PGP000019 | Schumacher FR et al. Nat Genet (2018) |
Prostate cancer | prostate carcinoma | 147 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000030/ScoringFiles/PGS000030.txt.gz |
| PGS000044 (PrCa66) |
PGP000031 | Pashayan N et al. Br J Cancer (2015) |
Prostate cancer | prostate carcinoma | 66 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000044/ScoringFiles/PGS000044.txt.gz |
| PGS000045 (BCPRS_Overall) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Breast cancer | breast carcinoma | 88 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000045/ScoringFiles/PGS000045.txt.gz |
| PGS000046 (BCPRS_ER+) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Estrogen receptor [ER]-positive breast cancer | estrogen-receptor positive breast cancer | 87 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000046/ScoringFiles/PGS000046.txt.gz |
| PGS000047 (BCPRS_ER-) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Estrogen receptor [ER]-negative breast cancer | estrogen-receptor negative breast cancer | 53 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000047/ScoringFiles/PGS000047.txt.gz |
| PGS000048 (OCPRS_Overall) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Ovarian cancer | ovarian carcinoma | 17 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000048/ScoringFiles/PGS000048.txt.gz |
| PGS000049 (PRS103_PrCa) |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Prostate cancer | prostate carcinoma | 103 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000049/ScoringFiles/PGS000049.txt.gz |
| PGS000050 (PRS44) |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Breast cancer | breast carcinoma | 44 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000050/ScoringFiles/PGS000050.txt.gz |
| PGS000051 (PRS67) |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Breast cancer | breast carcinoma | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000051/ScoringFiles/PGS000051.txt.gz |
| PGS000052 (sPRS161) |
PGP000037 | Lakeman IMM et al. J Med Genet (2019) |
Breast cancer | breast carcinoma | 161 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000052/ScoringFiles/PGS000052.txt.gz | |
| PGS000055 (PRS_CRC) |
PGP000040 | Schmit SL et al. J Natl Cancer Inst (2019) |
Colorectal cancer | colorectal cancer | 76 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000055/ScoringFiles/PGS000055.txt.gz |
| PGS000067 (PCa_PHS) |
PGP000047 | Seibert TM et al. BMJ (2018) |
Prostate cancer | prostate carcinoma | 54 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz |
| PGS000068 (PRS_EOC) |
PGP000048 | Yang X et al. J Med Genet (2018) |
Epithelial ovarian cancer | ovarian carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000068/ScoringFiles/PGS000068.txt.gz |
| PGS000069 (PRS_sEOC) |
PGP000048 | Yang X et al. J Med Genet (2018) |
Serous epithelial ovarian cancer | ovarian serous carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000069/ScoringFiles/PGS000069.txt.gz |
| PGS000070 (PRS_LC_C) |
PGP000049 | Dai J et al. Lancet Respir Med (2019) |
Lung cancer | lung adenocarcinoma | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000070/ScoringFiles/PGS000070.txt.gz |
| PGS000071 (CC_Bladder) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Bladder cancer | urinary bladder carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000071/ScoringFiles/PGS000071.txt.gz |
| PGS000072 (CC_Breast) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Breast cancer | breast carcinoma | 187 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000072/ScoringFiles/PGS000072.txt.gz |
| PGS000073 (CC_Cervix) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Cervical cancer | cervical carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000073/ScoringFiles/PGS000073.txt.gz |
| PGS000074 (CC_Colorectal) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Colorectal cancer | colorectal cancer | 103 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000074/ScoringFiles/PGS000074.txt.gz |
| PGS000075 (CC_Endo) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Endometrial cancer | endometrial carcinoma | 9 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000075/ScoringFiles/PGS000075.txt.gz |
| PGS000076 (CC_Kidney) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Kidney cancer | renal cell carcinoma | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000076/ScoringFiles/PGS000076.txt.gz |
| PGS000078 (CC_Lung) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Lung cancer | lung carcinoma | 109 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000078/ScoringFiles/PGS000078.txt.gz |
| PGS000081 (CC_Oral) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Oral cavity and pharyngeal cancers | oral cavity cancer, pharynx cancer |
14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000081/ScoringFiles/PGS000081.txt.gz |
| PGS000082 (CC_Ovary) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Ovarian cancer | ovarian carcinoma | 36 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000082/ScoringFiles/PGS000082.txt.gz |
| PGS000083 (CC_Pancreas) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Pancreatic cancer | pancreatic carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000083/ScoringFiles/PGS000083.txt.gz |
| PGS000084 (CC_Prostate) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Prostate cancer | prostate carcinoma | 161 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000084/ScoringFiles/PGS000084.txt.gz |
| PGS000086 (CC_Testis) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Testicular cancer | testicular carcinoma, Testicular Germ Cell Tumor |
52 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000086/ScoringFiles/PGS000086.txt.gz |
| PGS000087 (CC_Thyroid) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Thyroid cancer | thyroid carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000087/ScoringFiles/PGS000087.txt.gz |
| PGS000119 (BCC32) |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Basal cell carcinoma | basal cell carcinoma | 32 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000119/ScoringFiles/PGS000119.txt.gz |
| PGS000120 (SCC10) |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Squamous cell carcinoma | squamous cell carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000120/ScoringFiles/PGS000120.txt.gz | |
| PGS000146 (CRC_GRS_27) |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Colorectal cancer | colorectal cancer | 27 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000146/ScoringFiles/PGS000146.txt.gz |
| PGS000147 (CRC21) |
PGP000070 | Ibáñez-Sanz G et al. Sci Rep (2017) |
Colorectal cancer | colorectal cancer | 21 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000147/ScoringFiles/PGS000147.txt.gz |
| PGS000148 (CRC63) |
PGP000071 | Jeon J et al. Gastroenterology (2018) |
Colorectal cancer | colorectal cancer | 63 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000148/ScoringFiles/PGS000148.txt.gz | |
| PGS000149 (CRC41) |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Colorectal cancer | colorectal cancer | 41 | - - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000149/ScoringFiles/PGS000149.txt.gz |
| PGS000150 (GRS48) |
PGP000073 | Weigl K et al. Gastroenterology (2018) |
Colorectal cancer | colorectal cancer | 48 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000150/ScoringFiles/PGS000150.txt.gz |
| PGS000151 (SC_GRS) |
PGP000074 | Xin J et al. Gene (2018) |
Colorectal cancer | colorectal cancer | 14 | - - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000151/ScoringFiles/PGS000151.txt.gz |
| PGS000152 (cGRS_Bladder) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Bladder cancer | urinary bladder carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000152/ScoringFiles/PGS000152.txt.gz |
| PGS000153 (cGRS_Breast) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Breast cancer | breast carcinoma | 66 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000153/ScoringFiles/PGS000153.txt.gz |
| PGS000154 (cGRS_Colorectal) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Colorectal cancer | colorectal cancer | 30 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000154/ScoringFiles/PGS000154.txt.gz |
| PGS000156 (cGRS_Lung) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Lung cancer | lung carcinoma | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000156/ScoringFiles/PGS000156.txt.gz |
| PGS000158 (cGRS_Ovarian) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Ovarian cancer | ovarian carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000158/ScoringFiles/PGS000158.txt.gz |
| PGS000159 (cGRS_Pancreatic) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Pancreatic cancer | pancreatic carcinoma | 9 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000159/ScoringFiles/PGS000159.txt.gz |
| PGS000160 (cGRS_Prostate) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Prostate cancer | prostate carcinoma | 79 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000160/ScoringFiles/PGS000160.txt.gz |
| PGS000161 (cGRS_Renal) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Renal cancer | renal carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000161/ScoringFiles/PGS000161.txt.gz |
| PGS000162 (cGRS_Thyroid) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Thyroid cancer | thyroid carcinoma | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000162/ScoringFiles/PGS000162.txt.gz |
| PGS000207 (TC10_Ohio) |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Thyroid cancer | thyroid carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000207/ScoringFiles/PGS000207.txt.gz |
| PGS000208 (TC10_Iceland) |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Thyroid cancer | thyroid carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000208/ScoringFiles/PGS000208.txt.gz |
| PGS000209 (TC10_UKB) |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Thyroid cancer | thyroid carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000209/ScoringFiles/PGS000209.txt.gz |
| PGS000212 (PRS330_LumA) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal A-like) | luminal A breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000212/ScoringFiles/PGS000212.txt.gz |
| PGS000213 (PRS330_LumBHER2neg) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | HER2 negative breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000213/ScoringFiles/PGS000213.txt.gz |
| PGS000214 (PRS330_LumB) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal B-like) | luminal B breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000214/ScoringFiles/PGS000214.txt.gz |
| PGS000215 (PRS330_HER2) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (HER2-enriched-like) | HER2 Positive Breast Carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000215/ScoringFiles/PGS000215.txt.gz |
| PGS000216 (PRS330_TN) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (triple negative) | triple-negative breast cancer | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000216/ScoringFiles/PGS000216.txt.gz |
| PGS000317 (PRS180) |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Breast cancer | breast carcinoma | 180 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000317/ScoringFiles/PGS000317.txt.gz |
| PGS000332 (PRS_BC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Breast cancer | breast carcinoma | 6,390,808 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000332/ScoringFiles/PGS000332.txt.gz | |
| PGS000333 (PRS_PC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Prostate cancer | prostate carcinoma | 6,606,785 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz | |
| PGS000335 (BC_PRSCS) |
PGP000102 | Mars N et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 1,079,089 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000335/ScoringFiles/PGS000335.txt.gz |
| PGS000339 (PRS22_CM) |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Cutaneous melanoma | cutaneous melanoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000339/ScoringFiles/PGS000339.txt.gz | |
| PGS000344 (PRS287_BC) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000344/ScoringFiles/PGS000344.txt.gz | |
| PGS000345 (PRS229_BC) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 229 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000345/ScoringFiles/PGS000345.txt.gz | |
| PGS000346 (PRS287_ERneg) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000346/ScoringFiles/PGS000346.txt.gz | |
| PGS000347 (PRS287_ERpos) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000347/ScoringFiles/PGS000347.txt.gz | |
| PGS000348 (PRS_PrCa) |
PGP000113 | Black MH et al. Prostate (2020) |
Prostate cancer | prostate carcinoma | 72 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000348/ScoringFiles/PGS000348.txt.gz |
| PGS000351 (PRS_EOC) |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Invasive epithelial ovarian cancer | ovarian carcinoma | 30 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000351/ScoringFiles/PGS000351.txt.gz |
| PGS000352 (PRS_HGS) |
PGP000117 | Barnes DR et al. Genet Med (2020) |
High grade serous ovarian cancer | high grade ovarian serous adenocarcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000352/ScoringFiles/PGS000352.txt.gz |
| PGS000353 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000353/ScoringFiles/PGS000353.txt.gz | |
| PGS000354 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 1,118,667 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000354/ScoringFiles/PGS000354.txt.gz | |
| PGS000355 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000355/ScoringFiles/PGS000355.txt.gz | |
| PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 179 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000356/ScoringFiles/PGS000356.txt.gz | |
| PGS000357 (PRSWEB_PHECODE145_C3-LIP-ORAL-PHARYNX_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Oral cavity cancer | oral cavity cancer | 45 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000357/ScoringFiles/PGS000357.txt.gz | |
| PGS000358 (PRSWEB_PHECODE145_UKBB-SAIGE-HRC-X145_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Oral cavity cancer | oral cavity cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000358/ScoringFiles/PGS000358.txt.gz | |
| PGS000360 (PRSWEB_PHECODE149.4_C32_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Laryngeal cancer | Malignant Laryngeal Neoplasm | 25,920 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000360/ScoringFiles/PGS000360.txt.gz | |
| PGS000361 (PRSWEB_PHECODE149.4_C3-LARYNX_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Laryngeal cancer | Malignant Laryngeal Neoplasm | 87,893 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000361/ScoringFiles/PGS000361.txt.gz | |
| PGS000362 (PRSWEB_PHECODE149.4_UKBB-SAIGE-HRC-X149.4_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Laryngeal cancer | Malignant Laryngeal Neoplasm | 53 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000362/ScoringFiles/PGS000362.txt.gz | |
| PGS000363 (PRSWEB_PHECODE150_C15_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 1,081,646 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000363/ScoringFiles/PGS000363.txt.gz | |
| PGS000364 (PRSWEB_PHECODE150_C15_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 2,001 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000364/ScoringFiles/PGS000364.txt.gz | |
| PGS000365 (PRSWEB_PHECODE150_C3-OESOPHAGUS_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 1,070,434 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000365/ScoringFiles/PGS000365.txt.gz | |
| PGS000366 (PRSWEB_PHECODE150_UKBB-SAIGE-HRC-X150_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000366/ScoringFiles/PGS000366.txt.gz | |
| PGS000367 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 74 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000367/ScoringFiles/PGS000367.txt.gz | |
| PGS000368 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 74 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000368/ScoringFiles/PGS000368.txt.gz | |
| PGS000369 (PRSWEB_PHECODE153_CRC-Huyghe_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 81 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000369/ScoringFiles/PGS000369.txt.gz | |
| PGS000370 (PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 87 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000370/ScoringFiles/PGS000370.txt.gz | |
| PGS000371 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 18 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000371/ScoringFiles/PGS000371.txt.gz | |
| PGS000372 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000372/ScoringFiles/PGS000372.txt.gz | |
| PGS000373 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000373/ScoringFiles/PGS000373.txt.gz | |
| PGS000374 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 41 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000374/ScoringFiles/PGS000374.txt.gz | |
| PGS000375 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 370 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000375/ScoringFiles/PGS000375.txt.gz | |
| PGS000376 (PRSWEB_PHECODE153.2_C18_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000376/ScoringFiles/PGS000376.txt.gz | |
| PGS000377 (PRSWEB_PHECODE153.2_C18_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 5,740,814 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000377/ScoringFiles/PGS000377.txt.gz | |
| PGS000378 (PRSWEB_PHECODE153.2_C3-COLON_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 1,111,399 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000378/ScoringFiles/PGS000378.txt.gz | |
| PGS000379 (PRSWEB_PHECODE153.2_C3-COLON_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 5,715,093 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000379/ScoringFiles/PGS000379.txt.gz | |
| PGS000380 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000380/ScoringFiles/PGS000380.txt.gz | |
| PGS000381 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000381/ScoringFiles/PGS000381.txt.gz | |
| PGS000382 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 150 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000382/ScoringFiles/PGS000382.txt.gz | |
| PGS000383 (PRSWEB_PHECODE153.3_C19_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of rectum, rectosigmoid junction, and anus | rectum cancer, rectosigmoid junction neoplasm |
1,078,799 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000383/ScoringFiles/PGS000383.txt.gz | |
| PGS000384 (PRSWEB_PHECODE153.3_C3-RECTUM_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of rectum, rectosigmoid junction, and anus | rectum cancer, rectosigmoid junction neoplasm |
1,104,018 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000384/ScoringFiles/PGS000384.txt.gz | |
| PGS000385 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Pancreatic cancer | pancreatic carcinoma | 17 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000385/ScoringFiles/PGS000385.txt.gz | |
| PGS000386 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Pancreatic cancer | pancreatic carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000386/ScoringFiles/PGS000386.txt.gz | |
| PGS000387 (PRSWEB_PHECODE165_UKBB-SAIGE-HRC-X165_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Respiratory system cancer | respiratory system cancer | 879,334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000387/ScoringFiles/PGS000387.txt.gz | |
| PGS000388 (PRSWEB_PHECODE165.1_C3-BRONCHUS-LUNG_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,109,069 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000388/ScoringFiles/PGS000388.txt.gz | |
| PGS000389 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000389/ScoringFiles/PGS000389.txt.gz | |
| PGS000390 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000390/ScoringFiles/PGS000390.txt.gz | |
| PGS000391 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000391/ScoringFiles/PGS000391.txt.gz | |
| PGS000392 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000392/ScoringFiles/PGS000392.txt.gz | |
| PGS000393 (PRSWEB_PHECODE165.1_LUNG-CANCER_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,110,438 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000393/ScoringFiles/PGS000393.txt.gz | |
| PGS000394 (PRSWEB_PHECODE165.1_LUNG-CANCER-MESOT_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,110,438 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000394/ScoringFiles/PGS000394.txt.gz | |
| PGS000395 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000395/ScoringFiles/PGS000395.txt.gz | |
| PGS000396 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
75 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000396/ScoringFiles/PGS000396.txt.gz | |
| PGS000397 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
46,920 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000397/ScoringFiles/PGS000397.txt.gz | |
| PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,103,220 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000398/ScoringFiles/PGS000398.txt.gz | |
| PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000399/ScoringFiles/PGS000399.txt.gz | |
| PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000400/ScoringFiles/PGS000400.txt.gz | |
| PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000401/ScoringFiles/PGS000401.txt.gz | |
| PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 389 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000402/ScoringFiles/PGS000402.txt.gz | |
| PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 16,316 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000403/ScoringFiles/PGS000403.txt.gz | |
| PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000404/ScoringFiles/PGS000404.txt.gz | |
| PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000405/ScoringFiles/PGS000405.txt.gz | |
| PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 292 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000406/ScoringFiles/PGS000406.txt.gz | |
| PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 3,166 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000407/ScoringFiles/PGS000407.txt.gz | |
| PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 108 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000433/ScoringFiles/PGS000433.txt.gz | |
| PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000434/ScoringFiles/PGS000434.txt.gz | |
| PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 446 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000435/ScoringFiles/PGS000435.txt.gz | |
| PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 16,626 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000436/ScoringFiles/PGS000436.txt.gz | |
| PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 63 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000437/ScoringFiles/PGS000437.txt.gz | |
| PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000438/ScoringFiles/PGS000438.txt.gz | |
| PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 467 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000439/ScoringFiles/PGS000439.txt.gz | |
| PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 2,111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000440/ScoringFiles/PGS000440.txt.gz | |
| PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 77 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000441/ScoringFiles/PGS000441.txt.gz | |
| PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000442/ScoringFiles/PGS000442.txt.gz | |
| PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 177 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000443/ScoringFiles/PGS000443.txt.gz | |
| PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 7,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000444/ScoringFiles/PGS000444.txt.gz | |
| PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000445/ScoringFiles/PGS000445.txt.gz | |
| PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000446/ScoringFiles/PGS000446.txt.gz | |
| PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 72 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000447/ScoringFiles/PGS000447.txt.gz | |
| PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 183 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000448/ScoringFiles/PGS000448.txt.gz | |
| PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,073,162 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000449/ScoringFiles/PGS000449.txt.gz | |
| PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000450/ScoringFiles/PGS000450.txt.gz | |
| PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 2,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000451/ScoringFiles/PGS000451.txt.gz | |
| PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000452/ScoringFiles/PGS000452.txt.gz | |
| PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000453/ScoringFiles/PGS000453.txt.gz | |
| PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000454/ScoringFiles/PGS000454.txt.gz | |
| PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000455/ScoringFiles/PGS000455.txt.gz | |
| PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000456/ScoringFiles/PGS000456.txt.gz | |
| PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000457/ScoringFiles/PGS000457.txt.gz | |
| PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 23 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000458/ScoringFiles/PGS000458.txt.gz | |
| PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 24 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000459/ScoringFiles/PGS000459.txt.gz | |
| PGS000460 (PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 4,279,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000460/ScoringFiles/PGS000460.txt.gz | |
| PGS000461 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000461/ScoringFiles/PGS000461.txt.gz | |
| PGS000462 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000462/ScoringFiles/PGS000462.txt.gz | |
| PGS000463 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000463/ScoringFiles/PGS000463.txt.gz | |
| PGS000464 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000464/ScoringFiles/PGS000464.txt.gz | |
| PGS000465 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000465/ScoringFiles/PGS000465.txt.gz | |
| PGS000466 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000466/ScoringFiles/PGS000466.txt.gz | |
| PGS000467 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000467/ScoringFiles/PGS000467.txt.gz | |
| PGS000468 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000468/ScoringFiles/PGS000468.txt.gz | |
| PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000469/ScoringFiles/PGS000469.txt.gz | |
| PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000470/ScoringFiles/PGS000470.txt.gz | |
| PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000471/ScoringFiles/PGS000471.txt.gz | |
| PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000472/ScoringFiles/PGS000472.txt.gz | |
| PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000473/ScoringFiles/PGS000473.txt.gz | |
| PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 68 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000474/ScoringFiles/PGS000474.txt.gz | |
| PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 30,041 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000475/ScoringFiles/PGS000475.txt.gz | |
| PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 32 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000476/ScoringFiles/PGS000476.txt.gz | |
| PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000477/ScoringFiles/PGS000477.txt.gz | |
| PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 120 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000478/ScoringFiles/PGS000478.txt.gz | |
| PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,267 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000479/ScoringFiles/PGS000479.txt.gz | |
| PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000480/ScoringFiles/PGS000480.txt.gz | |
| PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000481/ScoringFiles/PGS000481.txt.gz | |
| PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000482/ScoringFiles/PGS000482.txt.gz | |
| PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 4,047 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000483/ScoringFiles/PGS000483.txt.gz | |
| PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 25 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000484/ScoringFiles/PGS000484.txt.gz | |
| PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000485/ScoringFiles/PGS000485.txt.gz | |
| PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000486/ScoringFiles/PGS000486.txt.gz | |
| PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000487/ScoringFiles/PGS000487.txt.gz | |
| PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 79 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000488/ScoringFiles/PGS000488.txt.gz | |
| PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000489/ScoringFiles/PGS000489.txt.gz | |
| PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000490/ScoringFiles/PGS000490.txt.gz | |
| PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000491/ScoringFiles/PGS000491.txt.gz | |
| PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000492/ScoringFiles/PGS000492.txt.gz | |
| PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 217 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000493/ScoringFiles/PGS000493.txt.gz | |
| PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000494/ScoringFiles/PGS000494.txt.gz | |
| PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,866 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000495/ScoringFiles/PGS000495.txt.gz | |
| PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41,744 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000496/ScoringFiles/PGS000496.txt.gz | |
| PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000497/ScoringFiles/PGS000497.txt.gz | |
| PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000498/ScoringFiles/PGS000498.txt.gz | |
| PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000499/ScoringFiles/PGS000499.txt.gz | |
| PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000500/ScoringFiles/PGS000500.txt.gz | |
| PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,142 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000501/ScoringFiles/PGS000501.txt.gz | |
| PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 747 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000502/ScoringFiles/PGS000502.txt.gz | |
| PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 61,635 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000503/ScoringFiles/PGS000503.txt.gz | |
| PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 148,560 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000504/ScoringFiles/PGS000504.txt.gz | |
| PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000505/ScoringFiles/PGS000505.txt.gz | |
| PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000506/ScoringFiles/PGS000506.txt.gz | |
| PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000507/ScoringFiles/PGS000507.txt.gz | |
| PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000508/ScoringFiles/PGS000508.txt.gz | |
| PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 3,038 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000509/ScoringFiles/PGS000509.txt.gz | |
| PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,682 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000510/ScoringFiles/PGS000510.txt.gz | |
| PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 118,388 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000511/ScoringFiles/PGS000511.txt.gz | |
| PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 286,144 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000512/ScoringFiles/PGS000512.txt.gz | |
| PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000513/ScoringFiles/PGS000513.txt.gz | |
| PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,237 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000514/ScoringFiles/PGS000514.txt.gz | |
| PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 84 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000515/ScoringFiles/PGS000515.txt.gz | |
| PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 6,977 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000516/ScoringFiles/PGS000516.txt.gz | |
| PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000517/ScoringFiles/PGS000517.txt.gz | |
| PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000518/ScoringFiles/PGS000518.txt.gz | |
| PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,376 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000519/ScoringFiles/PGS000519.txt.gz | |
| PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,435 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000520/ScoringFiles/PGS000520.txt.gz | |
| PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000521/ScoringFiles/PGS000521.txt.gz | |
| PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000522/ScoringFiles/PGS000522.txt.gz | |
| PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 270 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000523/ScoringFiles/PGS000523.txt.gz | |
| PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,708 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000524/ScoringFiles/PGS000524.txt.gz | |
| PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000525/ScoringFiles/PGS000525.txt.gz | |
| PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000526/ScoringFiles/PGS000526.txt.gz | |
| PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,436 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000527/ScoringFiles/PGS000527.txt.gz | |
| PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000528/ScoringFiles/PGS000528.txt.gz | |
| PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 310 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000529/ScoringFiles/PGS000529.txt.gz | |
| PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 174 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000530/ScoringFiles/PGS000530.txt.gz | |
| PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 98,026 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000531/ScoringFiles/PGS000531.txt.gz | |
| PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 12,277 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000532/ScoringFiles/PGS000532.txt.gz | |
| PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000533/ScoringFiles/PGS000533.txt.gz | |
| PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000534/ScoringFiles/PGS000534.txt.gz | |
| PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,484 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000535/ScoringFiles/PGS000535.txt.gz | |
| PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,546 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000536/ScoringFiles/PGS000536.txt.gz | |
| PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 363 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000537/ScoringFiles/PGS000537.txt.gz | |
| PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 85 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000538/ScoringFiles/PGS000538.txt.gz | |
| PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,356 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000539/ScoringFiles/PGS000539.txt.gz | |
| PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 7,118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000540/ScoringFiles/PGS000540.txt.gz | |
| PGS000541 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of uterus | uterine cancer | 18 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000541/ScoringFiles/PGS000541.txt.gz | |
| PGS000542 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of uterus | uterine cancer | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000542/ScoringFiles/PGS000542.txt.gz | |
| PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz | |
| PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,494 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz | |
| PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 78 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz | |
| PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,401 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz | |
| PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz | |
| PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,493 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz | |
| PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 100 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz | |
| PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,809 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz | |
| PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 31 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz | |
| PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,493 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz | |
| PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 47 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz | |
| PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 905 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz | |
| PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 117 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz | |
| PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 117 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz | |
| PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 122 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz | |
| PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz | |
| PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 377 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz | |
| PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 377 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz | |
| PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,119,311 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz | |
| PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,120,596 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz | |
| PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,301 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz | |
| PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,023 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz | |
| PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 26,418 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz | |
| PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 178,259 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz | |
| PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz | |
| PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,119,236 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz | |
| PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz | |
| PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz | |
| PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other male genital organs | male reproductive organ cancer | 45 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000593/ScoringFiles/PGS000593.txt.gz | |
| PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other male genital organs | male reproductive organ cancer | 97 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000594/ScoringFiles/PGS000594.txt.gz | |
| PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000595/ScoringFiles/PGS000595.txt.gz | |
| PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000596/ScoringFiles/PGS000596.txt.gz | |
| PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 771 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000597/ScoringFiles/PGS000597.txt.gz | |
| PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000598/ScoringFiles/PGS000598.txt.gz | |
| PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 31 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000599/ScoringFiles/PGS000599.txt.gz | |
| PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 250 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000600/ScoringFiles/PGS000600.txt.gz | |
| PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000601/ScoringFiles/PGS000601.txt.gz | |
| PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000602/ScoringFiles/PGS000602.txt.gz | |
| PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000603/ScoringFiles/PGS000603.txt.gz | |
| PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 44 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000604/ScoringFiles/PGS000604.txt.gz | |
| PGS000605 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of kidney, except pelvis | kidney cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000605/ScoringFiles/PGS000605.txt.gz | |
| PGS000606 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of kidney, except pelvis | kidney cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000606/ScoringFiles/PGS000606.txt.gz | |
| PGS000607 (PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,095,241 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000607/ScoringFiles/PGS000607.txt.gz | |
| PGS000608 (PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,097,063 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000608/ScoringFiles/PGS000608.txt.gz | |
| PGS000609 (PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,130 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000609/ScoringFiles/PGS000609.txt.gz | |
| PGS000610 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000610/ScoringFiles/PGS000610.txt.gz | |
| PGS000611 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000611/ScoringFiles/PGS000611.txt.gz | |
| PGS000612 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000612/ScoringFiles/PGS000612.txt.gz | |
| PGS000613 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000613/ScoringFiles/PGS000613.txt.gz | |
| PGS000614 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000614/ScoringFiles/PGS000614.txt.gz | |
| PGS000615 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 106 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000615/ScoringFiles/PGS000615.txt.gz | |
| PGS000616 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 24,359 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000616/ScoringFiles/PGS000616.txt.gz | |
| PGS000617 (PRSWEB_PHECODE190_20001-1030_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Ocular cancer | ocular cancer | 834,009 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000617/ScoringFiles/PGS000617.txt.gz | |
| PGS000618 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain and nervous system cancer | central nervous system cancer | 23 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000618/ScoringFiles/PGS000618.txt.gz | |
| PGS000619 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain and nervous system cancer | central nervous system cancer | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000619/ScoringFiles/PGS000619.txt.gz | |
| PGS000620 (PRSWEB_PHECODE191.11_C71_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 522 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000620/ScoringFiles/PGS000620.txt.gz | |
| PGS000621 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000621/ScoringFiles/PGS000621.txt.gz | |
| PGS000622 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000622/ScoringFiles/PGS000622.txt.gz | |
| PGS000623 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000623/ScoringFiles/PGS000623.txt.gz | |
| PGS000624 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000624/ScoringFiles/PGS000624.txt.gz | |
| PGS000625 (PRSWEB_PHECODE191.11_UKBB-SAIGE-HRC-X191.11_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000625/ScoringFiles/PGS000625.txt.gz | |
| PGS000626 (PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000626/ScoringFiles/PGS000626.txt.gz | |
| PGS000627 (PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000627/ScoringFiles/PGS000627.txt.gz | |
| PGS000628 (PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 656 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000628/ScoringFiles/PGS000628.txt.gz | |
| PGS000629 (PRSWEB_PHECODE193_C73_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000629/ScoringFiles/PGS000629.txt.gz | |
| PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000630/ScoringFiles/PGS000630.txt.gz | |
| PGS000631 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000631/ScoringFiles/PGS000631.txt.gz | |
| PGS000632 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000632/ScoringFiles/PGS000632.txt.gz | |
| PGS000633 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000633/ScoringFiles/PGS000633.txt.gz | |
| PGS000634 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000634/ScoringFiles/PGS000634.txt.gz | |
| PGS000635 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000635/ScoringFiles/PGS000635.txt.gz | |
| PGS000636 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 954 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000636/ScoringFiles/PGS000636.txt.gz | |
| PGS000652 (PRSWEB_PHECODE204.4_C90_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Multiple myeloma | multiple myeloma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000652/ScoringFiles/PGS000652.txt.gz | |
| PGS000653 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Multiple myeloma | multiple myeloma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000653/ScoringFiles/PGS000653.txt.gz | |
| PGS000654 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Multiple myeloma | multiple myeloma | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000654/ScoringFiles/PGS000654.txt.gz | |
| PGS000662 (GRS.PCa.269) |
PGP000122 | Conti DV et al. Nat Genet (2021) |
Prostate cancer | prostate carcinoma | 269 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000662/ScoringFiles/PGS000662.txt.gz |
| PGS000663 (wGRS22) |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Pancreatic cancer | pancreatic carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000663/ScoringFiles/PGS000663.txt.gz |
| PGS000714 (PRS55_PC) |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Prostate cancer | prostate carcinoma | 55 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000714/ScoringFiles/PGS000714.txt.gz |
| PGS000719 (PRS_Prostate) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Prostate cancer | prostate carcinoma | 134 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000719/ScoringFiles/PGS000719.txt.gz |
| PGS000720 (PRS_Colorectal) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Colorectal cancer | colorectal cancer | 95 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000720/ScoringFiles/PGS000720.txt.gz |
| PGS000721 (PRS_Lung) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Lung cancer | lung carcinoma | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000721/ScoringFiles/PGS000721.txt.gz |
| PGS000722 (PRS_Kidney) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Kidney cancer | renal carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000722/ScoringFiles/PGS000722.txt.gz |
| PGS000723 (PRS_Bladder) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Bladder cancer | urinary bladder carcinoma | 14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000723/ScoringFiles/PGS000723.txt.gz |
| PGS000724 (PRS_Ovary) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Epithelial ovarian cancer | ovarian carcinoma | 31 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000724/ScoringFiles/PGS000724.txt.gz |
| PGS000725 (PRS_Pancreas) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Pancreatic cancer | pancreatic carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000725/ScoringFiles/PGS000725.txt.gz |
| PGS000730 (PRS_BCC) |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Basal cell carcinoma | basal cell carcinoma | 47 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000730/ScoringFiles/PGS000730.txt.gz |
| PGS000731 (PRS_SCC) |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Squamous cell carcinoma | squamous cell carcinoma | 14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000731/ScoringFiles/PGS000731.txt.gz |
| PGS000733 (PHS46+African) |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Prostate cancer | prostate carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000733/ScoringFiles/PGS000733.txt.gz | |
| PGS000734 (PRS95_CRC) |
PGP000142 | Archambault AN et al. Gastroenterology (2019) |
Colorectal cancer | colorectal cancer | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000734/ScoringFiles/PGS000734.txt.gz | |
| PGS000740 (PRS128_LC) |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Lung cancer | lung carcinoma | 128 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000740/ScoringFiles/PGS000740.txt.gz | |
| PGS000741 (PCa_PHS2) |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Prostate cancer | prostate carcinoma | 46 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000741/ScoringFiles/PGS000741.txt.gz |
| PGS000742 (PHS166) |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Prostate cancer | prostate carcinoma | 166 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000742/ScoringFiles/PGS000742.txt.gz | |
| PGS000751 (PRS_PrCa_EuropeanWeighted) |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Prostate cancer | prostate carcinoma | 178 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000751/ScoringFiles/PGS000751.txt.gz |
| PGS000765 (PRS_CRC95) |
PGP000170 | Huyghe JR et al. Nat Genet (2018) |
Colorectal cancer | colorectal cancer | 95 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000765/ScoringFiles/PGS000765.txt.gz |
| PGS000766 (PRS56_CM) |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Cutaneous melanoma | cutaneous melanoma | 56 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000766/ScoringFiles/PGS000766.txt.gz |
| PGS000773 (PRS179_BC) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Breast cancer | breast carcinoma | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000773/ScoringFiles/PGS000773.txt.gz |
| PGS000774 (PRS179_ERpos) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000774/ScoringFiles/PGS000774.txt.gz |
| PGS000775 (PRS179_ERneg) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000775/ScoringFiles/PGS000775.txt.gz |
| PGS000782 (CC_Bladder_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Bladder cancer | urinary bladder carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000782/ScoringFiles/PGS000782.txt.gz |
| PGS000783 (CC_Breast_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 162 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000783/ScoringFiles/PGS000783.txt.gz |
| PGS000784 (CC_Cervix_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Cervical cancer | cervical carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000784/ScoringFiles/PGS000784.txt.gz |
| PGS000785 (CC_Colorectal_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Colorectal cancer | colorectal cancer | 103 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000785/ScoringFiles/PGS000785.txt.gz |
| PGS000786 (CC_Endo_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Endometrial cancer | endometrial carcinoma | 9 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000786/ScoringFiles/PGS000786.txt.gz |
| PGS000787 (CC_Kidney_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Kidney cancer | renal cell carcinoma | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000787/ScoringFiles/PGS000787.txt.gz |
| PGS000789 (CC_Lung_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Lung cancer | lung carcinoma | 109 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000789/ScoringFiles/PGS000789.txt.gz |
| PGS000792 (CC_Oral_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Oral cavity and pharyngeal cancers | oral cavity cancer, pharynx cancer |
14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000792/ScoringFiles/PGS000792.txt.gz |
| PGS000793 (CC_Ovary_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Ovarian cancer | ovarian carcinoma | 36 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000793/ScoringFiles/PGS000793.txt.gz |
| PGS000794 (CC_Pancreas_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Pancreatic cancer | pancreatic carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000794/ScoringFiles/PGS000794.txt.gz |
| PGS000795 (CC_Prostate_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Prostate cancer | prostate carcinoma | 161 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000795/ScoringFiles/PGS000795.txt.gz |
| PGS000796 (CC_Testis_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Testicular cancer | testicular carcinoma, Testicular Germ Cell Tumor |
52 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000796/ScoringFiles/PGS000796.txt.gz |
| PGS000797 (CC_Thyroid_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Thyroid cancer | thyroid carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000797/ScoringFiles/PGS000797.txt.gz |
| PGS000801 (GRS40_CRC) |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Colorectal cancer | colorectal cancer | 40 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000801/ScoringFiles/PGS000801.txt.gz |
| PGS000802 (CRC_19) |
PGP000191 | He CY et al. Genomics (2021) |
Colorectal cancer | colorectal cancer | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000802/ScoringFiles/PGS000802.txt.gz | |
| PGS000873 (SNP143) |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Breast cancer | breast carcinoma | 143 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000873/ScoringFiles/PGS000873.txt.gz |
| PGS000878 (PRS4_PC) |
PGP000224 | Oh JJ et al. Front Oncol (2020) |
Prostate cancer | prostate carcinoma | 4 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000878/ScoringFiles/PGS000878.txt.gz |
| PGS000880 (PRS18_LC) |
PGP000226 | Xie J et al. Sleep (2021) |
Lung cancer | lung carcinoma | 18 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000880/ScoringFiles/PGS000880.txt.gz |
| PGS000881 (GRS72_PCa) |
PGP000227 | Xu J et al. Prostate (2021) |
Prostate cancer | prostate carcinoma | 72 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000881/ScoringFiles/PGS000881.txt.gz |
| PGS001040 (GBE_cancer1060) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Non melanoma skin cancer | non-melanoma skin carcinoma | 1,610 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001040/ScoringFiles/PGS001040.txt.gz |
| PGS001041 (GBE_cancer1003) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Skin cancer | skin carcinoma | 1,298 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001041/ScoringFiles/PGS001041.txt.gz |
| PGS001111 (GBE_cancer1038) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Male genital tract cancer | male reproductive organ cancer | 313 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001111/ScoringFiles/PGS001111.txt.gz |
| PGS001164 (GBE_cancer1045) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Testicular cancer | testicular carcinoma | 280 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001164/ScoringFiles/PGS001164.txt.gz |
| PGS001289 (GBE_cancer1065) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Thyroid cancer | thyroid carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001289/ScoringFiles/PGS001289.txt.gz |
| PGS001291 (GBE_cancer1044) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Prostate cancer | prostate carcinoma | 948 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001291/ScoringFiles/PGS001291.txt.gz |
| PGS001299 (GBE_cancer1041) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Cervical cancer | cervical carcinoma | 24 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001299/ScoringFiles/PGS001299.txt.gz |
| PGS001336 (GBE_cancer1002) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Breast cancer | breast carcinoma | 555 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001336/ScoringFiles/PGS001336.txt.gz |
| PGS001354 (PRS12_TC) |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Thyroid cancer | thyroid carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001354/ScoringFiles/PGS001354.txt.gz |
| PGS001776 (PRS45_CC) |
PGP000256 | Gafni A et al. PLoS One (2021) |
Colorectal cancer | colorectal cancer | 45 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001776/ScoringFiles/PGS001776.txt.gz |
| PGS001778 (PRS15_BC) |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Breast cancer | breast carcinoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001778/ScoringFiles/PGS001778.txt.gz | |
| PGS001794 (1kgeur_gbmi_leaveUKBBout_ThC_pst_eff_a1_b0.5_phiauto) |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Thyroid cancer | thyroid carcinoma | 911,462 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001794/ScoringFiles/PGS001794.txt.gz |
| PGS001795 (1kgeur_gbmi_leaveUKBBout_UtC_pst_eff_a1_b0.5_phiauto) |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Uterine cancer | uterine carcinoma | 911,692 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001795/ScoringFiles/PGS001795.txt.gz |
| PGS001799 (1kgeur_gbmi_ThC_pst_eff_a1_b0.5_phiauto) |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Thyroid cancer | thyroid carcinoma | 885,482 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001799/ScoringFiles/PGS001799.txt.gz |
| PGS001802 (portability-PLR_153) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Colorectal cancer | colorectal cancer | 2,821 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001802/ScoringFiles/PGS001802.txt.gz |
| PGS001803 (portability-PLR_172) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Skin cancer | skin carcinoma | 4,371 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001803/ScoringFiles/PGS001803.txt.gz |
| PGS001804 (portability-PLR_174.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Breast cancer (female) | breast carcinoma | 2,984 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001804/ScoringFiles/PGS001804.txt.gz |
| PGS001805 (portability-PLR_185) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Prostate cancer | prostate carcinoma | 2,579 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001805/ScoringFiles/PGS001805.txt.gz |
| PGS001807 (portability-PLR_189.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Bladder cancer | urinary bladder carcinoma | 291 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001807/ScoringFiles/PGS001807.txt.gz |
| PGS001808 (portability-PLR_191.11) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Brain cancer | brain cancer | 117 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001808/ScoringFiles/PGS001808.txt.gz |
| PGS001809 (portability-PLR_193) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Thyroid cancer | thyroid carcinoma | 111 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001809/ScoringFiles/PGS001809.txt.gz |
| PGS001810 (portability-PLR_200.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Polycythemia vera | polycythemia vera | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001810/ScoringFiles/PGS001810.txt.gz |
| PGS002013 (portability-ldpred2_153) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Colorectal cancer | colorectal cancer | 648,559 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002013/ScoringFiles/PGS002013.txt.gz |
| PGS002014 (portability-ldpred2_172) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Skin cancer | skin carcinoma | 534,399 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002014/ScoringFiles/PGS002014.txt.gz |
| PGS002015 (portability-ldpred2_174.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Breast cancer (female) | breast carcinoma | 488,608 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002015/ScoringFiles/PGS002015.txt.gz |
| PGS002016 (portability-ldpred2_185) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Prostate cancer | prostate carcinoma | 450,963 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002016/ScoringFiles/PGS002016.txt.gz |
| PGS002017 (portability-ldpred2_189.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Bladder cancer | urinary bladder carcinoma | 510,453 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002017/ScoringFiles/PGS002017.txt.gz |
| PGS002018 (portability-ldpred2_193) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Thyroid cancer | thyroid carcinoma | 311,520 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002018/ScoringFiles/PGS002018.txt.gz |
| PGS002240 (prscs_prostatecancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Prostate cancer | prostate carcinoma | 1,092,093 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002240/ScoringFiles/PGS002240.txt.gz | |
| PGS002241 (ldpred_prostatecancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Prostate cancer | prostate carcinoma | 6,497,734 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002241/ScoringFiles/PGS002241.txt.gz | |
| PGS002242 (ldpred_breastcancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Breast cancer | breast carcinoma | 6,494,889 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002242/ScoringFiles/PGS002242.txt.gz | |
| PGS002250 (PRS_S4) |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Epithelial ovarian cancer | ovarian carcinoma | 27,240 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002250/ScoringFiles/PGS002250.txt.gz |
| PGS002252 (PRS_CRC) |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Colorectal cancer | colorectal cancer | 141 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002252/ScoringFiles/PGS002252.txt.gz |
| PGS002264 (PRS_Combined) |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Pancreatic ductal adenocarcinoma | pancreatic ductal adenocarcinoma | 49 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002264/ScoringFiles/PGS002264.txt.gz |
| PGS002265 (PRS140_CRC) |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 140 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002265/ScoringFiles/PGS002265.txt.gz |
| PGS002268 (PRS_csPCa) |
PGP000298 | Song SH et al. Investig Clin Urol (2022) |
Prostate cancer | prostate carcinoma | 29 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002268/ScoringFiles/PGS002268.txt.gz |
| PGS002270 (PRS33_LC) |
PGP000300 | Zhang P et al. Br J Cancer (2022) |
Lung cancer | lung carcinoma | 33 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002270/ScoringFiles/PGS002270.txt.gz |
| PGS002281 (PRS23_MM) |
PGP000310 | Canzian F et al. Eur J Hum Genet (2021) |
Multiple myeloma | multiple myeloma | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002281/ScoringFiles/PGS002281.txt.gz |
| PGS002294 (PRS111) |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Breast cancer | breast carcinoma | 111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002294/ScoringFiles/PGS002294.txt.gz | |
| PGS002298 (PRS14_esophageal) |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Esophageal cancer | esophageal carcinoma | 14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002298/ScoringFiles/PGS002298.txt.gz |
| PGS002299 (PRS3_gastric) |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Gastric cancer | gastric cancer | 3 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002299/ScoringFiles/PGS002299.txt.gz |
| PGS002300 (PRS19_endometrial) |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Endometrial cancer | endometrial cancer | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002300/ScoringFiles/PGS002300.txt.gz |
| PGS002306 (PRS23_MM) |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Multiple myeloma | multiple myeloma | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002306/ScoringFiles/PGS002306.txt.gz |
| PGS002735 (PRS19) |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Endometrial cancer | endometrial carcinoma | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002735/ScoringFiles/PGS002735.txt.gz | |
| PGS002736 (PRS24) |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Endometrial cancer | endometrial carcinoma | 24 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002736/ScoringFiles/PGS002736.txt.gz | |
| PGS002737 (PRS72) |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Endometrial cancer | endometrial carcinoma | 72 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002737/ScoringFiles/PGS002737.txt.gz | |
| PGS002740 (PRS22_PC) |
PGP000347 | Yuan C et al. Ann Oncol (2022) |
Pancreatic cancer | pancreatic carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002740/ScoringFiles/PGS002740.txt.gz |
| PGS002742 (PRS115_EAS) |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Colorectal cancer | colorectal cancer | 115 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002742/ScoringFiles/PGS002742.txt.gz | |
| PGS002743 (PRS115_EUR) |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Colorectal cancer | colorectal cancer | 115 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002743/ScoringFiles/PGS002743.txt.gz | |
| PGS002744 (PRS115_EUR_EAS) |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Colorectal cancer | colorectal cancer | 115 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002744/ScoringFiles/PGS002744.txt.gz | |
| PGS002747 (PRS_GI) |
PGP000359 | Liu Y et al. Cancer Med (2022) |
Gastrointestinal cancer | Digestive System Carcinoma | 106 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002747/ScoringFiles/PGS002747.txt.gz |
| PGS002758 (Colorectal_cancer_prscs) |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Colorectal cancer | colorectal cancer | 1,087,843 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002758/ScoringFiles/PGS002758.txt.gz |
| PGS002791 (PRS126_Pca) |
PGP000371 | Ruan X et al. Prostate (2022) |
Prostate cancer | prostate carcinoma | 126 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002791/ScoringFiles/PGS002791.txt.gz | |
| PGS002792 (PRS67_Pca) |
PGP000371 | Ruan X et al. Prostate (2022) |
Prostate cancer | prostate carcinoma | 67 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002792/ScoringFiles/PGS002792.txt.gz | |
| PGS002793 (PRS84_Pca) |
PGP000371 | Ruan X et al. Prostate (2022) |
Prostate cancer | prostate carcinoma | 82 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002793/ScoringFiles/PGS002793.txt.gz | |
| PGS002796 (GRS232_Eur) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 232 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002796/ScoringFiles/PGS002796.txt.gz |
| PGS002797 (GRS67_His) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002797/ScoringFiles/PGS002797.txt.gz |
| PGS002798 (GRS128_Afr) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 128 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002798/ScoringFiles/PGS002798.txt.gz |
| PGS002799 (GRS138_EA) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 138 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002799/ScoringFiles/PGS002799.txt.gz |
| PGS002808 (PGS20_LC) |
PGP000387 | Qin N et al. Lancet Oncol (2022) |
Lung cancer | lung carcinoma | 20 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002808/ScoringFiles/PGS002808.txt.gz |
| PGS003331 (PHS290) |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Prostate cancer | prostate carcinoma | 290 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003331/ScoringFiles/PGS003331.txt.gz | |
| PGS003335 (GRS18_BC) |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Bladder cancer | urinary bladder carcinoma | 18 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003335/ScoringFiles/PGS003335.txt.gz |
| PGS003380 (best_BRCA) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Breast cancer | breast carcinoma | 1,142,637 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003380/ScoringFiles/PGS003380.txt.gz |
| PGS003381 (best_UCEC) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Uterine endometrial carcinoma | endometrial carcinoma | 529,365 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003381/ScoringFiles/PGS003381.txt.gz |
| PGS003382 (best_SKCM) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Skin cutaneous melanoma | cutaneous melanoma | 672 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003382/ScoringFiles/PGS003382.txt.gz |
| PGS003383 (best_PRAD) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Prostate adenocarcinoma | prostate adenocarcinoma | 168,700 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003383/ScoringFiles/PGS003383.txt.gz |
| PGS003384 (best_GBM) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Glioblastoma | glioblastoma | 910 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003384/ScoringFiles/PGS003384.txt.gz |
| PGS003385 (best_OV) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Ovarian serous carcinoma | ovarian serous carcinoma | 144,810 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003385/ScoringFiles/PGS003385.txt.gz |
| PGS003386 (best_COADREAD) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Colorectal cancer | colorectal carcinoma | 61 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003386/ScoringFiles/PGS003386.txt.gz |
| PGS003387 (best_ESCA_BEEA) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Esophageal adenocarcinoma or Barrett’s esophagus | Barrett's esophagus, esophageal adenocarcinoma |
601,980 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003387/ScoringFiles/PGS003387.txt.gz |
| PGS003388 (best_ESCA_EA) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Esophageal adenocarcinoma | esophageal adenocarcinoma | 356,743 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003388/ScoringFiles/PGS003388.txt.gz |
| PGS003389 (best_CESC) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Cervical cancer | cervical carcinoma | 2,814 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003389/ScoringFiles/PGS003389.txt.gz |
| PGS003390 (best_HNSC) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Head and neck squamous cell carcinoma | head and neck squamous cell carcinoma | 931,477 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003390/ScoringFiles/PGS003390.txt.gz |
| PGS003391 (best_LUCA) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Lung cancer | lung carcinoma | 133 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003391/ScoringFiles/PGS003391.txt.gz |
| PGS003392 (best_LUSC) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Lung squamous cell carcinoma | squamous cell lung carcinoma | 90 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003392/ScoringFiles/PGS003392.txt.gz |
| PGS003393 (best_LUAD) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Lung adenocarcinoma | lung adenocarcinoma | 74 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003393/ScoringFiles/PGS003393.txt.gz |
| PGS003394 (PRS_Stepwise) |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Epithelial ovarian cancer | ovarian carcinoma | 36 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003394/ScoringFiles/PGS003394.txt.gz | |
| PGS003395 (PRScsx_CRC) |
PGP000414 | Xin J et al. Genome Med (2023) |
Colorectal cancer | colorectal cancer | 1,145,689 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003395/ScoringFiles/PGS003395.txt.gz |
| PGS003396 (PRS-11ASN) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003396/ScoringFiles/PGS003396.txt.gz |
| PGS003397 (PRS-42ASN) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 42 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003397/ScoringFiles/PGS003397.txt.gz |
| PGS003398 (PRS-136EUR) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 136 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003398/ScoringFiles/PGS003398.txt.gz |
| PGS003399 (PRS-209EUR) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 209 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003399/ScoringFiles/PGS003399.txt.gz |
| PGS003415 (PGS268_PCa) |
PGP000428 | Nyberg T et al. J Clin Oncol (2022) |
Prostate cancer | prostate carcinoma | 268 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003415/ScoringFiles/PGS003415.txt.gz | |
| PGS003416 (MTAGPRS) |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Basal cell carcinoma (MTAG) | basal cell carcinoma | 462 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003416/ScoringFiles/PGS003416.txt.gz |
| PGS003417 (UKBPRS) |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Basal cell carcinoma | basal cell carcinoma | 273 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003417/ScoringFiles/PGS003417.txt.gz |
| PGS003418 (PRState_Eur) |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Prostate cancer | prostate cancer | 7 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003418/ScoringFiles/PGS003418.txt.gz |
| PGS003419 (PRState_Trans) |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Prostate cancer | prostate cancer | 14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003419/ScoringFiles/PGS003419.txt.gz |
| PGS003428 (Ldpred_CC_170223) |
PGP000435 | Koel M et al. Hum Mol Genet (2023) |
Cervical cancer | cervical carcinoma | 2,894,555 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003428/ScoringFiles/PGS003428.txt.gz | |
| PGS003431 (LDPred2-inf) |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Colorectal cancer | colorectal cancer | 1,104,409 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003431/ScoringFiles/PGS003431.txt.gz | |
| PGS003432 (LDPred2-grid) |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Colorectal cancer | colorectal cancer | 1,104,409 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003432/ScoringFiles/PGS003432.txt.gz | |
| PGS003433 (LDPred2-grid-sp) |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Colorectal cancer | colorectal cancer | 616,956 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003433/ScoringFiles/PGS003433.txt.gz | |
| PGS003434 (SCT) |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Colorectal cancer | colorectal cancer | 194,756 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003434/ScoringFiles/PGS003434.txt.gz | |
| PGS003435 (CT) |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Colorectal cancer | colorectal cancer | 13,446 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003435/ScoringFiles/PGS003435.txt.gz | |
| PGS003436 (GWAS-sig) |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Colorectal cancer | colorectal cancer | 50 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003436/ScoringFiles/PGS003436.txt.gz | |
| PGS003437 (PRS23_TC) |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Thyroid cancer | thyroid carcinoma | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003437/ScoringFiles/PGS003437.txt.gz |
| PGS003439 (PRSCC_140) |
PGP000441 | Su YR et al. Cancer Epidemiol Biomarkers Prev (2023) |
Colorectal cancer | colorectal cancer | 140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003439/ScoringFiles/PGS003439.txt.gz | |
| PGS003450 (PRS24_MM) |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Multiple myeloma | multiple myeloma | 24 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003450/ScoringFiles/PGS003450.txt.gz |
| PGS003451 (PRS2_MZL) |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Marginal zone lymphoma | marginal zone B-cell lymphoma | 2 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003451/ScoringFiles/PGS003451.txt.gz |
| PGS003460 (PRS278_PCa) |
PGP000453 | Chen F et al. Eur Urol (2023) |
Prostate cancer | prostate carcinoma | 278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003460/ScoringFiles/PGS003460.txt.gz |
| PGS003736 (PRS13_BlC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Bladder cancer | urinary bladder cancer | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003736/ScoringFiles/PGS003736.txt.gz | |
| PGS003738 (PRS136_BC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Breast cancer | breast carcinoma | 136 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003738/ScoringFiles/PGS003738.txt.gz | |
| PGS003739 (PRS81_CoC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Colorectal cancer | colorectal carcinoma | 81 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003739/ScoringFiles/PGS003739.txt.gz | |
| PGS003740 (PRS16_CU) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Corpus Uteri | uterine corpus cancer | 16 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003740/ScoringFiles/PGS003740.txt.gz | |
| PGS003741 (PRS28_OC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Ovarian cancer | ovarian carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003741/ScoringFiles/PGS003741.txt.gz | |
| PGS003743 (PRS118_PrC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Prostate cancer | prostate carcinoma | 118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003743/ScoringFiles/PGS003743.txt.gz | |
| PGS003744 (PRS14_RC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Renal cancer | renal carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003744/ScoringFiles/PGS003744.txt.gz | |
| PGS003745 (PRS57_SM) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Skin Melanoma | cutaneous melanoma | 57 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003745/ScoringFiles/PGS003745.txt.gz | |
| PGS003746 (PRS11_TC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Thyroid cancer | thyroid carcinoma | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003746/ScoringFiles/PGS003746.txt.gz | |
| PGS003754 (PRS22_OCstepwise) |
PGP000474 | Hurwitz LM et al. JAMA Netw Open (2023) |
Nonmucinous Epithelial Ovarian Cancer | ovarian carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003754/ScoringFiles/PGS003754.txt.gz |
| PGS003758 (BrCa_PRS_JPHC_JPGWAS) |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Breast cancer | breast carcinoma | 46,861 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003758/ScoringFiles/PGS003758.txt.gz | |
| PGS003759 (BrCa_PRS_JPHC_EURGWAS) |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Breast cancer | breast carcinoma | 17,252 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003759/ScoringFiles/PGS003759.txt.gz | |
| PGS003760 (PRS49_EOCRC) |
PGP000480 | Wang H et al. Genome Med (2023) |
Early onset colorectal cancer | colorectal cancer | 49 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003760/ScoringFiles/PGS003760.txt.gz |
| PGS003765 (GRS.PCa.451) |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Prostate cancer | prostate carcinoma | 451 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003765/ScoringFiles/PGS003765.txt.gz |
| PGS003766 (GRS.PCa.451.TOPMed) |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Prostate cancer | prostate carcinoma | 451 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003766/ScoringFiles/PGS003766.txt.gz |
| PGS003850 (CRC_PRS_200loci) |
PGP000491 | Fernandez-Rozadilla C et al. Nat Genet (2022) |
Colorectal cancer | colorectal cancer | 205 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003850/ScoringFiles/PGS003850.txt.gz |
| PGS003851 (CRC_PRS_EUR) |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 1,180,765 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003851/ScoringFiles/PGS003851.txt.gz |
| PGS003852 (CRC_PRS_EUR_EAS) |
PGP000492 | Thomas M et al. Nat Commun (2023) |
Colorectal cancer | colorectal cancer | 1,016,596 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003852/ScoringFiles/PGS003852.txt.gz |
| PGS003979 (CRC_PRSCS) |
PGP000515 | Tamlander M et al. Br J Cancer (2023) |
Colorectal cancer | colorectal carcinoma | 1,088,133 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003979/ScoringFiles/PGS003979.txt.gz |
| PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,137,459 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003983/ScoringFiles/PGS003983.txt.gz | |
| PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,139,671 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003985/ScoringFiles/PGS003985.txt.gz | |
| PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 13,086 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003999/ScoringFiles/PGS003999.txt.gz | |
| PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 26,873 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004001/ScoringFiles/PGS004001.txt.gz | |
| PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,041,298 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004025/ScoringFiles/PGS004025.txt.gz | |
| PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,045,276 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004027/ScoringFiles/PGS004027.txt.gz | |
| PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,041,298 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004040/ScoringFiles/PGS004040.txt.gz | |
| PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,045,276 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004042/ScoringFiles/PGS004042.txt.gz | |
| PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 869,407 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004053/ScoringFiles/PGS004053.txt.gz | |
| PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 777,255 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004055/ScoringFiles/PGS004055.txt.gz | |
| PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 869,407 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004069/ScoringFiles/PGS004069.txt.gz | |
| PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 777,255 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004071/ScoringFiles/PGS004071.txt.gz | |
| PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,103,877 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004083/ScoringFiles/PGS004083.txt.gz | |
| PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,105,199 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004085/ScoringFiles/PGS004085.txt.gz | |
| PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,105,199 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004099/ScoringFiles/PGS004099.txt.gz | |
| PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 209 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004107/ScoringFiles/PGS004107.txt.gz | |
| PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 200 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004109/ScoringFiles/PGS004109.txt.gz | |
| PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 982 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004123/ScoringFiles/PGS004123.txt.gz | |
| PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 765 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004125/ScoringFiles/PGS004125.txt.gz | |
| PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 950,524 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004137/ScoringFiles/PGS004137.txt.gz | |
| PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 945,385 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004139/ScoringFiles/PGS004139.txt.gz | |
| PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,133,268 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004153/ScoringFiles/PGS004153.txt.gz | |
| PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,139,693 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004155/ScoringFiles/PGS004155.txt.gz | |
| PGS004164 (PRS16_LC) |
PGP000518 | Wei X et al. Int J Cancer (2023) |
Lung cancer in never smokers | lung carcinoma, smoking status measurement |
16 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004164/ScoringFiles/PGS004164.txt.gz |
| PGS004165 (PRS21_LC) |
PGP000518 | Wei X et al. Int J Cancer (2023) |
Lung cancer | lung carcinoma | 21 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004165/ScoringFiles/PGS004165.txt.gz |
| PGS004166 (bc_1) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 3,920 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004166/ScoringFiles/PGS004166.txt.gz |
| PGS004167 (bc_2) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 717 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004167/ScoringFiles/PGS004167.txt.gz |
| PGS004168 (bc_3) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 4,618 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004168/ScoringFiles/PGS004168.txt.gz |
| PGS004169 (bc_4) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 1,361 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004169/ScoringFiles/PGS004169.txt.gz |
| PGS004170 (bc_5) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 2,278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004170/ScoringFiles/PGS004170.txt.gz |
| PGS004240 (PRS89_CRC) |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Colorectal cancer | colorectal carcinoma | 89 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004240/ScoringFiles/PGS004240.txt.gz |
| PGS004241 (PRS12_bladder) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Bladder cancer | urinary bladder carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004241/ScoringFiles/PGS004241.txt.gz |
| PGS004242 (PRS306_breast) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Breast cancer | breast carcinoma | 306 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004242/ScoringFiles/PGS004242.txt.gz |
| PGS004243 (PRS67_colorectum) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Colorectal cancer | colorectal carcinoma | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004243/ScoringFiles/PGS004243.txt.gz |
| PGS004244 (PRS16_endometrium) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Endometrial cancer | endometrial carcinoma | 16 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004244/ScoringFiles/PGS004244.txt.gz |
| PGS004245 (PRS12_kidney) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Kidney cancer | renal cell carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004245/ScoringFiles/PGS004245.txt.gz |
| PGS004246 (PRS43_lung) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Lung cancer | lung carcinoma | 43 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004246/ScoringFiles/PGS004246.txt.gz |
| PGS004247 (PRS65_melanoma) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Melanoma | cutaneous melanoma | 65 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004247/ScoringFiles/PGS004247.txt.gz |
| PGS004249 (PRS25_ovary) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Ovarian cancer | ovarian carcinoma | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004249/ScoringFiles/PGS004249.txt.gz |
| PGS004250 (PRS19_pancreas) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Pancreatic cancer | pancreatic carcinoma | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004250/ScoringFiles/PGS004250.txt.gz |
| PGS004251 (PRS125_prostate) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Prostate cancer | prostate carcinoma | 125 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004251/ScoringFiles/PGS004251.txt.gz |
| PGS004295 (GenoBoost_breast_cancer_0) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 140 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004295/ScoringFiles/PGS004295.txt.gz |
| PGS004296 (GenoBoost_breast_cancer_1) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 80 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004296/ScoringFiles/PGS004296.txt.gz |
| PGS004297 (GenoBoost_breast_cancer_2) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 90 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004297/ScoringFiles/PGS004297.txt.gz |
| PGS004298 (GenoBoost_breast_cancer_3) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 900 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004298/ScoringFiles/PGS004298.txt.gz |
| PGS004299 (GenoBoost_breast_cancer_4) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 70 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004299/ScoringFiles/PGS004299.txt.gz |
| PGS004300 (GenoBoost_colorectal_cancer_0) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 70 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004300/ScoringFiles/PGS004300.txt.gz |
| PGS004301 (GenoBoost_colorectal_cancer_1) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 600 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004301/ScoringFiles/PGS004301.txt.gz |
| PGS004302 (GenoBoost_colorectal_cancer_2) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 300 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004302/ScoringFiles/PGS004302.txt.gz |
| PGS004303 (GenoBoost_colorectal_cancer_3) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 200 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004303/ScoringFiles/PGS004303.txt.gz |
| PGS004304 (GenoBoost_colorectal_cancer_4) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 700 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004304/ScoringFiles/PGS004304.txt.gz |
| PGS004320 (PRS16_UGI) |
PGP000551 | Liu W et al. Nutrients (2023) |
Upper gastrointestinal cancer | Digestive System Carcinoma | 16 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004320/ScoringFiles/PGS004320.txt.gz |
| PGS004325 (GRS19_LC) |
PGP000559 | Wang Y et al. Front Physiol (2023) |
Lung cancer | lung carcinoma | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004325/ScoringFiles/PGS004325.txt.gz |
| PGS004441 (disease.breast_cancer.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
Breast cancer | breast carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004441/ScoringFiles/PGS004441.txt.gz |
| PGS004442 (disease.C34.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
C34 (Malignant neoplasm of bronchus and lung) | lung carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004442/ScoringFiles/PGS004442.txt.gz |
| PGS004445 (disease.D12.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
D12 (Benign neoplasm of colon, rectum, anus and anal canal) | colorectal carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004445/ScoringFiles/PGS004445.txt.gz |
| PGS004511 (meta.breast_cancer.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
Breast cancer | breast carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004511/ScoringFiles/PGS004511.txt.gz |
| PGS004512 (meta.C34.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
C34 (Malignant neoplasm of bronchus and lung) | lung carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004512/ScoringFiles/PGS004512.txt.gz |
| PGS004515 (meta.D12.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
D12 (Benign neoplasm of colon, rectum, anus and anal canal) | colorectal carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004515/ScoringFiles/PGS004515.txt.gz |
| PGS004579 (BRCA_PRSCS) |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Breast cancer | breast carcinoma | 1,088,163 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004579/ScoringFiles/PGS004579.txt.gz |
| PGS004580 (CRC_PRSCS) |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Colorectal cancer | colorectal carcinoma | 1,099,906 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004580/ScoringFiles/PGS004580.txt.gz |
| PGS004581 (PRCA_PRSCS) |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Prostate cancer | prostate carcinoma | 1,102,292 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004581/ScoringFiles/PGS004581.txt.gz |
| PGS004586 (PPS_CRC) |
PGP000564 | Xin J et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 287 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004586/ScoringFiles/PGS004586.txt.gz |
| PGS004592 (PRS_KC) |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Keratinocyte cancer | keratinocyte carcinoma | 78 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004592/ScoringFiles/PGS004592.txt.gz |
| PGS004599 (PRS102_Pca) |
PGP000577 | Ruan X et al. J Clin Med (2023) |
Prostate cancer | prostate carcinoma | 102 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004599/ScoringFiles/PGS004599.txt.gz |
| PGS004601 (PRS17_Pca) |
PGP000579 | Wu Y et al. Clin Genet (2023) |
Prostate cancer | prostate carcinoma | 17 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004601/ScoringFiles/PGS004601.txt.gz |
| PGS004611 (RORP_PRS) |
PGP000590 | Shieh Y et al. NPJ Precis Oncol (2023) |
Breast cancer | breast carcinoma | 76 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004611/ScoringFiles/PGS004611.txt.gz | |
| PGS004687 (bladder_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Bladder cancer | urinary bladder carcinoma | 1,077,775 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004687/ScoringFiles/PGS004687.txt.gz | |
| PGS004688 (breast_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Breast cancer | breast carcinoma | 1,044,110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004688/ScoringFiles/PGS004688.txt.gz | |
| PGS004689 (colorectal_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Colorectal cancer | colorectal carcinoma | 1,077,789 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004689/ScoringFiles/PGS004689.txt.gz | |
| PGS004690 (kidney_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Kidney cancer | renal carcinoma | 6,351,669 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004690/ScoringFiles/PGS004690.txt.gz | |
| PGS004691 (lung_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Lung cancer | lung carcinoma | 950,353 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004691/ScoringFiles/PGS004691.txt.gz | |
| PGS004692 (ovarian_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Ovarian cancer | ovarian carcinoma | 6,385,666 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004692/ScoringFiles/PGS004692.txt.gz | |
| PGS004693 (pancreatic_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Pancreatic cancer | pancreatic carcinoma | 6,351,686 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004693/ScoringFiles/PGS004693.txt.gz | |
| PGS004694 (prostate_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Prostate cancer | prostate carcinoma | 1,016,708 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004694/ScoringFiles/PGS004694.txt.gz | |
| PGS004737 (breast_cancer_PRSmix_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Breast cancer | breast carcinoma | 3,666,245 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004737/ScoringFiles/PGS004737.txt.gz |
| PGS004738 (breast_cancer_PRSmixPlus_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Breast cancer | breast carcinoma | 3,666,321 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004738/ScoringFiles/PGS004738.txt.gz |
| PGS004815 (prostate_cancer_PRSmix_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Prostate cancer | prostate carcinoma | 922,102 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004815/ScoringFiles/PGS004815.txt.gz |
| PGS004816 (prostate_cancer_PRSmixPlus_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Prostate cancer | prostate carcinoma | 922,104 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004816/ScoringFiles/PGS004816.txt.gz |
| PGS004860 (Genome-wide-PRS) |
PGP000607 | Boumtje V et al. EBioMedicine (2024) |
Lung cancer | lung carcinoma | 1,143,554 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004860/ScoringFiles/PGS004860.txt.gz |
| PGS004865 (PRS105_BC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Breast cancer | breast carcinoma | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004865/ScoringFiles/PGS004865.txt.gz |
| PGS004866 (PRS105_ERposBC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004866/ScoringFiles/PGS004866.txt.gz |
| PGS004867 (PRS105_ERnegBC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004867/ScoringFiles/PGS004867.txt.gz |
| PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 872,060 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004869/ScoringFiles/PGS004869.txt.gz | |
| PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Prostate cancer | prostate carcinoma | 765,876 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004872/ScoringFiles/PGS004872.txt.gz | |
| PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
All Cancers | cancer | 818,872 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004875/ScoringFiles/PGS004875.txt.gz |
| PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Colorectal cancer | colorectal carcinoma | 843,248 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004880/ScoringFiles/PGS004880.txt.gz | |
| PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Lung cancer | lung carcinoma | 655,479 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004884/ScoringFiles/PGS004884.txt.gz | |
| PGS004890 (CC-GWAS_PRS) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer versus luminal breast cancer | triple-negative breast cancer | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004890/ScoringFiles/PGS004890.txt.gz |
| PGS004891 (TNBC_PRS25) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer | triple-negative breast cancer | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004891/ScoringFiles/PGS004891.txt.gz |
| PGS004892 (TNBC_PRS41) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer | triple-negative breast cancer | 41 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004892/ScoringFiles/PGS004892.txt.gz |
| PGS004893 (overall.hybrid.prs) |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Breast cancer | breast carcinoma | 56,943 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004893/ScoringFiles/PGS004893.txt.gz |
| PGS004894 (ERpos.prs) |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 29,309 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004894/ScoringFiles/PGS004894.txt.gz |
| PGS004895 (ERneg.prs) |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 28,405 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004895/ScoringFiles/PGS004895.txt.gz |
| PGS004904 (PRS127_CRC) |
PGP000636 | Jiang F et al. Int J Cancer (2023) |
Colorectal cancer | colorectal carcinoma | 127 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004904/ScoringFiles/PGS004904.txt.gz |
| PGS004908 (PRS107_KC) |
PGP000640 | Purdue MP et al. Nat Genet (2024) |
Kidney cancer | renal carcinoma | 107 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004908/ScoringFiles/PGS004908.txt.gz |
| PGS004912 (PRS183) |
PGP000643 | Tian J et al. Genome Med (2024) |
Colorectal neoplasm | colorectal carcinoma | 183 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004912/ScoringFiles/PGS004912.txt.gz | |
| PGS004945 (PRS87_CRC) |
PGP000671 | Gao P et al. Int J Cancer (2023) |
Colorectal cancer | colorectal cancer | 87 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004945/ScoringFiles/PGS004945.txt.gz |
| PGS004954 (PRS26_TC) |
PGP000676 | Pozdeyev N et al. J Clin Endocrinol Metab (2024) |
Thyroid cancer | thyroid carcinoma | 26 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004954/ScoringFiles/PGS004954.txt.gz |
| PGS004955 (PRS23) |
PGP000678 | Zhu M et al. Int J Epidemiol (2023) |
Lung cancer | lung carcinoma | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004955/ScoringFiles/PGS004955.txt.gz |
| PGS005086 (PGS64518_OC) |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Non-mucinous epithelial ovarian cancer | ovarian carcinoma | 64,518 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005086/ScoringFiles/PGS005086.txt.gz | |
| PGS005087 (PGS5957_OC) |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Non-mucinous epithelial ovarian cancer | ovarian carcinoma | 5,957 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005087/ScoringFiles/PGS005087.txt.gz | |
| PGS005088 (PGS3448_OC) |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Non-mucinous epithelial ovarian cancer | ovarian carcinoma | 3,448 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005088/ScoringFiles/PGS005088.txt.gz | |
| PGS005089 (PGS400_OC) |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Non-mucinous epithelial ovarian cancer | ovarian carcinoma | 400 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005089/ScoringFiles/PGS005089.txt.gz | |
| PGS005104 (PRSAFR) |
PGP000694 | Jia G et al. Nat Genet (2024) |
Breast cancer | breast carcinoma | 89 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005104/ScoringFiles/PGS005104.txt.gz | |
| PGS005105 (PRSAFR_ER+) |
PGP000694 | Jia G et al. Nat Genet (2024) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 44 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005105/ScoringFiles/PGS005105.txt.gz | |
| PGS005106 (PRSAFR_ER−) |
PGP000694 | Jia G et al. Nat Genet (2024) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 24 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005106/ScoringFiles/PGS005106.txt.gz | |
| PGS005160 (PRS-ESC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Esophageal cancer | esophageal carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005160/ScoringFiles/PGS005160.txt.gz |
| PGS005161 (PRS-GC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Stomach cancer | gastric cancer | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005161/ScoringFiles/PGS005161.txt.gz |
| PGS005162 (PRS-CRC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Colorectal cancer | colorectal carcinoma | 11,462 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005162/ScoringFiles/PGS005162.txt.gz |
| PGS005163 (PRS-LC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Lung cancer | lung carcinoma | 42 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005163/ScoringFiles/PGS005163.txt.gz |
| PGS005164 (PRS-BC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Breast cancer | breast carcinoma | 109 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005164/ScoringFiles/PGS005164.txt.gz |
| PGS005165 (PRS-CC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Cervical cancer | cervical carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005165/ScoringFiles/PGS005165.txt.gz |
| PGS005166 (PRS-OC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Ovarian cancer | ovarian carcinoma | 2,802 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005166/ScoringFiles/PGS005166.txt.gz |
| PGS005167 (PRS-PC) |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Prostate cancer | prostate carcinoma | 157 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005167/ScoringFiles/PGS005167.txt.gz |
| PGS005169 (PRS25_LUAD) |
PGP000713 | Blechter B et al. JAMA Netw Open (2023) |
Lung adenocarcinoma | lung adenocarcinoma | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005169/ScoringFiles/PGS005169.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000011 | PGS000001 (PRS77_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: Invasive breast cancer | OR: 1.46 [1.42, 1.49] | AUROC: 0.603 | — | study, genetic PCs 1-15 | — |
| PPM000114 | PGS000001 (PRS77_BC) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.13 [1.1, 1.16] | — | — | Country, birth year | — |
| PPM000117 | PGS000001 (PRS77_BC) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.28] | — | — | Country, birth year | — |
| PPM000001 | PGS000001 (PRS77_BC) |
PSS000001| European Ancestry| 67,054 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: All breast cancer | OR: 1.55 [1.52, 1.58] | C-index: 0.622 [0.619, 0.627] | — | — | — |
| PPM000962 | PGS000001 (PRS77_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.21 [1.13, 1.29] | — | — | Country | — |
| PPM000945 | PGS000001 (PRS77_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.21 [1.13, 1.29] | — | — | Country | — |
| PPM000944 | PGS000001 (PRS77_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.21 [1.14, 1.29] | — | — | Country | — |
| PPM000961 | PGS000001 (PRS77_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.21 [1.14, 1.29] | — | — | Country | — |
| PPM002152 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers 40 years of age or below | HR: 1.43 [1.04, 1.97] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002150 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.71 [1.36, 2.15] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002151 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 2.29 [1.56, 3.38] | — | — | Year of birth, counselling center of origin, PRS*c.1100delC carrier status | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002153 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 41 and 50 years of age | HR: 2.32 [1.69, 3.2] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM002154 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 51 and 60 years of age | HR: 1.59 [1.07, 2.35] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
| PPM017270 | PGS000001 (PRS77_BC) |
PSS010184| European Ancestry| 200,195 individuals |
PGP000455 | Spaeth EL et al. Cancer Prev Res (Phila) (2023) |Ext. |
Reported Trait: breast cancer | HR: 1.38 [1.34, 1.42] | C-index: 0.628 [0.618, 0.638] | — | — | — |
| PPM021128 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | OR: 1.41 [1.25, 1.59] β: 0.3432 (0.0696) |
— | — | — | — |
| PPM021129 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | OR: 1.37 [1.21, 1.55] β: 0.3154 (0.0631) |
— | — | Questionnaire score, percent mammographic density | — |
| PPM021130 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | — | AUROC: 0.658 | — | Age, percent mammographic density, questionnaire score | — |
| PPM021131 | PGS000001 (PRS77_BC) |
PSS011535| Ancestry Not Reported| 1,336 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | — | AUROC: 0.687 | — | Age, mammographic percent density, questionnaire score | — |
| PPM021132 | PGS000001 (PRS77_BC) |
PSS011536| Ancestry Not Reported| 1,166 individuals |
PGP000616 | Rosner B et al. Cancer Epidemiol Biomarkers Prev (2020) |Ext. |
Reported Trait: Incident invasive breast cancer (10- year risk) | — | AUROC: 0.659 | — | Age, BIRADs for mammographic density clasification, questionnaire score | — |
| PPM000012 | PGS000002 (PRS77_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: ER-positive breast cancer | OR: 1.52 [1.48, 1.56] | AUROC: 0.615 | — | study, genetic PCs 1-15 | — |
| PPM000002 | PGS000002 (PRS77_ERpos) |
PSS000003| European Ancestry| 53,923 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: ER-positive breast cancer | OR: 1.63 [1.6, 1.67] | — | — | — | — |
| PPM000115 | PGS000002 (PRS77_ERpos) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.09 [1.06, 1.12] | — | — | Country, birth year | — |
| PPM000118 | PGS000002 (PRS77_ERpos) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.27] | — | — | Country, birth year | — |
| PPM000013 | PGS000003 (PRS77_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: ER-negative breast cancer | OR: 1.35 [1.27, 1.43] | AUROC: 0.584 | — | study, genetic PCs 1-15 | — |
| PPM000116 | PGS000003 (PRS77_ERneg) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.24 [1.21, 1.28] | — | — | Country, birth year | — |
| PPM000119 | PGS000003 (PRS77_ERneg) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.13 [1.08, 1.18] | — | — | Country, birth year | — |
| PPM000003 | PGS000003 (PRS77_ERneg) |
PSS000002| European Ancestry| 38,722 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: ER-negative breast cancer | OR: 1.45 [1.4, 1.49] | — | — | — | — |
| PPM000005 | PGS000004 (PRS313_BC) |
PSS000007| European Ancestry| 190,040 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Incident breast cancer cases | HR: 1.59 [1.54, 1.64] | — | — | study, genetic PCs 1-15 | Included only 306 of the 313 SNPs |
| PPM000004 | PGS000004 (PRS313_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.61 [1.57, 1.65] | AUROC: 0.63 | — | study, genetic PCs 1-15 | — |
| PPM000940 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.39 [1.13, 1.7] | — | — | Age, country, PCs (1-10) | — |
| PPM000938 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.3 [1.26, 1.35] | — | — | Age, country | — |
| PPM001345 | PGS000004 (PRS313_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | HR: 1.55 [1.52, 1.58] | — | — | 10 ancestry PCs, batch, age as time scale | 260/313 variants in the PRS are polymorphic in FinnGen |
| PPM000941 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.67 [1.59, 1.76] | — | — | Age, country, PCs (1-10) | — |
| PPM000957 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.39 [1.13, 1.7] | — | — | Age, country, PCs (1-10) | — |
| PPM000959 | PGS000004 (PRS313_BC) |
PSS000481| Additional Asian Ancestries| 12,473 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.15 [1.02, 1.29] | — | — | Age, country | — |
| PPM000955 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.3 [1.26, 1.35] | — | — | Age, country | — |
| PPM001347 | PGS000004 (PRS313_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | OR: 1.61 [1.57, 1.64] | — | — | Age, 10 ancestry PCs, batch | 260/313 variants in the PRS are polymorphic in FinnGen |
| PPM000958 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.67 [1.59, 1.76] | — | — | Age, country, PCs (1-10) | — |
| PPM000954 | PGS000004 (PRS313_BC) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.38 [1.23, 1.55] | — | — | Country | — |
| PPM000953 | PGS000004 (PRS313_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.32] | — | — | Country | — |
| PPM000951 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.18, 1.33] | C-index: 0.563 [0.547, 0.586] | — | Country | — |
| PPM000942 | PGS000004 (PRS313_BC) |
PSS000481| Additional Asian Ancestries| 12,473 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.15 [1.02, 1.29] | — | — | Age, country | — |
| PPM000960 | PGS000004 (PRS313_BC) |
PSS000480| Additional Asian Ancestries| 25,531 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.56 [1.52, 1.6] | — | — | Age, country | — |
| PPM000956 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.82 [1.8, 1.84] | — | — | Age, country | — |
| PPM000943 | PGS000004 (PRS313_BC) |
PSS000480| Additional Asian Ancestries| 25,531 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.56 [1.52, 1.6] | — | — | Age, country | — |
| PPM000937 | PGS000004 (PRS313_BC) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.38 [1.23, 1.55] | — | — | Country | — |
| PPM000936 | PGS000004 (PRS313_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.32] | — | — | Country | — |
| PPM000935 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | — | C-index: 0.623 [0.591, 0.629] | — | Country, age at first diagnosis, year of first diagnosis, family history for breast cancer in a first degree relative, clinical characteristics of the first breast cancer (nodal status, tumor size, differentiation grade, morphology, estrogen receptor status, human epidermal growth factor receptor 2 status, chemotherapy, endocrine therapy, radiotherapy) | — |
| PPM000934 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.18, 1.33] | C-index: 0.563 [0.547, 0.586] | — | Country | — |
| PPM000952 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | — | C-index: 0.623 [0.591, 0.629] | — | Country, age at first diagnosis, year of first diagnosis, family history for breast cancer in a first degree relative, clinical characteristics of the first breast cancer (nodal status, tumor size, differentiation grade, morphology, estrogen receptor status, human epidermal growth factor receptor 2 status, chemotherapy, endocrine therapy, radiotherapy) | — |
| PPM000939 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.82 [1.8, 1.84] | — | — | Age, country | — |
| PPM001012 | PGS000004 (PRS313_BC) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.2 [1.17, 1.23] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001013 | PGS000004 (PRS313_BC) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.31 [1.26, 1.36] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001014 | PGS000004 (PRS313_BC) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.09 [1.05, 1.13] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001015 | PGS000004 (PRS313_BC) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.19 [1.1, 1.29] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001016 | PGS000004 (PRS313_BC) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.44 [1.35, 1.54] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001017 | PGS000004 (PRS313_BC) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.36 [1.3, 1.43] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001035 | PGS000004 (PRS313_BC) |
PSS000531| European Ancestry| 1,757 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Incidient breast cancer in BRCA2 carriers | HR: 1.36 [1.17, 1.57] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
| PPM000662 | PGS000004 (PRS313_BC) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.38 [1.31, 1.44] | AUROC: 0.5877 | — | — | — |
| PPM000659 | PGS000004 (PRS313_BC) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.49 [1.38, 1.6] | AUROC: 0.6093 | — | — | — |
| PPM000656 | PGS000004 (PRS313_BC) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.68 [1.6, 1.77] | AUROC: 0.6432 | — | — | — |
| PPM000653 | PGS000004 (PRS313_BC) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.55, 1.71] | AUROC: 0.6336 | — | — | — |
| PPM000650 | PGS000004 (PRS313_BC) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.8 [1.75, 1.86] | AUROC: 0.6573 | — | — | — |
| PPM001646 | PGS000004 (PRS313_BC) |
PSS000854| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.628 [0.62, 0.637] | — | Genotyping array | Missing 25 variants (8%) based on availability of variants in the cohort |
| PPM001647 | PGS000004 (PRS313_BC) |
PSS000854| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.633 [0.624, 0.641] | — | family history of cancer (in first-degree relatives), genotyping array | Missing 25 variants (8%) based on availability of variants in the cohort |
| PPM001945 | PGS000004 (PRS313_BC) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.55 [1.45, 1.66] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.86 [3.07, 4.87] | — | — |
| PPM001946 | PGS000004 (PRS313_BC) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.51 [1.42, 1.61] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.38 [2.74, 4.18] | — | — |
| PPM001958 | PGS000004 (PRS313_BC) |
PSS000979| Multi-ancestry (including European)| 19,264 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer in carriers of a hereditary breast and ovarian cancer variant | OR: 1.44 [1.19, 1.74] | — | Odds Ratio (OR, top 20% vs bottom 20%): 3.04 [1.61, 5.73] | Age, PCs (1-4) | — |
| PPM001959 | PGS000004 (PRS313_BC) |
PSS000979| Multi-ancestry (including European)| 19,264 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer in non-carriers of a hereditary breast and ovarian cancer variant | OR: 1.57 [1.49, 1.65] | — | — | Age, PCs (1-4) | — |
| PPM001960 | PGS000004 (PRS313_BC) |
PSS000980| Multi-ancestry (including European)| 26,595 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Prevalent breast cancer | OR: 1.61 [1.52, 1.7] | — | — | Age, PCs (1-4) | — |
| PPM001999 | PGS000004 (PRS313_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.27 [1.23, 1.31] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.54 [1.38, 1.72] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM002000 | PGS000004 (PRS313_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.571 [0.562, 0.579] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM005171 | PGS000004 (PRS313_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.51, 0.58] | R²: 0.0003 | — | — |
| PPM005118 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.4 [1.06, 1.85] | — | — | PCs(1-3) | — |
| PPM005168 | PGS000004 (PRS313_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.59, 0.61] | R²: 0.025 | — | — |
| PPM005148 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Incident invasive estrogen receptor postivie/progesterone receptor positive breast cancer | HR: 1.53 [1.22, 1.91] | — | — | Family history of breast cancer (first-degree blood relatives), treatment (asprin/placebo), age at enrolment, number of children, alcohol use, body mass index at enrolment, use of hormone replacement therapy at enrolment | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005150 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Diagnosis of prevalent invasive breast cancer before the age of 50 | OR: 1.39 [1.08, 1.8] | — | — | Family history of breast cancer (first-degree blood relatives) | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005151 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Diagnosis of prevalent invasive breast cancer at the age of 50 or over | OR: 1.47 [1.33, 1.63] | — | — | Family history of breast cancer (first-degree blood relatives) | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005159 | PGS000004 (PRS313_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.4 [1.35, 1.45] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005162 | PGS000004 (PRS313_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.26 [1.1, 1.44] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005165 | PGS000004 (PRS313_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.3 [1.08, 1.57] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005174 | PGS000004 (PRS313_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.5, 0.6] | R²: 0.0008 | — | — |
| PPM005119 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.39 [1.05, 1.84] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005120 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.44 [1.07, 1.95] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM005121 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.32 [1.15, 1.52] | — | — | PCs(1-3) | — |
| PPM005122 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.33 [1.15, 1.52] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005123 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.36 [1.18, 1.57] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM005147 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Incident invasive breast cancer | HR: 1.43 [1.18, 1.73] | C-index: 0.65 [0.59, 0.71] | Hazard Ratio (HR, top 20% vs bottom 20%): 2.16 [1.21, 3.86] | Family history of breast cancer (first-degree blood relatives), treatment (asprin/placebo), age at enrolment, number of children, alcohol use, body mass index at enrolment, use of hormone replacement therapy at enrolment | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM005149 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Prevalent invasive breast cancer | OR: 1.47 [1.34, 1.61] | AUROC: 0.62 [0.59, 0.65] | Odds Ratio (OR, top 20% vs bottom 20%): 3.16 [2.26, 4.49] | Family history of breast cancer (first-degree blood relatives), pathogenic variants in breast cancer-associated genes | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
| PPM012885 | PGS000004 (PRS313_BC) |
PSS009592| Ancestry Not Reported| 5,023 individuals |
PGP000292 | Saad M et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Breast cancer | OR: 1.432 [1.333, 1.538] | AUROC: 0.6 [0.581, 0.62] | — | — | — |
| PPM012909 | PGS000004 (PRS313_BC) |
PSS009609| European Ancestry| 54,949 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.631 [0.61, 0.651] | Calibration (E/O): 0.9 [0.7, 1.0] | — | — |
| PPM012910 | PGS000004 (PRS313_BC) |
PSS009610| European Ancestry| 238,663 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.622 [0.614, 0.63] | Calibration (E/O): 1.0 [0.7, 1.3] | — | — |
| PPM012912 | PGS000004 (PRS313_BC) |
PSS009610| European Ancestry| 238,663 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.64 [0.632, 0.647] | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012913 | PGS000004 (PRS313_BC) |
PSS009611| European Ancestry| 302,425 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.668 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012914 | PGS000004 (PRS313_BC) |
PSS009612| European Ancestry| 840,867 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.664 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012915 | PGS000004 (PRS313_BC) |
PSS009613| European Ancestry| 408,679 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.666 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012916 | PGS000004 (PRS313_BC) |
PSS009614| European Ancestry| 188,453 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.661 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012917 | PGS000004 (PRS313_BC) |
PSS009615| European Ancestry| 1,401,091 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.664 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012918 | PGS000004 (PRS313_BC) |
PSS009616| European Ancestry| 5,328,392 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.665 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM012911 | PGS000004 (PRS313_BC) |
PSS009609| European Ancestry| 54,949 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.64 [0.62, 0.66] | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
| PPM014886 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.061 [0.017, 0.105] | — | — | first 10 principal components | — |
| PPM014887 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.06 [0.016, 0.104] | — | — | first 10 principal components | — |
| PPM014888 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.081 [0.037, 0.125] | — | — | first 10 principal components | — |
| PPM014889 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.058 [0.016, 0.101] | — | — | first 10 principal components | — |
| PPM015579 | PGS000004 (PRS313_BC) |
PSS009990| Multi-ancestry (including European)| 207,510 individuals |
PGP000389 | Giardiello D et al. Breast Cancer Res (2022) |Ext. |
Reported Trait: Contralateral breast cancer | — | — | Subdistributional hazard ratio (sHR, 75th vs. 25th quartile): 1.35 [1.31, 1.39] | PredictCBC-2.0A | Calculated with PredictCBC-2.0A |
| PPM017271 | PGS000004 (PRS313_BC) |
PSS010184| European Ancestry| 200,195 individuals |
PGP000455 | Spaeth EL et al. Cancer Prev Res (Phila) (2023) |Ext. |
Reported Trait: breast cancer | HR: 1.45 [1.4, 1.49] | C-index: 0.567 [0.556, 0.577] | — | — | — |
| PPM018546 | PGS000004 (PRS313_BC) |
PSS011015| East Asian Ancestry| 8,001 individuals |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |Ext. |
Reported Trait: Incident breast cancer | — | C-index: 0.582 (0.018) | Improvement in C-index from age-only model: 0.042 Hazard ratio (HR, high vs low tertile): 1.89 [1.25, 2.86] |
age | — |
| PPM020279 | PGS000004 (PRS313_BC) |
PSS011321| African Ancestry| 10,717 individuals |
PGP000537 | Luoh SW et al. Health Equity (2023) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.579 [0.522, 0.636] | — | — | — |
| PPM020280 | PGS000004 (PRS313_BC) |
PSS011322| European Ancestry| 19,939 individuals |
PGP000537 | Luoh SW et al. Health Equity (2023) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.622 [0.58, 0.664] | — | — | — |
| PPM020422 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in women aged 40-54 years at study enrolment | HR: 1.68 [1.52, 1.84] | — | — | Age, genotyping method | — |
| PPM020423 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in women aged 55-74 years at study enrolment | HR: 1.53 [1.42, 1.65] | — | — | Age, genotyping method | — |
| PPM020424 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in full sisters of women aged 40-54 years at study enrolment | HR: 1.27 [1.04, 1.55] | — | — | Age, genotyping method | — |
| PPM020425 | PGS000004 (PRS313_BC) |
PSS011356| European Ancestry| 17,835 individuals |
PGP000553 | Mao X et al. J Natl Cancer Inst (2023) |Ext. |
Reported Trait: Incident breast cancer in full sisters of women aged 55-74 years at study enrolment | HR: 1.24 [1.07, 1.44] | — | — | Age, genotyping method | — |
| PPM020724 | PGS000004 (PRS313_BC) |
PSS011385| European Ancestry| 683 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Grade 3 tumour in females with invasive breast cancer | OR: 0.8 [0.65, 0.99] | — | — | — | Reference = grade 1 tumour |
| PPM020725 | PGS000004 (PRS313_BC) |
PSS011385| European Ancestry| 683 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: ER negative status in females with invasive breast cancer | OR: 0.8 [0.65, 0.99] | — | — | — | — |
| PPM020726 | PGS000004 (PRS313_BC) |
PSS011384| Additional Asian Ancestries| 12,920 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: ER negative status in females with invasive breast cancer | OR: 0.86 [0.82, 0.89] | — | — | — | — |
| PPM020727 | PGS000004 (PRS313_BC) |
PSS011385| European Ancestry| 683 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: PR negative status in females with invasive breast cancer | OR: 0.84 [0.71, 1.0] | — | — | — | — |
| PPM020728 | PGS000004 (PRS313_BC) |
PSS011384| Additional Asian Ancestries| 12,920 individuals |
PGP000572 | Lopes Cardozo JMN et al. J Clin Oncol (2023) |Ext. |
Reported Trait: PR negative status in females with invasive breast cancer | OR: 0.89 [0.86, 0.94] | — | — | — | — |
| PPM021285 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer | HR: 1.56 [1.4, 1.74] | — | — | Age at inclusion in the Rotterdam Study | — |
| PPM021286 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in women below the age of 50 | HR: 2.74 [1.72, 4.37] | — | — | Age at inclusion in the Rotterdam Study | — |
| PPM021287 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in women aged between 50 and 75 | HR: 1.74 [1.52, 2.0] | — | — | Age at inclusion in the Rotterdam Study | — |
| PPM021288 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in women above the age of 75 | HR: 1.29 [1.08, 1.55] | — | — | Age at inclusion in the Rotterdam Study | — |
| PPM021289 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident invasive breast cancer | HR: 1.57 [1.4, 1.77] | — | — | Age at inclusion in the Rotterdam Study | — |
| PPM021290 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident in situ breast cancer | HR: 1.43 [1.01, 2.01] | — | — | Age at inclusion in the Rotterdam Study | — |
| PPM021291 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in women below the age of 60 | — | C-index: 0.632 [0.58, 0.69] | — | — | — |
| PPM021292 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in women aged between the ages of 60 and 70 | — | C-index: 0.673 [0.61, 0.73] | — | — | — |
| PPM021293 | PGS000004 (PRS313_BC) |
PSS011678| European Ancestry| 6,522 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in women aged 70 or above | — | C-index: 0.562 [0.48, 0.62] | — | — | — |
| PPM021294 | PGS000004 (PRS313_BC) |
PSS011677| European Ancestry| 4,377 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer | — | C-index: 0.636 [0.59, 0.68] | — | Age at inclusion in the Rotterdam Study | Calculated using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICIEA) |
| PPM021295 | PGS000004 (PRS313_BC) |
PSS011677| European Ancestry| 4,377 individuals |
PGP000625 | Lakeman IMM et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer | — | C-index: 0.653 [0.6, 0.7] | — | Age at inclusion in the Rotterdam Study, age at menarche, age at menopause, number of children, age at first live birth, use of oral contraception, use of hormone replacement therapy, body mass index (BMI), height, alcohol use | Calculated using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICIEA) |
| PPM021373 | PGS000004 (PRS313_BC) |
PSS011707| European Ancestry| 110,869 individuals |
PGP000644 | Arthur RS et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Incident breast cancer in postmenopausal women | HR: 2.03 [1.91, 2.16] | — | Hazard ratio (HR, top PRS tertile vs. bottom PRS tertile): 2.51 [2.27, 2.77] | Age at recruitment, socioeconomic status, age at menarche, parity and age at first pregnancy (combined), family history of breast cancer, history of mammograms, oral contraceptive use, age at menopause, hormone replacement therapy use, 5 PCs, genotyping batch, lifestyle score | Only 304 of the 313 SNPs were available for analysis |
| PPM021372 | PGS000004 (PRS313_BC) |
PSS011708| European Ancestry| 35,457 individuals |
PGP000644 | Arthur RS et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Incident breast cancer in premenopausal women | HR: 2.14 [1.89, 2.42] | — | Hazard ratio (HR, top PRS tertile vs. bottom PRS tertile): 2.64 [2.17, 3.22] | Age at recruitment, socioeconomic status, age at menarche, parity and age at first pregnancy (combined), family history of breast cancer, history of mammograms, oral contraceptive use, BMI, 5 PCs, genotyping batch, lifestyle score | Only 304 of the 313 SNPs were available for analysis |
| PPM022285 | PGS000004 (PRS313_BC) |
PSS011899| African Ancestry| 7,096 individuals |
PGP000694 | Jia G et al. Nat Genet (2024) |Ext. |
Reported Trait: Breast cancer | OR: 1.31 [1.24, 1.4] | AUROC: 0.58 [0.56, 0.6] | — | Age, study, genotyping array, 5 PCs | — |
| PPM022380 | PGS000004 (PRS313_BC) |
PSS011931| Multi-ancestry (including European)| 25,591 individuals |
PGP000706 | Bolze A et al. JAMA Oncol (2024) |Ext. |
Reported Trait: breast cancer diagnosis | — | — | Hazard ratio (HR, low vs average tertile): 0.39 [0.29, 0.52] | — | — |
| PPM000006 | PGS000005 (PRS313_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-positive breast cancer | OR: 1.68 [1.63, 1.73] | AUROC: 0.641 | — | study, genetic PCs 1-15 | — |
| PPM000964 | PGS000005 (PRS313_ERpos) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.22 [1.15, 1.3] | — | — | Country | — |
| PPM000963 | PGS000005 (PRS313_ERpos) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.23 [1.16, 1.31] | — | — | Country | — |
| PPM000947 | PGS000005 (PRS313_ERpos) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.22 [1.15, 1.3] | — | — | Country | — |
| PPM000946 | PGS000005 (PRS313_ERpos) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.23 [1.16, 1.31] | — | — | Country | — |
| PPM000965 | PGS000005 (PRS313_ERpos) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.37 [1.22, 1.54] | — | — | Country | — |
| PPM000948 | PGS000005 (PRS313_ERpos) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.37 [1.22, 1.54] | — | — | Country | — |
| PPM001018 | PGS000005 (PRS313_ERpos) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.17 [1.14, 1.2] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001019 | PGS000005 (PRS313_ERpos) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.3 [1.26, 1.35] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001020 | PGS000005 (PRS313_ERpos) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.06 [1.02, 1.1] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001021 | PGS000005 (PRS313_ERpos) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.15 [1.07, 1.25] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001022 | PGS000005 (PRS313_ERpos) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.45 [1.35, 1.54] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001023 | PGS000005 (PRS313_ERpos) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.37 [1.31, 1.44] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM000654 | PGS000005 (PRS313_ERpos) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.54, 1.7] | AUROC: 0.6323 | — | — | — |
| PPM000663 | PGS000005 (PRS313_ERpos) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.59 [1.51, 1.66] | AUROC: 0.6276 | — | — | — |
| PPM000660 | PGS000005 (PRS313_ERpos) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.59 [1.48, 1.71] | AUROC: 0.6291 | — | — | — |
| PPM000657 | PGS000005 (PRS313_ERpos) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.66 [1.58, 1.75] | AUROC: 0.64 | — | — | — |
| PPM000651 | PGS000005 (PRS313_ERpos) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.82 [1.77, 1.87] | AUROC: 0.6595 | — | — | — |
| PPM001947 | PGS000005 (PRS313_ERpos) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.55 [1.45, 1.66] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 4.01 [3.17, 5.06] | — | — |
| PPM001948 | PGS000005 (PRS313_ERpos) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.5 [1.41, 1.6] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.26 [2.64, 4.03] | — | — |
| PPM002001 | PGS000005 (PRS313_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.37 [1.32, 1.43] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.85 [1.61, 2.13] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM002002 | PGS000005 (PRS313_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.588 [0.577, 0.599] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM005127 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.4 [1.07, 1.83] | AUROC: 0.6 [0.51, 0.69] | — | PCs(1-3) | — |
| PPM005128 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.39 [1.06, 1.82] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005129 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.46 [1.09, 1.94] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM005130 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.33 [1.16, 1.52] | AUROC: 0.59 [0.55, 0.63] | — | PCs(1-3) | — |
| PPM005131 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.33 [1.16, 1.53] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005132 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.36 [1.18, 1.57] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM014895 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.056 [0.012, 0.1] | — | — | first 10 principal components | — |
| PPM014896 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.055 [0.011, 0.099] | — | — | first 10 principal components | — |
| PPM014897 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.078 [0.034, 0.121] | — | — | first 10 principal components | — |
| PPM014898 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.056 [0.014, 0.099] | — | — | first 10 principal components | — |
| PPM022287 | PGS000005 (PRS313_ERpos) |
PSS011901| African Ancestry| 5,844 individuals |
PGP000694 | Jia G et al. Nat Genet (2024) |Ext. |
Reported Trait: ER-positive breast cancer | OR: 1.37 [1.27, 1.48] | AUROC: 0.59 [0.56, 0.61] | — | — | — |
| PPM000007 | PGS000006 (PRS313_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-negative breast cancer | OR: 1.45 [1.37, 1.53] | AUROC: 0.601 | — | study, genetic PCs 1-15 | — |
| PPM000950 | PGS000006 (PRS313_ERneg) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.33] | — | — | Country | — |
| PPM000949 | PGS000006 (PRS313_ERneg) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.17, 1.33] | — | — | Country | — |
| PPM000967 | PGS000006 (PRS313_ERneg) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.33] | — | — | Country | — |
| PPM000966 | PGS000006 (PRS313_ERneg) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.17, 1.33] | — | — | Country | — |
| PPM001024 | PGS000006 (PRS313_ERneg) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.29 [1.25, 1.33] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001025 | PGS000006 (PRS313_ERneg) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.23 [1.18, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001026 | PGS000006 (PRS313_ERneg) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.23 [1.18, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001027 | PGS000006 (PRS313_ERneg) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.29 [1.19, 1.41] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001028 | PGS000006 (PRS313_ERneg) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.29 [1.21, 1.37] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001029 | PGS000006 (PRS313_ERneg) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.21 [1.15, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001034 | PGS000006 (PRS313_ERneg) |
PSS000529| European Ancestry| 2,088 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in BRCA1 carriers | HR: 1.28 [1.14, 1.44] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
| PPM001949 | PGS000006 (PRS313_ERneg) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.37 [1.29, 1.47] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 2.39 [1.93, 2.96] | — | — |
| PPM001950 | PGS000006 (PRS313_ERneg) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.38 [1.29, 1.47] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 2.51 [2.05, 3.07] | — | — |
| PPM002003 | PGS000006 (PRS313_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor negative breast cancer | OR: 1.21 [1.15, 1.27] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.47 [1.25, 1.74] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM002004 | PGS000006 (PRS313_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor negative breast cancer | — | AUROC: 0.562 [0.551, 0.573] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
| PPM005124 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.23 [1.07, 1.41] | — | — | PCs(1-3) | — |
| PPM005125 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.23 [1.07, 1.42] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
| PPM005126 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.25 [1.09, 1.45] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
| PPM014890 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.059 [0.015, 0.103] | — | — | first 10 principal components | — |
| PPM014892 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.068 [0.024, 0.112] | — | — | first 10 principal components | — |
| PPM014893 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.046 [0.003, 0.089] | — | — | first 10 principal components | — |
| PPM014894 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus-white Mammogram Risk Scores | β: 0.045 [0.002, 0.089] | — | — | first 10 principal components | — |
| PPM014891 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.065 [0.021, 0.109] | — | — | first 10 principal components | — |
| PPM022289 | PGS000006 (PRS313_ERneg) |
PSS011900| African Ancestry| 4,814 individuals |
PGP000694 | Jia G et al. Nat Genet (2024) |Ext. |
Reported Trait: ER-negative breast cancer | OR: 1.42 [1.27, 1.6] | AUROC: 0.6 [0.56, 0.63] | — | — | — |
| PPM000008 | PGS000007 (PRS3820_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.66 [1.61, 1.7] | AUROC: 0.636 | — | study, genetic PCs 1-15 | — |
| PPM000386 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.78 | — | age, sex | — |
| PPM000384 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | OR: 1.56 [1.45, 1.68] | — | — | age at menarche | — |
| PPM000388 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.63 | — | — | — |
| PPM005169 | PGS000007 (PRS3820_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.59 [0.58, 0.6] | R²: 0.021 | — | — |
| PPM005172 | PGS000007 (PRS3820_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.53 [0.5, 0.57] | R²: 0.0002 | — | — |
| PPM005160 | PGS000007 (PRS3820_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.36 [1.31, 1.41] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005163 | PGS000007 (PRS3820_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.21 [1.06, 1.39] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM015517 | PGS000007 (PRS3820_BC) |
PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Breast cancer | OR: 2.38 [2.07, 2.73] | — | — | 4 genetic PCs | — |
| PPM000009 | PGS000008 (PRS3820_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-positive breast cancer | OR: 1.73 [1.68, 1.78] | AUROC: 0.647 | — | study, genetic PCs 1-15 | — |
| PPM000010 | PGS000009 (PRS3820_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-negative breast cancer | OR: 1.44 [1.36, 1.53] | AUROC: 0.6 | — | study, genetic PCs 1-15 | — |
| PPM000024 | PGS000015 (GPS_BC) |
PSS000014| European Ancestry| 157,895 individuals |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Reported Trait: Breast cancer | — | AUROC: 0.69 [0.68, 0.69] | Nagelkerke’s R2 (estimate of variance explained by the PGS after covariate adjustment): 0.027 | age; sex; Ancestry PC 1-4; genotyping chip | — |
| PPM005170 | PGS000015 (GPS_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.61 [0.6, 0.62] | R²: 0.017 | — | — |
| PPM005161 | PGS000015 (GPS_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.46 [1.41, 1.51] | — | Odds Ratio (OR, top 1% vs middle 20%): 2.48 [1.89, 3.25] | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005164 | PGS000015 (GPS_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.24 [1.08, 1.43] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005166 | PGS000015 (GPS_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.35 [1.11, 1.64] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005173 | PGS000015 (GPS_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.52, 0.59] | R²: 0.0004 | — | — |
| PPM005175 | PGS000015 (GPS_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.56 [0.51, 0.6] | R²: 0.001 | — | — |
| PPM000056 | PGS000028 (PRS) |
PSS000040| Multi-ancestry (including European)| 981 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.65 [0.61, 0.68] | — | BCSC risk model | BCSC risk model includes mammographic breast density, age, ethnicity, first-degree relative with breast cancer, and history of breast biopsy |
| PPM000055 | PGS000028 (PRS) |
PSS000040| Multi-ancestry (including European)| 981 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.57, 0.64] | — | — | — |
| PPM000060 | PGS000028 (PRS) |
PSS000039| European Ancestry| 774 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.63 [0.59, 0.67] | — | — | — |
| PPM000059 | PGS000028 (PRS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.62 [0.52, 0.73] | — | — | — |
| PPM000058 | PGS000029 (PRS_AS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.72 [0.62, 0.82] | — | BCSC risk model | BCSC risk model includes mammographic breast density, age, ethnicity, first-degree relative with breast cancer, and history of breast biopsy |
| PPM000057 | PGS000029 (PRS_AS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.64 [0.53, 0.74] | — | — | — |
| PPM000061 | PGS000030 (PrCa) |
PSS000041| European Ancestry| 74,849 individuals |
PGP000019 | Schumacher FR et al. Nat Genet (2018) |
Reported Trait: Prostate cancer | OR: 1.86 [1.83, 1.89] | — | — | Top 7 Genetic PCs, country | Samples were also part of the variant association |
| PPM001971 | PGS000030 (PrCa) |
PSS000983| European Ancestry| 81,094 individuals |
PGP000173 | Darst BF et al. Eur Urol (2021) |Ext. |
Reported Trait: Prostate cancer in carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants | OR: 2.58 [2.45, 2.71] | — | — | Age, PCs (1-10) | Only 145 SNPs from PGS000030 were utilised. 2 SNPs were not included as they were not present in the UK Biobank (UKB) data and had an imputation info score of > 0.50 (median info score = 0.997). |
| PPM005133 | PGS000030 (PrCa) |
PSS003583| European Ancestry| 450 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA1 carriers | OR: 1.73 [1.28, 2.33] | AUROC: 0.62 [0.54, 0.69] | — | PCs(1-3) | — |
| PPM005134 | PGS000030 (PrCa) |
PSS003583| European Ancestry| 450 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA1 carriers | OR: 1.74 [1.29, 2.35] | — | — | PCs(1-3), family history of prostate cancer in first and second degree relatives | — |
| PPM005135 | PGS000030 (PrCa) |
PSS003584| European Ancestry| 1,074 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA2 carriers | OR: 1.6 [1.34, 1.91] | AUROC: 0.62 [0.57, 0.67] | — | PCs(1-3) | — |
| PPM005136 | PGS000030 (PrCa) |
PSS003584| European Ancestry| 1,074 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA2 carriers | OR: 1.59 [1.32, 1.9] | — | — | PCs(1-3), family history of prostate cancer in first and second degree relatives | — |
| PPM012886 | PGS000030 (PrCa) |
PSS009594| Ancestry Not Reported| 4,580 individuals |
PGP000292 | Saad M et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.835 [1.664, 2.023] | AUROC: 0.672 [0.645, 0.698] | — | — | — |
| PPM013015 | PGS000030 (PrCa) |
PSS009648| European Ancestry| 991 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Prostate cancer metastasis or death | HR: 1.25 [1.1, 1.41] | — | — | — | — |
| PPM013016 | PGS000030 (PrCa) |
PSS009649| European Ancestry| 1,000 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Prostate cancer metastasis or death | HR: 1.65 | — | — | — | — |
| PPM013017 | PGS000030 (PrCa) |
PSS009648| European Ancestry| 991 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Incident prostate cancer | HR: 1.25 [1.11, 1.41] | — | — | — | — |
| PPM013018 | PGS000030 (PrCa) |
PSS009649| European Ancestry| 1,000 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Incident prostate cancer | HR: 1.69 | — | — | — | — |
| PPM013019 | PGS000030 (PrCa) |
PSS009650| European Ancestry| 1,991 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Prostate cancer metastasis or death | — | AUROC: 0.63 | — | — | — |
| PPM015484 | PGS000030 (PrCa) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (tumor stage T4) | OR: 1.14 [0.93, 1.4] | AUROC: 0.51 [0.438, 0.578] | — | — | — |
| PPM015481 | PGS000030 (PrCa) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.23 [0.91, 1.67] | AUROC: 0.538 [0.516, 0.56] | — | — | — |
| PPM015486 | PGS000030 (PrCa) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (Gleason score >=8) | OR: 1.13 [1.02, 1.25] | AUROC: 0.511 [0.475, 0.547] | — | — | — |
| PPM015519 | PGS000030 (PrCa) |
PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 2.22 [1.98, 2.48] | — | — | 4 genetic PCs | — |
| PPM000105 | PGS000044 (PrCa66) |
PSS000069| European Ancestry| 4,967 individuals |
PGP000032 | Pashayan N et al. Genet Med (2015) |Ext. |
Reported Trait: aggressive prostate cancer (Gleason score ⩾7) | — | — | OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1] | — | — |
| PPM000104 | PGS000044 (PrCa66) |
PSS000068| European Ancestry| 17,012 individuals |
PGP000031 | Pashayan N et al. Br J Cancer (2015) |
Reported Trait: Elevated serum prostate-specific antigen (PSA) levels | — | — | OR (per 1-point increase in PRS): 1.23 [1.1, 1.37] | cancer stage, Gleason score | — |
| PPM000120 | PGS000045 (BCPRS_Overall) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.36 [1.19, 1.56] | AUROC: 0.59 [0.55, 0.63] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
| PPM000106 | PGS000045 (BCPRS_Overall) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.14 [1.11, 1.17] | C-index: 0.541 [0.53, 0.551] | — | Country, birth year | — |
| PPM000107 | PGS000045 (BCPRS_Overall) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.28] | C-index: 0.566 [0.551, 0.581] | — | Country, birth year | — |
| PPM002156 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.9 [1.32, 2.75] | — | — | Year of birth, counselling center of origin, PRS*c.1100delC carrier status | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002155 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.71 [1.37, 2.13] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002157 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers 40 years of age or below | HR: 1.59 [1.2, 2.11] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002158 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 41 and 50 years of age | HR: 2.07 [1.53, 2.82] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM002159 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 51 and 60 years of age | HR: 1.56 [1.05, 2.31] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
| PPM014912 | PGS000045 (BCPRS_Overall) |
PSS009925| Ancestry Not Reported| 295 individuals |
PGP000355 | Borde J et al. BMC Cancer (2022) |Ext. |
Reported Trait: Breast cancer in BRAC1 PV carriers | OR: 1.62 [1.16, 2.31] | — | — | — | effective SNP set size of N=77 |
| PPM000121 | PGS000046 (BCPRS_ER+) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.36 [1.19, 1.56] | AUROC: 0.59 [0.55, 0.63] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
| PPM000108 | PGS000046 (BCPRS_ER+) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.11 [1.08, 1.15] | C-index: 0.532 [0.522, 0.543] | — | Country, birth year | — |
| PPM000109 | PGS000046 (BCPRS_ER+) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.16, 1.27] | C-index: 0.566 [0.551, 0.581] | — | Country, birth year | — |
| PPM000122 | PGS000047 (BCPRS_ER-) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.19 [1.05, 1.35] | AUROC: 0.55 [0.51, 0.59] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
| PPM000110 | PGS000047 (BCPRS_ER-) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.27 [1.23, 1.31] | C-index: 0.581 [0.571, 0.592] | — | Country, birth year | — |
| PPM000111 | PGS000047 (BCPRS_ER-) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.15 [1.1, 1.2] | C-index: 0.538 [0.523, 0.553] | — | Country, birth year | — |
| PPM014913 | PGS000047 (BCPRS_ER-) |
PSS009925| Ancestry Not Reported| 295 individuals |
PGP000355 | Borde J et al. BMC Cancer (2022) |Ext. |
Reported Trait: Estrogen receptor [ER]-negative breast cancer in BRAC2 PV carriers | OR: 2.27 [1.45, 3.78] | — | — | — | effective SNP set size of N=50 |
| PPM000112 | PGS000048 (OCPRS_Overall) |
PSS000072| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Ovarian cancer in BRCA1 mutation carriers | HR: 1.28 [1.22, 1.34] | C-index: 0.579 [0.559, 0.6] | — | Country, birth year | — |
| PPM000113 | PGS000048 (OCPRS_Overall) |
PSS000073| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Ovarian cancer in BRCA2 mutation carriers | HR: 1.49 [1.34, 1.65] | C-index: 0.628 [0.592, 0.665] | — | Country, birth year | — |
| PPM000123 | PGS000049 (PRS103_PrCa) |
PSS000075| European Ancestry| 1,525 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutations | OR: 1.56 [1.35, 1.81] | AUROC: 0.62 [0.58, 0.66] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
| PPM000124 | PGS000049 (PRS103_PrCa) |
PSS000077| European Ancestry| 1,366 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7) | OR: 1.44 [1.1, 1.87] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
| PPM000125 | PGS000049 (PRS103_PrCa) |
PSS000076| European Ancestry| 3,325 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7) | OR: 1.67 [1.37, 2.04] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
| PPM000126 | PGS000050 (PRS44) |
PSS000078| East Asian Ancestry| 23,567 individuals |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.606 | Odds Ratio (OR; per decile of PRS): 1.13 [1.12, 1.14] | NR | Potentially overfit: samples were used to select the variants included in the PRS (see paper's Discussion section for more information). |
| PPM000127 | PGS000050 (PRS44) |
PSS000079| East Asian Ancestry| 5,152 individuals |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Reported Trait: Breast cancer | — | C-index: 0.602 | C-index improvement (with PRS): 0.0386 [0.0259, 0.0513] | age at menarche, age at first live birth, waist-to-hip ratio, breast cancer family history, prior benign breast disease | Potentially overfit: samples were used to select the variants included in the PRS (see paper's Discussion section for more information). |
| PPM000128 | PGS000051 (PRS67) |
PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.65 [0.64, 0.66] | — | Gail BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
| PPM000130 | PGS000051 (PRS67) |
PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | — | Relative Risk (RR; higest vs. lowest quartile PRS): 2.5 [2.2, 2.8] | Demographics and parameters of baseline blood draw (age, BMI, fasting status, time of day, season), history of benign breast disease, family history of breast cancer, age at menopause, age at menarche, physical activity, age at first birth and parity | — |
| PPM000129 | PGS000051 (PRS67) |
PSS000081| Multi-ancestry (including European)| 8,160 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.678 [0.666, 0.69] | — | Rosner-Colditz BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
| PPM000131 | PGS000052 (sPRS161) |
PSS000082| European Ancestry| 585 individuals |
PGP000037 | Lakeman IMM et al. J Med Genet (2019) |
Reported Trait: breast cancer | HR: 1.16 [1.03, 1.28] | — | — | family history (estimated using the BOADICEA risk model) | — |
| PPM000139 | PGS000055 (PRS_CRC) |
PSS000087| European Ancestry| 61,335 individuals |
PGP000040 | Schmit SL et al. J Natl Cancer Inst (2019) |
Reported Trait: Colorectal cancer | — | — | Familial relative risk explained (%): 11.9 [9.2, 15.5] PRS percentile threshold for Odds Ratio > 2: 95.7 |
age, sex, PCs, PC*study | — |
| PPM000140 | PGS000055 (PRS_CRC) |
PSS000086| East Asian Ancestry| 21,630 individuals |
PGP000040 | Schmit SL et al. J Natl Cancer Inst (2019) |
Reported Trait: Colorectal cancer | — | — | PRS percentile threshold for Odds Ratio > 2: 99.1 | age, sex, PCs, PC*study | — |
| PPM018698 | PGS000055 (PRS_CRC) |
PSS011070| East Asian Ancestry| 332 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.65 [0.62, 0.69] | Hazard ratio (HR, high vs low tertile): 2.27 [1.6, 3.21] | age at recruitment | — |
| PPM000182 | PGS000067 (PCa_PHS) |
PSS000105| European Ancestry| 5,456 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: aggressive prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4, 3.4] | — | — |
| PPM000184 | PGS000067 (PCa_PHS) |
PSS000106| European Ancestry| 6,411 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: any prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2, 2.8] | — | — |
| PPM001675 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 2% vs. middle 40%): 2.1 [1.99, 2.21] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001677 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR bottom 20% vs. middle 40%): 0.65 [0.63, 0.67] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000393 | PGS000067 (PCa_PHS) |
PSS000221| African Ancestry| 4,437 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 2.4 [2.3, 2.6] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000392 | PGS000067 (PCa_PHS) |
PSS000222| Additional Asian Ancestries| 1,901 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.2 [4.8, 5.6] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000391 | PGS000067 (PCa_PHS) |
PSS000223| European Ancestry| 50,656 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.6 [5.2, 6.0] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000390 | PGS000067 (PCa_PHS) |
PSS000220| Multi-ancestry (including European)| 56,994 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.9 [5.5, 6.3] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001679 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 2.21 [2.04, 2.38] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000394 | PGS000067 (PCa_PHS) |
PSS000224| Multi-ancestry (including European)| 34,558 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of prostate cancer death | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.7 [4.6, 7.0] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001683 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (bottom 20% vs. middle 40%): 0.7 [0.68, 0.73] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001681 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 2% vs. middle 40%): 1.91 [1.79, 2.04] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000186 | PGS000067 (PCa_PHS) |
PSS000107| European Ancestry| 5,048 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: very aggressive prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2, 4.0] | — | — |
| PPM001673 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 2.47 [2.32, 2.62] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001812 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 5.15 [3.29, 6.18] | — | Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067) |
| PPM001813 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.44 [0.4, 0.49] | — | Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067) |
| PPM001817 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 3.72 [2.89, 4.43] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001818 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 6.12 [4.18, 7.67] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001819 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.41 [0.35, 0.47] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001823 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 3.2 [2.59, 3.78] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001824 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 4.96 [3.61, 6.14] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001825 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.45 [0.39, 0.5] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001811 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 3.29 [2.73, 3.77] | — | Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067) |
| PPM000187 | PGS000067 (PCa_PHS) |
PSS000107| European Ancestry| 5,048 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: very aggressive prostate cancer (age at onset) | — | — | z-test (p-value) <: 1.00e-16 | — | — |
| PPM000183 | PGS000067 (PCa_PHS) |
PSS000105| European Ancestry| 5,456 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: aggressive prostate cancer (age at onset) | — | — | z-test (p-value) <: 1.00e-16 | — | — |
| PPM000185 | PGS000067 (PCa_PHS) |
PSS000106| European Ancestry| 6,411 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: any prostate cancer (age at onset) | — | — | z-test (p-value) <: 1.00e-16 | — | — |
| PPM000188 | PGS000068 (PRS_EOC) |
PSS000108| European Ancestry| 4,095 individuals |
PGP000048 | Yang X et al. J Med Genet (2018) |
Reported Trait: all invasive epithelial ovarian cancer | OR: 1.32 [1.21, 1.45] | C-index: 0.58 [0.55, 0.6] | — | — | — |
| PPM000189 | PGS000069 (PRS_sEOC) |
PSS000108| European Ancestry| 4,095 individuals |
PGP000048 | Yang X et al. J Med Genet (2018) |
Reported Trait: serous epithelial ovarian cancer | OR: 1.43 [1.29, 1.58] | C-index: 0.6 [0.57, 0.63] | — | — | — |
| PPM000190 | PGS000070 (PRS_LC_C) |
PSS000109| East Asian Ancestry| 95,408 individuals |
PGP000049 | Dai J et al. Lancet Respir Med (2019) |
Reported Trait: Incident lung cancer | — | — | HR (High genetic risk: top 5% vs. bottom 5% of PRS): 2.37 [1.64, 3.44] HR (Intermediate genetic risk: 5-95% vs. bottom 5% of PRS): 1.6 [1.17, 2.2] |
age, sex, source of region, smoking status | — |
| PPM015573 | PGS000070 (PRS_LC_C) |
PSS009987| East Asian Ancestry| 19,546 individuals |
PGP000387 | Qin N et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Lung cancer | — | — | Odds ratio (OR, high vs low risk): 2.18 [2.00, 2.38] | — | — |
| PPM015575 | PGS000070 (PRS_LC_C) |
PSS009987| East Asian Ancestry| 19,546 individuals |
PGP000387 | Qin N et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Lung cancer x autosomal mosaic loss abnormalities interaction | OR: 2.36 [1.09, 5.08] | — | — | — | — |
| PPM018700 | PGS000070 (PRS_LC_C) |
PSS011073| East Asian Ancestry| 381 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.68 [0.65, 0.71] | Hazard ratio (HR, high vs low tertile): 2.01 [1.44, 2.81] | age at recruitment | — |
| PPM020283 | PGS000070 (PRS_LC_C) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.726 [0.698, 0.754] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM021774 | PGS000070 (PRS_LC_C) |
PSS011793| East Asian Ancestry| 100,615 individuals |
PGP000678 | Zhu M et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Incident lung cancer | HR: 1.19 [1.13, 1.25] | — | — | Age, sex, smoking status, BMI, highest education level, family history of cancer, personal medical history (previous cancer diagnoses and chronic obstructive pulmonary disease), the forced expiratory volume in 1 second, 10 PCs | — |
| PPM022188 | PGS000070 (PRS_LC_C) |
PSS011836| East Asian Ancestry| 1,197 individuals |
PGP000687 | Lee PH et al. JCO Precis Oncol (2024) |Ext. |
Reported Trait: Incident non-small cell lung cancer | — | — | Hazard ratio (HR, high vs low PGS quartile): 2.33 [0.6, 9.04] | Age, smoking, family history of lung cancer | — |
| PPM022189 | PGS000070 (PRS_LC_C) |
PSS011835| East Asian Ancestry| 1,090 individuals |
PGP000687 | Lee PH et al. JCO Precis Oncol (2024) |Ext. |
Reported Trait: Incident non-small cell lung cancer | — | — | Hazard ratio (HR, high vs low PGS quartile): 2.97 [1.25, 7.07] | Age, smoking, family history of lung cancer | — |
| PPM000191 | PGS000071 (CC_Bladder) |
PSS000110| European Ancestry| 412,602 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Bladder cancer | OR: 1.3 [1.25, 1.36] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002037 | PGS000071 (CC_Bladder) |
PSS001010| European Ancestry| 391,888 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident blader cancer | HR: 1.28 [1.2, 1.37] | AUROC: 0.803 C-index: 0.813 (0.008) |
— | Age at assessment, sex, genotyping array, PCs(1-15), cigarette pack-years, smoking status(never vs. former vs. current), body mass index | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017172 | PGS000071 (CC_Bladder) |
PSS010143| European Ancestry| 424 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Bladder cancer | HR: 1.21 [1.1, 1.33] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index | — |
| PPM000192 | PGS000072 (CC_Breast) |
PSS000111| European Ancestry| 237,549 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Breast cancer | OR: 1.26 [1.24, 1.28] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002038 | PGS000072 (CC_Breast) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident breast cancer | HR: 1.52 [1.47, 1.56] | AUROC: 0.637 C-index: 632.0 (0.005) |
— | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity( ≥1 live birth vs. none), age at menarche, body mass index, menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use, alcool intake, body mass index*menopausal status | Only 162 of the original 187 SNPs used based on those that reached p<5e-8 in the BCAC meta-analysis. C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017165 | PGS000072 (CC_Breast) |
PSS010142| European Ancestry| 1,990 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Post-menopausal breast cancer | HR: 1.26 [1.2, 1.32] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000193 | PGS000073 (CC_Cervix) |
PSS000112| European Ancestry| 226,216 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Cervical cancer | OR: 1.22 [1.19, 1.25] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002039 | PGS000073 (CC_Cervix) |
PSS001012| European Ancestry| 211,795 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident cervical cancer | HR: 1.22 [1.09, 1.37] | AUROC: 0.745 C-index: 0.75 (0.017) |
— | Age at assessment, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), cigarette pack-years | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM000194 | PGS000074 (CC_Colorectal) |
PSS000113| European Ancestry| 416,249 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Colorectal cancer | OR: 1.37 [1.33, 1.4] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002040 | PGS000074 (CC_Colorectal) |
PSS001013| European Ancestry| 393,723 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident colorectal cancer | HR: 1.32 [1.27, 1.37] | AUROC: 0.704 C-index: 0.704 (0.006) |
— | Age at assessment, sex, family history of bowel cancer, genotyping array, PCs(1-15), wasit to hip ratio, cigarette pack years, frequency of processed meat intake (<1 per week vs. ≥1 per week), moderate and/or strenuous physical activity (days per week), alcohol intake | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017164 | PGS000074 (CC_Colorectal) |
PSS010144| European Ancestry| 2,150 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Colorectal cancer | HR: 1.36 [1.31, 1.42] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000195 | PGS000075 (CC_Endo) |
PSS000114| European Ancestry| 221,699 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Endometrial cancer | OR: 1.19 [1.14, 1.24] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002041 | PGS000075 (CC_Endo) |
PSS001014| European Ancestry| 212,156 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident endometrial cancer | HR: 1.19 [1.1, 1.29] | AUROC: 0.755 C-index: 0.749 (0.011) |
— | Age at assessment, family history of cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), age at menarche, body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017170 | PGS000075 (CC_Endo) |
PSS010152| European Ancestry| 494 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Uterine cancer | HR: 1.31 [1.2, 1.44] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000196 | PGS000076 (CC_Kidney) |
PSS000115| European Ancestry| 411,695 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Kidney cancer | OR: 1.21 [1.14, 1.27] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002042 | PGS000076 (CC_Kidney) |
PSS001015| European Ancestry| 391,610 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident kidney cancer | HR: 1.16 [1.08, 1.26] | AUROC: 0.722 C-index: 0.724 (0.011) |
— | Age at assessment, sex, genotyping array, PCs(1-15), body mass index, smoking status (never vs. former vs. current), cigarette pack-years, ever diagnosed with hypertension | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017169 | PGS000076 (CC_Kidney) |
PSS010145| European Ancestry| 547 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Kidney cancer | HR: 1.14 [1.05, 1.24] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000198 | PGS000078 (CC_Lung) |
PSS000117| European Ancestry| 412,842 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Lung cancer | OR: 1.12 [1.08, 1.17] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002044 | PGS000078 (CC_Lung) |
PSS001017| European Ancestry| 392,539 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident lung cancer | HR: 1.16 [1.11, 1.22] | AUROC: 0.846 C-index: 0.849 (0.006) |
— | Age at assessment, sex, genotyping array, PCs(1-15), family history of lung cancer, PM2.5 in 2010, cigarettes per day, years of smoking, smoking status (never vs. former vs. current), smoking status*cigarettes per day, smoking stutus*years of smoking | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017166 | PGS000078 (CC_Lung) |
PSS010146| European Ancestry| 1,256 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Lung cancer | HR: 1.26 [1.19, 1.33] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM020285 | PGS000078 (CC_Lung) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.728 [0.7, 0.756] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM000201 | PGS000081 (CC_Oral) |
PSS000120| European Ancestry| 411,577 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Oral cavity and pharyngeal cancers | OR: 1.08 [1.02, 1.14] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002047 | PGS000081 (CC_Oral) |
PSS001020| European Ancestry| 391,479 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident oral cavity and pharyngeal cancer | HR: 1.11 [1.01, 1.21] | AUROC: 0.702 C-index: 0.686 (0.015) |
— | Age at assessment, sex, genotyping array, PCs(1-15), weekly alcohol intake, cigarettes per day, years of smoking, smoing status (never vs. former vs. current) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017173 | PGS000081 (CC_Oral) |
PSS010150| European Ancestry| 415 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Oral cavity and pharyngeal cancers | HR: 1.03 [0.94, 1.14] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000202 | PGS000082 (CC_Ovary) |
PSS000121| European Ancestry| 220,909 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Ovarian cancer | OR: 1.14 [1.08, 1.2] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002048 | PGS000082 (CC_Ovary) |
PSS001021| European Ancestry| 211,958 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident ovarian cancer | HR: 1.13 [1.04, 1.24] | AUROC: 0.656 C-index: 0.655 (0.015) |
— | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), BMI*menopausal status | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017174 | PGS000082 (CC_Ovary) |
PSS010149| European Ancestry| 315 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Ovarian cancer | HR: 1.09 [0.97, 1.21] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000203 | PGS000083 (CC_Pancreas) |
PSS000122| European Ancestry| 411,019 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Pancreatic cancer | OR: 1.44 [1.33, 1.55] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002049 | PGS000083 (CC_Pancreas) |
PSS001022| European Ancestry| 391,491 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident pancreatic cancer | HR: 1.49 [1.36, 1.62] | AUROC: 0.745 C-index: 0.742 (0.012) |
— | Age at assessment, sex, genotyping array, PCs(1-15), family history of cancer (prostate, breast, lung, bowel), body mass index, cigarette pack-years, smoking status (never vs. former vs. current) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017171 | PGS000083 (CC_Pancreas) |
PSS010154| European Ancestry| 451 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Pancreatic cancer | HR: 1.51 [1.38, 1.66] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000204 | PGS000084 (CC_Prostate) |
PSS000123| European Ancestry| 201,516 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Prostate cancer | OR: 1.44 [1.41, 1.47] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB. Sample overlap: the GERA dataset contributed to the effect estimates for 4 of the 161 variants in the prostate cancer PRS. |
| PPM002050 | PGS000084 (CC_Prostate) |
PSS001023| European Ancestry| 184,225 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident prostate cancer | HR: 1.39 [1.35, 1.43] | AUROC: 0.74 C-index: 0.738 (0.004) |
— | Age at assessment, family history of prostate cancer, genotyping array, PCs(1-15), family history of prostate cancer | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017163 | PGS000084 (CC_Prostate) |
PSS010151| European Ancestry| 4,476 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Prostate cancer | HR: 1.36 [1.32, 1.4] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000206 | PGS000086 (CC_Testis) |
PSS000125| European Ancestry| 170,680 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Testicular cancer | OR: 2.29 [2.13, 2.47] | — | — | Genotyping array, age, 10 PCs. | — |
| PPM002051 | PGS000086 (CC_Testis) |
PSS001024| European Ancestry| 179,537 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident testicular cancer | HR: 2.18 [1.66, 2.87] | AUROC: 0.783 C-index: 0.749 (0.034) |
— | Age at assessment, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM000207 | PGS000087 (CC_Thyroid) |
PSS000126| European Ancestry| 411,118 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Thyroid cancer | OR: 1.55 [1.44, 1.67] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
| PPM002052 | PGS000087 (CC_Thyroid) |
PSS001025| European Ancestry| 391,189 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident thyroid cancer | HR: 1.57 [1.36, 1.82] | AUROC: 0.679 C-index: 0.666 (0.023) |
— | Age at assessment, sex,, genotyping array, PCs(1-15), body mass index (BMI <25 vs. 25≤BMI<30, BMI≥30) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM000344 | PGS000119 (BCC32) |
PSS000207| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.32 [1.27, 1.36] | AUROC: 0.58 [0.56, 0.58] | — | age, sex, batch, PC1-4 | — |
| PPM000341 | PGS000119 (BCC32) |
PSS000209| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Basal cell carcinoma | OR: 1.65 [1.56, 1.75] | AUROC: 0.64 [0.62, 0.66] | — | age, sex, batch, PC1-4 | — |
| PPM000347 | PGS000119 (BCC32) |
PSS000211| European Ancestry| 149,857 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.4 [1.42, 1.48] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
| PPM000343 | PGS000120 (SCC10) |
PSS000207| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.34 [1.3, 1.38] | AUROC: 0.58 [0.57, 0.6] | — | age, sex, batch, PC1-4 | — |
| PPM000340 | PGS000120 (SCC10) |
PSS000208| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Squamous cell carcinoma | OR: 1.4 [1.31, 1.5] | AUROC: 0.59 [0.56, 0.61] | — | age, sex, batch, PC1-4 | — |
| PPM000346 | PGS000120 (SCC10) |
PSS000211| European Ancestry| 149,857 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.3 [1.3, 1.34] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
| PPM000439 | PGS000146 (CRC_GRS_27) |
PSS000252| European Ancestry| 3,269 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Distal colon cancer | OR: 1.08 [1.06, 1.11] | — | — | Study, age, endoscopy, family history | — |
| PPM000438 | PGS000146 (CRC_GRS_27) |
PSS000254| European Ancestry| 3,292 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Proximal colon cancer | OR: 1.07 [1.04, 1.1] | — | — | Study, age, endoscopy, family history | — |
| PPM000445 | PGS000146 (CRC_GRS_27) |
PSS000257| European Ancestry| 733 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Colorectal cancer | — | AUROC: 0.56 [0.51, 0.61] | — | Age, endoscopy, family history | — |
| PPM000444 | PGS000146 (CRC_GRS_27) |
PSS000258| European Ancestry| 1,002 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Colorectal cancer | — | AUROC: 0.59 [0.54, 0.64] | — | Age, endoscopy, family history | — |
| PPM000443 | PGS000146 (CRC_GRS_27) |
PSS000255| European Ancestry| 4,573 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Rectal cancer | OR: 1.12 [1.08, 1.15] | — | — | Study, age, endoscopy, family history | — |
| PPM000442 | PGS000146 (CRC_GRS_27) |
PSS000251| European Ancestry| 4,886 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Distal colon cancer | OR: 1.08 [1.05, 1.1] | — | — | Study, age, endoscopy, family history | — |
| PPM000441 | PGS000146 (CRC_GRS_27) |
PSS000253| European Ancestry| 5,530 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Proximal colon cancer | OR: 1.06 [1.03, 1.08] | — | — | Study, age, endoscopy, family history | — |
| PPM000440 | PGS000146 (CRC_GRS_27) |
PSS000256| European Ancestry| 3,167 individuals |
PGP000069 | Hsu L et al. Gastroenterology (2015) |
Reported Trait: Rectal cancer | OR: 1.06 [1.03, 1.09] | — | — | Study, age, endoscopy, family history | — |
| PPM000448 | PGS000147 (CRC21) |
PSS000259| European Ancestry| 4,080 individuals |
PGP000070 | Ibáñez-Sanz G et al. Sci Rep (2017) |
Reported Trait: Colorectal cancer | — | AUROC: 0.63 [0.6, 0.66] | Odds Ratio (OR; per allele): 1.07 [1.04, 1.1] | environmental risk factors ( alcohol consumption, obesity, physical activity, red meat and vegetable consumption, nonsteroidal anti-inflammatory drug use), family history | — |
| PPM000447 | PGS000147 (CRC21) |
PSS000259| European Ancestry| 4,080 individuals |
PGP000070 | Ibáñez-Sanz G et al. Sci Rep (2017) |
Reported Trait: Rectal cancer | — | — | Odds Ratio (OR; per allele): 1.1 [1.06, 1.15] | environmental risk factors ( alcohol consumption, obesity, physical activity, red meat and vegetable consumption, nonsteroidal anti-inflammatory drug use), family history | — |
| PPM000446 | PGS000147 (CRC21) |
PSS000259| European Ancestry| 4,080 individuals |
PGP000070 | Ibáñez-Sanz G et al. Sci Rep (2017) |
Reported Trait: Colon cancer | — | — | Odds Ratio (OR; per allele): 1.06 [1.03, 1.09] | environmental risk factors ( alcohol consumption, obesity, physical activity, red meat and vegetable consumption, nonsteroidal anti-inflammatory drug use), family history | — |
| PPM000449 | PGS000147 (CRC21) |
PSS000259| European Ancestry| 4,080 individuals |
PGP000070 | Ibáñez-Sanz G et al. Sci Rep (2017) |
Reported Trait: Colorectal cancer | — | AUROC: 0.56 [0.54, 0.58] | — | — | — |
| PPM000452 | PGS000148 (CRC63) |
PSS000260| European Ancestry| 5,500 individuals |
PGP000071 | Jeon J et al. Gastroenterology (2018) |
Reported Trait: Colorectal cancer | — | AUROC: 0.59 [0.58, 0.6] | — | age, family history, study, endoscopy history | Risk prediction using Model III (Family History & G-score) |
| PPM000451 | PGS000148 (CRC63) |
PSS000261| European Ancestry| 4,666 individuals |
PGP000071 | Jeon J et al. Gastroenterology (2018) |
Reported Trait: Colorectal cancer | — | AUROC: 0.63 [0.62, 0.64] | — | age, family history, study, endoscopy history, E-score (height, body mass index, education, history of type 2 diabetes mellitus, smoking status, alcohol consumption, regular aspirin use, regular NSAIDs use, smoking pack-years, dietary factors, total-energy, physical activity) | Risk prediction using Model IV (Family history & E-score & G-score) |
| PPM000450 | PGS000148 (CRC63) |
PSS000261| European Ancestry| 4,666 individuals |
PGP000071 | Jeon J et al. Gastroenterology (2018) |
Reported Trait: Colorectal cancer | — | AUROC: 0.59 [0.58, 0.6] | — | age, family history, study, endoscopy history | Risk prediction using Model III (Family History & G-score) |
| PPM000453 | PGS000148 (CRC63) |
PSS000260| European Ancestry| 5,500 individuals |
PGP000071 | Jeon J et al. Gastroenterology (2018) |
Reported Trait: Colorectal cancer | — | AUROC: 0.62 [0.61, 0.63] | — | age, family history, study, endoscopy history, E-score (height, body mass index, education, history of type 2 diabetes mellitus, smoking status, alcohol consumption, regular aspirin use, regular NSAIDs use, regular use of post-menopausal hormones, smoking pack-years, dietary factors, total-energy, physical activity) | Risk prediction using Model IV (Family history & E-score & G-score) |
| PPM000464 | PGS000149 (CRC41) |
PSS000263| European Ancestry| 286,877 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals with a family history | — | C-index: 0.68 [0.67, 0.7] | — | Wells et al. model (age, diabetes, multi-vitamin usage, family history of colon cancer, years of education, body mass index, alcohol intake, physical activity, non-steroidal anti-inflammatory drug usage, red meat intake, smoking and oestrogen use [women only]) | Fully recalibrated model |
| PPM000463 | PGS000149 (CRC41) |
PSS000263| European Ancestry| 286,877 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer | — | C-index: 0.68 [0.67, 0.7] | — | Wells et al. model (age, diabetes, multi-vitamin usage, family history of colon cancer, years of education, body mass index, alcohol intake, physical activity, non-steroidal anti-inflammatory drug usage, red meat intake, smoking and oestrogen use [women only]) | Fully recalibrated model |
| PPM000459 | PGS000149 (CRC41) |
PSS000262| European Ancestry| 361,543 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals without a family history | — | C-index: 0.66 [0.62, 0.69] | — | Taylor et al. model (age-specific rates of CRC with estimated relative risks for different degrees of CRC family history) | Fully recalibrated model |
| PPM000458 | PGS000149 (CRC41) |
PSS000262| European Ancestry| 361,543 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals with a family history | — | C-index: 0.69 [0.67, 0.7] | — | Taylor et al. model (age-specific rates of CRC with estimated relative risks for different degrees of CRC family history) | Fully recalibrated model |
| PPM000457 | PGS000149 (CRC41) |
PSS000262| European Ancestry| 361,543 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer | — | C-index: 0.68 [0.67, 0.7] | — | Taylor et al. model (age-specific rates of CRC with estimated relative risks for different degrees of CRC family history) | Fully recalibrated model |
| PPM000465 | PGS000149 (CRC41) |
PSS000263| European Ancestry| 286,877 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals without a family history | — | C-index: 0.67 [0.63, 0.71] | — | Wells et al. model (age, diabetes, multi-vitamin usage, family history of colon cancer, years of education, body mass index, alcohol intake, physical activity, non-steroidal anti-inflammatory drug usage, red meat intake, smoking and oestrogen use [women only]) | Fully recalibrated model |
| PPM000462 | PGS000149 (CRC41) |
PSS000263| European Ancestry| 286,877 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals without a family history | — | C-index: 0.57 [0.53, 0.6] | — | — | — |
| PPM000461 | PGS000149 (CRC41) |
PSS000263| European Ancestry| 286,877 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals with a family history | — | C-index: 0.56 [0.55, 0.58] | — | — | — |
| PPM000460 | PGS000149 (CRC41) |
PSS000263| European Ancestry| 286,877 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer | — | C-index: 0.57 [0.55, 0.58] | — | — | — |
| PPM000456 | PGS000149 (CRC41) |
PSS000262| European Ancestry| 361,543 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals without a family history | — | C-index: 0.55 [0.52, 0.59] | — | — | — |
| PPM000455 | PGS000149 (CRC41) |
PSS000262| European Ancestry| 361,543 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer in individuals with a family history | — | C-index: 0.57 [0.55, 0.58] | — | — | — |
| PPM000454 | PGS000149 (CRC41) |
PSS000262| European Ancestry| 361,543 individuals |
PGP000072 | Smith T et al. Br J Cancer (2018) |
Reported Trait: Incident colorectal cancer | — | C-index: 0.56 [0.55, 0.58] | — | — | — |
| PPM000469 | PGS000150 (GRS48) |
PSS000269| European Ancestry| 749 individuals |
PGP000073 | Weigl K et al. Gastroenterology (2018) |
Reported Trait: advanced neoplasm (colorectal cancer) | — | C-index: 0.615 | Odds Ratio (OR; highest vs. lowest tertile of GRS): 2.74 [1.84, 4.09] | sex, age, previous colonoscopy, physical activity | — |
| PPM000468 | PGS000150 (GRS48) |
PSS000269| European Ancestry| 749 individuals |
PGP000073 | Weigl K et al. Gastroenterology (2018) |
Reported Trait: advanced neoplasm (colorectal cancer) | — | C-index: 0.599 | Odds Ratio (OR; highest vs. lowest tertile of GRS): 2.64 [1.77, 3.92] | sex, age | — |
| PPM000467 | PGS000150 (GRS48) |
PSS000268| European Ancestry| 1,043 individuals |
PGP000073 | Weigl K et al. Gastroenterology (2018) |
Reported Trait: non-advanced adenoma (colorectal) | — | C-index: 0.596 | Odds Ratio (OR; highest vs. lowest tertile of GRS): 1.05 [0.7, 1.55] | sex, age, previous colonoscopy, physical activity | — |
| PPM000466 | PGS000150 (GRS48) |
PSS000268| European Ancestry| 1,043 individuals |
PGP000073 | Weigl K et al. Gastroenterology (2018) |
Reported Trait: non-advanced adenoma (colorectal) | — | C-index: 0.584 | Odds Ratio (OR; highest vs. lowest tertile of GRS): 1.04 [0.7, 1.55] | sex, age | — |
| PPM000471 | PGS000151 (SC_GRS) |
PSS000271| East Asian Ancestry| 3,523 individuals |
PGP000074 | Xin J et al. Gene (2018) |
Reported Trait: Colorectal cancer | — | AUROC: 0.607 [0.581, 0.633] | — | smoking status | — |
| PPM000470 | PGS000151 (SC_GRS) |
PSS000271| East Asian Ancestry| 3,523 individuals |
PGP000074 | Xin J et al. Gene (2018) |
Reported Trait: Colorectal cancer | — | AUROC: 0.6 [0.579, 0.622] | — | — | — |
| PPM000472 | PGS000152 (cGRS_Bladder) |
PSS000272| European Ancestry| 13,770 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Bladder cancer | — | — | Mean realative risk: 1.04 [1.0, 1.08] Wilcoxon test (case vs. control) p-value: 0.00377 |
— | — |
| PPM000483 | PGS000152 (cGRS_Bladder) |
PSS000272| European Ancestry| 13,770 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Bladder cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.58 [1.1, 2.25] | — | — |
| PPM000484 | PGS000153 (cGRS_Breast) |
PSS000273| European Ancestry| 7,847 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.47 [1.23, 1.76] | — | — |
| PPM000473 | PGS000153 (cGRS_Breast) |
PSS000273| European Ancestry| 7,847 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Breast cancer | — | — | Mean realative risk: 1.15 [1.11, 1.2] Wilcoxon test (case vs. control) p-value: 1.48e-14 |
— | — |
| PPM000474 | PGS000154 (cGRS_Colorectal) |
PSS000274| European Ancestry| 13,814 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Colorectal cancer | — | — | Mean realative risk: 1.08 [1.04, 1.12] Wilcoxon test (case vs. control) p-value: 8.29e-06 |
— | — |
| PPM000485 | PGS000154 (cGRS_Colorectal) |
PSS000274| European Ancestry| 13,814 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Colorectal cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.18 [0.87, 1.61] | — | — |
| PPM000487 | PGS000156 (cGRS_Lung) |
PSS000276| European Ancestry| 14,335 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Lung cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 0.88 [0.57, 1.36] | — | — |
| PPM000476 | PGS000156 (cGRS_Lung) |
PSS000276| European Ancestry| 14,335 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Lung cancer | — | — | Mean realative risk: 1.01 [0.99, 1.02] Wilcoxon test (case vs. control) p-value: 0.0116 |
— | — |
| PPM020284 | PGS000156 (cGRS_Lung) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.732 [0.704, 0.76] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM000489 | PGS000158 (cGRS_Ovarian) |
PSS000278| European Ancestry| 7,551 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Ovarian cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.63 [1.3, 2.06] | — | — |
| PPM000478 | PGS000158 (cGRS_Ovarian) |
PSS000278| European Ancestry| 7,551 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Ovarian cancer | — | — | Mean realative risk: 1.12 [1.08, 1.16] Wilcoxon test (case vs. control) p-value: 0.00015 |
— | — |
| PPM000490 | PGS000159 (cGRS_Pancreatic) |
PSS000279| European Ancestry| 13,590 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Pancreatic cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.67 [1.1, 2.53] | — | — |
| PPM000479 | PGS000159 (cGRS_Pancreatic) |
PSS000279| European Ancestry| 13,590 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Pancreatic cancer | — | — | Mean realative risk: 1.13 [1.07, 1.18] Wilcoxon test (case vs. control) p-value: 0.00015 |
— | — |
| PPM000491 | PGS000160 (cGRS_Prostate) |
PSS000280| European Ancestry| 6,828 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Prostate cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.73 [1.38, 2.17] | — | — |
| PPM000480 | PGS000160 (cGRS_Prostate) |
PSS000280| European Ancestry| 6,828 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Prostate cancer | — | — | Mean realative risk: 1.3 [1.21, 1.38] Wilcoxon test (case vs. control) p-value: 2.07e-18 |
— | — |
| PPM000492 | PGS000161 (cGRS_Renal) |
PSS000281| European Ancestry| 13,880 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Renal cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.58 [1.14, 2.18] | — | — |
| PPM000481 | PGS000161 (cGRS_Renal) |
PSS000281| European Ancestry| 13,880 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Renal cancer | — | — | Mean realative risk: 1.09 [1.06, 1.12] Wilcoxon test (case vs. control) p-value: 8.66e-10 |
— | — |
| PPM000493 | PGS000162 (cGRS_Thyroid) |
PSS000282| European Ancestry| 13,814 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Thyroid cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.7 [1.29, 2.25] | — | — |
| PPM000482 | PGS000162 (cGRS_Thyroid) |
PSS000282| European Ancestry| 13,814 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Thyroid cancer | — | — | Mean realative risk: 1.09 [1.04, 1.15] Wilcoxon test (case vs. control) p-value: 4e-05 |
— | — |
| PPM000631 | PGS000207 (TC10_Ohio) |
PSS000342| European Ancestry| 3,137 individuals |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Reported Trait: Thyroid cancer | — | AUROC: 0.692 [0.673, 0.71] | — | gender, birth year, family history of disease (1st or 2nd degree relative) | AUROC (Clinical factors alone) = 0.585 [0.565 - 0.605] |
| PPM017146 | PGS000207 (TC10_Ohio) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |Ext. |
Reported Trait: Thyroid cancer | HR: 1.74 [1.56, 1.94] | AUROC: 0.62 [0.59, 0.64] | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
| PPM000632 | PGS000208 (TC10_Iceland) |
PSS000341| European Ancestry| 130,279 individuals |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Reported Trait: Thyroid cancer | — | AUROC: 0.751 [0.736, 0.768] | — | gender, birth year, family history of disease (1st or 2nd degree relative) | AUROC (Clinical factors alone) = 0.697 [0.680 - 0.714] |
| PPM000633 | PGS000209 (TC10_UKB) |
PSS000343| European Ancestry| 408,479 individuals |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Reported Trait: Thyroid cancer | — | AUROC: 0.694 [0.673, 0.716] | — | gender, birth year | AUROC (Clinical factors alone) = 0.629 [0.606 - 0.651] |
| PPM000649 | PGS000212 (PRS330_LumA) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.83 [1.78, 1.88] | AUROC: 0.6609 | — | — | — |
| PPM000652 | PGS000213 (PRS330_LumBHER2neg) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.54, 1.7] | AUROC: 0.633 | — | — | — |
| PPM000655 | PGS000214 (PRS330_LumB) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.69 [1.61, 1.77] | AUROC: 0.6431 | — | — | — |
| PPM000658 | PGS000215 (PRS330_HER2) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.53 [1.42, 1.65] | AUROC: 0.6208 | — | — | — |
| PPM000661 | PGS000216 (PRS330_TN) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.65 [1.57, 1.73] | AUROC: 0.6358 | — | — | — |
| PPM000849 | PGS000317 (PRS180) |
PSS000407| Hispanic or Latin American Ancestry| 2,001 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer (Latin american women) | OR: 1.54 [1.45, 1.63] | AUROC: 0.62 [0.61, 0.64] | — | study, genetic ancestry (ADMIXTURE) | — |
| PPM000848 | PGS000317 (PRS180) |
PSS000408| Hispanic or Latin American Ancestry| 7,317 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer (US Latinas) | OR: 1.62 [1.52, 1.71] | AUROC: 0.63 [0.62, 0.65] | — | study, genetic ancestry (ADMIXTURE) | — |
| PPM000846 | PGS000317 (PRS180) |
PSS000406| Hispanic or Latin American Ancestry| 12,280 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer | OR: 1.58 [1.52, 1.64] | AUROC: 0.63 [0.62, 0.64] | — | study, genetic ancestry (ADMIXTURE) | — |
| PPM000847 | PGS000317 (PRS180) |
PSS000406| Hispanic or Latin American Ancestry| 12,280 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer | OR: 1.7 [1.63, 1.78] | — | — | — | — |
| PPM005167 | PGS000317 (PRS180) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.2 [1.0, 1.46] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005176 | PGS000317 (PRS180) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.54 [0.47, 0.62] | R²: 0.05 | — | — |
| PPM000899 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.75 | — | age, family history of breast cancer, current smoking, BMI, alcohol use disorder, years of hormone replacement therapy, having given birth to one or more children, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM000894 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.737 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM001346 | PGS000332 (PRS_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | HR: 1.63 [1.6, 1.67] | — | — | 10 ancestry PCs, batch, age as time scale | — |
| PPM001348 | PGS000332 (PRS_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | OR: 1.71 [1.67, 1.75] | — | — | Age, 10 ancestry PCs, batch | — |
| PPM000889 | PGS000332 (PRS_BC) |
PSS000443| European Ancestry| 76,173 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Breast cancer (incident and prevalent cases) | HR: 1.64 [1.6, 1.69] | — | — | genotyping array/batch, 10 ancestry PCs | — |
| PPM000900 | PGS000333 (PRS_PC) |
PSS000447| European Ancestry| 48,851 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident prostate cancer | — | C-index: 0.866 | — | age, family history, history of benign prostate hyperplasia, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM000895 | PGS000333 (PRS_PC) |
PSS000447| European Ancestry| 48,851 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident prostate cancer | — | C-index: 0.857 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM000890 | PGS000333 (PRS_PC) |
PSS000446| European Ancestry| 59,126 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Prostate cancer (incident and prevalent cases) | HR: 1.83 [1.78, 1.9] | — | — | genotyping array/batch, 10 ancestry PCs | — |
| PPM014914 | PGS000333 (PRS_PC) |
PSS009926| Multi-ancestry (including European)| 91,106 individuals |
PGP000356 | Varma A et al. Cancer Med (2022) |Ext. |
Reported Trait: Prostate cancer | — | AUROC: 0.788 [0.758, 0.819] | — | Age, father's history, body mass index (BMI), smoking status, glycated hemoglobin, C-reactive protein, insulin-like growth factor 1, number of sex partners, diabetes diagnosis, and diabetes medication | — |
| PPM000903 | PGS000335 (BC_PRSCS) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.8 [1.76, 1.84] | — | — | Age, 10 ancestry PCs, batch | — |
| PPM000902 | PGS000335 (BC_PRSCS) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |
Reported Trait: Breast cancer | HR: 1.71 [1.68, 1.75] | — | — | 10 ancestry PCs, batch, age as time scale | — |
| PPM000922 | PGS000339 (PRS22_CM) |
PSS000464| European Ancestry| 1,885 individuals |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; unaffected melanoma family members vs. unrelated controls): 0.347 (0.104) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
| PPM000921 | PGS000339 (PRS22_CM) |
PSS000463| European Ancestry| 3,066 individuals |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; melanoma family cases vs. unrelated controls): 0.505 (0.036) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
| PPM000979 | PGS000344 (PRS287_BC) |
PSS000497| Additional Asian Ancestries| 2,719 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.36 [1.25, 1.49] | AUROC: 0.577 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000976 | PGS000344 (PRS287_BC) |
PSS000494| Multi-ancestry (excluding European)| 14,406 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.55 [1.5, 1.61] | — | — | PCs (1-10), study, array,batch | — |
| PPM000973 | PGS000344 (PRS287_BC) |
PSS000491| Additional Asian Ancestries| 32,238 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.52 [1.49, 1.56] | AUROC: 0.613 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000983 | PGS000345 (PRS229_BC) |
PSS000491| Additional Asian Ancestries| 32,238 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.49 [1.45, 1.52] | AUROC: 0.611 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000982 | PGS000345 (PRS229_BC) |
PSS000500| East Asian Ancestry| 10,255 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | HR: 1.49 [1.33, 1.67] | C-index: 0.61 | — | PCs (1-7), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000984 | PGS000345 (PRS229_BC) |
PSS000497| Additional Asian Ancestries| 2,719 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.33 [1.22, 1.45] | AUROC: 0.579 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000981 | PGS000346 (PRS287_ERneg) |
PSS000498| Additional Asian Ancestries| 1,492 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.49 [1.26, 1.75] | AUROC: 0.587 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000978 | PGS000346 (PRS287_ERneg) |
PSS000495| Multi-ancestry (excluding European)| 9,391 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.43 [1.35, 1.52] | — | — | PCs (1-10), study, array,batch | — |
| PPM000975 | PGS000346 (PRS287_ERneg) |
PSS000493| Additional Asian Ancestries| 21,247 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.41 [1.36, 1.46] | AUROC: 0.594 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000980 | PGS000347 (PRS287_ERpos) |
PSS000499| Additional Asian Ancestries| 2,234 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.38 [1.25, 1.53] | AUROC: 0.586 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000977 | PGS000347 (PRS287_ERpos) |
PSS000496| Multi-ancestry (excluding European)| 12,222 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.59 [1.53, 1.66] | — | — | PCs (1-10), study, array,batch | — |
| PPM000974 | PGS000347 (PRS287_ERpos) |
PSS000492| Additional Asian Ancestries| 26,960 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.62 [1.57, 1.67] | AUROC: 0.627 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
| PPM000987 | PGS000348 (PRS_PrCa) |
PSS000502| European Ancestry| 1,039 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | OR: 1.9 [1.53, 2.4] | — | — | Age | — |
| PPM000986 | PGS000348 (PRS_PrCa) |
PSS000501| European Ancestry| 3,891 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer | — | AUROC: 0.64 | — | Age | — |
| PPM000985 | PGS000348 (PRS_PrCa) |
PSS000501| European Ancestry| 3,891 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer | OR: 1.72 [1.59, 1.88] | AUROC: 0.64 [0.62, 0.66] | — | — | — |
| PPM000988 | PGS000348 (PRS_PrCa) |
PSS000503| European Ancestry| 2,305 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer in men with no family history of prostate cancer | OR: 1.65 [1.49, 1.84] | — | — | Age | — |
| PPM001030 | PGS000351 (PRS_EOC) |
PSS000524| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Reported Trait: Ovarian cancer in BRCA1 carriers | HR: 1.31 [1.24, 1.39] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001031 | PGS000351 (PRS_EOC) |
PSS000528| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Reported Trait: Ovarian cancer in BRCA2 carriers | HR: 1.42 [1.28, 1.58] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001032 | PGS000352 (PRS_HGS) |
PSS000524| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Reported Trait: Ovarian cancer in BRCA1 carriers | HR: 1.32 [1.25, 1.4] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001033 | PGS000352 (PRS_HGS) |
PSS000528| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Reported Trait: Ovarian cancer in BRCA2 carriers | HR: 1.43 [1.29, 1.59] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
| PPM001036 | PGS000352 (PRS_HGS) |
PSS000530| European Ancestry| 3,152 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Reported Trait: Incident ovarian cancer in BRCA1 carriers | HR: 1.28 [1.06, 1.55] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
| PPM001037 | PGS000352 (PRS_HGS) |
PSS000532| European Ancestry| 2,495 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |
Reported Trait: Incident ovarian cancer in BRCA2 carriers | HR: 1.45 [1.13, 1.86] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
| PPM001038 | PGS000353 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_P_5e-08_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.08 [1.041, 1.122] β: 0.0774 (0.0191) |
AUROC: 0.515 [0.503, 0.526] | Nagelkerke's Pseudo-R²: 0.00151 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.48 [1.04, 2.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_P_5e-08_MGI_20200608 |
| PPM001039 | PGS000354 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PRS-CS_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.079 [1.039, 1.119] β: 0.0758 (0.0189) |
AUROC: 0.521 [0.51, 0.532] | Nagelkerke's Pseudo-R²: 0.00112 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.27 [0.887, 1.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PRS-CS_MGI_20200608 |
| PPM001040 | PGS000355 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PT_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.084 [1.044, 1.125] β: 0.0803 (0.0191) |
AUROC: 0.517 [0.506, 0.527] | Nagelkerke's Pseudo-R²: 0.00167 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.42 [1.0, 2.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PT_MGI_20200608 |
| PPM001041 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.106 [1.065, 1.148] β: 0.101 (0.0192) |
AUROC: 0.523 [0.512, 0.535] | Nagelkerke's Pseudo-R²: 0.00294 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.61 [1.14, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608 |
| PPM021339 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011694| European Ancestry| 4,322 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in nonirridated childhood cancer survivors | HR: 1.28 [1.13, 1.45] | — | — | Sex, age at diagnosis, 5 PCs, study cohort, treatment, and doses of alkylating agents, anthracyclines, epipodophyllotoxins, and platinums | — |
| PPM021337 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011696| European Ancestry| 9,895 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in childhood cancer survivors | HR: 1.11 [1.05, 1.17] | — | — | Sex, age at diagnosis, 5 PCs, radiation therapy and chemotherapy dosages, cohort/batch effects | — |
| PPM021338 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011695| African Ancestry| 718 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in childhood cancer survivors | HR: 1.01 [0.66, 1.55] | — | — | Sex, age at diagnosis, 5 PCs, radiation therapy and chemotherapy dosages, cohort/batch effects | — |
| PPM021340 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011693| African Ancestry| 414 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in nonirridated childhood cancer survivors | HR: 0.86 [0.35, 2.13] | — | — | Sex, age at diagnosis, 5 PCs, study cohort, treatment, and doses of alkylating agents, anthracyclines, epipodophyllotoxins, and platinums | — |
| PPM001042 | PGS000357 (PRSWEB_PHECODE145_C3-LIP-ORAL-PHARYNX_PT_MGI_20200608) |
PSS000535| European Ancestry| 6,328 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of mouth | OR: 1.111 [1.021, 1.208] β: 0.105 (0.0427) |
AUROC: 0.519 [0.498, 0.542] | Nagelkerke's Pseudo-R²: 0.0021 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.26 [0.585, 2.73] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE145_C3-LIP-ORAL-PHARYNX_PT_MGI_20200608 |
| PPM001043 | PGS000358 (PRSWEB_PHECODE145_UKBB-SAIGE-HRC-X145_PRS-CS_MGI_20200608) |
PSS000535| European Ancestry| 6,328 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of mouth | OR: 1.116 [1.024, 1.216] β: 0.11 (0.0438) |
AUROC: 0.528 [0.502, 0.552] | Nagelkerke's Pseudo-R²: 0.00207 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.63 [0.812, 3.26] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE145_UKBB-SAIGE-HRC-X145_PRS-CS_MGI_20200608 |
| PPM001045 | PGS000360 (PRSWEB_PHECODE149.4_C32_LASSOSUM_MGI_20200608) |
PSS000536| European Ancestry| 1,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of larynx | OR: 1.282 [1.09, 1.508] β: 0.249 (0.0827) |
AUROC: 0.57 [0.522, 0.618] | Nagelkerke's Pseudo-R²: 0.0112 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.14 [0.649, 7.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE149.4_C32_LASSOSUM_MGI_20200608 |
| PPM001046 | PGS000361 (PRSWEB_PHECODE149.4_C3-LARYNX_LASSOSUM_MGI_20200608) |
PSS000536| European Ancestry| 1,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of larynx | OR: 1.195 [1.014, 1.408] β: 0.178 (0.0836) |
AUROC: 0.55 [0.504, 0.593] | Nagelkerke's Pseudo-R²: 0.00551 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.51 [0.382, 5.94] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE149.4_C3-LARYNX_LASSOSUM_MGI_20200608 |
| PPM001047 | PGS000362 (PRSWEB_PHECODE149.4_UKBB-SAIGE-HRC-X149.4_PT_MGI_20200608) |
PSS000536| European Ancestry| 1,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of larynx | OR: 1.195 [1.023, 1.396] β: 0.178 (0.0793) |
AUROC: 0.543 [0.494, 0.59] | Nagelkerke's Pseudo-R²: 0.00609 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.52 [0.384, 5.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE149.4_UKBB-SAIGE-HRC-X149.4_PT_MGI_20200608 |
| PPM001048 | PGS000363 (PRSWEB_PHECODE150_C15_PRS-CS_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.249 [1.075, 1.45] β: 0.222 (0.0762) |
AUROC: 0.564 [0.525, 0.604] | Nagelkerke's Pseudo-R²: 0.0089 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.84 [1.07, 7.54] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_C15_PRS-CS_MGI_20200608 |
| PPM001049 | PGS000364 (PRSWEB_PHECODE150_C15_LASSOSUM_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.203 [1.041, 1.391] β: 0.185 (0.074) |
AUROC: 0.551 [0.51, 0.588] | Nagelkerke's Pseudo-R²: 0.00648 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.81 [0.56, 5.82] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_C15_LASSOSUM_MGI_20200608 |
| PPM001050 | PGS000365 (PRSWEB_PHECODE150_C3-OESOPHAGUS_PRS-CS_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.187 [1.021, 1.38] β: 0.171 (0.0769) |
AUROC: 0.553 [0.514, 0.596] | Nagelkerke's Pseudo-R²: 0.00521 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.27 [0.329, 4.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_C3-OESOPHAGUS_PRS-CS_MGI_20200608 |
| PPM001051 | PGS000366 (PRSWEB_PHECODE150_UKBB-SAIGE-HRC-X150_PRS-CS_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.24 [1.067, 1.441] β: 0.215 (0.0766) |
AUROC: 0.564 [0.522, 0.605] | Nagelkerke's Pseudo-R²: 0.00839 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.28 [0.332, 4.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_UKBB-SAIGE-HRC-X150_PRS-CS_MGI_20200608 |
| PPM001052 | PGS000367 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.198 [1.102, 1.302] β: 0.181 (0.0425) |
AUROC: 0.55 [0.522, 0.574] | Nagelkerke's Pseudo-R²: 0.00586 Brier score: 0.0828 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.21, 4.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_MGI_20200608 |
| PPM001053 | PGS000368 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.516 [1.451, 1.585] β: 0.416 (0.0225) |
AUROC: 0.612 [0.6, 0.625] | Nagelkerke's Pseudo-R²: 0.0304 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.85 [2.99, 4.96] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_UKB_20200608 |
| PPM001054 | PGS000369 (PRSWEB_PHECODE153_CRC-Huyghe_PT_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.214 [1.117, 1.32] β: 0.194 (0.0426) |
AUROC: 0.553 [0.525, 0.577] | Nagelkerke's Pseudo-R²: 0.00671 Brier score: 0.0828 Odds Ratio (OR, top 1% vs. Rest): 3.04 [1.79, 5.17] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_PT_MGI_20200608 |
| PPM012887 | PGS000370 (PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608) |
PSS009593| Ancestry Not Reported| 9,666 individuals |
PGP000292 | Saad M et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Colorectal cancer | OR: 1.543 [1.411, 1.686] | AUROC: 0.621 [0.597, 0.645] | — | — | — |
| PPM001055 | PGS000370 (PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.547 [1.48, 1.617] β: 0.436 (0.0226) |
AUROC: 0.617 [0.605, 0.63] | Nagelkerke's Pseudo-R²: 0.0332 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 4.0 [3.11, 5.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608 |
| PPM001056 | PGS000371 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_P_5e-08_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.254 [1.202, 1.309] β: 0.226 (0.0217) |
AUROC: 0.561 [0.548, 0.573] | Nagelkerke's Pseudo-R²: 0.00946 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_P_5e-08_UKB_20200608 |
| PPM001057 | PGS000372 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_PT_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.279 [1.225, 1.335] β: 0.246 (0.0218) |
AUROC: 0.565 [0.551, 0.577] | Nagelkerke's Pseudo-R²: 0.0111 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.1 [1.53, 2.89] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_PT_UKB_20200608 |
| PPM001058 | PGS000373 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PRS-CS_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.189 [1.093, 1.293] β: 0.173 (0.0428) |
AUROC: 0.548 [0.523, 0.572] | Nagelkerke's Pseudo-R²: 0.00529 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.71 [0.882, 3.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PRS-CS_MGI_20200608 |
| PPM001059 | PGS000374 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PT_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.091 [1.004, 1.185] β: 0.0872 (0.0423) |
AUROC: 0.517 [0.493, 0.541] | Nagelkerke's Pseudo-R²: 0.00134 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.88 [0.99, 3.55] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PT_MGI_20200608 |
| PPM001060 | PGS000375 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_LASSOSUM_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.113 [1.024, 1.21] β: 0.107 (0.0425) |
AUROC: 0.53 [0.503, 0.555] | Nagelkerke's Pseudo-R²: 0.00205 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 2.76 [1.59, 4.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_LASSOSUM_MGI_20200608 |
| PPM001061 | PGS000376 (PRSWEB_PHECODE153.2_C18_PRS-CS_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.177 [1.069, 1.297] β: 0.163 (0.0491) |
AUROC: 0.547 [0.518, 0.576] | Nagelkerke's Pseudo-R²: 0.0046 Brier score: 0.0832 Odds Ratio (OR, top 1% vs. Rest): 1.65 [0.753, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C18_PRS-CS_MGI_20200608 |
| PPM001062 | PGS000377 (PRSWEB_PHECODE153.2_C18_LASSOSUM_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.174 [1.066, 1.292] β: 0.16 (0.049) |
AUROC: 0.545 [0.518, 0.574] | Nagelkerke's Pseudo-R²: 0.00441 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.4 [0.607, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C18_LASSOSUM_MGI_20200608 |
| PPM001063 | PGS000378 (PRSWEB_PHECODE153.2_C3-COLON_PRS-CS_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.141 [1.038, 1.254] β: 0.132 (0.0484) |
AUROC: 0.536 [0.509, 0.565] | Nagelkerke's Pseudo-R²: 0.00301 Brier score: 0.0832 Odds Ratio (OR, top 1% vs. Rest): 1.82 [0.867, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C3-COLON_PRS-CS_MGI_20200608 |
| PPM001064 | PGS000379 (PRSWEB_PHECODE153.2_C3-COLON_LASSOSUM_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.143 [1.038, 1.258] β: 0.134 (0.049) |
AUROC: 0.536 [0.51, 0.567] | Nagelkerke's Pseudo-R²: 0.00302 Brier score: 0.0832 Odds Ratio (OR, top 1% vs. Rest): 0.757 [0.252, 2.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C3-COLON_LASSOSUM_MGI_20200608 |
| PPM001065 | PGS000380 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PRS-CS_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.324 [1.203, 1.457] β: 0.281 (0.0489) |
AUROC: 0.569 [0.539, 0.599] | Nagelkerke's Pseudo-R²: 0.0138 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 3.85 [2.19, 6.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PRS-CS_MGI_20200608 |
| PPM001066 | PGS000381 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PT_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.212 [1.105, 1.33] β: 0.193 (0.0472) |
AUROC: 0.55 [0.522, 0.577] | Nagelkerke's Pseudo-R²: 0.00703 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.6 [0.733, 3.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PT_MGI_20200608 |
| PPM001067 | PGS000382 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_LASSOSUM_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.247 [1.134, 1.371] β: 0.221 (0.0483) |
AUROC: 0.567 [0.54, 0.594] | Nagelkerke's Pseudo-R²: 0.00899 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.17 [0.477, 2.87] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_LASSOSUM_MGI_20200608 |
| PPM001068 | PGS000383 (PRSWEB_PHECODE153.3_C19_PRS-CS_MGI_20200608) |
PSS000539| European Ancestry| 3,557 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of rectum, rectosigmoid junction, and anus | OR: 1.126 [1.005, 1.262] β: 0.119 (0.0579) |
AUROC: 0.533 [0.5, 0.567] | Nagelkerke's Pseudo-R²: 0.00257 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.34 [0.491, 3.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.3_C19_PRS-CS_MGI_20200608 |
| PPM001069 | PGS000384 (PRSWEB_PHECODE153.3_C3-RECTUM_PRS-CS_MGI_20200608) |
PSS000539| European Ancestry| 3,557 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of rectum, rectosigmoid junction, and anus | OR: 1.122 [1.001, 1.257] β: 0.115 (0.058) |
AUROC: 0.531 [0.495, 0.563] | Nagelkerke's Pseudo-R²: 0.00251 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.02 [0.334, 3.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.3_C3-RECTUM_PRS-CS_MGI_20200608 |
| PPM001070 | PGS000385 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_P_5e-08_UKB_20200608) |
PSS000565| European Ancestry| 3,591 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Pancreatic cancer | OR: 1.384 [1.235, 1.552] β: 0.325 (0.0583) |
AUROC: 0.589 [0.559, 0.622] | Nagelkerke's Pseudo-R²: 0.019 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.58 [1.19, 5.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_P_5e-08_UKB_20200608 |
| PPM001071 | PGS000386 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_PT_UKB_20200608) |
PSS000565| European Ancestry| 3,591 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Pancreatic cancer | OR: 1.342 [1.199, 1.503] β: 0.294 (0.0577) |
AUROC: 0.579 [0.548, 0.611] | Nagelkerke's Pseudo-R²: 0.0157 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.64 [0.655, 4.12] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_PT_UKB_20200608 |
| PPM001072 | PGS000387 (PRSWEB_PHECODE165_UKBB-SAIGE-HRC-X165_LASSOSUM_MGI_20200608) |
PSS000542| European Ancestry| 5,218 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer within the respiratory system | OR: 1.109 [1.008, 1.22] β: 0.103 (0.0486) |
AUROC: 0.53 [0.502, 0.557] | Nagelkerke's Pseudo-R²: 0.0018 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.12, 4.37] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165_UKBB-SAIGE-HRC-X165_LASSOSUM_MGI_20200608 |
| PPM001073 | PGS000388 (PRSWEB_PHECODE165.1_C3-BRONCHUS-LUNG_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.132 [1.024, 1.25] β: 0.124 (0.0508) |
AUROC: 0.533 [0.505, 0.562] | Nagelkerke's Pseudo-R²: 0.00265 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.96 [0.926, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_C3-BRONCHUS-LUNG_PRS-CS_MGI_20200608 |
| PPM001074 | PGS000389 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.11 [1.006, 1.225] β: 0.105 (0.0501) |
AUROC: 0.52 [0.492, 0.547] | Nagelkerke's Pseudo-R²: 0.00202 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.19 [1.07, 4.49] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_MGI_20200608 |
| PPM001075 | PGS000390 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_UKB_20200608) |
PSS000566| European Ancestry| 12,201 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.194 [1.124, 1.269] β: 0.178 (0.0309) |
AUROC: 0.543 [0.526, 0.562] | Nagelkerke's Pseudo-R²: 0.00583 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 0.852 [0.437, 1.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_UKB_20200608 |
| PPM001076 | PGS000391 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.12 [1.015, 1.237] β: 0.114 (0.0507) |
AUROC: 0.529 [0.503, 0.558] | Nagelkerke's Pseudo-R²: 0.00234 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.75 [0.796, 3.85] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608 |
| PPM020287 | PGS000391 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.731 [0.703, 0.759] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM001077 | PGS000392 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608) |
PSS000566| European Ancestry| 12,201 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.221 [1.149, 1.298] β: 0.2 (0.0313) |
AUROC: 0.552 [0.534, 0.569] | Nagelkerke's Pseudo-R²: 0.00728 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.22, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608 |
| PPM020288 | PGS000392 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.733 [0.705, 0.761] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM001078 | PGS000393 (PRSWEB_PHECODE165.1_LUNG-CANCER_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.149 [1.04, 1.269] β: 0.139 (0.0509) |
AUROC: 0.539 [0.508, 0.568] | Nagelkerke's Pseudo-R²: 0.00329 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.18 [1.06, 4.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_LUNG-CANCER_PRS-CS_MGI_20200608 |
| PPM001079 | PGS000394 (PRSWEB_PHECODE165.1_LUNG-CANCER-MESOT_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.149 [1.04, 1.269] β: 0.139 (0.0509) |
AUROC: 0.539 [0.508, 0.568] | Nagelkerke's Pseudo-R²: 0.00329 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.18 [1.06, 4.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_LUNG-CANCER-MESOT_PRS-CS_MGI_20200608 |
| PPM001080 | PGS000395 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.133 [1.025, 1.252] β: 0.125 (0.051) |
AUROC: 0.533 [0.505, 0.562] | Nagelkerke's Pseudo-R²: 0.00277 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.27 [0.514, 3.12] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PRS-CS_MGI_20200608 |
| PPM001081 | PGS000396 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PT_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.121 [1.015, 1.238] β: 0.114 (0.0507) |
AUROC: 0.525 [0.496, 0.554] | Nagelkerke's Pseudo-R²: 0.00233 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.08, 4.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PT_MGI_20200608 |
| PPM001082 | PGS000397 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_LASSOSUM_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.114 [1.009, 1.23] β: 0.108 (0.0507) |
AUROC: 0.528 [0.503, 0.556] | Nagelkerke's Pseudo-R²: 0.00202 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.03 [0.387, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_LASSOSUM_MGI_20200608 |
| PPM001083 | PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.042 [1.003, 1.082] β: 0.0407 (0.0195) |
AUROC: 0.51 [0.499, 0.521] | Nagelkerke's Pseudo-R²: 0.00028 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.7 [1.22, 2.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608 |
| PPM001084 | PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.158 [1.116, 1.202] β: 0.147 (0.0189) |
AUROC: 0.513 [0.503, 0.523] | Nagelkerke's Pseudo-R²: 0.00545 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.56 [1.12, 2.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608 |
| PPM001085 | PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.395] β: 0.294 (0.0197) |
AUROC: 0.581 [0.57, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.63, 2.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608 |
| PPM001086 | PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.396] β: 0.294 (0.0199) |
AUROC: 0.581 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.67, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608 |
| PPM001087 | PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.366 [1.314, 1.421] β: 0.312 (0.0198) |
AUROC: 0.586 [0.576, 0.597] | Nagelkerke's Pseudo-R²: 0.0224 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.23 [1.64, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608 |
| PPM001088 | PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.359 [1.307, 1.413] β: 0.307 (0.0199) |
AUROC: 0.584 [0.573, 0.594] | Nagelkerke's Pseudo-R²: 0.0219 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.2, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608 |
| PPM001089 | PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.369 [1.317, 1.422] β: 0.314 (0.0196) |
AUROC: 0.584 [0.574, 0.594] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.3 [1.72, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608 |
| PPM001090 | PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.338 [1.287, 1.391] β: 0.291 (0.0199) |
AUROC: 0.58 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0192 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.81, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608 |
| PPM001091 | PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.392 [1.339, 1.447] β: 0.331 (0.0199) |
AUROC: 0.591 [0.581, 0.602] | Nagelkerke's Pseudo-R²: 0.0249 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.89, 3.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608 |
| PPM001092 | PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.38 [1.328, 1.434] β: 0.322 (0.0197) |
AUROC: 0.586 [0.575, 0.597] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.26 [1.69, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608 |
| PPM001118 | PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.367 [1.31, 1.426] β: 0.312 (0.0215) |
AUROC: 0.584 [0.572, 0.598] | Nagelkerke's Pseudo-R²: 0.0215 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.73 [2.01, 3.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608 |
| PPM001119 | PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.304, 1.42] β: 0.308 (0.0217) |
AUROC: 0.586 [0.573, 0.598] | Nagelkerke's Pseudo-R²: 0.0208 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.43, 2.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608 |
| PPM001120 | PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.415] β: 0.305 (0.0215) |
AUROC: 0.584 [0.572, 0.597] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.99, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608 |
| PPM001121 | PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.305, 1.42] β: 0.308 (0.0216) |
AUROC: 0.584 [0.571, 0.596] | Nagelkerke's Pseudo-R²: 0.021 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.61, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608 |
| PPM001122 | PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.352 [1.296, 1.409] β: 0.301 (0.0213) |
AUROC: 0.579 [0.566, 0.592] | Nagelkerke's Pseudo-R²: 0.0206 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.6, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608 |
| PPM001123 | PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.31 [1.256, 1.367] β: 0.27 (0.0216) |
AUROC: 0.575 [0.562, 0.587] | Nagelkerke's Pseudo-R²: 0.0162 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608 |
| PPM001124 | PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.348 [1.293, 1.407] β: 0.299 (0.0216) |
AUROC: 0.583 [0.57, 0.595] | Nagelkerke's Pseudo-R²: 0.0197 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.57, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PT_MGI_20200608 |
| PPM001125 | PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.351 [1.296, 1.409] β: 0.301 (0.0215) |
AUROC: 0.581 [0.569, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.87, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608 |
| PPM001126 | PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.39 [1.333, 1.449] β: 0.329 (0.0214) |
AUROC: 0.586 [0.574, 0.599] | Nagelkerke's Pseudo-R²: 0.0241 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.94, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608 |
| PPM001127 | PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.417] β: 0.306 (0.0217) |
AUROC: 0.584 [0.572, 0.595] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.71, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608 |
| PPM001128 | PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.41 [1.352, 1.471] β: 0.344 (0.0216) |
AUROC: 0.591 [0.579, 0.603] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.89 [2.14, 3.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608 |
| PPM001129 | PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.399 [1.341, 1.46] β: 0.336 (0.0216) |
AUROC: 0.59 [0.578, 0.601] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.5 [2.63, 4.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608 |
| PPM001130 | PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.334 [1.264, 1.409] β: 0.289 (0.0278) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0184 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.72, 3.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608 |
| PPM001131 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.291 [1.221, 1.366] β: 0.256 (0.0286) |
AUROC: 0.575 [0.559, 0.591] | Nagelkerke's Pseudo-R²: 0.0139 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.871, 2.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608 |
| PPM018452 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Skin colour | β: -0.02375 | — | R²: 0.01374 | — | — |
| PPM018453 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: 0.04205 | — | R²: 0.02091 | — | — |
| PPM018454 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease suntan | β: -0.0266 | — | R²: 0.01362 | — | — |
| PPM018455 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease sunburn | β: 0.04289 | — | R²: 0.01118 | — | — |
| PPM018456 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: -0.62656 | — | R²: 0.03377 | — | — |
| PPM018457 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: -0.02673 | — | R²: 0.0294 | — | — |
| PPM018458 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Red hair | β: 1.77173 | — | R²: 0.05421 pseudo R²: 0.05421 |
— | — |
| PPM001132 | PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.398 [1.322, 1.477] β: 0.335 (0.0282) |
AUROC: 0.591 [0.575, 0.607] | Nagelkerke's Pseudo-R²: 0.0237 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.5 [1.68, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608 |
| PPM001133 | PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.411 [1.335, 1.491] β: 0.344 (0.0282) |
AUROC: 0.587 [0.57, 0.604] | Nagelkerke's Pseudo-R²: 0.0254 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.03, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608 |
| PPM001134 | PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.093 [1.034, 1.155] β: 0.0888 (0.0282) |
AUROC: 0.525 [0.509, 0.54] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.04, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608 |
| PPM001135 | PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.079 [1.022, 1.139] β: 0.0759 (0.0278) |
AUROC: 0.504 [0.489, 0.52] | Nagelkerke's Pseudo-R²: 0.00145 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.882, 2.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608 |
| PPM001136 | PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.144 [1.084, 1.208] β: 0.135 (0.0278) |
AUROC: 0.521 [0.506, 0.536] | Nagelkerke's Pseudo-R²: 0.00396 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.65, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608 |
| PPM001137 | PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.663 [1.57, 1.761] β: 0.508 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.53, 5.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608 |
| PPM001138 | PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608 |
| PPM001139 | PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.661 [1.568, 1.759] β: 0.507 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0489 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.79 [2.68, 5.35] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608 |
| PPM001140 | PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608 |
| PPM001141 | PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.633 [1.541, 1.729] β: 0.49 (0.0293) |
AUROC: 0.63 [0.615, 0.646] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.95 [2.79, 5.58] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608 |
| PPM001142 | PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.535 [1.493, 1.579] β: 0.429 (0.0144) |
AUROC: 0.617 [0.609, 0.625] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.11 [2.6, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608 |
| PPM001143 | PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.634 [1.542, 1.732] β: 0.491 (0.0296) |
AUROC: 0.628 [0.612, 0.644] | Nagelkerke's Pseudo-R²: 0.0457 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.86, 5.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608 |
| PPM001144 | PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.528 [1.485, 1.572] β: 0.424 (0.0144) |
AUROC: 0.615 [0.608, 0.623] | Nagelkerke's Pseudo-R²: 0.0314 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.05 [2.55, 3.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608 |
| PPM001145 | PGS000460 (PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.096 [1.025, 1.172] β: 0.0917 (0.0344) |
AUROC: 0.523 [0.503, 0.543] | Nagelkerke's Pseudo-R²: 0.00155 Brier score: 0.0996 Odds Ratio (OR, top 1% vs. Rest): 1.56 [0.892, 2.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608 |
| PPM001146 | PGS000461 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.491 [1.395, 1.593] β: 0.4 (0.0338) |
AUROC: 0.599 [0.579, 0.618] | Nagelkerke's Pseudo-R²: 0.0304 Brier score: 0.0974 Odds Ratio (OR, top 1% vs. Rest): 3.51 [2.29, 5.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608 |
| PPM001147 | PGS000462 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.324 [1.288, 1.361] β: 0.28 (0.014) |
AUROC: 0.573 [0.564, 0.58] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.13 [1.74, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608 |
| PPM001148 | PGS000463 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.448 [1.356, 1.546] β: 0.37 (0.0335) |
AUROC: 0.593 [0.573, 0.613] | Nagelkerke's Pseudo-R²: 0.0268 Brier score: 0.0977 Odds Ratio (OR, top 1% vs. Rest): 3.74 [2.46, 5.68] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608 |
| PPM001149 | PGS000464 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.332 [1.296, 1.369] β: 0.287 (0.014) |
AUROC: 0.575 [0.567, 0.582] | Nagelkerke's Pseudo-R²: 0.0147 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.19 [1.79, 2.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608 |
| PPM001150 | PGS000465 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.457 [1.365, 1.554] β: 0.376 (0.033) |
AUROC: 0.589 [0.57, 0.61] | Nagelkerke's Pseudo-R²: 0.0282 Brier score: 0.0976 Odds Ratio (OR, top 1% vs. Rest): 4.54 [3.07, 6.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608 |
| PPM001151 | PGS000466 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | β: 0.283 (0.0138) OR: 1.327 [1.292, 1.364] |
AUROC: 0.57 [0.562, 0.578] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 1.75 [1.4, 2.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608 |
| PPM001152 | PGS000467 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.43 [1.341, 1.525] β: 0.358 (0.0328) |
AUROC: 0.583 [0.564, 0.603] | Nagelkerke's Pseudo-R²: 0.0261 Brier score: 0.0978 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.49, 5.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608 |
| PPM001153 | PGS000468 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.334 [1.299, 1.371] β: 0.288 (0.0138) |
AUROC: 0.571 [0.563, 0.579] | Nagelkerke's Pseudo-R²: 0.0151 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 1.93 [1.56, 2.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608 |
| PPM001154 | PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.09 [1.001, 1.188] β: 0.0865 (0.0437) |
AUROC: 0.524 [0.499, 0.549] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.0939 Odds Ratio (OR, top 1% vs. Rest): 1.48 [0.703, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608 |
| PPM001155 | PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.308 [1.208, 1.417] β: 0.269 (0.0407) |
AUROC: 0.557 [0.531, 0.582] | Nagelkerke's Pseudo-R²: 0.0154 Brier score: 0.093 Odds Ratio (OR, top 1% vs. Rest): 2.45 [1.34, 4.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608 |
| PPM001156 | PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.401 [1.297, 1.513] β: 0.337 (0.0393) |
AUROC: 0.569 [0.541, 0.595] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0923 Odds Ratio (OR, top 1% vs. Rest): 3.77 [2.24, 6.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608 |
| PPM001157 | PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.343 [1.266, 1.426] β: 0.295 (0.0303) |
AUROC: 0.579 [0.561, 0.597] | Nagelkerke's Pseudo-R²: 0.0204 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.49, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608 |
| PPM001158 | PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.315 [1.238, 1.398] β: 0.274 (0.0311) |
AUROC: 0.576 [0.56, 0.592] | Nagelkerke's Pseudo-R²: 0.0167 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.6 [0.981, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608 |
| PPM001159 | PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.26, 1.422] β: 0.291 (0.0308) |
AUROC: 0.58 [0.563, 0.597] | Nagelkerke's Pseudo-R²: 0.0188 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.54 [0.924, 2.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608 |
| PPM001160 | PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.349 [1.269, 1.434] β: 0.299 (0.0312) |
AUROC: 0.586 [0.57, 0.603] | Nagelkerke's Pseudo-R²: 0.0196 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.59 [0.962, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608 |
| PPM001161 | PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.365 [1.286, 1.45] β: 0.311 (0.0305) |
AUROC: 0.585 [0.569, 0.603] | Nagelkerke's Pseudo-R²: 0.0218 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.97 [1.24, 3.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608 |
| PPM001162 | PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.259, 1.421] β: 0.291 (0.0308) |
AUROC: 0.581 [0.564, 0.597] | Nagelkerke's Pseudo-R²: 0.0193 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.38, 3.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608 |
| PPM001163 | PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.411 [1.328, 1.5] β: 0.344 (0.031) |
AUROC: 0.595 [0.578, 0.611] | Nagelkerke's Pseudo-R²: 0.0257 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.31 [1.47, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608 |
| PPM001164 | PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.438 [1.354, 1.528] β: 0.364 (0.0308) |
AUROC: 0.6 [0.584, 0.616] | Nagelkerke's Pseudo-R²: 0.03 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.37 [1.54, 3.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608 |
| PPM001165 | PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.253, 1.412] β: 0.285 (0.0304) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0186 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.91 [1.2, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608 |
| PPM001166 | PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.246, 1.406] β: 0.28 (0.0307) |
AUROC: 0.578 [0.56, 0.596] | Nagelkerke's Pseudo-R²: 0.0183 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.29, 3.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608 |
| PPM001167 | PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.358 [1.279, 1.442] β: 0.306 (0.0306) |
AUROC: 0.584 [0.568, 0.601] | Nagelkerke's Pseudo-R²: 0.0212 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.43 [0.853, 2.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PT_MGI_20200608 |
| PPM001168 | PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.404 [1.322, 1.491] β: 0.339 (0.0308) |
AUROC: 0.595 [0.579, 0.61] | Nagelkerke's Pseudo-R²: 0.0264 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.05 [1.3, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608 |
| PPM001169 | PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.12 [1.056, 1.187] β: 0.113 (0.0297) |
AUROC: 0.52 [0.504, 0.538] | Nagelkerke's Pseudo-R²: 0.00286 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.817, 2.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_D05_PT_MGI_20200608 |
| PPM001170 | PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608 |
| PPM001171 | PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.4 [1.363, 1.437] β: 0.336 (0.0134) |
AUROC: 0.592 [0.585, 0.6] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.58 [2.16, 3.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608 |
| PPM001172 | PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608 |
| PPM001173 | PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.426 [1.389, 1.464] β: 0.355 (0.0134) |
AUROC: 0.598 [0.59, 0.605] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608 |
| PPM001174 | PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.254 [1.181, 1.33] β: 0.226 (0.0304) |
AUROC: 0.564 [0.547, 0.58] | Nagelkerke's Pseudo-R²: 0.012 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.05, 2.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
| PPM001175 | PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | β: 0.221 (0.0132) OR: 1.248 [1.216, 1.28] |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
| PPM001176 | PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.326 [1.246, 1.411] β: 0.282 (0.0317) |
AUROC: 0.578 [0.56, 0.594] | Nagelkerke's Pseudo-R²: 0.0179 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.13, 2.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
| PPM001177 | PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.296, 1.366] β: 0.286 (0.0134) |
AUROC: 0.579 [0.572, 0.586] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.34 [1.95, 2.82] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
| PPM001178 | PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.31 [1.234, 1.391] β: 0.27 (0.0306) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0173 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.84 [1.14, 2.97] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
| PPM001179 | PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.248 [1.216, 1.28] β: 0.221 (0.0132) |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
| PPM001180 | PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.297 [1.221, 1.377] β: 0.26 (0.0307) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0152 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.87 [1.16, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
| PPM001181 | PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.289, 1.358] β: 0.28 (0.0133) |
AUROC: 0.576 [0.568, 0.583] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.86, 2.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
| PPM001182 | PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.521 [1.43, 1.619] β: 0.42 (0.0316) |
AUROC: 0.614 [0.599, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.51, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
| PPM001183 | PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.553] β: 0.414 (0.0133) |
AUROC: 0.613 [0.606, 0.621] | Nagelkerke's Pseudo-R²: 0.0311 Brier score: 0.0815 Odds Ratio (OR, top 1% vs. Rest): 2.71 [2.28, 3.23] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
| PPM001184 | PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.708 [1.601, 1.822] β: 0.535 (0.033) |
AUROC: 0.643 [0.627, 0.658] | Nagelkerke's Pseudo-R²: 0.0603 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 3.71 [2.52, 5.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
| PPM001185 | PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.674 [1.63, 1.719] β: 0.515 (0.0137) |
AUROC: 0.64 [0.634, 0.647] | Nagelkerke's Pseudo-R²: 0.0463 Brier score: 0.0809 Odds Ratio (OR, top 1% vs. Rest): 3.64 [3.12, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
| PPM001186 | PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.564 [1.469, 1.665] β: 0.447 (0.0318) |
AUROC: 0.621 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0438 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.77, 4.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
| PPM001187 | PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.555 [1.514, 1.596] β: 0.441 (0.0135) |
AUROC: 0.621 [0.614, 0.628] | Nagelkerke's Pseudo-R²: 0.0347 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.36 [2.87, 3.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
| PPM001188 | PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.656 [1.554, 1.766] β: 0.505 (0.0326) |
AUROC: 0.634 [0.618, 0.65] | Nagelkerke's Pseudo-R²: 0.0546 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.78, 5.85] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
| PPM001189 | PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.621 [1.578, 1.665] β: 0.483 (0.0136) |
AUROC: 0.631 [0.624, 0.638] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.86 [3.31, 4.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
| PPM001190 | PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.584 [1.488, 1.686] β: 0.46 (0.0318) |
AUROC: 0.625 [0.609, 0.641] | Nagelkerke's Pseudo-R²: 0.0462 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.24, 4.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
| PPM001191 | PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.567 [1.526, 1.609] β: 0.449 (0.0134) |
AUROC: 0.622 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.0361 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.69 [3.16, 4.31] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
| PPM001192 | PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.772 [1.659, 1.891] β: 0.572 (0.0334) |
AUROC: 0.651 [0.635, 0.666] | Nagelkerke's Pseudo-R²: 0.0661 Brier score: 0.133 Odds Ratio (OR, top 1% vs. Rest): 3.22 [2.15, 4.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
| PPM001193 | PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.756 [1.709, 1.804] β: 0.563 (0.0138) |
AUROC: 0.652 [0.645, 0.658] | Nagelkerke's Pseudo-R²: 0.0548 Brier score: 0.0805 Odds Ratio (OR, top 1% vs. Rest): 4.38 [3.79, 5.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
| PPM001194 | PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.643 [1.542, 1.75] β: 0.496 (0.0323) |
AUROC: 0.635 [0.618, 0.651] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 2.84 [1.88, 4.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608 |
| PPM001195 | PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.612 [1.57, 1.656] β: 0.478 (0.0136) |
AUROC: 0.63 [0.623, 0.637] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.83, 3.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608 |
| PPM001196 | PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.7 [1.594, 1.813] β: 0.53 (0.0328) |
AUROC: 0.641 [0.625, 0.656] | Nagelkerke's Pseudo-R²: 0.0592 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 2.48 [1.63, 3.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
| PPM001197 | PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.699 [1.654, 1.746] β: 0.53 (0.0138) |
AUROC: 0.643 [0.637, 0.65] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.0807 Odds Ratio (OR, top 1% vs. Rest): 4.02 [3.46, 4.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
| PPM001198 | PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.402 [1.32, 1.489] β: 0.338 (0.0307) |
AUROC: 0.595 [0.577, 0.612] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.12, 2.91] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608 |
| PPM001199 | PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.391 [1.309, 1.478] β: 0.33 (0.031) |
AUROC: 0.59 [0.573, 0.607] | Nagelkerke's Pseudo-R²: 0.0248 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.12, 2.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608 |
| PPM001200 | PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.453 [1.367, 1.544] β: 0.374 (0.0311) |
AUROC: 0.605 [0.588, 0.621] | Nagelkerke's Pseudo-R²: 0.0307 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.31, 3.32] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608 |
| PPM001201 | PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.477 [1.39, 1.57] β: 0.39 (0.031) |
AUROC: 0.609 [0.592, 0.624] | Nagelkerke's Pseudo-R²: 0.034 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.21, 3.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608 |
| PPM001202 | PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.229 [1.157, 1.305] β: 0.206 (0.0306) |
AUROC: 0.55 [0.533, 0.566] | Nagelkerke's Pseudo-R²: 0.0097 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.17, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
| PPM001203 | PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.18 [1.15, 1.21] β: 0.165 (0.0131) |
AUROC: 0.542 [0.534, 0.55] | Nagelkerke's Pseudo-R²: 0.00504 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.49 [1.2, 1.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
| PPM001204 | PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.151 [1.084, 1.221] β: 0.14 (0.0305) |
AUROC: 0.539 [0.52, 0.556] | Nagelkerke's Pseudo-R²: 0.00453 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.51 [0.907, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
| PPM001205 | PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.188 [1.158, 1.22] β: 0.172 (0.0133) |
AUROC: 0.549 [0.542, 0.556] | Nagelkerke's Pseudo-R²: 0.00537 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.82 [1.48, 2.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
| PPM001206 | PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.22 [1.149, 1.295] β: 0.199 (0.0304) |
AUROC: 0.548 [0.53, 0.564] | Nagelkerke's Pseudo-R²: 0.00934 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.18, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
| PPM001207 | PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.201 [1.171, 1.233] β: 0.183 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.00619 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.73 [1.41, 2.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
| PPM001208 | PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.225 [1.155, 1.299] β: 0.203 (0.0301) |
AUROC: 0.546 [0.529, 0.562] | Nagelkerke's Pseudo-R²: 0.00979 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 2.11 [1.34, 3.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
| PPM001209 | PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.2 [1.169, 1.231] β: 0.182 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.0061 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.4, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
| PPM001210 | PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.427 [1.343, 1.516] β: 0.356 (0.0309) |
AUROC: 0.597 [0.58, 0.614] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.28 [1.46, 3.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
| PPM001211 | PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.424 [1.387, 1.461] β: 0.353 (0.0132) |
AUROC: 0.597 [0.59, 0.604] | Nagelkerke's Pseudo-R²: 0.0228 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.19] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
| PPM001212 | PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.509 [1.418, 1.605] β: 0.411 (0.0314) |
AUROC: 0.613 [0.595, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.55, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
| PPM001213 | PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.554] β: 0.414 (0.0136) |
AUROC: 0.614 [0.607, 0.62] | Nagelkerke's Pseudo-R²: 0.0303 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 2.98 [2.52, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
| PPM001214 | PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.43 [1.346, 1.52] β: 0.358 (0.0311) |
AUROC: 0.597 [0.58, 0.612] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.98 [1.98, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
| PPM001215 | PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.441 [1.404, 1.479] β: 0.365 (0.0132) |
AUROC: 0.6 [0.593, 0.608] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.92 [2.47, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
| PPM001216 | PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.501 [1.411, 1.596] β: 0.406 (0.0314) |
AUROC: 0.61 [0.594, 0.626] | Nagelkerke's Pseudo-R²: 0.037 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.29 [1.47, 3.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
| PPM001217 | PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.49 [1.451, 1.529] β: 0.399 (0.0134) |
AUROC: 0.608 [0.601, 0.615] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 3.0 [2.54, 3.54] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
| PPM001218 | PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.489 [1.401, 1.583] β: 0.398 (0.0312) |
AUROC: 0.607 [0.591, 0.623] | Nagelkerke's Pseudo-R²: 0.0354 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.63, 3.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
| PPM001219 | PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.443 [1.406, 1.481] β: 0.367 (0.0132) |
AUROC: 0.601 [0.594, 0.608] | Nagelkerke's Pseudo-R²: 0.0246 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.5 [2.09, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
| PPM001220 | PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.568 [1.473, 1.668] β: 0.45 (0.0317) |
AUROC: 0.622 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0443 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 3.43 [2.32, 5.05] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
| PPM001221 | PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.571 [1.53, 1.614] β: 0.452 (0.0136) |
AUROC: 0.623 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.036 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.54 [3.02, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
| PPM001222 | PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.498 [1.408, 1.593] β: 0.404 (0.0314) |
AUROC: 0.609 [0.592, 0.626] | Nagelkerke's Pseudo-R²: 0.0353 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.44 [2.31, 5.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608 |
| PPM001223 | PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.448 [1.411, 1.486] β: 0.37 (0.0132) |
AUROC: 0.602 [0.594, 0.609] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.78 [2.34, 3.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608 |
| PPM001224 | PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.585 [1.489, 1.687] β: 0.46 (0.0319) |
AUROC: 0.624 [0.607, 0.641] | Nagelkerke's Pseudo-R²: 0.0464 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.49 [1.61, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
| PPM001225 | PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.528 [1.489, 1.569] β: 0.424 (0.0134) |
AUROC: 0.615 [0.607, 0.622] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.55 [3.04, 4.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
| PPM001226 | PGS000541 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608) |
PSS000571| European Ancestry| 6,987 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of uterus | OR: 1.311 [1.209, 1.422] β: 0.271 (0.0415) |
AUROC: 0.576 [0.553, 0.6] | Nagelkerke's Pseudo-R²: 0.0133 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.12 [1.17, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608 |
| PPM001227 | PGS000542 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608) |
PSS000571| European Ancestry| 6,987 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of uterus | OR: 1.302 [1.2, 1.413] β: 0.264 (0.0416) |
AUROC: 0.572 [0.549, 0.596] | Nagelkerke's Pseudo-R²: 0.0126 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.6 [1.5, 4.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608 |
| PPM001250 | PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.434 [1.336, 1.54] β: 0.361 (0.0363) |
AUROC: 0.596 [0.579, 0.615] | Nagelkerke's Pseudo-R²: 0.0271 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.41, 4.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608 |
| PPM001251 | PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.393 [1.3, 1.493] β: 0.332 (0.0352) |
AUROC: 0.591 [0.573, 0.609] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.152 Odds Ratio (OR, top 1% vs. Rest): 2.85 [1.76, 4.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608 |
| PPM001252 | PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.505 [1.404, 1.613] β: 0.409 (0.0354) |
AUROC: 0.608 [0.59, 0.628] | Nagelkerke's Pseudo-R²: 0.0379 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 3.17 [1.98, 5.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608 |
| PPM001253 | PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.426 [1.332, 1.527] β: 0.355 (0.035) |
AUROC: 0.595 [0.577, 0.614] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.88, 2.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608 |
| PPM001254 | PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.643 [1.531, 1.763] β: 0.496 (0.036) |
AUROC: 0.63 [0.613, 0.648] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.86 [1.79, 4.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608 |
| PPM001255 | PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.572 [1.465, 1.687] β: 0.452 (0.0359) |
AUROC: 0.622 [0.604, 0.639] | Nagelkerke's Pseudo-R²: 0.0453 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.63, 4.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608 |
| PPM001256 | PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.67 [1.555, 1.793] β: 0.513 (0.0363) |
AUROC: 0.634 [0.617, 0.653] | Nagelkerke's Pseudo-R²: 0.0583 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.96 [1.85, 4.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608 |
| PPM001257 | PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.649] β: 0.43 (0.0358) |
AUROC: 0.616 [0.597, 0.636] | Nagelkerke's Pseudo-R²: 0.0418 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.59, 6.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608 |
| PPM001258 | PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.603 [1.495, 1.718] β: 0.472 (0.0355) |
AUROC: 0.622 [0.603, 0.641] | Nagelkerke's Pseudo-R²: 0.0497 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.83, 4.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608 |
| PPM001259 | PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.506 [1.406, 1.614] β: 0.41 (0.0352) |
AUROC: 0.612 [0.593, 0.63] | Nagelkerke's Pseudo-R²: 0.039 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.24, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608 |
| PPM001260 | PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.577 [1.47, 1.692] β: 0.456 (0.0359) |
AUROC: 0.619 [0.601, 0.637] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.1 [1.96, 4.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PT_MGI_20200608 |
| PPM001261 | PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.489 [1.39, 1.596] β: 0.398 (0.0353) |
AUROC: 0.607 [0.589, 0.627] | Nagelkerke's Pseudo-R²: 0.0358 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.46 [1.5, 4.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608 |
| PPM001262 | PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.756 [1.634, 1.886] β: 0.563 (0.0366) |
AUROC: 0.646 [0.627, 0.665] | Nagelkerke's Pseudo-R²: 0.0678 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.57 [2.29, 5.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608 |
| PPM001263 | PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.746 [1.681, 1.813] β: 0.557 (0.0192) |
AUROC: 0.653 [0.642, 0.662] | Nagelkerke's Pseudo-R²: 0.0565 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.31 [3.48, 5.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608 |
| PPM001264 | PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.747 [1.626, 1.876] β: 0.558 (0.0364) |
AUROC: 0.646 [0.627, 0.664] | Nagelkerke's Pseudo-R²: 0.0675 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.53 [2.26, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608 |
| PPM001265 | PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.748 [1.684, 1.815] β: 0.559 (0.0192) |
AUROC: 0.653 [0.643, 0.663] | Nagelkerke's Pseudo-R²: 0.0568 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.34 [3.51, 5.37] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608 |
| PPM001266 | PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.79 [1.665, 1.925] β: 0.582 (0.0371) |
AUROC: 0.651 [0.634, 0.669] | Nagelkerke's Pseudo-R²: 0.071 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 4.44 [2.87, 6.87] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608 |
| PPM001267 | PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.957 [1.882, 2.035] β: 0.671 (0.0201) |
AUROC: 0.681 [0.671, 0.692] | Nagelkerke's Pseudo-R²: 0.0776 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.85 [3.95, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608 |
| PPM001268 | PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.929 [1.79, 2.078] β: 0.657 (0.038) |
AUROC: 0.668 [0.651, 0.687] | Nagelkerke's Pseudo-R²: 0.0874 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.28, 5.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608 |
| PPM001269 | PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.173 [2.087, 2.263] β: 0.776 (0.0206) |
AUROC: 0.705 [0.695, 0.715] | Nagelkerke's Pseudo-R²: 0.1 Brier score: 0.0791 Odds Ratio (OR, top 1% vs. Rest): 5.58 [4.58, 6.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608 |
| PPM001270 | PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.907 [1.771, 2.053] β: 0.645 (0.0378) |
AUROC: 0.67 [0.652, 0.688] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.3 [2.06, 5.29] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608 |
| PPM001271 | PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.018 [1.94, 2.1] β: 0.702 (0.0203) |
AUROC: 0.687 [0.678, 0.698] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.0799 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.84, 7.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608 |
| PPM001272 | PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.906 [1.771, 2.051] β: 0.645 (0.0375) |
AUROC: 0.665 [0.647, 0.684] | Nagelkerke's Pseudo-R²: 0.0861 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 4.92 [3.21, 7.55] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608 |
| PPM001273 | PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.127 [2.043, 2.215] β: 0.755 (0.0206) |
AUROC: 0.699 [0.69, 0.71] | Nagelkerke's Pseudo-R²: 0.0943 Brier score: 0.0794 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.85, 7.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608 |
| PPM001274 | PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.63 [1.52, 1.748] β: 0.489 (0.0356) |
AUROC: 0.63 [0.612, 0.648] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 3.14 [1.99, 4.96] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608 |
| PPM001275 | PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.516 [1.415, 1.624] β: 0.416 (0.0353) |
AUROC: 0.614 [0.595, 0.633] | Nagelkerke's Pseudo-R²: 0.0395 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.42, 3.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608 |
| PPM001276 | PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.608 [1.498, 1.725] β: 0.475 (0.0359) |
AUROC: 0.627 [0.608, 0.645] | Nagelkerke's Pseudo-R²: 0.051 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.18 [2.01, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608 |
| PPM001277 | PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.648] β: 0.43 (0.0357) |
AUROC: 0.616 [0.598, 0.635] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.55, 4.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608 |
| PPM001278 | PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) |
PSS000554| European Ancestry| 1,490 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other male genital organs | OR: 1.193 [1.002, 1.419] β: 0.176 (0.0887) |
AUROC: 0.551 [0.5, 0.6] | Nagelkerke's Pseudo-R²: 0.00553 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.01 [0.177, 5.76] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608 |
| PPM001279 | PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) |
PSS000554| European Ancestry| 1,490 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other male genital organs | OR: 1.227 [1.029, 1.464] β: 0.205 (0.0899) |
AUROC: 0.558 [0.506, 0.606] | Nagelkerke's Pseudo-R²: 0.00729 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.04 [0.183, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608 |
| PPM001280 | PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.713 [1.33, 2.206] β: 0.538 (0.129) |
AUROC: 0.658 [0.594, 0.719] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.0838 Odds Ratio (OR, top 1% vs. Rest): 2.64 [0.535, 13.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608 |
| PPM001281 | PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.68 [1.28, 2.206] β: 0.519 (0.139) |
AUROC: 0.649 [0.586, 0.714] | Nagelkerke's Pseudo-R²: 0.0475 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.49 [0.816, 14.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608 |
| PPM001282 | PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.667 [1.296, 2.143] β: 0.511 (0.128) |
AUROC: 0.656 [0.593, 0.717] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 2.72 [0.568, 13.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608 |
| PPM001283 | PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.639 [1.263, 2.126] β: 0.494 (0.133) |
AUROC: 0.648 [0.581, 0.712] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.85 [0.942, 15.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608 |
| PPM001284 | PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.628 [1.281, 2.069] β: 0.487 (0.122) |
AUROC: 0.637 [0.568, 0.703] | Nagelkerke's Pseudo-R²: 0.0473 Brier score: 0.0844 Odds Ratio (OR, top 1% vs. Rest): 4.35 [1.08, 17.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608 |
| PPM001285 | PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.619 [1.267, 2.067] β: 0.482 (0.125) |
AUROC: 0.636 [0.565, 0.698] | Nagelkerke's Pseudo-R²: 0.046 Brier score: 0.0839 Odds Ratio (OR, top 1% vs. Rest): 6.35 [1.81, 22.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608 |
| PPM001286 | PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.438 [1.132, 1.827] β: 0.363 (0.122) |
AUROC: 0.598 [0.526, 0.672] | Nagelkerke's Pseudo-R²: 0.0258 Brier score: 0.085 |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608 |
| PPM001287 | PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) |
PSS000574| European Ancestry| 1,484 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 2.055 [1.692, 2.496] β: 0.72 (0.0993) |
AUROC: 0.698 [0.656, 0.74] | Nagelkerke's Pseudo-R²: 0.0839 Brier score: 0.0795 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608 |
| PPM001288 | PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.625 [1.27, 2.079] β: 0.485 (0.126) |
AUROC: 0.625 [0.557, 0.693] | Nagelkerke's Pseudo-R²: 0.044 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 6.05 [1.73, 21.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608 |
| PPM001289 | PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) |
PSS000574| European Ancestry| 1,484 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 2.106 [1.729, 2.565] β: 0.745 (0.101) |
AUROC: 0.703 [0.659, 0.745] | Brier score: 0.0793 Nagelkerke's Pseudo-R²: 0.0882 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608 |
| PPM001290 | PGS000605 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_P_5e-08_UKB_20200608) |
PSS000575| European Ancestry| 5,818 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of kidney, except pelvis | OR: 1.154 [1.062, 1.254] β: 0.143 (0.0426) |
AUROC: 0.517 [0.492, 0.54] | Nagelkerke's Pseudo-R²: 0.00398 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.13, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_P_5e-08_UKB_20200608 |
| PPM001291 | PGS000606 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_PT_UKB_20200608) |
PSS000575| European Ancestry| 5,818 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of kidney, except pelvis | OR: 1.154 [1.062, 1.254] β: 0.143 (0.0426) |
AUROC: 0.517 [0.492, 0.54] | Nagelkerke's Pseudo-R²: 0.00398 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.13, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_PT_UKB_20200608 |
| PPM001292 | PGS000607 (PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.096 [1.018, 1.18] β: 0.0918 (0.0377) |
AUROC: 0.531 [0.509, 0.551] | Nagelkerke's Pseudo-R²: 0.00156 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.671 [0.279, 1.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608 |
| PPM001293 | PGS000608 (PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.084 [1.006, 1.167] β: 0.0803 (0.0377) |
AUROC: 0.521 [0.499, 0.541] | Nagelkerke's Pseudo-R²: 0.00124 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.832, 2.83] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608 |
| PPM001294 | PGS000609 (PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.106 [1.027, 1.191] β: 0.101 (0.0376) |
AUROC: 0.528 [0.508, 0.549] | Nagelkerke's Pseudo-R²: 0.00205 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 1.69 [0.934, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608 |
| PPM001295 | PGS000610 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.292 [1.201, 1.391] β: 0.256 (0.0375) |
AUROC: 0.572 [0.55, 0.594] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0917 Odds Ratio (OR, top 1% vs. Rest): 1.47 [0.779, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608 |
| PPM001296 | PGS000611 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608) |
PSS000576| European Ancestry| 13,530 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.284 [1.211, 1.361] β: 0.25 (0.0298) |
AUROC: 0.567 [0.551, 0.584] | Nagelkerke's Pseudo-R²: 0.0114 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.79, 3.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608 |
| PPM001297 | PGS000612 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.292 [1.201, 1.391] β: 0.256 (0.0375) |
AUROC: 0.572 [0.55, 0.594] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0917 Odds Ratio (OR, top 1% vs. Rest): 1.47 [0.779, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608 |
| PPM001298 | PGS000613 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608) |
PSS000576| European Ancestry| 13,530 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.301 [1.227, 1.379] β: 0.263 (0.0299) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0125 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.91 [1.99, 4.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608 |
| PPM001299 | PGS000614 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.087 [1.01, 1.171] β: 0.0836 (0.0377) |
AUROC: 0.525 [0.503, 0.547] | Nagelkerke's Pseudo-R²: 0.00135 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.675 [0.28, 1.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608 |
| PPM001300 | PGS000615 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.084 [1.007, 1.167] β: 0.0809 (0.0376) |
AUROC: 0.519 [0.498, 0.541] | Nagelkerke's Pseudo-R²: 0.00137 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.788 [0.35, 1.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608 |
| PPM001301 | PGS000616 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.138 [1.057, 1.225] β: 0.129 (0.0376) |
AUROC: 0.538 [0.517, 0.557] | Nagelkerke's Pseudo-R²: 0.00345 Brier score: 0.0921 Odds Ratio (OR, top 1% vs. Rest): 0.983 [0.459, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608 |
| PPM001302 | PGS000617 (PRSWEB_PHECODE190_20001-1030_PRS-CS_MGI_20200608) |
PSS000556| European Ancestry| 672 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of eye | OR: 1.339 [1.033, 1.736] β: 0.292 (0.132) |
AUROC: 0.586 [0.508, 0.658] | Nagelkerke's Pseudo-R²: 0.0152 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 4.74 [1.2, 18.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE190_20001-1030_PRS-CS_MGI_20200608 |
| PPM001303 | PGS000618 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_P_5e-08_UKB_20200608) |
PSS000578| European Ancestry| 3,110 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain and nervous system | OR: 1.569 [1.399, 1.759] β: 0.45 (0.0585) |
AUROC: 0.623 [0.592, 0.656] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 3.64 [1.76, 7.53] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_P_5e-08_UKB_20200608 |
| PPM001304 | PGS000619 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_PT_UKB_20200608) |
PSS000578| European Ancestry| 3,110 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain and nervous system | OR: 1.564 [1.396, 1.753] β: 0.448 (0.0581) |
AUROC: 0.622 [0.59, 0.653] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.34, 6.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_PT_UKB_20200608 |
| PPM001305 | PGS000620 (PRSWEB_PHECODE191.11_C71_LASSOSUM_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.195 [1.045, 1.367] β: 0.179 (0.0686) |
AUROC: 0.546 [0.504, 0.587] | Nagelkerke's Pseudo-R²: 0.00561 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.453, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_C71_LASSOSUM_MGI_20200608 |
| PPM001306 | PGS000621 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.159 [1.015, 1.324] β: 0.148 (0.068) |
AUROC: 0.54 [0.503, 0.579] | Nagelkerke's Pseudo-R²: 0.00394 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.02 [0.271, 3.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_MGI_20200608 |
| PPM001307 | PGS000622 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_UKB_20200608) |
PSS000577| European Ancestry| 3,020 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.486 [1.315, 1.679] β: 0.396 (0.0624) |
AUROC: 0.605 [0.569, 0.639] | Nagelkerke's Pseudo-R²: 0.0289 Brier score: 0.0815 Odds Ratio (OR, top 1% vs. Rest): 3.38 [1.59, 7.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_UKB_20200608 |
| PPM001308 | PGS000623 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.153 [1.01, 1.316] β: 0.142 (0.0676) |
AUROC: 0.538 [0.501, 0.577] | Nagelkerke's Pseudo-R²: 0.00369 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 0.602 [0.113, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_MGI_20200608 |
| PPM001309 | PGS000624 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_UKB_20200608) |
PSS000577| European Ancestry| 3,020 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.515 [1.344, 1.708] β: 0.415 (0.0611) |
AUROC: 0.606 [0.568, 0.642] | Nagelkerke's Pseudo-R²: 0.0326 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.15 [2.04, 8.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_UKB_20200608 |
| PPM001310 | PGS000625 (PRSWEB_PHECODE191.11_UKBB-SAIGE-HRC-X191.11_PT_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.142 [1.004, 1.299] β: 0.133 (0.0657) |
AUROC: 0.53 [0.492, 0.57] | Nagelkerke's Pseudo-R²: 0.00328 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.28 [0.88, 5.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_UKBB-SAIGE-HRC-X191.11_PT_MGI_20200608 |
| PPM001311 | PGS000626 (PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.161 [1.048, 1.285] β: 0.149 (0.052) |
AUROC: 0.529 [0.496, 0.559] | Nagelkerke's Pseudo-R²: 0.0041 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.18, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608 |
| PPM001312 | PGS000627 (PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.27 [1.148, 1.405] β: 0.239 (0.0515) |
AUROC: 0.56 [0.53, 0.59] | Nagelkerke's Pseudo-R²: 0.0107 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.17, 4.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608 |
| PPM001313 | PGS000628 (PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.276 [1.155, 1.41] β: 0.244 (0.0509) |
AUROC: 0.565 [0.535, 0.595] | Nagelkerke's Pseudo-R²: 0.0114 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 1.91 [0.861, 4.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608 |
| PPM001314 | PGS000629 (PRSWEB_PHECODE193_C73_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | β: 0.114 (0.0517) OR: 1.121 [1.013, 1.24] |
AUROC: 0.52 [0.488, 0.55] | Nagelkerke's Pseudo-R²: 0.00247 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.15 [1.01, 4.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C73_PT_MGI_20200608 |
| PPM001315 | PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.598 [1.439, 1.775] β: 0.469 (0.0536) |
AUROC: 0.626 [0.597, 0.655] | Nagelkerke's Pseudo-R²: 0.0393 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.53 [1.87, 6.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608 |
| PPM021099 | PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PSS011527| Multi-ancestry (including European)| 359 individuals |
PGP000610 | Wang JR et al. J Clin Endocrinol Metab (2023) |Ext. |
Reported Trait: BRAFV600E tumor driver subtype in individuals with papillary thyroid carcinoma | OR: 1.51 [1.09, 2.08] | — | — | — | — |
| PPM001316 | PGS000631 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608) |
PSS000579| European Ancestry| 1,778 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.651 [1.41, 1.934] β: 0.501 (0.0806) |
AUROC: 0.636 [0.589, 0.682] | Nagelkerke's Pseudo-R²: 0.0478 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.4 [1.81, 10.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608 |
| PPM001317 | PGS000632 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.568 [1.412, 1.74] β: 0.45 (0.0532) |
AUROC: 0.618 [0.587, 0.647] | Nagelkerke's Pseudo-R²: 0.0365 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 5.14 [2.94, 8.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608 |
| PPM001318 | PGS000633 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608) |
PSS000579| European Ancestry| 1,778 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.609 [1.38, 1.876] β: 0.476 (0.0783) |
AUROC: 0.628 [0.582, 0.675] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0804 Odds Ratio (OR, top 1% vs. Rest): 4.41 [1.81, 10.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608 |
| PPM001319 | PGS000634 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.119 [1.008, 1.241] β: 0.112 (0.053) |
AUROC: 0.535 [0.504, 0.567] | Nagelkerke's Pseudo-R²: 0.00228 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.562, 3.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608 |
| PPM001320 | PGS000635 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.315 [1.194, 1.448] β: 0.274 (0.0492) |
AUROC: 0.569 [0.538, 0.598] | Nagelkerke's Pseudo-R²: 0.0151 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.65 [0.708, 3.83] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608 |
| PPM001321 | PGS000636 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.385 [1.254, 1.529] β: 0.325 (0.0507) |
AUROC: 0.578 [0.548, 0.607] | Nagelkerke's Pseudo-R²: 0.0205 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 3.21 [1.67, 6.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608 |
| PPM001337 | PGS000652 (PRSWEB_PHECODE204.4_C90_PT_MGI_20200608) |
PSS000563| European Ancestry| 908 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Multiple myeloma | OR: 1.24 [1.005, 1.529] β: 0.215 (0.107) |
AUROC: 0.547 [0.479, 0.613] | Nagelkerke's Pseudo-R²: 0.00945 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 2.6 [0.593, 11.4] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.4_C90_PT_MGI_20200608 |
| PPM001338 | PGS000653 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_P_5e-08_UKB_20200608) |
PSS000582| European Ancestry| 2,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Multiple myeloma | OR: 1.327 [1.165, 1.511] β: 0.283 (0.0663) |
AUROC: 0.577 [0.537, 0.617] | Nagelkerke's Pseudo-R²: 0.0145 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.2 [0.855, 5.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_P_5e-08_UKB_20200608 |
| PPM001339 | PGS000654 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_PT_UKB_20200608) |
PSS000582| European Ancestry| 2,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Multiple myeloma | OR: 1.316 [1.156, 1.499] β: 0.275 (0.0662) |
AUROC: 0.576 [0.536, 0.616] | Nagelkerke's Pseudo-R²: 0.0137 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.2 [0.854, 5.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_PT_UKB_20200608 |
| PPM001365 | PGS000662 (GRS.PCa.269) |
PSS000596| European Ancestry| 199,969 individuals |
PGP000122 | Conti DV et al. Nat Genet (2021) |
Reported Trait: Prostate Cancer | — | AUROC: 0.833 | Odds ratio (OR, top 10% versus 40-60% GRS): 4.17 Overall Net Reclassification Index (NRI [%]): 59.4 |
Age, 10 PCs | — |
| PPM001366 | PGS000662 (GRS.PCa.269) |
PSS000595| African Ancestry| 2,633 individuals |
PGP000122 | Conti DV et al. Nat Genet (2021) |
Reported Trait: Prostate Cancer | — | AUROC: 0.679 | Odds ratio (OR, top 10% versus 40-60% GRS): 3.53 | Age, 10 PCs, study | — |
| PPM001951 | PGS000662 (GRS.PCa.269) |
PSS000976| European Ancestry| 12,472 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | OR: 2.04 | — | Odds ratio (OR, top 10% vs. middle 20%): 3.89 [3.24, 4.68] | Age at blood collection, genotyping platform, PCs(1-10) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001952 | PGS000662 (GRS.PCa.269) |
PSS000976| European Ancestry| 12,472 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | — | — | Odds ratio (OR, bottom 10% vs. middle 20%): 0.34 [0.25, 0.46] | Age at blood collection, genotyping platform, PCs(1-10) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001953 | PGS000662 (GRS.PCa.269) |
PSS000976| European Ancestry| 12,472 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Elevated prostate specific antigen | OR: 1.54 | — | — | Age at blood collection, genotyping platform, PCs(1-10) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001954 | PGS000662 (GRS.PCa.269) |
PSS000975| African Ancestry| 524 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | — | — | Odds ratio (OR, top 10% vs. middle 20%): 3.81 [1.48, 10.19] | Age at blood collection, genotyping platform, PCs(1-2) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001955 | PGS000662 (GRS.PCa.269) |
PSS000975| African Ancestry| 524 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | — | — | Odds ratio (OR, bottom 10% vs. middle 20%): 0.15 [0.01, 0.92] | Age at blood collection, genotyping platform, PCs(1-2) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001970 | PGS000662 (GRS.PCa.269) |
PSS000983| European Ancestry| 81,094 individuals |
PGP000173 | Darst BF et al. Eur Urol (2021) |Ext. |
Reported Trait: Prostate cancer in carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants | OR: 2.62 [2.51, 2.74] | — | — | Age, PCs (1-10) | Only 267 SNPs from PGS000662 were utilised. 2 SNPs were not included as they were not present in the UK Biobank (UKB) data and had an imputation info score of > 0.50 (median info score = 0.99). |
| PPM012964 | PGS000662 (GRS.PCa.269) |
PSS009633| Multi-ancestry (including European)| 110,706 individuals |
PGP000308 | Schaid DJ et al. Am J Hum Genet (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Relative Risk (RR): 2.14 [2.09, 2.19] | Ancestry, study | — |
| PPM012965 | PGS000662 (GRS.PCa.269) |
PSS009632| European Ancestry| 91,623 individuals |
PGP000308 | Schaid DJ et al. Am J Hum Genet (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Relative Risk (RR: 30 - 55 years old): 2.56 [2.47, 2.65] Relative Risk (RR: 55 - 60 years old): 2.39 Relative Risk (RR: 60 - 65 years old): 2.24 Relative Risk (RR: 65 - 70 years old): 2.04 Relative risk per adjusted standard error (OPERA) per year of age: 0.00014 Relative Risk (RR: 70 - 88 years old): 1.86 [1.76, 1.98] |
— | — |
| PPM014985 | PGS000662 (GRS.PCa.269) |
PSS009945| European Ancestry| 6,715 individuals |
PGP000367 | Green HD et al. Br J Cancer (2022) |Ext. |
Reported Trait: Prostate cancer incidence in men with symptoms | OR: 2.12 [1.86, 2.41] | — | — | — | — |
| PPM014986 | PGS000662 (GRS.PCa.269) |
PSS009945| European Ancestry| 6,715 individuals |
PGP000367 | Green HD et al. Br J Cancer (2022) |Ext. |
Reported Trait: Prostate cancer incidence in men with symptoms | — | AUROC: 0.772 [0.744, 0.8] | — | Age | — |
| PPM014987 | PGS000662 (GRS.PCa.269) |
PSS009945| European Ancestry| 6,715 individuals |
PGP000367 | Green HD et al. Br J Cancer (2022) |Ext. |
Reported Trait: Prostate cancer incidence in men with symptoms | — | AUROC: 0.782 [0.755, 0.81] | — | Age, family history, symptom profile | — |
| PPM015482 | PGS000662 (GRS.PCa.269) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.86 [1.41, 2.47] | AUROC: 0.579 [0.558, 0.601] | — | — | — |
| PPM015485 | PGS000662 (GRS.PCa.269) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (tumor stage T4) | OR: 1.17 [0.95, 1.43] | AUROC: 0.505 [0.435, 0.574] | — | — | — |
| PPM015487 | PGS000662 (GRS.PCa.269) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (Gleason score >=8) | OR: 1.26 [1.15, 1.4] | AUROC: 0.523 [0.488, 0.559] | — | — | — |
| PPM015500 | PGS000662 (GRS.PCa.269) |
PSS009964| Multi-ancestry (including European)| 10,120 individuals |
PGP000377 | Plym A et al. Clin Cancer Res (2022) |Ext. |
Reported Trait: Risk of prostate cancer with family history of prostate or breast cancer | — | — | Hazard Ratio (HR, top vs. bottom quartile): 6.95 [5.57, 8.66] | Age (underlying time-scale), calendar period of DNA collection (1993-1999, 2005-2006), and genetic ancestry (principal components 1-3) | — |
| PPM015501 | PGS000662 (GRS.PCa.269) |
PSS009964| Multi-ancestry (including European)| 10,120 individuals |
PGP000377 | Plym A et al. Clin Cancer Res (2022) |Ext. |
Reported Trait: Prostate cancer death with family history of prostate or breast cancer | — | — | Hazard Ratio (HR, top vs. bottom quartile): 4.84 [2.59, 9.03] | Age (underlying time-scale), calendar period of DNA collection (1993-1999, 2005-2006), and genetic ancestry (principal components 1-3) | — |
| PPM015510 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Prostate cancer risk in 10 years | OR: 2.12 [1.55, 2.93] | — | — | — | — |
| PPM015511 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Total prostate cancer risk in 10 years | — | AUROC: 0.932 [0.918, 0.947] | — | — | — |
| PPM015512 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Gleason <=7 prostate cancer risk in 10 years | — | AUROC: 0.943 [0.928, 0.959] | — | — | — |
| PPM015513 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Gleason >=8 prostate cancer risk in 10 years | — | AUROC: 0.942 [0.919, 0.964] | — | — | — |
| PPM015514 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Localized prostate cancer risk in 10 years | — | AUROC: 0.936 [0.918, 0.953] | — | — | — |
| PPM015515 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Non-localized prostate cancer risk in 10 years | — | AUROC: 0.948 [0.922, 0.974] | — | — | — |
| PPM015516 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Lethal prostate cancer risk in 10 years | — | AUROC: 0.961 [0.941, 0.982] | — | — | — |
| PPM017262 | PGS000662 (GRS.PCa.269) |
PSS010181| Multi-ancestry (including European)| 655 individuals |
PGP000452 | Schaffer KR et al. JAMA Intern Med (2023) |Ext. |
Reported Trait: Any prostate cancer on biopsy | OR: 2.0 [1.6, 2.4] | — | — | Age | — |
| PPM017263 | PGS000662 (GRS.PCa.269) |
PSS010181| Multi-ancestry (including European)| 655 individuals |
PGP000452 | Schaffer KR et al. JAMA Intern Med (2023) |Ext. |
Reported Trait: Any prostate cancer on biopsy | — | C-index: 0.71 [0.66, 0.74] | — | Prostate Biopsy Collaborative Group risk calculator (age, PSA level prior to biopsy, digital rectal exam findings, ancestry (African vs. other), prior biopsy status, family history of prostate cancer) | — |
| PPM018702 | PGS000662 (GRS.PCa.269) |
PSS011074| East Asian Ancestry| 308 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Prostate cancer | — | AUROC: 0.72 [0.7, 0.75] | Hazard ratio (HR, high vs low tertile): 8.99 [5.27, 15.35] | age at recruitment | — |
| PPM019114 | PGS000662 (GRS.PCa.269) |
PSS011185| European Ancestry| 189,338 individuals |
PGP000508 | Dite GS et al. Prostate (2023) |Ext. |
Reported Trait: Prostate cancer | — | — | Hazard Ratio (HR per change in transformed PRS): 5.846 [4.264, 8.013] | age, family history | Effect sized based on ln(PRS) |
| PPM021705 | PGS000662 (GRS.PCa.269) |
PSS011753| European Ancestry| 3,368 individuals |
PGP000659 | Hurwitz LM et al. Environ Res (2023) |Ext. |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, PGS above median vs PGS below median): 1.17 [1.02, 1.35] | Age at enrollment, state of residence | — |
| PPM021706 | PGS000662 (GRS.PCa.269) |
PSS011754| European Ancestry| 2,794 individuals |
PGP000659 | Hurwitz LM et al. Environ Res (2023) |Ext. |
Reported Trait: Aggressive prostate cancer | — | — | Odds ratio (OR, PGS above median vs PGS below median): 1.17 [0.97, 1.41] | Age at enrollment, state of residence | — |
| PPM022293 | PGS000662 (GRS.PCa.269) |
PSS011904| Multi-ancestry (including European)| 3,110 individuals |
PGP000696 | Shi M et al. EBioMedicine (2023) |Ext. |
Reported Trait: Prostate specific antigen level > 4 ng/mL | HR: 1.45 [1.31, 1.61] | — | — | Age at first PSA measurement, 10 PCs | — |
| PPM022455 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Overall prostate cancer | — | — | Hazard ratio (HR, intermediate vs low tertile): 3.0 [2.52, 3.57] | — | — |
| PPM022456 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Metastatic prostate cancer | — | — | Hazard ratio (HR, intermediate vs low tertile): 3.11 [2.14, 4.52] | — | — |
| PPM022457 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Aggressive prostate cancer | — | — | Hazard ratio (HR, intermediate vs low tertile): 3.14 [2.54, 3.86] | — | — |
| PPM022458 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Non-aggressive prostate cancer | — | — | Hazard ratio (HR, intermediate vs low tertile): 3.1 [2.43, 3.95] | — | — |
| PPM022459 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Overall prostate cancer x P/LP/D variants in BRCA2, ATM, NBN, and PALB2 carrier status interaction | — | — | Hazard ratio (HR, non-carrier of P/LP/D variants in BRCA2, ATM, NBN, and PALB2 and high PRS vs. carrier of P/LP/D variants in BRCA2, ATM, NBN, and PALB2 and intermediate PRS): 18.06 [4.24, 76.84] | — | — |
| PPM022460 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Metastatic prostate cancer x P/LP/D variants in BRCA2, ATM, NBN, and PALB2 carrier status interaction | — | — | Hazard ratio (HR, non-carrier of P/LP/D variants in BRCA2, ATM, NBN, and PALB2 and high PRS vs. carrier of P/LP/D variants in BRCA2, ATM, NBN, and PALB2 and intermediate PRS): 28.99 [4.39, 191.43] | — | — |
| PPM022461 | PGS000662 (GRS.PCa.269) |
PSS011949| African Ancestry| 2,760 individuals |
PGP000715 | Hughley RW et al. Cancer Res Commun (2023) |Ext. |
Reported Trait: Aggressive prostate cancer x P/LP/D variants in BRCA2, ATM, NBN, and PALB2 carrier status interaction | — | — | Hazard ratio (HR, non-carrier of P/LP/D variants in BRCA2, ATM, NBN, and PALB2 and high PRS vs. carrier of P/LP/D variants in BRCA2, ATM, NBN, and PALB2 and intermediate PRS): 23.58 [5.39, 103.2] | — | — |
| PPM001367 | PGS000663 (wGRS22) |
PSS000598| European Ancestry| 1,591 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer | OR: 1.37 [1.23, 1.53] | — | — | — | Cross validation approach-testing sample = 20% |
| PPM001368 | PGS000663 (wGRS22) |
PSS000597| European Ancestry| 956 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer (0-10 years of follow-up) | OR: 1.46 [1.27, 1.68] | — | — | — | Cross validation approach-testing sample = 20% |
| PPM001369 | PGS000663 (wGRS22) |
PSS000598| European Ancestry| 1,591 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer | OR: 1.37 [1.22, 1.53] | AUROC: 0.65 | — | matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status | Cross validation approach-testing sample = 20% |
| PPM001370 | PGS000663 (wGRS22) |
PSS000597| European Ancestry| 956 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer (0-10 years of follow-up) | OR: 1.44 [1.25, 1.67] | AUROC: 0.67 | — | matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status | Cross validation approach-testing sample = 20% |
| PPM022400 | PGS000663 (wGRS22) |
PSS011940| East Asian Ancestry| 100,219 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |Ext. |
Reported Trait: Pancreatic Cancer | HR: 1.28 [1.1, 1.48] β: 0.246 |
C-index: 0.586 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM001624 | PGS000714 (PRS55_PC) |
PSS000840| European Ancestry| 5,138 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Prostate cancer | OR: 2.13 [1.9, 2.39] | AUROC: 0.618 [0.6, 0.63] | — | — | — |
| PPM001625 | PGS000714 (PRS55_PC) |
PSS000841| European Ancestry| 4,683 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Prostate cancer (clinical cases) | OR: 2.18 [1.93, 2.45] | AUROC: 0.622 [0.61, 0.64] | — | — | — |
| PPM001626 | PGS000714 (PRS55_PC) |
PSS000843| European Ancestry| 2,855 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Prostate cancer (screening trial detected) | OR: 1.92 [1.56, 2.37] | AUROC: 0.597 [0.57, 0.63] | — | — | — |
| PPM001627 | PGS000714 (PRS55_PC) |
PSS000842| European Ancestry| 2,591 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Metastatic prostate cancer | OR: 1.47 | AUROC: 0.549 | — | — | — |
| PPM001644 | PGS000719 (PRS_Prostate) |
PSS000860| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident prostate cancer | — | AUROC: 0.662 [0.655, 0.67] | — | Genotyping array | — |
| PPM001645 | PGS000719 (PRS_Prostate) |
PSS000860| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident prostate cancer | — | AUROC: 0.669 [0.661, 0.676] | — | family history of cancer (in first-degree relatives), genotyping array | — |
| PPM001648 | PGS000720 (PRS_Colorectal) |
PSS000855| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident colorectal cancer | — | AUROC: 0.609 [0.598, 0.62] | — | Genotyping array | — |
| PPM001649 | PGS000720 (PRS_Colorectal) |
PSS000855| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident colorectal cancer | — | AUROC: 0.613 [0.602, 0.624] | — | family history of cancer (in first-degree relatives), genotyping array | — |
| PPM001650 | PGS000721 (PRS_Lung) |
PSS000857| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident lung cancer | — | AUROC: 0.591 [0.576, 0.606] | — | Genotyping array | — |
| PPM001651 | PGS000721 (PRS_Lung) |
PSS000857| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident lung cancer | — | AUROC: 0.615 [0.6, 0.629] | — | family history of cancer (in first-degree relatives), genotyping array | — |
| PPM018701 | PGS000721 (PRS_Lung) |
PSS011072| East Asian Ancestry| 181 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.69 [0.65, 0.73] | Hazard ratio (HR, high vs low tertile): 1.69 [1.03, 2.79] | age at recruitment | — |
| PPM020286 | PGS000721 (PRS_Lung) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.738 [0.71, 0.766] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM001652 | PGS000722 (PRS_Kidney) |
PSS000856| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident kidney cancer | — | AUROC: 0.567 [0.543, 0.591] | — | Genotyping array | — |
| PPM001653 | PGS000723 (PRS_Bladder) |
PSS000853| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident bladder cancer | — | AUROC: 0.583 [0.559, 0.607] | — | Genotyping array | — |
| PPM001654 | PGS000724 (PRS_Ovary) |
PSS000858| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident epithelial ovarian cancer | — | AUROC: 0.568 [0.537, 0.598] | — | Genotyping array | — |
| PPM001655 | PGS000725 (PRS_Pancreas) |
PSS000859| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident Pancreatic cancer | — | AUROC: 0.639 [0.613, 0.664] | — | Genotyping array | — |
| PPM001670 | PGS000730 (PRS_BCC) |
PSS000871| European Ancestry| 88,924 individuals |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Reported Trait: Basal cell carcinoma | OR: 1.57 [1.55, 1.6] | AUROC: 0.624 | — | — | — |
| PPM001671 | PGS000731 (PRS_SCC) |
PSS000873| European Ancestry| 88,924 individuals |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Reported Trait: Squamous cell carcinoma | OR: 1.44 [1.41, 1.48] | AUROC: 0.605 | — | — | — |
| PPM001674 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 4.42 [4.16, 4.67] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001676 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 2% vs. middle 40%): 3.67 [3.48, 3.87] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001678 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR bottom 20% vs. middle 40%): 0.51 [0.49, 0.52] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001680 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 20% vs. bottom 20%): 4.71 [4.38, 5.05] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001682 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 2% vs. middle 40%): 3.89 [3.64, 4.13] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001684 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (bottom 20% vs. middle 40%): 0.5 [0.48, 0.52] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM015483 | PGS000733 (PHS46+African) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.58 [1.2, 2.11] | AUROC: 0.547 [0.525, 0.569] | — | — | — |
| PPM015488 | PGS000733 (PHS46+African) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (tumor stage T4) | OR: 0.96 [0.78, 1.17] | AUROC: 0.568 [0.494, 0.631] | — | — | — |
| PPM015489 | PGS000733 (PHS46+African) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (Gleason score >=8) | OR: 1.18 [1.07, 1.13] | AUROC: 0.515 [0.479, 0.55] | — | — | — |
| PPM001742 | PGS000734 (PRS95_CRC) |
PSS000896| European Ancestry| 24,472 individuals |
PGP000142 | Archambault AN et al. Gastroenterology (2019) |
Reported Trait: Early-onset colorectal cancer in individuals with no family history of colorectal cancer | HR: 1.76 [1.11, 2.78] | — | — | Sex, PCs | — |
| PPM001743 | PGS000734 (PRS95_CRC) |
PSS000895| European Ancestry| 61,129 individuals |
PGP000142 | Archambault AN et al. Gastroenterology (2019) |
Reported Trait: Late-onset colorectal cancer in individuals with no family history of colorectal cancer | HR: 1.42 [1.33, 1.52] | — | — | Sex, PCs | — |
| PPM001744 | PGS000734 (PRS95_CRC) |
PSS000897| European Ancestry| 6,668 individuals |
PGP000142 | Archambault AN et al. Gastroenterology (2019) |
Reported Trait: Late-onset colorectal cancer in individuals with a family history of colorectal cancer | HR: 1.34 [1.17, 1.54] | — | — | Sex, PCs | — |
| PPM001740 | PGS000734 (PRS95_CRC) |
PSS000894| European Ancestry| 26,938 individuals |
PGP000142 | Archambault AN et al. Gastroenterology (2019) |
Reported Trait: Early-onset colorectal cancer | HR: 1.73 [1.17, 2.56] | — | — | Sex, PCs | — |
| PPM001741 | PGS000734 (PRS95_CRC) |
PSS000893| European Ancestry| 67,792 individuals |
PGP000142 | Archambault AN et al. Gastroenterology (2019) |
Reported Trait: Late-onset colorectal cancer | HR: 1.43 [1.34, 1.51] | — | — | Sex, PCs | — |
| PPM018699 | PGS000734 (PRS95_CRC) |
PSS011071| East Asian Ancestry| 409 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.66 [0.63, 0.69] | Hazard ratio (HR, high vs low tertile): 3.25 [2.24, 4.73] | age at recruitment | — |
| PPM001780 | PGS000740 (PRS128_LC) |
PSS000921| European Ancestry| 183,671 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals who have never smoked | OR: 1.28 [1.13, 1.46] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001781 | PGS000740 (PRS128_LC) |
PSS000920| European Ancestry| 118,310 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals who are former smokers | OR: 1.25 [1.17, 1.34] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001784 | PGS000740 (PRS128_LC) |
PSS000916| European Ancestry| 42,540 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals with no family history of lung cancer | OR: 1.29 [1.22, 1.36] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001785 | PGS000740 (PRS128_LC) |
PSS000917| European Ancestry| 330,046 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals with COPD | OR: 1.26 [1.09, 1.46] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001789 | PGS000740 (PRS128_LC) |
PSS000913| European Ancestry| 167,955 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Early onset lung cancer (< 50 years) | — | AUROC: 0.811 [0.701, 0.922] | — | Age, sex, education, body mass index, personal history of cancer, family history of lung cancer, lung function | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001779 | PGS000740 (PRS128_LC) |
PSS000912| European Ancestry| 335,931 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer | OR: 1.26 [1.2, 1.32] | — | Odds Ratio (OR, top 10% vs low risk): 2.39 [1.92, 3.0] | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001782 | PGS000740 (PRS128_LC) |
PSS000919| European Ancestry| 33,950 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals who currently smoke | OR: 1.28 [1.19, 1.38] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001783 | PGS000740 (PRS128_LC) |
PSS000918| European Ancestry| 287,620 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals with a family history of lung cancer | OR: 1.16 [1.05, 1.27] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001786 | PGS000740 (PRS128_LC) |
PSS000915| European Ancestry| 5,491 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals with no COPD diagnosis | OR: 1.26 [1.2, 1.32] | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001787 | PGS000740 (PRS128_LC) |
PSS000913| European Ancestry| 167,955 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer (absolute risk) | β: 0.663 | — | — | Age, sex, PCs(1-5) | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM001788 | PGS000740 (PRS128_LC) |
PSS000914| European Ancestry| 67,186 individuals |
PGP000148 | Hung RJ et al. Cancer Res (2021) |
Reported Trait: Lung cancer in individuals who have never smoked | — | AUROC: 0.687 [0.628, 0.746] | — | Age, sex, education, body mass index, personal history of cancer, family history of lung cancer, lung function | 14/128 were omitted from the analysis (missing in HRC panel) |
| PPM020289 | PGS000740 (PRS128_LC) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.73 [0.702, 0.758] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM021377 | PGS000740 (PRS128_LC) |
PSS011713| European Ancestry| 1,915 individuals |
PGP000646 | Trendowski MR et al. Cancer Epidemiol Biomarkers Prev (2023) |Ext. |
Reported Trait: Lung cancer | OR: 1.16 [1.04, 1.29] | — | — | Age, sex, pack-years, history of COPD, family history of lung cancer, 5 PCs | Only 80 of 128 SNPs were available for analysis |
| PPM021378 | PGS000740 (PRS128_LC) |
PSS011712| African Ancestry| 1,123 individuals |
PGP000646 | Trendowski MR et al. Cancer Epidemiol Biomarkers Prev (2023) |Ext. |
Reported Trait: Lung cancer | OR: 0.99 [0.85, 1.15] | — | — | Age, sex, pack-years, history of COPD, family history of lung cancer, 5 PCs | Only 80 of 128 SNPs were available for analysis |
| PPM001790 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.32 [4.99, 5.7] | — | — |
| PPM001791 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.54 [5.18, 5.93] | — | — |
| PPM001792 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.49 [3.23, 6.33] | — | — |
| PPM001793 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.54 [2.08, 3.1] | — | — |
| PPM001797 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.43 [1.51, 4.05] | — | — |
| PPM001798 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer mortality (age at death) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.68 [5.07, 6.46] | — | — |
| PPM001800 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 2.06 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.8 | — | — |
| PPM001795 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.62 [5.25, 6.05] | — | — |
| PPM001803 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 2.16 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.12 | — | — |
| PPM001804 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 2.1 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.93 | — | — |
| PPM001805 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 1.73 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 3.6 | — | — |
| PPM001806 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 1.1 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.16 | — | — |
| PPM001807 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer mortality in men with a family history of prostate cancer | β: 2.2 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.29 | — | — |
| PPM001794 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.88 [5.48, 6.34] | — | — |
| PPM001796 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.16 [3.45, 7.78] | — | — |
| PPM001799 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 1.98 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.48 | — | — |
| PPM001801 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 1.89 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.17 | — | — |
| PPM001802 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 1.11 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.22 | — | — |
| PPM002489 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer mortality (age at death) | HR: 3.41 [2.78, 4.17] | — | — | — | — |
| PPM002490 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age at diagnosis) | HR: 5.35 [4.97, 5.76] | — | — | — | — |
| PPM002491 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | HR: 3.78 [3.45, 4.13] | — | — | — | — |
| PPM002492 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer mortality (age at death) | HR: 2.45 [1.99, 2.97] β: 0.9 |
— | — | Family history of prostate cancer, alcohol intake, diabetes history | — |
| PPM001808 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 4.45 [3.68, 5.06] | — | — |
| PPM001809 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 7.85 [6.04, 9.33] | — | — |
| PPM001810 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.37 [0.33, 0.4] | — | — |
| PPM001814 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 5.09 [3.84, 6.05] | — | — |
| PPM001815 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 9.45 [6.17, 11.79] | — | — |
| PPM001816 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.34 [0.29, 0.39] | — | — |
| PPM001820 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 4.28 [3.49, 4.96] | — | — |
| PPM001821 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 7.47 [5.49, 9.07] | — | — |
| PPM001822 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.37 [0.33, 0.42] | — | — |
| PPM001907 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, top 10% vs. middle 50%): 3.1 [2.55, 3.76] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001908 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, top 1% vs. middle 50%): 4.02 [2.46, 6.55] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001909 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, bottom 10% vs. middle 50%): 0.38 [0.28, 0.51] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001910 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, bottom 1% vs. middle 50%): 0.25 [0.09, 0.67] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001961 | PGS000765 (PRS_CRC95) |
PSS000981| Multi-ancestry (including European)| 48,807 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Prevalent colorectal cancer | OR: 1.65 [1.48, 1.85] | — | — | Age, sex, PCs (1-4) | — |
| PPM015518 | PGS000765 (PRS_CRC95) |
PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Colorectal cancer | OR: 2.37 [1.74, 3.24] | — | — | 4 genetic PCs | — |
| PPM018551 | PGS000765 (PRS_CRC95) |
PSS011020| Multi-ancestry (including European)| 163,516 individuals |
PGP000482 | Hassanin E et al. BMC Med Genomics (2023) |Ext. |
Reported Trait: Colorectal cancer with pathogenic variant carriers | — | AUROC: 0.693 [0.66, 0.71] C-index: 0.646 |
Odds ratio (OR, high vs low tertile): 17.5 [9.0, 32.4] | — | — |
| PPM018552 | PGS000765 (PRS_CRC95) |
PSS011020| Multi-ancestry (including European)| 163,516 individuals |
PGP000482 | Hassanin E et al. BMC Med Genomics (2023) |Ext. |
Reported Trait: Incident colorectal cancer with pathogenic variant carriers | — | — | Odds ratio (OR, high vs low tertile): 7.0 [2.04, 23.7] | — | — |
| PPM018553 | PGS000765 (PRS_CRC95) |
PSS011020| Multi-ancestry (including European)| 163,516 individuals |
PGP000482 | Hassanin E et al. BMC Med Genomics (2023) |Ext. |
Reported Trait: Colorectal cancer with family history of cancer | — | AUROC: 0.698 [0.67, 0.72] C-index: 0.652 |
Odds ratio (OR, high vs low tertile): 3.1 [2.6, 3.8] | — | — |
| PPM018554 | PGS000765 (PRS_CRC95) |
PSS011020| Multi-ancestry (including European)| 163,516 individuals |
PGP000482 | Hassanin E et al. BMC Med Genomics (2023) |Ext. |
Reported Trait: Colorectal cancer with family history of cancer and pathogenic variant carriers | — | AUROC: 0.704 [0.68, 0.73] C-index: 0.657 |
Odds ratio (OR, high vs low tertile): 39.9 [12.69, 125.41] | — | — |
| PPM018555 | PGS000765 (PRS_CRC95) |
PSS011020| Multi-ancestry (including European)| 163,516 individuals |
PGP000482 | Hassanin E et al. BMC Med Genomics (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.688 [0.66, 0.71] C-index: 0.64 |
— | — | — |
| PPM020769 | PGS000765 (PRS_CRC95) |
PSS011399| European Ancestry| 1,428 individuals |
PGP000583 | Dueñas N et al. J Med Genet (2023) |Ext. |
Reported Trait: Colorectal cancer or advanced adenoma in individuals with Lynch syndrome | HR: 1.019 [1.005, 1.032] | — | — | Sex, birth cohort, other Lynch syndrome-related cancers | — |
| PPM020782 | PGS000765 (PRS_CRC95) |
PSS011409| European Ancestry| 2,059 individuals |
PGP000589 | Mur P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Familial / early-onset colorectal cancer | OR: 1.12 [1.09, 1.14] | — | — | Age, sex | Only 92 SNPs were included. 3 SNPs had an R^2 lower than 0.3 and were excluded |
| PPM020783 | PGS000765 (PRS_CRC95) |
PSS011410| European Ancestry| 2,719 individuals |
PGP000589 | Mur P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Sporadic colorectal cancer | OR: 1.08 [1.06, 1.09] | — | — | Age, sex | Only 92 SNPs were included. 3 SNPs had an R^2 lower than 0.3 and were excluded |
| PPM020784 | PGS000765 (PRS_CRC95) |
PSS011409| European Ancestry| 2,059 individuals |
PGP000589 | Mur P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Familial / early-onset colorectal cancer | — | AUROC: 0.833 | R²: 0.373 | Age at cancer diagnosis, sex | Only 92 SNPs were included. 3 SNPs had an R^2 lower than 0.3 and were excluded |
| PPM020785 | PGS000765 (PRS_CRC95) |
PSS011409| European Ancestry| 2,059 individuals |
PGP000589 | Mur P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Familial / early-onset colorectal cancer | — | AUROC: 0.905 | R²: 0.598 | Age at cancer diagnosis, sex, family history of colorectal cancer | Only 92 SNPs were included. 3 SNPs had an R^2 lower than 0.3 and were excluded. Only 405 cases and 1,094 controls were included in this analysis |
| PPM001963 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma | — | — | Hazard Ratio (HR, top 20% vs bottom 20%): 2.51 [1.28, 4.92] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001964 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma (males) | — | — | Hazard Ratio (HR, top 20% vs bottom 20%): 3.7 [1.37, 9.98] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001965 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma (males) | — | — | Hazard Ratio (HR, middle 60% vs bottom 20%): 2.61 [1.03, 6.63] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001966 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma | OR: 1.55 [1.42, 1.69] | AUROC: 0.64 [0.62, 0.66] | Odds Ratio (OR, top 20% vs bottom 20%): 3.66 [2.69, 5.05] | Sex, family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001967 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma (males) | OR: 1.39 [1.23, 1.57] | — | — | Family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001968 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma (females) | OR: 1.72 [1.53, 1.94] | — | — | Family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM001962 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma | HR: 1.46 [1.2, 1.77] | C-index: 0.643 [0.584, 0.702] | — | Sex, melanoma family history, treatment (aspirin/placebo), age at enrolment, PRS*treatment | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
| PPM002005 | PGS000773 (PRS179_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Breast cancer | OR: 1.26 [1.22, 1.3] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002006 | PGS000773 (PRS179_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Breast cancer | — | AUROC: 0.568 [0.56, 0.576] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002007 | PGS000774 (PRS179_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.33 [1.27, 1.38] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002008 | PGS000774 (PRS179_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.576 [0.566, 0.585] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002009 | PGS000775 (PRS179_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor negative breast cancer | OR: 1.31 [1.24, 1.37] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002010 | PGS000775 (PRS179_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor negative breast cancer | — | AUROC: 0.578 [0.564, 0.591] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
| PPM002053 | PGS000782 (CC_Bladder_IV) |
PSS001010| European Ancestry| 391,888 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident blader cancer | HR: 1.3 [1.22, 1.39] | AUROC: 0.804 C-index: 0.814 (0.008) |
R²: 0.628 | Age at assessment, sex, genotyping array, PCs(1-15), cigarette pack-years, smoking status(never vs. former vs. current), body mass index | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002054 | PGS000783 (CC_Breast_IV) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | HR: 1.52 [1.47, 1.56] | AUROC: 0.637 C-index: 0.635 (0.004) |
R²: 0.146 | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity( ≥1 live birth vs. none), age at menarche, body mass index, menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use, alcool intake, (Body mass index)*(menopausal status) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002070 | PGS000783 (CC_Breast_IV) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | — | AUROC: 0.626 C-index: 0.62 (0.005) |
R²: 0.122 | Age, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002055 | PGS000784 (CC_Cervix_IV) |
PSS001012| European Ancestry| 211,795 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident cervical cancer | HR: 1.21 [1.07, 1.35] | AUROC: 0.745 C-index: 0.749 (0.017) |
R²: 0.437 | Age at assessment, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), cigarette pack-years | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002056 | PGS000785 (CC_Colorectal_IV) |
PSS001013| European Ancestry| 393,723 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident colorectal cancer | HR: 1.48 [1.43, 1.54] | AUROC: 0.716 C-index: 0.716 (0.006) |
R²: 0.345 | Age at assessment, sex, family history of bowel cancer, genotyping array, PCs(1-15), wasit to hip ratio, cigarette pack years, frequency of processed meat intake (<1 per week vs. ≥1 per week), moderate and/or strenuous physical activity (days per week), alcohol intake | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002071 | PGS000785 (CC_Colorectal_IV) |
PSS001013| European Ancestry| 393,723 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident colorectal cancer | — | AUROC: 0.708 C-index: 0.708 (0.006) |
R²: 0.319 | Age, sex, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002057 | PGS000786 (CC_Endo_IV) |
PSS001014| European Ancestry| 212,156 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident endometrial cancer | HR: 1.18 [1.09, 1.27] | AUROC: 0.754 C-index: 0.749 (0.011) |
R²: 0.486 | Age at assessment, family history of cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), age at menarche, body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002058 | PGS000787 (CC_Kidney_IV) |
PSS001015| European Ancestry| 391,610 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident kidney cancer | HR: 1.15 [1.07, 1.24] | AUROC: 0.722 C-index: 0.723 (0.011) |
R²: 0.366 | Age at assessment, sex, genotyping array, PCs(1-15), body mass index, smoking status (never vs. former vs. current), cigarette pack-years, ever diagnosed with hypertension | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002060 | PGS000789 (CC_Lung_IV) |
PSS001017| European Ancestry| 392,539 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident lung cancer | HR: 1.17 [1.12, 1.23] | AUROC: 0.846 C-index: 0.849 (0.006) |
R²: 0.799 | Age at assessment, sex, genotyping array, PCs(1-15), family history of lung cancer, PM2.5 in 2010, cigarettes per day, years of smoking, smoking status (never vs. former vs. current), smoking status*cigarettes per day, smoking stutus*years of smoking | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002072 | PGS000789 (CC_Lung_IV) |
PSS001017| European Ancestry| 392,539 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident lung cancer | — | AUROC: 0.71 C-index: 0.711 (0.007) |
R²: 0.322 | Age, sex, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002073 | PGS000789 (CC_Lung_IV) |
PSS001017| European Ancestry| 392,539 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident lung cancer in never smokers | — | AUROC: 0.723 C-index: 0.723 (0.02) |
R²: 0.354 | Age, sex, genotyping array, PCs(1-15), family history of lung cancer, PM2.5 level in 2010 | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002074 | PGS000789 (CC_Lung_IV) |
PSS001017| European Ancestry| 392,539 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident lung cancer in smokers | — | AUROC: 0.808 C-index: 0.809 (0.007) |
R²: 0.657 | Age, sex, genotyping array, PCs(1-15), family history of lung cancer, PM2.5 level in 2010, cigarettes per day, years of smoking, smoking status (former vs. current), years since quitting, (smoking status)*(cigarettes per day), (smoking status*years of smoking) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002063 | PGS000792 (CC_Oral_IV) |
PSS001020| European Ancestry| 391,479 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident oral cavity and pharyngeal cancer | HR: 1.12 [1.02, 1.23] | AUROC: 0.702 C-index: 0.687 (0.015) |
R²: 0.356 | Age at assessment, sex, genotyping array, PCs(1-15), weekly alcohol intake, cigarettes per day, years of smoking, smoing status (never vs. former vs. current) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002064 | PGS000793 (CC_Ovary_IV) |
PSS001021| European Ancestry| 211,958 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident ovarian cancer | HR: 1.2 [1.1, 1.32] | AUROC: 0.66 C-index: 0.654 (0.015) |
R²: 0.193 | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), BMI*menopausal status | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002065 | PGS000794 (CC_Pancreas_IV) |
PSS001022| European Ancestry| 391,491 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident pancreatic cancer | HR: 1.49 [1.37, 1.63] | AUROC: 0.745 C-index: 0.743 (0.012) |
R²: 0.439 | Age at assessment, sex, genotyping array, PCs(1-15), family history of cancer (prostate, breast, lung, bowel), body mass index, cigarette pack-years, smoking status (never vs. former vs. current) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002066 | PGS000795 (CC_Prostate_IV) |
PSS001023| European Ancestry| 184,225 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident prostate cancer | HR: 1.77 [1.72, 1.82] | AUROC: 0.769 C-index: 0.768 (0.004) |
R²: 0.51 | Age at assessment, family history of prostate cancer, genotyping array, PCs(1-15), family history of prostate cancer | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002069 | PGS000795 (CC_Prostate_IV) |
PSS001023| European Ancestry| 184,225 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident prostate cancer | — | AUROC: 0.766 C-index: 0.763 (0.004) |
R²: 0.496 | Age, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002067 | PGS000796 (CC_Testis_IV) |
PSS001024| European Ancestry| 179,537 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident testicular cancer | HR: 2.26 [1.71, 2.99] | AUROC: 0.787 C-index: 0.766 (0.033) |
R²: 0.605 | Age at assessment, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002068 | PGS000797 (CC_Thyroid_IV) |
PSS001025| European Ancestry| 391,189 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident thyroid cancer | HR: 1.75 [1.53, 2.01] | AUROC: 0.701 C-index: 0.692 (0.022) |
R²: 0.31 | Age at assessment, sex,, genotyping array, PCs(1-15), body mass index (BMI <25 vs. 25≤BMI<30, BMI≥30) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002087 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Advanced conventional adenoma | OR: 1.22 [1.16, 1.28] | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.91 [1.59, 2.29] | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002092 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Multiple conventional adenomas | OR: 1.25 [1.17, 1.34] | — | — | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002093 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Multiple serrated polyps | OR: 1.09 [1.01, 1.18] | — | — | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002085 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Conventional adeonma | OR: 1.17 [1.12, 1.21] | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.63 [1.44, 1.83] | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002086 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Non-advanced conventional adenoma | OR: 1.12 [1.07, 1.18] | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.44 [1.23, 1.68] | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002088 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Serrated polyp | OR: 1.09 [1.03, 1.14] | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.24 [1.06, 1.45] | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002089 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Serrated polyp with high risk of malignancy | OR: 1.1 [1.01, 1.19] | — | — | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002090 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Serrated polyp with low risk of malignancy | OR: 1.08 [1.02, 1.15] | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.25 [1.03, 1.53] | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002091 | PGS000801 (GRS40_CRC) |
PSS001030| European Ancestry| 27,426 individuals |
PGP000190 | Hang D et al. Int J Epidemiol (2020) |
Reported Trait: Synchronous conventional adenoma and serrated polyp | OR: 1.24 [1.16, 1.32] | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.96 [1.54, 2.49] | Study cohort (NHS, NHSII, HPFS), time period of endoscopy (in 2-year interval), number of previous endoscopies, time in years since the most recent endoscopy, age, PCs(1-3) | Effect weights for SNPs within the PGS were obtained using the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) dataset. The GECCO dataset had no overlap with the dataset used to evaluate the score. |
| PPM002098 | PGS000802 (CRC_19) |
PSS001032| East Asian Ancestry| 2,566 individuals |
PGP000191 | He CY et al. Genomics (2021) |
Reported Trait: Colorectal cancer | — | — | Odds Ratio (OR, top 75% vs bottom 25%): 2.53 [1.99, 3.22] | Gender, age | — |
| PPM002099 | PGS000802 (CRC_19) |
PSS001031| East Asian Ancestry| 2,269 individuals |
PGP000191 | He CY et al. Genomics (2021) |
Reported Trait: Colorectal cancer | — | — | Odds Ratio (OR, top 75% vs bottom 25%): 2.12 [1.63, 2.77] | Gender, age | — |
| PPM002094 | PGS000802 (CRC_19) |
PSS001033| East Asian Ancestry| 5,465 individuals |
PGP000191 | He CY et al. Genomics (2021) |
Reported Trait: Colorectal cancer | — | AUROC: 0.59 [0.57, 0.6] | — | — | Possible overlap with score development samples |
| PPM002095 | PGS000802 (CRC_19) |
PSS001032| East Asian Ancestry| 2,566 individuals |
PGP000191 | He CY et al. Genomics (2021) |
Reported Trait: Colorectal cancer | — | AUROC: 0.61 [0.59, 0.63] | — | — | — |
| PPM002096 | PGS000802 (CRC_19) |
PSS001031| East Asian Ancestry| 2,269 individuals |
PGP000191 | He CY et al. Genomics (2021) |
Reported Trait: Colorectal cancer | — | AUROC: 0.59 [0.57, 0.61] | — | — | — |
| PPM002097 | PGS000802 (CRC_19) |
PSS001033| East Asian Ancestry| 5,465 individuals |
PGP000191 | He CY et al. Genomics (2021) |
Reported Trait: Colorectal cancer | — | — | Odds Ratio (OR, top 75% vs bottom 25%): 2.27 [1.95, 2.64] | Gender, age | possible overlap with score development samples |
| PPM002456 | PGS000873 (SNP143) |
PSS001111| Ancestry Not Reported| 2,073 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.12 [1.81, 2.49] | Age | — |
| PPM002458 | PGS000873 (SNP143) |
PSS001105| Ancestry Not Reported| 2,021 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.17 [1.83, 2.58] | Age | — |
| PPM002460 | PGS000873 (SNP143) |
PSS001108| Ancestry Not Reported| 1,707 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.86 [1.18, 2.91] | Age | — |
| PPM002462 | PGS000873 (SNP143) |
PSS001113| Ancestry Not Reported| 1,991 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.14 [1.79, 2.55] | Age | — |
| PPM002464 | PGS000873 (SNP143) |
PSS001112| Ancestry Not Reported| 1,750 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 2.0 [1.46, 2.75] | Age | — |
| PPM002466 | PGS000873 (SNP143) |
PSS001107| Ancestry Not Reported| 1,956 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.55 [1.86, 2.7] | Age | — |
| PPM002468 | PGS000873 (SNP143) |
PSS001106| Ancestry Not Reported| 1,733 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.84 [1.3, 2.6] | Age | — |
| PPM002470 | PGS000873 (SNP143) |
PSS001110| Ancestry Not Reported| 1,694 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.44 [0.84, 2.47] | Age | — |
| PPM002471 | PGS000873 (SNP143) |
PSS001109| Ancestry Not Reported| 1,681 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 3.12 [1.41, 6.88] | Age | — |
| PPM002457 | PGS000873 (SNP143) |
PSS001111| Ancestry Not Reported| 2,073 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.06 [1.75, 2.42] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002459 | PGS000873 (SNP143) |
PSS001105| Ancestry Not Reported| 2,021 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.11 [1.78, 2.51] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002461 | PGS000873 (SNP143) |
PSS001108| Ancestry Not Reported| 1,707 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.81 [1.16, 2.84] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002463 | PGS000873 (SNP143) |
PSS001113| Ancestry Not Reported| 1,991 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.07 [1.74, 2.48] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002465 | PGS000873 (SNP143) |
PSS001112| Ancestry Not Reported| 1,750 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.93 [1.41, 2.65] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002469 | PGS000873 (SNP143) |
PSS001106| Ancestry Not Reported| 1,733 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.77 [1.24, 2.51] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002472 | PGS000873 (SNP143) |
PSS001109| Ancestry Not Reported| 1,681 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 2.99 [1.35, 6.6] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM002467 | PGS000873 (SNP143) |
PSS001107| Ancestry Not Reported| 1,956 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.18 [1.81, 2.63] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
| PPM018697 | PGS000873 (SNP143) |
PSS011069| East Asian Ancestry| 495 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.58, 0.63] | Hazard ratio (HR, high vs low tertile): 2.68 [1.97, 3.66] | age at recruitment | — |
| PPM002516 | PGS000878 (PRS4_PC) |
PSS001135| East Asian Ancestry| 638 individuals |
PGP000224 | Oh JJ et al. Front Oncol (2020) |
Reported Trait: Prostate cancer | — | AUROC: 0.637 | Odds Ratio (OR, top 25% vs bottom 25%): 4.2 [2.32, 7.98] | Age | — |
| PPM002521 | PGS000880 (PRS18_LC) |
PSS001139| European Ancestry| 382,598 individuals |
PGP000226 | Xie J et al. Sleep (2021) |
Reported Trait: Incident lung cancer | HR: 1.2 [1.15, 1.26] | — | — | Sex, education (college or uni- versity degree/vocational qualification, other qualification), smoking status (never, former, current), pack-years, alcohol in- take (nondrinker, <1, 1-10, 10-20, ≥20 g/day), physical activity (Metabolic Equivalent Task hours per week, MET-h/week), and body mass index (BMI, kg/m2) | — |
| PPM002522 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Number of positive prostate cancer tumour cores at diagnostic biposy | OR: 1.23 [1.06, 1.41] | — | — | Age at diagnosis, study site | — |
| PPM002523 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Number of positive prostate cancer tumour cores at surveillance biposy | OR: 1.26 [1.11, 1.44] | — | — | Age at diagnosis, study site | — |
| PPM002524 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Bilateral positive prostate cancer tumor cores at diagnostic biopsy | OR: 1.27 [1.01, 1.61] | — | — | Age at diagnosis, study site | — |
| PPM002525 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Bilateral positive prostate cancer tumor cores at surveillance biopsy | OR: 1.19 [1.04, 1.36] | — | — | Age at diagnosis, study site | — |
| PPM007958 | PGS001040 (GBE_cancer1060) |
PSS007651| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.80478 [0.72556, 0.884] | R²: 0.07029 Incremental AUROC (full-covars): -0.00066 PGS R2 (no covariates): 0.00133 PGS AUROC (no covariates): 0.54127 [0.39017, 0.69237] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007959 | PGS001040 (GBE_cancer1060) |
PSS007652| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.86455 [0.80574, 0.92335] | R²: 0.12918 Incremental AUROC (full-covars): -0.00442 PGS R2 (no covariates): 0.00152 PGS AUROC (no covariates): 0.4523 [0.1694, 0.73519] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007960 | PGS001040 (GBE_cancer1060) |
PSS007653| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.73342 [0.72065, 0.74619] | R²: 0.10751 Incremental AUROC (full-covars): 0.0378 PGS R2 (no covariates): 0.05185 PGS AUROC (no covariates): 0.66327 [0.64889, 0.67765] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007961 | PGS001040 (GBE_cancer1060) |
PSS007654| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.76366 [0.66832, 0.85901] | R²: 0.06447 Incremental AUROC (full-covars): -0.00934 PGS R2 (no covariates): 0.00078 PGS AUROC (no covariates): 0.47181 [0.35611, 0.58752] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007962 | PGS001040 (GBE_cancer1060) |
PSS007655| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.70656 [0.69863, 0.7145] | R²: 0.08615 Incremental AUROC (full-covars): 0.04717 PGS R2 (no covariates): 0.03949 PGS AUROC (no covariates): 0.64209 [0.6334, 0.65078] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM018463 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease sunburn | β: 0.08836 | — | R²: 0.01475 | — | — |
| PPM018465 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: -0.0689 | — | R²: 0.03786 | — | — |
| PPM018459 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Eye colour | β: -0.11302 | — | R²: 0.0106 | — | — |
| PPM018460 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Skin colour | β: -0.05462 | — | R²: 0.01757 | — | — |
| PPM018461 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: 0.09955 | — | R²: 0.02643 | — | — |
| PPM018462 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease suntan | β: -0.06804 | — | R²: 0.01892 | — | — |
| PPM018464 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: -1.51455 | — | R²: 0.04441 | — | — |
| PPM018466 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Blond hair | β: 1.14835 | — | pseudo R²: 0.01006 | — | — |
| PPM007963 | PGS001041 (GBE_cancer1003) |
PSS007621| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.78777 [0.7126, 0.86293] | R²: 0.06151 Incremental AUROC (full-covars): 0.00386 PGS R2 (no covariates): 0.00103 PGS AUROC (no covariates): 0.5229 [0.37426, 0.67153] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007964 | PGS001041 (GBE_cancer1003) |
PSS007622| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.83061 [0.75233, 0.9089] | R²: 0.10839 Incremental AUROC (full-covars): 0.0017 PGS R2 (no covariates): 0.00376 PGS AUROC (no covariates): 0.56985 [0.36492, 0.77477] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007965 | PGS001041 (GBE_cancer1003) |
PSS007623| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.71667 [0.70431, 0.72902] | R²: 0.09613 Incremental AUROC (full-covars): 0.03439 PGS R2 (no covariates): 0.04566 PGS AUROC (no covariates): 0.65086 [0.63722, 0.6645] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007966 | PGS001041 (GBE_cancer1003) |
PSS007624| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.76232 [0.67332, 0.85131] | R²: 0.07091 Incremental AUROC (full-covars): -0.01012 PGS R2 (no covariates): 6e-05 PGS AUROC (no covariates): 0.49291 [0.37897, 0.60686] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007967 | PGS001041 (GBE_cancer1003) |
PSS007625| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.6935 [0.68584, 0.70116] | R²: 0.07834 Incremental AUROC (full-covars): 0.04393 PGS R2 (no covariates): 0.03573 PGS AUROC (no covariates): 0.63289 [0.62459, 0.64118] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008293 | PGS001111 (GBE_cancer1038) |
PSS007626| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.94061 [0.92454, 0.95668] | R²: 0.33303 Incremental AUROC (full-covars): 0.00101 PGS R2 (no covariates): 0.00403 PGS AUROC (no covariates): 0.56122 [0.49463, 0.62782] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008294 | PGS001111 (GBE_cancer1038) |
PSS007627| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.87441 [0.81711, 0.93171] | R²: 0.13571 Incremental AUROC (full-covars): 0.0 PGS R2 (no covariates): 0.0007 PGS AUROC (no covariates): 0.45176 [0.26684, 0.63669] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008295 | PGS001111 (GBE_cancer1038) |
PSS007628| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.88352 [0.86817, 0.89886] | R²: 0.21048 Incremental AUROC (full-covars): 0.00892 PGS R2 (no covariates): 0.01449 PGS AUROC (no covariates): 0.61572 [0.57768, 0.65376] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008296 | PGS001111 (GBE_cancer1038) |
PSS007629| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.85217 [0.80773, 0.89661] | R²: 0.15181 Incremental AUROC (full-covars): 0.00129 PGS R2 (no covariates): 0.00325 PGS AUROC (no covariates): 0.54773 [0.44057, 0.65489] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008297 | PGS001111 (GBE_cancer1038) |
PSS007630| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.8538 [0.84546, 0.86213] | R²: 0.18861 Incremental AUROC (full-covars): 0.00805 PGS R2 (no covariates): 0.00804 PGS AUROC (no covariates): 0.58084 [0.56034, 0.60134] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008542 | PGS001164 (GBE_cancer1045) |
PSS007643| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Testicular cancer | — | AUROC: 0.89735 [0.86792, 0.92679] | R²: 0.1704 Incremental AUROC (full-covars): 0.01226 PGS R2 (no covariates): 0.01529 PGS AUROC (no covariates): 0.62484 [0.5376, 0.71208] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008543 | PGS001164 (GBE_cancer1045) |
PSS007644| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Testicular cancer | — | AUROC: 0.9816 [0.96678, 0.99641] | R²: 0.29699 Incremental AUROC (full-covars): 0.00299 PGS R2 (no covariates): 0.00616 PGS AUROC (no covariates): 0.386 [0.0998, 0.67219] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008544 | PGS001164 (GBE_cancer1045) |
PSS007645| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Testicular cancer | — | AUROC: 0.83915 [0.8185, 0.85981] | R²: 0.1291 Incremental AUROC (full-covars): 0.03126 PGS R2 (no covariates): 0.01573 PGS AUROC (no covariates): 0.62956 [0.58302, 0.67611] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008943 | PGS001289 (GBE_cancer1065) |
PSS007656| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.72837 [0.59989, 0.85685] | R²: 0.0395 Incremental AUROC (full-covars): 0.01385 PGS R2 (no covariates): 0.0141 PGS AUROC (no covariates): 0.6101 [0.46446, 0.75575] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008944 | PGS001289 (GBE_cancer1065) |
PSS007657| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.83233 [0.67782, 0.98683] | R²: 0.16699 Incremental AUROC (full-covars): -0.00184 PGS R2 (no covariates): 0.01024 PGS AUROC (no covariates): 0.54057 [0.24283, 0.83831] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008945 | PGS001289 (GBE_cancer1065) |
PSS007658| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.71465 [0.65621, 0.77309] | R²: 0.04643 Incremental AUROC (full-covars): 0.00897 PGS R2 (no covariates): 0.00455 PGS AUROC (no covariates): 0.55967 [0.48236, 0.63699] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008946 | PGS001289 (GBE_cancer1065) |
PSS007659| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.71171 [0.57425, 0.84917] | R²: 0.04277 Incremental AUROC (full-covars): 0.00229 PGS R2 (no covariates): 0.00022 PGS AUROC (no covariates): 0.51375 [0.35907, 0.66843] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008947 | PGS001289 (GBE_cancer1065) |
PSS007660| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.63744 [0.5901, 0.68478] | R²: 0.016 Incremental AUROC (full-covars): 0.03389 PGS R2 (no covariates): 0.01236 PGS AUROC (no covariates): 0.61843 [0.56413, 0.67273] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008953 | PGS001291 (GBE_cancer1044) |
PSS007636| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.92615 [0.91516, 0.93714] | R²: 0.36445 Incremental AUROC (full-covars): 0.0009 PGS R2 (no covariates): 0.00433 PGS AUROC (no covariates): 0.55467 [0.51548, 0.59387] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008954 | PGS001291 (GBE_cancer1044) |
PSS007637| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.97011 [0.94971, 0.99051] | R²: 0.40156 Incremental AUROC (full-covars): 0.00138 PGS R2 (no covariates): 0.01286 PGS AUROC (no covariates): 0.63402 [0.52345, 0.74459] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008955 | PGS001291 (GBE_cancer1044) |
PSS007638| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.91101 [0.90322, 0.91879] | R²: 0.29589 Incremental AUROC (full-covars): 0.01454 PGS R2 (no covariates): 0.03164 PGS AUROC (no covariates): 0.65437 [0.62906, 0.67968] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008956 | PGS001291 (GBE_cancer1044) |
PSS007639| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.9026 [0.88127, 0.92393] | R²: 0.25031 Incremental AUROC (full-covars): 0.01068 PGS R2 (no covariates): 0.02013 PGS AUROC (no covariates): 0.62511 [0.56383, 0.6864] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008957 | PGS001291 (GBE_cancer1044) |
PSS007640| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.8892 [0.88431, 0.89409] | R²: 0.27234 Incremental AUROC (full-covars): 0.01941 PGS R2 (no covariates): 0.02942 PGS AUROC (no covariates): 0.63978 [0.62584, 0.65373] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008992 | PGS001299 (GBE_cancer1041) |
PSS007631| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Cervical cancer | — | AUROC: 0.81923 [0.77827, 0.86018] | R²: 0.1174 Incremental AUROC (full-covars): -0.00507 PGS R2 (no covariates): 0.00206 PGS AUROC (no covariates): 0.46736 [0.35923, 0.57549] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008993 | PGS001299 (GBE_cancer1041) |
PSS007632| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Cervical cancer | — | AUROC: 0.91431 [0.84118, 0.98744] | R²: 0.22017 Incremental AUROC (full-covars): 0.00128 PGS R2 (no covariates): 0.0 PGS AUROC (no covariates): 0.52896 [0.28465, 0.77326] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008994 | PGS001299 (GBE_cancer1041) |
PSS007633| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Cervical cancer | — | AUROC: 0.76761 [0.74661, 0.7886] | R²: 0.11284 Incremental AUROC (full-covars): 0.00676 PGS R2 (no covariates): 0.00263 PGS AUROC (no covariates): 0.55215 [0.51478, 0.58952] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008995 | PGS001299 (GBE_cancer1041) |
PSS007634| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Cervical cancer | — | AUROC: 0.83945 [0.77567, 0.90324] | R²: 0.13265 Incremental AUROC (full-covars): -0.00075 PGS R2 (no covariates): 0.00058 PGS AUROC (no covariates): 0.46169 [0.30956, 0.61382] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008996 | PGS001299 (GBE_cancer1041) |
PSS007635| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Cervical cancer | — | AUROC: 0.7705 [0.75816, 0.78284] | R²: 0.11652 Incremental AUROC (full-covars): 0.00962 PGS R2 (no covariates): 0.00294 PGS AUROC (no covariates): 0.54769 [0.52291, 0.57247] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009166 | PGS001336 (GBE_cancer1002) |
PSS007616| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.79293 [0.76728, 0.81858] | R²: 0.15047 Incremental AUROC (full-covars): 0.01474 PGS R2 (no covariates): 0.00598 PGS AUROC (no covariates): 0.56918 [0.51783, 0.62054] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009167 | PGS001336 (GBE_cancer1002) |
PSS007617| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.7602 [0.71475, 0.80565] | R²: 0.14344 Incremental AUROC (full-covars): 0.01509 PGS R2 (no covariates): 0.01507 PGS AUROC (no covariates): 0.59411 [0.51563, 0.67258] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009168 | PGS001336 (GBE_cancer1002) |
PSS007618| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.80561 [0.79545, 0.81577] | R²: 0.18447 Incremental AUROC (full-covars): 0.01345 PGS R2 (no covariates): 0.01264 PGS AUROC (no covariates): 0.58544 [0.56669, 0.6042] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009169 | PGS001336 (GBE_cancer1002) |
PSS007619| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.83564 [0.81289, 0.85838] | R²: 0.18535 Incremental AUROC (full-covars): 0.00869 PGS R2 (no covariates): 0.00739 PGS AUROC (no covariates): 0.5725 [0.52745, 0.61755] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009170 | PGS001336 (GBE_cancer1002) |
PSS007620| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.80961 [0.80348, 0.81573] | R²: 0.1894 Incremental AUROC (full-covars): 0.02139 PGS R2 (no covariates): 0.01602 PGS AUROC (no covariates): 0.59627 [0.58498, 0.60756] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005178 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors | — | — | Relative Rate (RR): 1.57 [1.24, 1.98] | Attained age modeled by restricted cubic splines | — |
| PPM005179 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors who had received neck radiotherapy | — | — | Relative Rate (RR): 1.68 [1.29, 2.18] | Attained age modeled by restricted cubic splines | — |
| PPM005180 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors | — | — | Relative Rate (RR): 1.52 [1.25, 1.83] | Attained age modeled by restricted cubic splines | — |
| PPM005181 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors who had received neck radiotherapy | — | — | Relative Rate (RR): 1.42 [1.09, 1.85] | Attained age modeled by restricted cubic splines | — |
| PPM005182 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors who had not received neck radiotherapy | — | — | Relative Rate (RR): 1.66 [1.26, 2.2] | Attained age modeled by restricted cubic splines | — |
| PPM005183 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 40 | — | AUROC: 0.83 C-index: 0.842 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
| PPM005184 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 40 | — | AUROC: 0.73 C-index: 0.73 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
| PPM005185 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 50 | — | AUROC: 0.82 C-index: 0.834 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
| PPM005186 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 50 | — | AUROC: 0.72 C-index: 0.727 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
| PPM009239 | PGS001776 (PRS45_CC) |
PSS007664| European Ancestry| 403,998 individuals |
PGP000256 | Gafni A et al. PLoS One (2021) |
Reported Trait: Full lifetime risk of colorectal cancer | β: 1.848 | AUROC: 0.673 [0.664, 0.682] | — | Family history | — |
| PPM009240 | PGS001776 (PRS45_CC) |
PSS007664| European Ancestry| 403,998 individuals |
PGP000256 | Gafni A et al. PLoS One (2021) |
Reported Trait: 10-year risk of colorectal cancer | β: 1.088 | AUROC: 0.674 [0.665, 0.683] | — | Family history | — |
| PPM009262 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.66 [1.25, 2.2] | AUROC: 0.548 | — | Age | — |
| PPM009264 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.57 [1.18, 2.08] | AUROC: 0.578 | — | Age, family history | — |
| PPM009261 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.66 [1.25, 2.19] | AUROC: 0.547 [0.52, 0.57] | — | — | — |
| PPM009263 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.56 [1.18, 2.08] | AUROC: 0.578 | — | Family history | — |
| PPM009265 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | — | AUROC: 0.6975 [0.673, 0.722] | Odds Ratio (OR, top 10% vs middle10%): 4.58 [2.88, 7.4] | Age at interview, menopausal status, age at menarche, age at first full-term pregnancy(1-4), parous, breast feeding, smoking status, body mass index, height, hormone-replacement therapy ever use, family history | — |
| PPM009298 | PGS001794 (1kgeur_gbmi_leaveUKBBout_ThC_pst_eff_a1_b0.5_phiauto) |
PSS007717| European Ancestry| 358,476 individuals |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Reported Trait: Thyroid cancer | — | AUROC: 0.676 | Nagelkerke's R2 (covariates regressed out): 0.01366 | sex,age,age2,age*sex,age^2*sex, 20PCs | — |
| PPM009299 | PGS001795 (1kgeur_gbmi_leaveUKBBout_UtC_pst_eff_a1_b0.5_phiauto) |
PSS007718| European Ancestry| 170,276 individuals |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Reported Trait: Uterine cancer | — | AUROC: 0.66 | Nagelkerke's R2 (covariates regressed out): 0.00195 | sex,age,age2,age*sex,age^2*sex, 20PCs | — |
| PPM009315 | PGS001799 (1kgeur_gbmi_ThC_pst_eff_a1_b0.5_phiauto) |
PSS007697| European Ancestry| 7,128 individuals |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Reported Trait: Thyroid cancer | — | AUROC: 0.685 | Nagelkerke's R2 (covariates regressed out): 0.01036 | sex,age, 20PCs | — |
| PPM009322 | PGS001802 (portability-PLR_153) |
PSS009272| European Ancestry| 18,722 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0376 [0.0233, 0.0519] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009323 | PGS001802 (portability-PLR_153) |
PSS009046| European Ancestry| 3,922 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0422 [0.0108, 0.0735] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009324 | PGS001802 (portability-PLR_153) |
PSS008600| European Ancestry| 6,241 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0237 [-0.0012, 0.0485] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009325 | PGS001802 (portability-PLR_153) |
PSS008378| Greater Middle Eastern Ancestry| 1,123 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0416 [-0.0175, 0.1004] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009326 | PGS001802 (portability-PLR_153) |
PSS008154| South Asian Ancestry| 6,010 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0135 [-0.0118, 0.0389] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009327 | PGS001802 (portability-PLR_153) |
PSS007942| East Asian Ancestry| 1,719 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0226 [-0.025, 0.0701] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009328 | PGS001802 (portability-PLR_153) |
PSS007724| African Ancestry| 2,362 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0193 [-0.0212, 0.0598] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009329 | PGS001802 (portability-PLR_153) |
PSS008826| African Ancestry| 3,757 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0259 [-0.0062, 0.0579] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009332 | PGS001803 (portability-PLR_172) |
PSS008601| European Ancestry| 6,656 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0762 [0.0522, 0.1001] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009333 | PGS001803 (portability-PLR_172) |
PSS008379| Greater Middle Eastern Ancestry| 1,200 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0694 [0.0123, 0.1259] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009334 | PGS001803 (portability-PLR_172) |
PSS008155| South Asian Ancestry| 6,328 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0135 [-0.0382, 0.0112] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009330 | PGS001803 (portability-PLR_172) |
PSS009273| European Ancestry| 19,990 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.1136 [0.0999, 0.1272] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009331 | PGS001803 (portability-PLR_172) |
PSS009047| European Ancestry| 4,134 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0962 [0.0659, 0.1264] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009335 | PGS001803 (portability-PLR_172) |
PSS007943| East Asian Ancestry| 1,810 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0054 [-0.041, 0.0517] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009336 | PGS001803 (portability-PLR_172) |
PSS007725| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0065 [-0.046, 0.033] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009337 | PGS001803 (portability-PLR_172) |
PSS008827| African Ancestry| 3,924 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0165 [-0.0149, 0.0479] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009338 | PGS001804 (portability-PLR_174.1) |
PSS009274| European Ancestry| 10,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1101 [0.0908, 0.1292] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009339 | PGS001804 (portability-PLR_174.1) |
PSS009048| European Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0843 [0.0446, 0.1237] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009340 | PGS001804 (portability-PLR_174.1) |
PSS008602| European Ancestry| 3,484 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1125 [0.0795, 0.1453] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009343 | PGS001804 (portability-PLR_174.1) |
PSS007944| East Asian Ancestry| 1,143 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0983 [0.0401, 0.1559] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009344 | PGS001804 (portability-PLR_174.1) |
PSS007726| African Ancestry| 1,482 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0416 [-0.0097, 0.0927] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009345 | PGS001804 (portability-PLR_174.1) |
PSS008828| African Ancestry| 2,035 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0889 [0.0454, 0.132] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009341 | PGS001804 (portability-PLR_174.1) |
PSS008380| Greater Middle Eastern Ancestry| 467 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0772 [-0.0155, 0.1687] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009342 | PGS001804 (portability-PLR_174.1) |
PSS008156| South Asian Ancestry| 2,782 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0673 [0.0301, 0.1044] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009346 | PGS001805 (portability-PLR_185) |
PSS009275| European Ancestry| 8,501 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1532 [0.1323, 0.1739] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009347 | PGS001805 (portability-PLR_185) |
PSS009049| European Ancestry| 1,468 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.168 [0.1175, 0.2176] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009348 | PGS001805 (portability-PLR_185) |
PSS008603| European Ancestry| 2,749 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0919 [0.0546, 0.129] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009349 | PGS001805 (portability-PLR_185) |
PSS008381| Greater Middle Eastern Ancestry| 664 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1243 [0.0476, 0.1996] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009350 | PGS001805 (portability-PLR_185) |
PSS008157| South Asian Ancestry| 3,182 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0832 [0.0484, 0.1177] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009351 | PGS001805 (portability-PLR_185) |
PSS007945| East Asian Ancestry| 575 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0843 [0.0011, 0.1663] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009353 | PGS001805 (portability-PLR_185) |
PSS008829| African Ancestry| 1,711 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0537 [0.006, 0.1011] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009352 | PGS001805 (portability-PLR_185) |
PSS007727| African Ancestry| 844 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0638 [-0.0044, 0.1315] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009359 | PGS001807 (portability-PLR_189.2) |
PSS009277| European Ancestry| 19,893 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0197 [0.0058, 0.0336] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009360 | PGS001807 (portability-PLR_189.2) |
PSS009051| European Ancestry| 4,121 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0266 [-0.004, 0.0572] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009361 | PGS001807 (portability-PLR_189.2) |
PSS008605| European Ancestry| 6,645 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0169 [-0.0072, 0.041] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009362 | PGS001807 (portability-PLR_189.2) |
PSS008382| Greater Middle Eastern Ancestry| 1,195 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0347 [-0.0225, 0.0917] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009363 | PGS001807 (portability-PLR_189.2) |
PSS008159| South Asian Ancestry| 6,301 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): -0.0016 [-0.0263, 0.0231] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009365 | PGS001807 (portability-PLR_189.2) |
PSS007728| African Ancestry| 2,471 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): -0.0043 [-0.0439, 0.0353] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009366 | PGS001807 (portability-PLR_189.2) |
PSS008831| African Ancestry| 3,914 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0359 [0.0045, 0.0673] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009364 | PGS001807 (portability-PLR_189.2) |
PSS007946| East Asian Ancestry| 1,803 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0321 [-0.0144, 0.0784] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009371 | PGS001808 (portability-PLR_191.11) |
PSS007947| East Asian Ancestry| 1,801 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0004 [-0.0461, 0.0468] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009367 | PGS001808 (portability-PLR_191.11) |
PSS009278| European Ancestry| 19,895 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0144 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009368 | PGS001808 (portability-PLR_191.11) |
PSS009052| European Ancestry| 4,114 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0179 [-0.0128, 0.0485] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009369 | PGS001808 (portability-PLR_191.11) |
PSS008606| European Ancestry| 6,626 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0237 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009370 | PGS001808 (portability-PLR_191.11) |
PSS008160| South Asian Ancestry| 6,310 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0098 [-0.0149, 0.0345] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009372 | PGS001808 (portability-PLR_191.11) |
PSS007729| African Ancestry| 2,477 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0217 [-0.0179, 0.0612] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009373 | PGS001808 (portability-PLR_191.11) |
PSS008832| African Ancestry| 3,913 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of brain | — | — | Partial Correlation (partial-r): 0.0343 [0.0029, 0.0657] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009374 | PGS001809 (portability-PLR_193) |
PSS009279| European Ancestry| 19,923 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0307 [0.0168, 0.0446] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009377 | PGS001809 (portability-PLR_193) |
PSS008383| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0014 [-0.0586, 0.0557] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009378 | PGS001809 (portability-PLR_193) |
PSS008161| South Asian Ancestry| 6,305 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0052 [-0.0195, 0.0299] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009379 | PGS001809 (portability-PLR_193) |
PSS007948| East Asian Ancestry| 1,801 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0121 [-0.0585, 0.0344] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009380 | PGS001809 (portability-PLR_193) |
PSS007730| African Ancestry| 2,453 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0102 [-0.0296, 0.0499] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009381 | PGS001809 (portability-PLR_193) |
PSS008833| African Ancestry| 3,896 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0008 [-0.0307, 0.0323] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009375 | PGS001809 (portability-PLR_193) |
PSS009053| European Ancestry| 4,120 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0082 [-0.0388, 0.0225] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009376 | PGS001809 (portability-PLR_193) |
PSS008607| European Ancestry| 6,640 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0196 [-0.0045, 0.0437] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009382 | PGS001810 (portability-PLR_200.1) |
PSS009280| European Ancestry| 19,539 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Polycythemia vera | — | — | Partial Correlation (partial-r): 0.017 [0.003, 0.031] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009383 | PGS001810 (portability-PLR_200.1) |
PSS009054| European Ancestry| 4,052 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Polycythemia vera | — | — | Partial Correlation (partial-r): 0.0195 [-0.0114, 0.0503] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009384 | PGS001810 (portability-PLR_200.1) |
PSS008608| European Ancestry| 6,489 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Polycythemia vera | — | — | Partial Correlation (partial-r): 0.026 [0.0016, 0.0503] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009385 | PGS001810 (portability-PLR_200.1) |
PSS008384| Greater Middle Eastern Ancestry| 1,178 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Polycythemia vera | — | — | Partial Correlation (partial-r): -0.0173 [-0.0748, 0.0404] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009386 | PGS001810 (portability-PLR_200.1) |
PSS008162| South Asian Ancestry| 6,171 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Polycythemia vera | — | — | Partial Correlation (partial-r): -0.0038 [-0.0288, 0.0212] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009387 | PGS001810 (portability-PLR_200.1) |
PSS007949| East Asian Ancestry| 1,787 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Polycythemia vera | — | — | Partial Correlation (partial-r): -0.0072 [-0.0538, 0.0395] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010978 | PGS002013 (portability-ldpred2_153) |
PSS009272| European Ancestry| 18,722 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0397 [0.0254, 0.054] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010979 | PGS002013 (portability-ldpred2_153) |
PSS009046| European Ancestry| 3,922 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0419 [0.0105, 0.0732] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010980 | PGS002013 (portability-ldpred2_153) |
PSS008600| European Ancestry| 6,241 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0234 [-0.0015, 0.0482] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010981 | PGS002013 (portability-ldpred2_153) |
PSS008378| Greater Middle Eastern Ancestry| 1,123 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0315 [-0.0276, 0.0904] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010982 | PGS002013 (portability-ldpred2_153) |
PSS008154| South Asian Ancestry| 6,010 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0275 [0.0021, 0.0528] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010983 | PGS002013 (portability-ldpred2_153) |
PSS007942| East Asian Ancestry| 1,719 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.026 [-0.0215, 0.0735] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010984 | PGS002013 (portability-ldpred2_153) |
PSS007724| African Ancestry| 2,362 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0053 [-0.0352, 0.0458] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010985 | PGS002013 (portability-ldpred2_153) |
PSS008826| African Ancestry| 3,757 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | — | — | Partial Correlation (partial-r): 0.0265 [-0.0056, 0.0585] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010986 | PGS002014 (portability-ldpred2_172) |
PSS009273| European Ancestry| 19,990 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.1242 [0.1105, 0.1378] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010990 | PGS002014 (portability-ldpred2_172) |
PSS008155| South Asian Ancestry| 6,328 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0147 [-0.0394, 0.01] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010991 | PGS002014 (portability-ldpred2_172) |
PSS007943| East Asian Ancestry| 1,810 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0041 [-0.0504, 0.0423] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010992 | PGS002014 (portability-ldpred2_172) |
PSS007725| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0062 [-0.0457, 0.0333] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010993 | PGS002014 (portability-ldpred2_172) |
PSS008827| African Ancestry| 3,924 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0146 [-0.0168, 0.0459] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010987 | PGS002014 (portability-ldpred2_172) |
PSS009047| European Ancestry| 4,134 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0876 [0.0572, 0.1178] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010988 | PGS002014 (portability-ldpred2_172) |
PSS008601| European Ancestry| 6,656 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.076 [0.0521, 0.0999] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010989 | PGS002014 (portability-ldpred2_172) |
PSS008379| Greater Middle Eastern Ancestry| 1,200 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0717 [0.0147, 0.1282] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010994 | PGS002015 (portability-ldpred2_174.1) |
PSS009274| European Ancestry| 10,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1132 [0.094, 0.1324] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010995 | PGS002015 (portability-ldpred2_174.1) |
PSS009048| European Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0807 [0.041, 0.1201] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010996 | PGS002015 (portability-ldpred2_174.1) |
PSS008602| European Ancestry| 3,484 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1091 [0.076, 0.1419] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010997 | PGS002015 (portability-ldpred2_174.1) |
PSS008380| Greater Middle Eastern Ancestry| 467 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0976 [0.005, 0.1885] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010998 | PGS002015 (portability-ldpred2_174.1) |
PSS008156| South Asian Ancestry| 2,782 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0798 [0.0426, 0.1167] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010999 | PGS002015 (portability-ldpred2_174.1) |
PSS007944| East Asian Ancestry| 1,143 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1146 [0.0565, 0.1719] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011000 | PGS002015 (portability-ldpred2_174.1) |
PSS007726| African Ancestry| 1,482 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0482 [-0.0031, 0.0992] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011001 | PGS002015 (portability-ldpred2_174.1) |
PSS008828| African Ancestry| 2,035 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0842 [0.0407, 0.1274] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011002 | PGS002016 (portability-ldpred2_185) |
PSS009275| European Ancestry| 8,501 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1489 [0.128, 0.1696] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011003 | PGS002016 (portability-ldpred2_185) |
PSS009049| European Ancestry| 1,468 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1605 [0.1099, 0.2103] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011004 | PGS002016 (portability-ldpred2_185) |
PSS008603| European Ancestry| 2,749 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0944 [0.057, 0.1314] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011006 | PGS002016 (portability-ldpred2_185) |
PSS008157| South Asian Ancestry| 3,182 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0875 [0.0528, 0.1219] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011007 | PGS002016 (portability-ldpred2_185) |
PSS007945| East Asian Ancestry| 575 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0813 [-0.0018, 0.1634] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011008 | PGS002016 (portability-ldpred2_185) |
PSS007727| African Ancestry| 844 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0792 [0.011, 0.1466] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011009 | PGS002016 (portability-ldpred2_185) |
PSS008829| African Ancestry| 1,711 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0467 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011005 | PGS002016 (portability-ldpred2_185) |
PSS008381| Greater Middle Eastern Ancestry| 664 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1504 [0.0741, 0.225] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011010 | PGS002017 (portability-ldpred2_189.2) |
PSS009277| European Ancestry| 19,893 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0181 [0.0042, 0.032] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011011 | PGS002017 (portability-ldpred2_189.2) |
PSS009051| European Ancestry| 4,121 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0333 [0.0026, 0.0638] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011012 | PGS002017 (portability-ldpred2_189.2) |
PSS008605| European Ancestry| 6,645 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0144 [-0.0097, 0.0385] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011013 | PGS002017 (portability-ldpred2_189.2) |
PSS008382| Greater Middle Eastern Ancestry| 1,195 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0296 [-0.0276, 0.0867] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011014 | PGS002017 (portability-ldpred2_189.2) |
PSS008159| South Asian Ancestry| 6,301 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0047 [-0.02, 0.0294] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011015 | PGS002017 (portability-ldpred2_189.2) |
PSS007946| East Asian Ancestry| 1,803 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0257 [-0.0208, 0.072] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011017 | PGS002017 (portability-ldpred2_189.2) |
PSS008831| African Ancestry| 3,914 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0257 [-0.0057, 0.0571] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011016 | PGS002017 (portability-ldpred2_189.2) |
PSS007728| African Ancestry| 2,471 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): -0.0071 [-0.0467, 0.0325] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011018 | PGS002018 (portability-ldpred2_193) |
PSS009279| European Ancestry| 19,923 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0295 [0.0157, 0.0434] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011019 | PGS002018 (portability-ldpred2_193) |
PSS009053| European Ancestry| 4,120 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0056 [-0.0362, 0.0251] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011020 | PGS002018 (portability-ldpred2_193) |
PSS008607| European Ancestry| 6,640 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0208 [-0.0033, 0.0448] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011021 | PGS002018 (portability-ldpred2_193) |
PSS008383| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0107 [-0.0677, 0.0465] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011022 | PGS002018 (portability-ldpred2_193) |
PSS008161| South Asian Ancestry| 6,305 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0149 [-0.0098, 0.0396] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011023 | PGS002018 (portability-ldpred2_193) |
PSS007948| East Asian Ancestry| 1,801 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.004 [-0.0505, 0.0424] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011024 | PGS002018 (portability-ldpred2_193) |
PSS007730| African Ancestry| 2,453 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0184 [-0.0213, 0.0581] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011025 | PGS002018 (portability-ldpred2_193) |
PSS008833| African Ancestry| 3,896 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0029 [-0.0286, 0.0343] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012760 | PGS002240 (prscs_prostatecancer) |
PSS009544| European Ancestry| 343,676 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 2.14 [2.09, 2.19] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012770 | PGS002240 (prscs_prostatecancer) |
PSS009548| South Asian Ancestry| 7,628 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 2.54 [1.98, 3.26] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012765 | PGS002240 (prscs_prostatecancer) |
PSS009540| African Ancestry| 7,618 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.43 [1.21, 1.69] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012739 | PGS002241 (ldpred_prostatecancer) |
PSS009520| European Ancestry| 110,597 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.79 [1.68, 1.91] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012743 | PGS002241 (ldpred_prostatecancer) |
PSS009516| East Asian Ancestry| 178,726 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.69 [1.64, 1.74] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012747 | PGS002241 (ldpred_prostatecancer) |
PSS009528| European Ancestry| 69,422 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.8 [1.72, 1.88] | — | — | birth year, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012751 | PGS002241 (ldpred_prostatecancer) |
PSS009536| European Ancestry| 25,696 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.66 [1.57, 1.76] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012755 | PGS002241 (ldpred_prostatecancer) |
PSS009532| African Ancestry| 1,535 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.19 [0.91, 1.55] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012759 | PGS002241 (ldpred_prostatecancer) |
PSS009544| European Ancestry| 343,676 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.91 [1.86, 1.96] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012764 | PGS002241 (ldpred_prostatecancer) |
PSS009540| African Ancestry| 7,618 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.35 [1.14, 1.61] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012769 | PGS002241 (ldpred_prostatecancer) |
PSS009548| South Asian Ancestry| 7,628 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 2.21 [1.73, 2.81] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012735 | PGS002241 (ldpred_prostatecancer) |
PSS009524| European Ancestry| 258,402 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.96 [1.91, 2.01] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012734 | PGS002242 (ldpred_breastcancer) |
PSS009523| European Ancestry| 258,402 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.48 [1.45, 1.51] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012738 | PGS002242 (ldpred_breastcancer) |
PSS009519| European Ancestry| 110,597 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.45 [1.37, 1.53] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012742 | PGS002242 (ldpred_breastcancer) |
PSS009515| East Asian Ancestry| 178,726 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.25 [1.21, 1.28] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012746 | PGS002242 (ldpred_breastcancer) |
PSS009527| European Ancestry| 69,422 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.5 [1.43, 1.58] | — | — | birth year, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012750 | PGS002242 (ldpred_breastcancer) |
PSS009535| European Ancestry| 25,696 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.45 [1.38, 1.54] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012754 | PGS002242 (ldpred_breastcancer) |
PSS009531| African Ancestry| 1,535 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 0.9 [0.69, 1.17] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012758 | PGS002242 (ldpred_breastcancer) |
PSS009543| European Ancestry| 343,676 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.5 [1.47, 1.53] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012763 | PGS002242 (ldpred_breastcancer) |
PSS009539| African Ancestry| 7,618 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.12 [0.93, 1.35] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012768 | PGS002242 (ldpred_breastcancer) |
PSS009547| South Asian Ancestry| 7,628 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.47 [1.23, 1.75] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM016269 | PGS002250 (PRS_S4) |
PSS010091| European Ancestry| 198,758 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer | OR: 1.38 [1.28, 1.48] | AUROC: 0.588 | — | — | — |
| PPM016270 | PGS002250 (PRS_S4) |
PSS010087| European Ancestry| 18,915 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer in BRCA1 carriers | HR: 1.36 [1.29, 1.43] | AUROC: 0.592 | — | — | — |
| PPM016271 | PGS002250 (PRS_S4) |
PSS010088| European Ancestry| 12,337 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer in BRCA2 carriers | HR: 1.49 [1.35, 1.64] | AUROC: 0.624 | — | — | — |
| PPM016272 | PGS002250 (PRS_S4) |
PSS010090| East Asian Ancestry| 7,669 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer | OR: 1.14 [1.08, 1.19] | AUROC: 0.538 | — | — | — |
| PPM016273 | PGS002250 (PRS_S4) |
PSS010089| African Ancestry| 1,072 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer | OR: 1.38 [1.21, 1.58] | AUROC: 0.593 | — | — | — |
| PPM012805 | PGS002252 (PRS_CRC) |
PSS009566| European Ancestry| 7,376 individuals |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Reported Trait: Early-onset colorectal cancer | OR: 1.59 [1.51, 1.68] | AUROC: 0.628 [0.613, 0.644] | — | Age, sex, genotype platform, family history, principal components | — |
| PPM012806 | PGS002252 (PRS_CRC) |
PSS009566| European Ancestry| 7,376 individuals |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Reported Trait: Early-onset colorectal cancer (men) | — | AUROC: 0.61 [0.592, 0.651] | — | Age, family history, genotype platform, principal components | — |
| PPM012807 | PGS002252 (PRS_CRC) |
PSS009566| European Ancestry| 7,376 individuals |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Reported Trait: Early-onset colorectal cancer (women) | — | AUROC: 0.633 [0.612, 0.655] | — | Age, family history, genotype platform, principal components | — |
| PPM012808 | PGS002252 (PRS_CRC) |
PSS009566| European Ancestry| 7,376 individuals |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Reported Trait: Proximal colon cancer | OR: 1.38 [1.27, 1.5] | AUROC: 0.592 [0.554, 0.63] | — | Age, family history, genotype platform, principal components | — |
| PPM012809 | PGS002252 (PRS_CRC) |
PSS009566| European Ancestry| 7,376 individuals |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Reported Trait: Distal colon cancer | OR: 1.73 [1.6, 1.87] | AUROC: 0.643 [0.614, 0.671] | — | Age, family history, genotype platform, principal components | — |
| PPM012810 | PGS002252 (PRS_CRC) |
PSS009566| European Ancestry| 7,376 individuals |
PGP000279 | Archambault AN et al. J Natl Cancer Inst (2022) |
Reported Trait: Rectal cancer | OR: 1.67 [1.55, 1.8] | AUROC: 0.654 [0.63, 0.68] | — | Age, family history, genotype platform, principal components | — |
| PPM012888 | PGS002264 (PRS_Combined) |
PSS009595| Ancestry Not Reported| 11,462 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma | — | AUROC: 0.605 [0.587, 0.623] | Positive predictive values (PPV highest quintile): 14.4 [13, 15.9] | — | — |
| PPM012894 | PGS002264 (PRS_Combined) |
PSS009600| Ancestry Not Reported| 206 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (with long-standing diabetes mellitus) | — | — | Positive predictive values (PPV highest quintile): 0.239 [0.181, 0.303] | — | — |
| PPM012892 | PGS002264 (PRS_Combined) |
PSS009598| Ancestry Not Reported| 10,259 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (without diabetes mellitus) | — | AUROC: 0.594 [0.573, 0.614] | Positive predictive values (PPV highest quintile): 0.119 [0.105, 0.134] | — | — |
| PPM012895 | PGS002264 (PRS_Combined) |
PSS009600| Ancestry Not Reported| 206 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (with long-standing diabetes mellitus) | OR: 1.873 [1.53, 2.292] | — | — | principal components (PC 1-10) | — |
| PPM012896 | PGS002264 (PRS_Combined) |
PSS009601| Ancestry Not Reported| 998 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (with new onset diabetes mellitus) | — | — | Positive predictive values (PPV highest quintile): 0.867 [0.732, 0.949] | — | — |
| PPM012897 | PGS002264 (PRS_Combined) |
PSS009601| Ancestry Not Reported| 998 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (with new onset diabetes mellitus) | OR: 1.885 [1.279, 2.778] | — | — | principal components (PC 1-10) | — |
| PPM012898 | PGS002264 (PRS_Combined) |
PSS009596| Ancestry Not Reported| 1,203 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (with diabetes mellitus) | OR: 1.674 [1.443, 1.942] | — | — | principal components (PC 1-10) | — |
| PPM012899 | PGS002264 (PRS_Combined) |
PSS009596| Ancestry Not Reported| 1,203 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (with diabetes mellitus) | — | AUROC: 0.645 | — | — | — |
| PPM012900 | PGS002264 (PRS_Combined) |
PSS009597| Ancestry Not Reported| 242 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (< 60 years) | OR: 1.633 [1.292, 2.064] | — | — | principal components (PC 1-10) | — |
| PPM012901 | PGS002264 (PRS_Combined) |
PSS009599| Ancestry Not Reported| 274 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (60 years) | OR: 1.538 [1.287, 1.837] | — | — | principal components (PC 1-10) | — |
| PPM012893 | PGS002264 (PRS_Combined) |
PSS009598| Ancestry Not Reported| 10,259 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma (without diabetes mellitus) | OR: 1.386 [1.288, 1.492] | — | — | principal components (PC 1-10) | — |
| PPM012889 | PGS002264 (PRS_Combined) |
PSS009595| Ancestry Not Reported| 11,462 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma | — | — | HR (highest vs lowest quintile): 2.738 [2.227, 3.365] | Smoking (never, current and previous), waist circumference (cm), DM onset (No DM, NODM, LSDM) and first-degree family history of digestive cancer (yes/no) | — |
| PPM012890 | PGS002264 (PRS_Combined) |
PSS009595| Ancestry Not Reported| 11,462 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma | — | AUROC: 0.83 [0.8, 0.86] | — | Age of participants at recruitment, age when DM diagnosed, DM onset (No DM, NODM, LSDM), waist circumference (cm), and first-degree family history of digestive cancer (yes/no)., clinical risk | — |
| PPM012891 | PGS002264 (PRS_Combined) |
PSS009595| Ancestry Not Reported| 11,462 individuals |
PGP000293 | Sharma S et al. Gastroenterology (2022) |
Reported Trait: Incident pancreatic ductal adenocarcinoma | OR: 1.43 | — | — | principal components (PC 1-10) | — |
| PPM013009 | PGS002265 (PRS140_CRC) |
PSS009645| Ancestry Not Reported| 8,405 individuals |
PGP000319 | Guo F et al. Clin Gastroenterol Hepatol (2022) |Ext. |
Reported Trait: Risk of colorectal cancer | — | — | Odds ratio (OR, high vs low): 2.61 [2.33, 2.93] | Age, sex, education, body mass index, participation in a health check-up, family history of colorectal cancer, smoking, ever regular use of nonsteroidal anti-inflammatory drugs, and ever regular use of hormone replacement therapy | — |
| PPM014884 | PGS002265 (PRS140_CRC) |
PSS009918| European Ancestry| 5,306 individuals |
PGP000350 | Niedermaier T et al. Cancer Prev Res (Phila) (2022) |Ext. |
Reported Trait: Advanced colorectal neoplasia (Ridascreen model) | OR: 1.025 β: 0.02451 |
AUROC: 0.524 [0.499, 0.55] | — | — | — |
| PPM014885 | PGS002265 (PRS140_CRC) |
PSS009918| European Ancestry| 5,306 individuals |
PGP000350 | Niedermaier T et al. Cancer Prev Res (Phila) (2022) |Ext. |
Reported Trait: Advanced colorectal neoplasia (FOB Gold model) | OR: 1.036 β: 0.03518 |
AUROC: 0.53 [0.516, 0.545] | — | — | — |
| PPM018664 | PGS002265 (PRS140_CRC) |
PSS011059| European Ancestry| 72,791 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.629 [0.613, 0.645] | Hazard Ratio (HR, top 30% of PGS vs. remainder): 1.92 [1.75, 2.23] | age, sex | — |
| PPM018665 | PGS002265 (PRS140_CRC) |
PSS011058| East Asian Ancestry| 6,966 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.591 [0.536, 0.625] | — | age, sex | — |
| PPM018666 | PGS002265 (PRS140_CRC) |
PSS011060| Hispanic or Latin American Ancestry| 6,660 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.592 [0.531, 0.652] | — | age, sex | — |
| PPM018667 | PGS002265 (PRS140_CRC) |
PSS011057| African Ancestry| 5,249 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.581 [0.5, 0.645] | — | age, sex | — |
| PPM018668 | PGS002265 (PRS140_CRC) |
PSS011061| European Ancestry| 38,214 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.591 | — | age, sex | — |
| PPM020729 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.615 [0.529, 0.7] | — | — | — |
| PPM020730 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Advanced adenoma | — | AUROC: 0.589 [0.562, 0.616] | — | — | — |
| PPM020731 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Non-advanced adenoma | — | AUROC: 0.555 [0.534, 0.576] | — | — | — |
| PPM020732 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms | — | AUROC: 0.591 [0.564, 0.617] | — | — | — |
| PPM020733 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (50 - 59 years) | — | AUROC: 0.586 [0.544, 0.628] | — | — | — |
| PPM020734 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (60 - 79 years) | — | AUROC: 0.597 [0.563, 0.631] | — | — | — |
| PPM020735 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (men) | — | AUROC: 0.593 [0.558, 0.629] | — | — | — |
| PPM020736 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (women) | — | AUROC: 0.593 [0.553, 0.633] | — | — | — |
| PPM020737 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (family history) | — | AUROC: 0.555 [0.471 - 0.639 | — | — | — |
| PPM020738 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (non family history) | — | AUROC: 0.599 [0.57, 0.627] | — | — | — |
| PPM020739 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (previous colonoscopy) | — | AUROC: 0.607 [0.551, 0.663] | — | — | — |
| PPM020740 | PGS002265 (PRS140_CRC) |
PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (no previous colonoscopy) | — | AUROC: 0.585 [0.555, 0.616] | — | — | — |
| PPM020902 | PGS002265 (PRS140_CRC) |
PSS011444| Multi-ancestry (including European)| 4,035 individuals |
PGP000601 | Niedermaier T et al. Clin Transl Gastroenterol (2022) |Ext. |
Reported Trait: Advanced neoplasia (colorectal cancer or advanced adenoma) | — | — | Positive predictive value (PPV, highest PRS tertile): 39.0 [36.0, 42.0] | — | Intermediate (90% specificity) FIT cutoff. |
| PPM020901 | PGS002265 (PRS140_CRC) |
PSS011445| Multi-ancestry (including European)| 1,271 individuals |
PGP000601 | Niedermaier T et al. Clin Transl Gastroenterol (2022) |Ext. |
Reported Trait: Advanced neoplasia (colorectal cancer or advanced adenoma) | — | — | Positive predictive value (PPV, highest PRS tertile): 37.0 [31.0, 43.0] | — | Intermediate (90% specificity) FIT cutoff. |
| PPM012919 | PGS002268 (PRS_csPCa) |
PSS009617| East Asian Ancestry| 1,133 individuals |
PGP000298 | Song SH et al. Investig Clin Urol (2022) |
Reported Trait: Clinically significant prostate cancer | — | AUROC: 0.7 [0.667, 0.734] | OR (very high vs moderate group): 4.92 | — | — |
| PPM017160 | PGS002268 (PRS_csPCa) |
PSS010141| East Asian Ancestry| 3,695 individuals |
PGP000442 | Song SH et al. Sci Rep (2023) |Ext. |
Reported Trait: Aggressive prostate cancer (Grade 3 or above) | — | — | Hazard Ratio (HR, top 25% vs bottom 25%): 2.026 [1.678, 2.446] | — | Only 22 SNPs from PGS002268 were utilised. 7 SNPs were not included due to inadequately low allele frequencies or call rates. rs72725879 was replaced with the next highest performing variant (rs1456315) in the same LD block (Locus PRNCR1) due to replication inconsistencies. |
| PPM017161 | PGS002268 (PRS_csPCa) |
PSS010140| East Asian Ancestry| 3,695 individuals |
PGP000442 | Song SH et al. Sci Rep (2023) |Ext. |
Reported Trait: Aggressive prostate cancer (Grade 2 or above) | — | — | Hazard Ratio (HR, top 25% vs bottom 25%): 4.649 [3.544, 6.098] | — | Only 22 SNPs from PGS002268 were utilised. 7 SNPs were not included due to inadequately low allele frequencies or call rates. rs72725879 was replaced with the next highest performing variant (rs1456315) in the same LD block (Locus PRNCR1) due to replication inconsistencies. |
| PPM017162 | PGS002268 (PRS_csPCa) |
PSS010139| East Asian Ancestry| 3,695 individuals |
PGP000442 | Song SH et al. Sci Rep (2023) |Ext. |
Reported Trait: Early-onset prostate cancer | — | AUROC: 0.627 [0.55, 0.703] | — | — | Only 22 SNPs from PGS002268 were utilised. 7 SNPs were not included due to inadequately low allele frequencies or call rates. rs72725879 was replaced with the next highest performing variant (rs1456315) in the same LD block (Locus PRNCR1) due to replication inconsistencies. |
| PPM012923 | PGS002270 (PRS33_LC) |
PSS009619| European Ancestry| 345,794 individuals |
PGP000300 | Zhang P et al. Br J Cancer (2022) |
Reported Trait: Incident lung cancer | HR: 1.16 [1.11, 1.22] | — | — | Age, sex, education, Townsend deprivation index, income, BMI, diet, physical activity, alcohol consumption, occupational exposure, passive smoking, relatedness and first 20 principal components of ancestry | — |
| PPM020290 | PGS002270 (PRS33_LC) |
PSS011324| European Ancestry| 1,202 individuals |
PGP000539 | Lebrett MB et al. Genet Med (2023) |Ext. |
Reported Trait: Lung cancer | — | AUROC: 0.725 [0.697, 0.754] | — | Age, sex, current smoking status, BMI, forced expiratory volume in 1 second/forced vital capacity ratio | — |
| PPM012970 | PGS002281 (PRS23_MM) |
PSS009636| European Ancestry| 2,395 individuals |
PGP000310 | Canzian F et al. Eur J Hum Genet (2021) |
Reported Trait: Multiple myeloma | — | AUROC: 0.644 [0.622, 0.666] | Odds Ratio (OR, highest vs lowest quintiles): 3.18 [2.34, 4.33] | Age, sex, and geographic region of origin | Unweighted score (100% call rate) |
| PPM012971 | PGS002281 (PRS23_MM) |
PSS009636| European Ancestry| 2,395 individuals |
PGP000310 | Canzian F et al. Eur J Hum Genet (2021) |
Reported Trait: Multiple myeloma | — | AUROC: 0.628 [0.605, 0.65] | Odds Ratio (OR, highest vs lowest quintiles): 3.44 [2.53, 4.69] | Age, sex, and geographic region of origin | Weighted score (100% call rate) |
| PPM013022 | PGS002294 (PRS111) |
PSS009652| East Asian Ancestry| 1,104 individuals |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.648 [0.613, 0.682] | — | Nongenetic risk score (body mass index, waist-to-hip ratio (WHR), benign breast disease, age at menarche, age at first live birth, family history of breast cancer) | — |
| PPM013021 | PGS002294 (PRS111) |
PSS009652| East Asian Ancestry| 1,104 individuals |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Reported Trait: Breast cancer | OR: 1.67 [1.46, 1.92] | AUROC: 0.639 [0.604, 0.674] | — | — | — |
| PPM013027 | PGS002298 (PRS14_esophageal) |
PSS009661| European Ancestry| 406 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Esophageal cancer | — | AUROC: 0.53 [0.51, 0.56] | — | — | — |
| PPM013028 | PGS002299 (PRS3_gastric) |
PSS009662| European Ancestry| 272 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Gastric cancer | — | AUROC: 0.56 [0.54, 0.58] | — | — | — |
| PPM013036 | PGS002299 (PRS3_gastric) |
PSS009662| European Ancestry| 272 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Gastric cancer | — | — | Hazard ratio (HR top 5% vs average): 1.27 [0.75, 2.15] | Age, birth cohort, genotyping array, top 10 PCs for ancestry and sex (for nonsex specific cancer only) | — |
| PPM013029 | PGS002300 (PRS19_endometrial) |
PSS009660| European Ancestry| 629 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Endometrial cancer | — | AUROC: 0.64 [0.61, 0.67] | — | — | — |
| PPM013037 | PGS002300 (PRS19_endometrial) |
PSS009660| European Ancestry| 629 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Endometrial cancer | — | — | Hazard ratio (HR top 5% vs average): 1.34 [0.96, 1.88] | Age, birth cohort, genotyping array, top 10 PCs for ancestry and sex (for nonsex specific cancer only) | — |
| PPM013035 | PGS002306 (PRS23_MM) |
PSS009659| European Ancestry| 290 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Multiple myeloma | — | AUROC: 0.69 [0.64, 0.7] | — | — | — |
| PPM013043 | PGS002306 (PRS23_MM) |
PSS009659| European Ancestry| 290 individuals |
PGP000328 | Choi J et al. Int J Cancer (2020) |
Reported Trait: Multiple myeloma | — | — | Hazard ratio (HR top 5% vs average): 2.41 [1.56, 3.72] | Age, birth cohort, genotyping array, top 10 PCs for ancestry and sex (for nonsex specific cancer only) | — |
| PPM014832 | PGS002735 (PRS19) |
PSS009907| European Ancestry| 118,636 individuals |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Reported Trait: Risk of endometrial cancer | — | AUROC: 0.56 [0.54, 0.57] | Odds ratio (OR, third vs first tertile): 1.55 [1.37, 1.74] | — | — |
| PPM014835 | PGS002735 (PRS19) |
PSS009907| European Ancestry| 118,636 individuals |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Reported Trait: Risk of endometrial cancer | HR: 0.2 [0.15, 0.25] | — | — | BMI | — |
| PPM014833 | PGS002736 (PRS24) |
PSS009907| European Ancestry| 118,636 individuals |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Reported Trait: Risk of endometrial cancer | — | AUROC: 0.53 [0.52, 0.54] | Odds ratio (OR, third vs first tertile): 1.27 [1.13, 1.43] | — | — |
| PPM014836 | PGS002736 (PRS24) |
PSS009907| European Ancestry| 118,636 individuals |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Reported Trait: Risk of endometrial cancer | HR: 0.11 [0.07, 0.16] | — | — | BMI | — |
| PPM014834 | PGS002737 (PRS72) |
PSS009907| European Ancestry| 118,636 individuals |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Reported Trait: Risk of endometrial cancer | — | AUROC: 0.54 [0.52, 0.55] | Odds ratio (OR, third vs first tertile): 1.32 [1.17, 1.48] | — | — |
| PPM014837 | PGS002737 (PRS72) |
PSS009907| European Ancestry| 118,636 individuals |
PGP000344 | Bafligil C et al. Genet Med (2022) |
Reported Trait: Risk of endometrial cancer | HR: 0.13 [0.08, 0.18] | — | — | BMI | — |
| PPM014844 | PGS002740 (PRS22_PC) |
PSS009913| European Ancestry| 13,952 individuals |
PGP000347 | Yuan C et al. Ann Oncol (2022) |
Reported Trait: Pancreatic cancer in those aged <= 60 years | — | — | Odds ratio (OR, top vs bottom 10%): 6.91 [4.6, 10.4] | — | — |
| PPM014843 | PGS002740 (PRS22_PC) |
PSS009913| European Ancestry| 13,952 individuals |
PGP000347 | Yuan C et al. Ann Oncol (2022) |
Reported Trait: Pancreatic cancer in those aged >70 years | — | — | Odds ratio (OR, top vs bottom 10%): 4.12 [3.08, 5.52] | — | — |
| PPM014906 | PGS002742 (PRS115_EAS) |
PSS009924| East Asian Ancestry| 1,454 individuals |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Reported Trait: Colorectal cancer | OR: 1.63 [1.46, 1.83] | AUROC: 0.63 [0.6, 0.66] | — | — | — |
| PPM014909 | PGS002742 (PRS115_EAS) |
PSS009923| East Asian Ancestry| 1,736 individuals |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Reported Trait: Colorectal cancer | OR: 1.51 [1.37, 1.67] | AUROC: 0.61 [0.59, 0.64] | — | — | — |
| PPM014907 | PGS002743 (PRS115_EUR) |
PSS009924| East Asian Ancestry| 1,454 individuals |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Reported Trait: Colorectal cancer | OR: 1.44 [1.29, 1.6] | AUROC: 0.6 [0.57, 0.63] | — | — | — |
| PPM014910 | PGS002743 (PRS115_EUR) |
PSS009923| East Asian Ancestry| 1,736 individuals |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Reported Trait: Colorectal cancer | OR: 1.39 [1.26, 1.53] | AUROC: 0.59 [0.56, 0.61] | — | — | — |
| PPM014908 | PGS002744 (PRS115_EUR_EAS) |
PSS009924| East Asian Ancestry| 1,454 individuals |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Reported Trait: Colorectal cancer | OR: 1.68 [1.5, 1.89] | AUROC: 0.64 [0.61, 0.67] | — | — | — |
| PPM014911 | PGS002744 (PRS115_EUR_EAS) |
PSS009923| East Asian Ancestry| 1,736 individuals |
PGP000354 | Ping J et al. Int J Cancer (2022) |
Reported Trait: Colorectal cancer | OR: 1.5 [1.36, 1.66] | AUROC: 0.61 [0.58, 0.64] | — | — | — |
| PPM014926 | PGS002747 (PRS_GI) |
PSS009932| European Ancestry| 430,036 individuals |
PGP000359 | Liu Y et al. Cancer Med (2022) |
Reported Trait: Incident gastrointestinal cancer | — | — | Hazard Ratio (HR, high vs low): 2.28 [2.09, 2.49] | Age group, gender, qualification, Townsend Deprivation Index, family history of cancer, smoking status, alcohol consumption and the top 10 genetic principal components | — |
| PPM014927 | PGS002747 (PRS_GI) |
PSS009932| European Ancestry| 430,036 individuals |
PGP000359 | Liu Y et al. Cancer Med (2022) |
Reported Trait: Incident gastrointestinal cancer (with metabolic syndrome) | — | — | Hazard Ratio (HR, high vs low): 2.75 [2.43, 3.12] | — | — |
| PPM014958 | PGS002758 (Colorectal_cancer_prscs) |
PSS009939| European Ancestry| 39,444 individuals |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Reported Trait: Colorectal cancer | OR: 1.61 [1.46, 1.77] | — | — | age, sex, 10 PCs, technical covariates | — |
| PPM015448 | PGS002791 (PRS126_Pca) |
PSS009957| European Ancestry| 104,586 individuals |
PGP000371 | Ruan X et al. Prostate (2022) |
Reported Trait: Prostate cancer risk | — | — | Odds Ratio (OR, top vs average percentile): 3.79 [3.46, 4.16] | disease diagnostic age or age at recruitment, subgroups and 10 principal components | — |
| PPM015449 | PGS002792 (PRS67_Pca) |
PSS009955| African Ancestry| 3,008 individuals |
PGP000371 | Ruan X et al. Prostate (2022) |
Reported Trait: Prostate cancer risk | — | — | Odds Ratio (OR, top vs average percentile): 1.77 [1.22, 2.58] | disease diagnostic age or age at recruitment, subgroups and 10 principal components | — |
| PPM015450 | PGS002793 (PRS84_Pca) |
PSS009956| East Asian Ancestry| 1,190 individuals |
PGP000371 | Ruan X et al. Prostate (2022) |
Reported Trait: Prostate cancer risk | — | — | Odds Ratio (OR, top vs average percentile): 2.87 [1.29, 6.4] | disease diagnostic age or age at recruitment, subgroups and 10 principal components | — |
| PPM015506 | PGS002796 (GRS232_Eur) |
PSS009968| European Ancestry| 888,086 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.46 [1.45, 1.46] | — | — | age, 10 genetic PCs | — |
| PPM015507 | PGS002797 (GRS67_His) |
PSS009969| Hispanic or Latin American Ancestry| 81,109 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.5 [1.46, 1.53] | — | — | age, 10 genetic PCs | — |
| PPM015508 | PGS002798 (GRS128_Afr) |
PSS009966| African Ancestry| 30,472 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.44 [1.4, 1.47] | — | — | age, 10 genetic PCs | — |
| PPM015509 | PGS002799 (GRS138_EA) |
PSS009967| East Asian Ancestry| 13,985 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.34 [1.28, 1.42] | — | — | age, 10 genetic PCs | — |
| PPM015574 | PGS002808 (PGS20_LC) |
PSS009988| European Ancestry| 450,821 individuals |
PGP000387 | Qin N et al. Lancet Oncol (2022) |
Reported Trait: Lung cancer | — | — | Hazard ratio (HR, high vs low risk): 1.48 [1.31, 1.68] | — | — |
| PPM015576 | PGS002808 (PGS20_LC) |
PSS009988| European Ancestry| 450,821 individuals |
PGP000387 | Qin N et al. Lancet Oncol (2022) |
Reported Trait: Lung cancer x autosomal mosaic loss abnormalities interaction | HR: 1.95 [1.02, 3.7] | — | — | — | — |
| PPM016134 | PGS003331 (PHS290) |
PSS010046| Ancestry Not Reported| 6,411 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 2.11 | — | Hazard ratio (HR, top vs bottom 20%): 11.16 [10.48, 11.88] | — | — |
| PPM016135 | PGS003331 (PHS290) |
PSS010046| Ancestry Not Reported| 6,411 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 2.32 | — | Hazard ratio (HR, top vs bottom 20%): 13.73 [12.43, 15.16] | — | — |
| PPM016136 | PGS003331 (PHS290) |
PSS010043| African Ancestry| 6,253 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 1.64 | — | Hazard ratio (HR, top vs bottom 20%): 5.95 [5.59, 6.34] | — | — |
| PPM016137 | PGS003331 (PHS290) |
PSS010043| African Ancestry| 6,253 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 1.67 | — | Hazard ratio (HR, top vs bottom 20%): 7.07 [6.58, 7.6] | — | — |
| PPM016138 | PGS003331 (PHS290) |
PSS010044| Additional Asian Ancestries| 2,378 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 1.99 | — | Hazard ratio (HR, top vs bottom 20%): 8.75 [8.21, 9.32] | — | — |
| PPM016139 | PGS003331 (PHS290) |
PSS010044| Additional Asian Ancestries| 2,378 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 1.89 | — | Hazard ratio (HR, top vs bottom 20%): 10.31 [9.58, 11.11] | — | — |
| PPM016140 | PGS003331 (PHS290) |
PSS010045| European Ancestry| 3,279 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 2.13 | — | Hazard ratio (HR, top vs bottom 20%): 10.87 [10.21, 11.57] | — | — |
| PPM016141 | PGS003331 (PHS290) |
PSS010045| European Ancestry| 3,279 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 2.13 | — | Hazard ratio (HR, top vs bottom 20%): 11.18 [10.34, 12.09] | — | — |
| PPM016142 | PGS003331 (PHS290) |
PSS010045| European Ancestry| 3,279 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Fatal prostate cancer | β: 1.68 | — | Hazard ratio (HR, top vs bottom 20%): 7.73 [6.45, 9.27] | — | — |
| PPM016145 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Fatal prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.42 [3.91, 5.02] | — | — |
| PPM016146 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Metastatic prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.89 [4.57, 5.21] | — | — |
| PPM016147 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 5.2 [5.09, 5.31] | — | — |
| PPM016149 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Metastatic prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.15 [3.81, 4.53] | self-reported Race and Ethnicity, Family History | — |
| PPM016150 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.69 [4.57, 4.81] | self-reported Race and Ethnicity, Family History | — |
| PPM016148 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Fatal prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.17 [3.59, 4.88] | self-reported Race and Ethnicity, Family History | — |
| PPM016166 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Urothelial carcinoma | HR: 1.27 [1.15, 1.4] | — | — | Smoking, BMI, education, and physical activity | — |
| PPM016167 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Non-aggressive urothelial carcinoma | HR: 1.34 [1.18, 1.52] | — | — | Smoking, BMI, education, and physical activity | — |
| PPM016168 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Aggressive urothelial carcinoma | HR: 1.19 [1.0, 1.42] | — | — | Smoking, BMI, education, and physical activity | — |
| PPM016169 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Urothelial carcinoma x systolic blood pressure interaction | HR: 1.55 [1.14, 2.1] | — | — | Smoking, BMI, physical activity and level of education | — |
| PPM016170 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Non-aggressive urothelial carcinoma x systolic blood pressure interaction | HR: 1.59 [1.07, 2.35] | — | — | Smoking, BMI, physical activity and level of education | — |
| PPM016171 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Aggressive urothelial carcinoma x systolic blood pressure interaction | HR: 1.72 [1.03, 2.87] | — | — | Smoking, BMI, physical activity and level of education | — |
| PPM016172 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Urothelial carcinoma x diastolic blood pressure interaction | HR: 1.45 [1.09, 1.92] | — | — | Smoking, BMI, physical activity and level of education | — |
| PPM016173 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Non-aggressive urothelial carcinoma x diastolic blood pressure interaction | HR: 1.54 [1.07, 2.22] | — | — | Smoking, BMI, physical activity and level of education | — |
| PPM016174 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Aggressive urothelial carcinoma x diastolic blood pressure interaction | HR: 1.38 [0.82, 2.31] | — | — | Smoking, BMI, physical activity and level of education | — |
| PPM016255 | PGS003380 (best_BRCA) |
PSS010074| European Ancestry| 154,361 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: breast cancer | — | AUROC: 0.696 | R²: 0.0555 | age, top 20 genetic principal components | — |
| PPM016256 | PGS003381 (best_UCEC) |
PSS010086| European Ancestry| 144,479 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: uterine endometrial carcinoma | — | AUROC: 0.761 | R²: 0.11 | age, top 20 genetic principal components | — |
| PPM016257 | PGS003382 (best_SKCM) |
PSS010085| European Ancestry| 273,786 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: skin cutaneous melanoma | — | AUROC: 0.682 | R²: 0.0261 | age, sex, top 20 genetic principal components | — |
| PPM016258 | PGS003383 (best_PRAD) |
PSS010084| European Ancestry| 133,752 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: prostate adenocarcinoma | — | AUROC: 0.813 | R²: 0.0798 | age, top 20 genetic principal components | — |
| PPM016259 | PGS003384 (best_GBM) |
PSS010078| European Ancestry| 269,806 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: glioblastoma | — | AUROC: 0.758 | R²: 0.0216 | age, sex, top 20 genetic principal components | — |
| PPM016260 | PGS003385 (best_OV) |
PSS010083| European Ancestry| 143,259 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: ovarian serous carcinoma | — | AUROC: 0.717 | R²: 0.0142 | age, top 20 genetic principal components | — |
| PPM016261 | PGS003386 (best_COADREAD) |
PSS010076| European Ancestry| 274,069 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: colorectal cancer | — | AUROC: 0.724 | R²: 0.0115 | age, sex, top 20 genetic principal components | — |
| PPM016262 | PGS003387 (best_ESCA_BEEA) |
PSS010077| European Ancestry| 270,026 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: esophageal adenocarcinoma | — | AUROC: 0.819 | R²: 0.0123 | age, sex, top 20 genetic principal components | — |
| PPM016263 | PGS003388 (best_ESCA_EA) |
PSS010077| European Ancestry| 270,026 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: esophageal adenocarcinoma | — | AUROC: 0.814 | R²: 0.00875 | age, sex, top 20 genetic principal components | — |
| PPM016264 | PGS003389 (best_CESC) |
PSS010075| European Ancestry| 144,374 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: cervical cancer | — | AUROC: 0.563 | R²: 0.00158 | age, top 20 genetic principal components | — |
| PPM016265 | PGS003390 (best_HNSC) |
PSS010079| European Ancestry| 270,233 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: head and neck squamous cell carcinoma | — | AUROC: 0.672 | R²: 0.00561 | age, sex, top 20 genetic principal components | — |
| PPM016266 | PGS003391 (best_LUCA) |
PSS010081| European Ancestry| 271,540 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: lung cancer | — | AUROC: 0.729 | R²: 0.00135 | age, sex, top 20 genetic principal components | — |
| PPM016267 | PGS003392 (best_LUSC) |
PSS010082| European Ancestry| 270,054 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: lung squamous cell carcinoma | — | AUROC: 0.778 | R²: 0.00075 | age, sex, top 20 genetic principal components | — |
| PPM016268 | PGS003393 (best_LUAD) |
PSS010080| European Ancestry| 270,412 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: lung adenocarcinoma | — | AUROC: 0.743 | R²: 0.00649 | age, sex, top 20 genetic principal components | — |
| PPM016274 | PGS003394 (PRS_Stepwise) |
PSS010091| European Ancestry| 198,758 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer | OR: 1.39 [1.29, 1.5] | AUROC: 0.595 | — | — | — |
| PPM016275 | PGS003394 (PRS_Stepwise) |
PSS010090| East Asian Ancestry| 7,669 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer | OR: 1.17 [1.11, 1.23] | AUROC: 0.542 | — | — | — |
| PPM017029 | PGS003394 (PRS_Stepwise) |
PSS010098| European Ancestry| 189,171 individuals |
PGP000417 | Dite GS et al. Eur J Cancer Prev (2022) |Ext. |
Reported Trait: 10-year ovarian cancer risks | — | C-index: 0.623 [0.603, 0.642] | — | — | — |
| PPM016276 | PGS003394 (PRS_Stepwise) |
PSS010089| African Ancestry| 1,072 individuals |
PGP000277 | Dareng EO et al. Eur J Hum Genet (2022) |
Reported Trait: Epithelial non-mucinous ovarian cancer | OR: 1.37 [1.2, 1.56] | AUROC: 0.594 | — | — | — |
| PPM016277 | PGS003395 (PRScsx_CRC) |
PSS010093| East Asian Ancestry| 2,179 individuals |
PGP000414 | Xin J et al. Genome Med (2023) |
Reported Trait: Incident colorectal cancer | OR: 1.73 [1.56, 1.91] | AUROC: 0.646 | — | sex, age and principal components | — |
| PPM016278 | PGS003395 (PRScsx_CRC) |
PSS010092| European Ancestry| 2,573 individuals |
PGP000414 | Xin J et al. Genome Med (2023) |
Reported Trait: Incident colorectal cancer | OR: 1.48 [1.36, 1.62] | AUROC: 0.608 | — | sex, age and principal components | — |
| PPM016279 | PGS003395 (PRScsx_CRC) |
PSS010094| European Ancestry| 355,543 individuals |
PGP000414 | Xin J et al. Genome Med (2023) |
Reported Trait: Incident colorectal cancer | HR: 1.42 [1.37, 1.48] | AUROC: 0.597 | — | sex, age, center and principal components | — |
| PPM016280 | PGS003396 (PRS-11ASN) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.35 [1.25, 1.45] | AUROC: 0.58 [0.56, 0.61] | — | principal component | — |
| PPM016281 | PGS003397 (PRS-42ASN) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.4 [1.3, 1.51] | AUROC: 0.6 [0.58, 0.62] | — | principal component | — |
| PPM016282 | PGS003398 (PRS-136EUR) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.55 [1.44, 1.66] | AUROC: 0.62 [0.6, 0.64] | — | principal component | — |
| PPM016283 | PGS003399 (PRS-209EUR) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.54 [1.43, 1.66] | AUROC: 0.62 [0.6, 0.64] | — | principal component | — |
| PPM017067 | PGS003415 (PGS268_PCa) |
PSS010112| European Ancestry| 170,850 individuals |
PGP000428 | Nyberg T et al. J Clin Oncol (2022) |
Reported Trait: 5 years incident prostate cancer risk | — | C-index: 0.79 [0.783, 0.797] | — | — | — |
| PPM017068 | PGS003415 (PGS268_PCa) |
PSS010112| European Ancestry| 170,850 individuals |
PGP000428 | Nyberg T et al. J Clin Oncol (2022) |
Reported Trait: 10 years incident prostate cancer risk | — | C-index: 0.772 [0.768, 0.777] | — | — | — |
| PPM017069 | PGS003416 (MTAGPRS) |
PSS010113| European Ancestry| 18,933 individuals |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Reported Trait: Keratinocyte cancers | OR: 1.66 [1.55, 1.79] | — | — | age, sex, 10 ancesty PCs | — |
| PPM017070 | PGS003417 (UKBPRS) |
PSS010113| European Ancestry| 18,933 individuals |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Reported Trait: Keratinocyte cancers | OR: 1.56 [1.45, 1.67] | — | — | age, sex, 10 ancesty PCs | — |
| PPM017071 | PGS003418 (PRState_Eur) |
PSS010114| African Ancestry| 4,533 individuals |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.52 [0.5, 0.53] | — | genetics, age and family history | — |
| PPM017072 | PGS003419 (PRState_Trans) |
PSS010114| African Ancestry| 4,533 individuals |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.66 [0.65, 0.68] | — | genetics, age and family history | — |
| PPM017102 | PGS003428 (Ldpred_CC_170223) |
PSS010125| European Ancestry| 128,113 individuals |
PGP000435 | Koel M et al. Hum Mol Genet (2023) |
Reported Trait: Incident cervical cancer | HR: 1.33 (0.069) | C-index: 0.613 | — | age, smoking | — |
| PPM017117 | PGS003431 (LDPred2-inf) |
PSS010132| European Ancestry| 34,152 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.726 [0.704, 0.748] | R²: 7.0 [5.7, 8.4] | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017123 | PGS003431 (LDPred2-inf) |
PSS010133| European Ancestry| 33,893 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.715 [0.686, 0.743] | R²: 27.0 [21.7, 32.1] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017129 | PGS003431 (LDPred2-inf) |
PSS010134| Multi-ancestry (excluding European)| 27,503 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.588 [0.545, 0.627] | — | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017135 | PGS003431 (LDPred2-inf) |
PSS010135| Multi-ancestry (excluding European)| 27,310 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.647 [0.593, 0.7] | R²: 17.2 [9.2, 27.9] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017105 | PGS003431 (LDPred2-inf) |
PSS010130| European Ancestry| 280,664 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | OR: 1.435 [1.391, 1.48] | AUROC: 0.704 [0.697, 0.712] | R²: 5.5 [5.1, 5.9] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy and scaled Brier available in source publication |
| PPM017111 | PGS003431 (LDPred2-inf) |
PSS010131| European Ancestry| 278,493 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer | HR: 1.368 [1.31, 1.428] | C-index: 0.696 [0.685, 0.707] | R²: 22.0 [20.1, 24.0] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017106 | PGS003432 (LDPred2-grid) |
PSS010130| European Ancestry| 280,664 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | OR: 1.584 [1.536, 1.633] | AUROC: 0.717 [0.711, 0.725] | R²: 6.3 [5.9, 6.8] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy and scaled Brier available in source publication |
| PPM017118 | PGS003432 (LDPred2-grid) |
PSS010132| European Ancestry| 34,152 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.732 [0.71, 0.752] | R²: 7.6 [6.1, 8.9] | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017124 | PGS003432 (LDPred2-grid) |
PSS010133| European Ancestry| 33,893 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.724 [0.696, 0.751] | R²: 28.3 [23.2, 33.3] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017130 | PGS003432 (LDPred2-grid) |
PSS010134| Multi-ancestry (excluding European)| 27,503 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.602 [0.558, 0.64] | — | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017136 | PGS003432 (LDPred2-grid) |
PSS010135| Multi-ancestry (excluding European)| 27,310 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.666 [0.61, 0.72] | R²: 20.3 [11.5, 31.1] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017112 | PGS003432 (LDPred2-grid) |
PSS010131| European Ancestry| 278,493 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer | HR: 1.563 [1.498, 1.631] | C-index: 0.714 [0.704, 0.726] | R²: 25.6 [23.8, 27.8] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017107 | PGS003433 (LDPred2-grid-sp) |
PSS010130| European Ancestry| 280,664 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | OR: 1.571 [1.524, 1.62] | AUROC: 0.716 [0.71, 0.723] | R²: 6.2 [5.8, 6.7] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy and scaled Brier available in source publication |
| PPM017119 | PGS003433 (LDPred2-grid-sp) |
PSS010132| European Ancestry| 34,152 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.733 [0.71, 0.753] | R²: 7.6 [6.1, 8.9] | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017125 | PGS003433 (LDPred2-grid-sp) |
PSS010133| European Ancestry| 33,893 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.725 [0.696, 0.752] | R²: 28.5 [23.4, 33.7] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017131 | PGS003433 (LDPred2-grid-sp) |
PSS010134| Multi-ancestry (excluding European)| 27,503 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.601 [0.559, 0.64] | — | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017137 | PGS003433 (LDPred2-grid-sp) |
PSS010135| Multi-ancestry (excluding European)| 27,310 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.664 [0.609, 0.718] | R²: 20.2 [11.4, 30.7] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017141 | PGS003433 (LDPred2-grid-sp) |
PSS010129| Multi-ancestry (excluding European)| 196,091 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer in men | — | C-index: 0.73 [0.72, 0.741] | R²: 28.2 [26.3, 30.1] For top 20% absolute risk sensitivity: 47.8 % specificty: 80.3 % |
QCancer-10 score | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017142 | PGS003433 (LDPred2-grid-sp) |
PSS010128| Multi-ancestry (excluding European)| 238,496 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer in females | — | C-index: 0.687 [0.673, 0.702] | R²: 21.0 [18.7, 23.7] For top 20% absolute risk sensitivity: 42.7 % specificty: 80.1 % |
QCancer-10 score | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017113 | PGS003433 (LDPred2-grid-sp) |
PSS010131| European Ancestry| 278,493 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer | HR: 1.545 [1.48, 1.612] | C-index: 0.712 [0.702, 0.723] | R²: 25.3 [23.4, 27.3] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017108 | PGS003434 (SCT) |
PSS010130| European Ancestry| 280,664 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | OR: 1.417 [1.375, 1.461] | AUROC: 0.702 [0.695, 0.711] | R²: 5.4 [5.0, 5.9] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy and scaled Brier available in source publication |
| PPM017114 | PGS003434 (SCT) |
PSS010131| European Ancestry| 278,493 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer | HR: 1.378 [1.321, 1.438] | C-index: 0.695 [0.685, 0.706] | R²: 22.3 [20.3, 24.4] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017120 | PGS003434 (SCT) |
PSS010132| European Ancestry| 34,152 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.718 [0.696, 0.739] | R²: 6.4 [5.0, 7.7] | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017126 | PGS003434 (SCT) |
PSS010133| European Ancestry| 33,893 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.713 [0.686, 0.74] | R²: 25.1 [20.2, 30.2] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017132 | PGS003434 (SCT) |
PSS010134| Multi-ancestry (excluding European)| 27,503 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.589 [0.546, 0.626] | — | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017138 | PGS003434 (SCT) |
PSS010135| Multi-ancestry (excluding European)| 27,310 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.65 [0.596, 0.705] | R²: 17.4 [8.9, 28.1] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017109 | PGS003435 (CT) |
PSS010130| European Ancestry| 280,664 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | OR: 1.425 [1.382, 1.47] | AUROC: 0.704 [0.697, 0.711] | R²: 5.4 [5.1, 5.9] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy and scaled Brier available in source publication |
| PPM017115 | PGS003435 (CT) |
PSS010131| European Ancestry| 278,493 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer | HR: 1.397 [1.338, 1.459] | C-index: 0.698 [0.689, 0.709] | R²: 22.4 [20.6, 24.4] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017121 | PGS003435 (CT) |
PSS010132| European Ancestry| 34,152 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.719 [0.696, 0.74] | R²: 6.6 [5.2, 7.9] | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017127 | PGS003435 (CT) |
PSS010133| European Ancestry| 33,893 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.707 [0.681, 0.734] | R²: 25.1 [20.0, 30.3] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017133 | PGS003435 (CT) |
PSS010134| Multi-ancestry (excluding European)| 27,503 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.597 [0.554, 0.636] | — | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017139 | PGS003435 (CT) |
PSS010135| Multi-ancestry (excluding European)| 27,310 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.658 [0.606, 0.71] | R²: 18.7 [10.0, 29.4] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017110 | PGS003436 (GWAS-sig) |
PSS010130| European Ancestry| 280,664 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | OR: 1.39 [1.348, 1.433] | AUROC: 0.7 [0.693, 0.707] | R²: 5.3 [4.9, 5.7] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy and scaled Brier available in source publication |
| PPM017116 | PGS003436 (GWAS-sig) |
PSS010131| European Ancestry| 278,493 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer | HR: 1.377 [1.32, 1.436] | C-index: 0.695 [0.685, 0.706] | R²: 22.2 [20.2, 24.4] | age, sex, PC1-4, array | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017122 | PGS003436 (GWAS-sig) |
PSS010132| European Ancestry| 34,152 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.703 [0.679, 0.724] | R²: 5.4 [4.0, 6.7] | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017128 | PGS003436 (GWAS-sig) |
PSS010133| European Ancestry| 33,893 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.701 [0.675, 0.729] | R²: 23.8 [19.0, 29.4] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017134 | PGS003436 (GWAS-sig) |
PSS010134| Multi-ancestry (excluding European)| 27,503 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Colorectal cancer | — | AUROC: 0.587 [0.543, 0.624] | — | age, sex, PC1-4, array | Dxy, scaled Brier, calibration slope and CITL available in source publication |
| PPM017140 | PGS003436 (GWAS-sig) |
PSS010135| Multi-ancestry (excluding European)| 27,310 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer | — | C-index: 0.659 [0.605, 0.715] | R²: 19.1 [10.3, 29.9] | age, sex, PC1-4, array | Dxy, D statistic, scaled Brier, calibration slope, available in source publication |
| PPM017143 | PGS003436 (GWAS-sig) |
PSS010129| Multi-ancestry (excluding European)| 196,091 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: Incident Colorectal cancer in men | — | C-index: 0.715 [0.706, 0.726] | R²: 25.6 [23.9, 27.5] For top 20% absolute risk sensitivity: 44.4 % specificty: 80.2 % |
QCancer-10 score | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017144 | PGS003436 (GWAS-sig) |
PSS010128| Multi-ancestry (excluding European)| 238,496 individuals |
PGP000438 | Briggs SEW et al. BMJ (2022) |
Reported Trait: incident Colorectal cancer in females | — | C-index: 0.669 [0.655, 0.683] | R²: 17.0 [14.8, 19.3] For top 20% absolute risk sensitivity: 39.2 % specificty: 80.1 % |
QCancer-10 score | Apparent performance presented, results for internal validation presented in source publication. Dxy, D statistic, and scaled Brier available in source publication |
| PPM017148 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Incident thyroid cancer x total moderate to vigorous physical activity interaction | HR: 0.74 [0.57, 0.97] | — | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
| PPM017149 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Incident thyroid cancer x smoke intake interaction | HR: 0.48 [0.32, 0.72] | — | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
| PPM017145 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Thyroid cancer | HR: 1.95 [1.68, 2.26] | AUROC: 0.64 [0.61, 66.0] | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
| PPM017147 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Incident thyroid cancer x healthy lifestyle interaction | HR: 0.52 [0.37, 0.73] | — | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
| PPM017158 | PGS003439 (PRSCC_140) |
PSS010138| European Ancestry| 66,282 individuals |
PGP000441 | Su YR et al. Cancer Epidemiol Biomarkers Prev (2023) |
Reported Trait: 5 year colorectal cancer risk | — | AUROC: 0.73 [0.71, 0.76] | — | age, first-degree CRC family history, sex, endoscopy history | — |
| PPM017159 | PGS003439 (PRSCC_140) |
PSS010138| European Ancestry| 66,282 individuals |
PGP000441 | Su YR et al. Cancer Epidemiol Biomarkers Prev (2023) |
Reported Trait: 10 year colorectal cancer risk | — | AUROC: 0.72 [0.7, 0.74] | — | age, first-degree CRC family history, sex, endoscopy history | — |
| PPM017229 | PGS003450 (PRS24_MM) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Chronic lymphocytic leukemia | OR: 1.09 [1.02, 1.16] | — | — | — | — |
| PPM017237 | PGS003450 (PRS24_MM) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Diffuse large B-cell lymphoma | OR: 0.98 [0.93, 1.04] | — | — | — | — |
| PPM017245 | PGS003450 (PRS24_MM) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Follicular lymphoma | OR: 1.01 [0.95, 1.09] | — | — | — | — |
| PPM017253 | PGS003450 (PRS24_MM) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Marginal zone lymphoma | OR: 1.05 [0.94, 1.18] | — | — | — | — |
| PPM017227 | PGS003451 (PRS2_MZL) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Chronic lymphocytic leukemia | OR: 1.26 [1.09, 1.46] | — | — | — | — |
| PPM017235 | PGS003451 (PRS2_MZL) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Diffuse large B-cell lymphoma | OR: 1.53 [1.34, 1.75] | — | — | — | — |
| PPM017243 | PGS003451 (PRS2_MZL) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Follicular lymphoma | OR: 1.39 [1.21, 1.61] | — | — | — | — |
| PPM017251 | PGS003451 (PRS2_MZL) |
PSS010176| European Ancestry| 20,134 individuals |
PGP000448 | Berndt SI et al. Leukemia (2022) |
Reported Trait: Marginal zone lymphoma | OR: 2.43 [1.93, 3.06] | — | — | — | — |
| PPM017264 | PGS003460 (PRS278_PCa) |
PSS010182| African Ancestry| 801 individuals |
PGP000453 | Chen F et al. Eur Urol (2023) |
Reported Trait: Prostate cancer | OR: 1.68 [1.45, 1.94] | — | — | — | — |
| PPM019149 | PGS003460 (PRS278_PCa) |
PSS011212| African Ancestry| 113 individuals |
PGP000516 | Soh P X.Y. et al. Nature Communications (2023) |Ext. |
Reported Trait: Aggresiveness of prostate cancer (ISUP = 3, 4, 5 vs ISUP = 1, 2) | OR: 1.13 [0.67, 1.9] | — | — | age | — |
| PPM019148 | PGS003460 (PRS278_PCa) |
PSS011212| African Ancestry| 113 individuals |
PGP000516 | Soh P X.Y. et al. Nature Communications (2023) |Ext. |
Reported Trait: Aggresiveness of prostate cancer (ISUP = 4, 5 or PSA >= 20 ng/ml vs the rest) | OR: 1.24 [0.65, 2.34] | — | — | age | — |
| PPM018492 | PGS003736 (PRS13_BlC) |
PSS010986| European Ancestry| 327 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Bladder cancer | OR: 1.14 [1.01, 1.29] | — | — | — | — |
| PPM018494 | PGS003738 (PRS136_BC) |
PSS010985| European Ancestry| 738 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Breast cancer | OR: 1.4 [1.27, 1.54] | — | — | — | — |
| PPM018495 | PGS003739 (PRS81_CoC) |
PSS010988| European Ancestry| 470 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Colorectal cancer | OR: 1.37 [1.24, 1.51] | — | — | — | — |
| PPM018496 | PGS003740 (PRS16_CU) |
PSS010989| European Ancestry| 372 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Corpus Uteri | OR: 1.38 [1.2, 1.58] | — | — | — | — |
| PPM018497 | PGS003741 (PRS28_OC) |
PSS010991| European Ancestry| 501 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Ovarian cancer | OR: 1.15 [1.04, 1.28] | — | — | — | — |
| PPM018499 | PGS003743 (PRS118_PrC) |
PSS010992| European Ancestry| 408 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Prostate cancer | OR: 1.58 [1.41, 1.76] | — | — | — | — |
| PPM018500 | PGS003744 (PRS14_RC) |
PSS010994| European Ancestry| 692 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Renal cancer | OR: 1.24 [1.14, 1.35] | — | — | — | — |
| PPM018501 | PGS003745 (PRS57_SM) |
PSS010995| European Ancestry| 448 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Skin Melanoma | OR: 1.49 [1.34, 1.66] | — | — | — | — |
| PPM018502 | PGS003746 (PRS11_TC) |
PSS010996| European Ancestry| 360 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Thyroid cancer | OR: 1.63 [1.44, 1.85] | — | — | — | — |
| PPM018518 | PGS003754 (PRS22_OCstepwise) |
PSS011005| Multi-ancestry (including European)| 11,135 individuals |
PGP000474 | Hurwitz LM et al. JAMA Netw Open (2023) |
Reported Trait: Nonmucinous Epithelial Ovarian Cancer x aspirin use interaction | — | — | Odds ratio (OR, <median): 0.85 [0.7, 1.02] Odds ratio (OR, >=median): 0.86 [0.74, 1.01] |
— | — |
| PPM018544 | PGS003758 (BrCa_PRS_JPHC_JPGWAS) |
PSS011015| East Asian Ancestry| 8,001 individuals |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Reported Trait: Incident breast cancer | — | C-index: 0.598 (0.018) | Improvement in C-index from age-only model: 0.058 Hazard ratio (HR, high vs low tertile): 2.47 [1.64, 3.7] |
age | — |
| PPM018545 | PGS003759 (BrCa_PRS_JPHC_EURGWAS) |
PSS011015| East Asian Ancestry| 8,001 individuals |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Reported Trait: Incident breast cancer | — | C-index: 0.586 (0.018) | Improvement in C-index from age-only model: 0.046 Hazard ratio (HR, high vs low tertile): 2.25 [1.51, 3.33] |
age | — |
| PPM018549 | PGS003760 (PRS49_EOCRC) |
PSS011018| Multi-ancestry (including European)| 25,150 individuals |
PGP000480 | Wang H et al. Genome Med (2023) |
Reported Trait: Early onset colorectal cancer | — | — | Odds ratio (OR, Quartile 4 vs Quartile 1): 1.64 [1.32, 2.03] | Sex, ethnicity, drinking frequency, smoke status, and family history | — |
| PPM018571 | PGS003765 (GRS.PCa.451) |
PSS011032| African Ancestry| 556 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.08 | — | Odds ratio (OR, top 10% vs 40-60%): 4.93 | Age, 10 PCs | — |
| PPM018568 | PGS003765 (GRS.PCa.451) |
PSS011033| European Ancestry| 12,848 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.21 | — | Odds ratio (OR, top 10% vs 40-60%): 4.33 | Age, 10 PCs | — |
| PPM018569 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011035| European Ancestry| 13,781 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.09 | — | Odds ratio (OR, top 10% vs 40-60%): 3.95 | Age, 10 PCs | — |
| PPM018573 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011031| African Ancestry| 4,665 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 1.78 | — | Odds ratio (OR, top 10% vs 40-60%): 3.54 | Age, sub-studies, 10 PCs | — |
| PPM018570 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011030| European Ancestry| 30,898 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.32 | — | Odds ratio (OR, top 10% vs 40-60%): 3.51 | Age, 10 PCs | — |
| PPM018572 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011034| African Ancestry| 639 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 1.76 | — | Odds ratio (OR, top 10% vs 40-60%): 3.54 | Age, 10 PCs | — |
| PPM018677 | PGS003850 (CRC_PRS_200loci) |
PSS011062| Additional Asian Ancestries| 12,025 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | OR: 1.3 | AUROC: 0.6 [0.59, 0.62] | — | Age, sex, PCs 1-4 | — |
| PPM018678 | PGS003850 (CRC_PRS_200loci) |
PSS011063| African Ancestry| 13,823 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | OR: 1.25 | AUROC: 0.58 [0.56, 0.59] | — | Age, sex, PCs 1-4 | — |
| PPM018679 | PGS003850 (CRC_PRS_200loci) |
PSS011064| Hispanic or Latin American Ancestry| 10,377 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | OR: 1.37 | AUROC: 0.59 [0.57, 0.6] | — | Age, sex, PCs 1-4 | — |
| PPM018680 | PGS003850 (CRC_PRS_200loci) |
PSS011065| European Ancestry| 118,756 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | OR: 1.62 | AUROC: 0.61 [0.6, 0.62] | — | Age, sex, PCs 1-4 | — |
| PPM018681 | PGS003851 (CRC_PRS_EUR) |
PSS011062| Additional Asian Ancestries| 12,025 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.619 [0.547, 0.689] | — | Age, sex, PCs 1-10 | — |
| PPM018682 | PGS003851 (CRC_PRS_EUR) |
PSS011063| African Ancestry| 13,823 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.526 [0.419, 0.62] | — | Age, sex, PCs 1-10 | — |
| PPM018683 | PGS003851 (CRC_PRS_EUR) |
PSS011064| Hispanic or Latin American Ancestry| 10,377 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.584 [0.511, 0.656] | — | Age, sex, PCs 1-10 | — |
| PPM018684 | PGS003851 (CRC_PRS_EUR) |
PSS011065| European Ancestry| 118,756 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.638 [0.624, 0.652] | — | Age, sex, PCs 1-10 | — |
| PPM018669 | PGS003851 (CRC_PRS_EUR) |
PSS011059| European Ancestry| 72,791 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.654 [0.639, 0.669] | — | age, sex | — |
| PPM018670 | PGS003851 (CRC_PRS_EUR) |
PSS011058| East Asian Ancestry| 6,966 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.601 [0.538, 0.664] | — | age, sex | — |
| PPM018671 | PGS003851 (CRC_PRS_EUR) |
PSS011057| African Ancestry| 5,249 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.543 [0.5, 0.6241] | — | age, sex | — |
| PPM018672 | PGS003851 (CRC_PRS_EUR) |
PSS011060| Hispanic or Latin American Ancestry| 6,660 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.602 [0.542, 0.662] | — | age, sex | — |
| PPM018673 | PGS003852 (CRC_PRS_EUR_EAS) |
PSS011062| Additional Asian Ancestries| 12,025 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |
Reported Trait: Colorectal cancer | OR: 1.64 [1.55, 1.74] | AUROC: 0.63 [0.62, 0.64] | — | Age, sex, PCs 1-4 | — |
| PPM018674 | PGS003852 (CRC_PRS_EUR_EAS) |
PSS011063| African Ancestry| 13,823 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |
Reported Trait: Colorectal cancer | OR: 1.39 [1.31, 1.47] | AUROC: 0.59 [0.57, 0.61] | — | Age, sex, PCs 1-4 | — |
| PPM018675 | PGS003852 (CRC_PRS_EUR_EAS) |
PSS011064| Hispanic or Latin American Ancestry| 10,377 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |
Reported Trait: Colorectal cancer | OR: 1.62 [1.51, 1.73] | AUROC: 0.62 [0.6, 0.63] | — | Age, sex, PCs 1-4 | — |
| PPM018676 | PGS003852 (CRC_PRS_EUR_EAS) |
PSS011065| European Ancestry| 118,756 individuals |
PGP000492 | Thomas M et al. Nat Commun (2023) |
Reported Trait: Colorectal cancer | OR: 1.67 [1.6, 1.75] | AUROC: 0.65 [0.64, 0.66] | — | Age, sex, PCs 1-4 | — |
| PPM019147 | PGS003979 (CRC_PRSCS) |
PSS011211| European Ancestry| 453,733 individuals |
PGP000515 | Tamlander M et al. Br J Cancer (2023) |
Reported Trait: Colorectal cancer | OR: 1.63 [1.6, 1.67] | AUROC: 0.795 [0.791, 0.799] | — | year of birth, sex, ten first principal components of ancestry, genotyping batch, genotyping array | — |
| PPM019389 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.60508 [1.54448557, 1.66804298] β: 0.47317 [0.43469089, 0.51165107] |
AUROC: 0.63154 [0.6209314, 0.6421403] | R²: 0.04847 [0.04130408, 0.05684615] | 0 | beta = log(or)/sd_pgs |
| PPM019390 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.71525 [1.68709681, 1.74386827] β: 0.53956 [0.52300919, 0.55610579] |
AUROC: 0.64804 [0.64364562, 0.65244004] | R²: 0.06199 [0.05814535, 0.06545043] | 0 | beta = log(or)/sd_pgs |
| PPM019391 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.53934 [1.33718466, 1.77206857] β: 0.43136 [0.2905664, 0.57214755] |
AUROC: 0.61683 [0.57775913, 0.65589892] | R²: 0.03275 [0.01407293, 0.05769946] | 0 | beta = log(or)/sd_pgs |
| PPM019392 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | β: 0.53147 [0.48220528, 0.58073623] OR: 1.70143 [1.61964223, 1.78735386] |
AUROC: 0.64271 [0.62948583, 0.65593293] | R²: 0.06062 [0.04977566, 0.07136047] | 0 | beta = log(or)/sd_pgs |
| PPM019394 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.75801 [1.6931535, 1.82535722] β: 0.56418 [0.52659276, 0.6017757] |
AUROC: 0.65329 [0.64349623, 0.66307795] | R²: 0.06676 [0.05869412, 0.07488231] | 0 | beta = log(or)/sd_pgs |
| PPM019393 | PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.467 [1.26742431, 1.69799758] β: 0.38322 [0.23698674, 0.52944966] |
AUROC: 0.60326 [0.56283686, 0.64369262] | R²: 0.02527 [0.01023305, 0.04785722] | 0 | beta = log(or)/sd_pgs |
| PPM019527 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | β: 0.56562 [0.52256591, 0.60866794] OR: 1.76053 [1.68634913, 1.83798146] |
AUROC: 0.6534 [0.64200647, 0.66479563] | R²: 0.07116 [0.06149625, 0.08112238] | 0 | beta = log(or)/sd_pgs |
| PPM019528 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.01802 [1.98114399, 2.05558361] β: 0.70212 [0.68367445, 0.7205598] |
AUROC: 0.68946 [0.68491786, 0.69400552] | R²: 0.10789 [0.10250031, 0.11315488] | 0 | beta = log(or)/sd_pgs |
| PPM019529 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88516 [1.54774056, 2.2961445] β: 0.63401 [0.43679617, 0.83123141] |
AUROC: 0.67831 [0.62440187, 0.7322239] | R²: 0.06162 [0.02782852, 0.10948346] | 0 | beta = log(or)/sd_pgs |
| PPM019530 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.83859 [1.75834334, 1.92250764] β: 0.609 [0.56437208, 0.6536304] |
AUROC: 0.66728 [0.656, 0.67855695] | R²: 0.08166 [0.07064743, 0.09305334] | 0 | beta = log(or)/sd_pgs |
| PPM019531 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.1788 [1.80797703, 2.62568559] β: 0.77878 [0.59220855, 0.96534204] |
AUROC: 0.71889 [0.66993694, 0.76784283] | R²: 0.09456 [0.05453021, 0.14785044] | 0 | beta = log(or)/sd_pgs |
| PPM019532 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93585 [1.85556023, 2.01960741] β: 0.66054 [0.61818666, 0.70290314] |
AUROC: 0.67753 [0.66663702, 0.68842668] | R²: 0.09742 [0.0854653, 0.10979243] | 0 | beta = log(or)/sd_pgs |
| PPM019425 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.65454 [1.59239759, 1.71911272] β: 0.50352 [0.4652408, 0.5418083] |
AUROC: 0.63947 [0.62889119, 0.65004547] | R²: 0.0555 [0.04797205, 0.06390807] | 0 | beta = log(or)/sd_pgs |
| PPM019426 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.7112 [1.68318494, 1.73969104] β: 0.5372 [0.5206878, 0.55370753] |
AUROC: 0.64797 [0.6435976, 0.65233588] | R²: 0.06177 [0.05792732, 0.06529816] | 0 | beta = log(or)/sd_pgs |
| PPM019427 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.60371 [1.39434739, 1.84450091] β: 0.47232 [0.33242648, 0.61220873] |
AUROC: 0.63037 [0.59126423, 0.66947401] | R²: 0.03979 [0.01942893, 0.06698512] | 0 | beta = log(or)/sd_pgs |
| PPM019428 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.71179 [1.62971047, 1.79800083] β: 0.53754 [0.48840237, 0.5866754] |
AUROC: 0.64444 [0.6312226, 0.65766239] | R²: 0.06247 [0.05174001, 0.07360675] | 0 | beta = log(or)/sd_pgs |
| PPM019429 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.48538 [1.28422223, 1.71804972] β: 0.39567 [0.25015327, 0.54118977] |
AUROC: 0.60906 [0.56630285, 0.65182352] | R²: 0.02726 [0.01122822, 0.05190103] | 0 | beta = log(or)/sd_pgs |
| PPM019430 | PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.75341 [1.6889839, 1.82030397] β: 0.56157 [0.52412711, 0.5990035] |
AUROC: 0.6524 [0.64250552, 0.66229219] | R²: 0.06677 [0.05835915, 0.07564263] | 0 | beta = log(or)/sd_pgs |
| PPM019575 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.81364 [1.73722963, 1.89340697] β: 0.59533 [0.55229168, 0.63837784] |
AUROC: 0.66161 [0.65023058, 0.67297992] | R²: 0.07893 [0.06883311, 0.08997126] | 0 | beta = log(or)/sd_pgs |
| PPM019576 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.03616 [1.99874966, 2.07426625] β: 0.71106 [0.69252182, 0.72960748] |
AUROC: 0.69043 [0.68586972, 0.69498057] | R²: 0.10955 [0.10434197, 0.1151718] | 0 | beta = log(or)/sd_pgs |
| PPM019577 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.06139 [1.6897379, 2.51479538] β: 0.72338 [0.52457343, 0.92219144] |
AUROC: 0.70213 [0.64836545, 0.75589427] | R²: 0.07903 [0.03979759, 0.13138207] | 0 | beta = log(or)/sd_pgs |
| PPM019578 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.87698 [1.79440804, 1.96335592] β: 0.62967 [0.58467519, 0.67465521] |
AUROC: 0.67189 [0.6605923, 0.68317852] | R²: 0.08601 [0.07524584, 0.09784449] | 0 | beta = log(or)/sd_pgs |
| PPM019579 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.36011 [1.94792322, 2.85952474] β: 0.85871 [0.66676379, 1.05065544] |
AUROC: 0.73225 [0.68819317, 0.7763138] | R²: 0.1098 [0.06700924, 0.16296955] | 0 | beta = log(or)/sd_pgs |
| PPM019580 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.94974 [1.86869624, 2.03429921] β: 0.6677 [0.62524099, 0.71015139] |
AUROC: 0.67897 [0.6680745, 0.68985602] | R²: 0.09923 [0.08824506, 0.11201856] | 0 | beta = log(or)/sd_pgs |
| PPM019401 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.66191 [1.59929671, 1.72697924] β: 0.50797 [0.46956397, 0.54637378] |
AUROC: 0.64171 [0.63118121, 0.65224553] | R²: 0.05608 [0.04909415, 0.06472665] | 0 | beta = log(or)/sd_pgs |
| PPM019402 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.77035 [1.74117276, 1.80002055] β: 0.57118 [0.55455889, 0.58779808] |
AUROC: 0.65593 [0.65157997, 0.66028305] | R²: 0.06913 [0.06491623, 0.07286341] | 0 | beta = log(or)/sd_pgs |
| PPM019403 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.61352 [1.40208165, 1.85683331] β: 0.47842 [0.33795803, 0.61887252] |
AUROC: 0.63169 [0.59299282, 0.67038513] | R²: 0.04043 [0.01973305, 0.06848248] | 0 | beta = log(or)/sd_pgs |
| PPM019404 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.74007 [1.65600677, 1.82841046] β: 0.55393 [0.50440914, 0.60344699] |
AUROC: 0.64863 [0.63550699, 0.66174475] | R²: 0.06532 [0.05411845, 0.07675006] | 0 | beta = log(or)/sd_pgs |
| PPM019405 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.44836 [1.25210644, 1.67537516] β: 0.37043 [0.22482729, 0.51603712] |
AUROC: 0.60329 [0.56051089, 0.64607018] | R²: 0.02382 [0.00880191, 0.04697128] | 0 | beta = log(or)/sd_pgs |
| PPM019406 | PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.80647 [1.73980278, 1.87569651] β: 0.59138 [0.55377176, 0.62898006] |
AUROC: 0.65976 [0.65001199, 0.66950573] | R²: 0.07359 [0.06487413, 0.08290854] | 0 | beta = log(or)/sd_pgs |
| PPM019545 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.82561 [1.74872905, 1.90587328] β: 0.60191 [0.55888927, 0.64494032] |
AUROC: 0.66494 [0.65364949, 0.67623003] | R²: 0.08081 [0.07028398, 0.09106408] | 0 | beta = log(or)/sd_pgs |
| PPM019546 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.07696 [2.03866736, 2.11597128] β: 0.73091 [0.71229634, 0.74951394] |
AUROC: 0.69616 [0.69165306, 0.70066719] | R²: 0.11538 [0.11020074, 0.12097632] | 0 | beta = log(or)/sd_pgs |
| PPM019547 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.12005 [1.73909535, 2.58444454] β: 0.75144 [0.55336506, 0.94951061] |
AUROC: 0.70701 [0.65372607, 0.76030223] | R²: 0.08588 [0.04466036, 0.13831751] | 0 | beta = log(or)/sd_pgs |
| PPM019548 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93632 [1.85068513, 2.0259163] β: 0.66079 [0.61555591, 0.70602209] |
AUROC: 0.67844 [0.66710517, 0.68977315] | R²: 0.09414 [0.08297157, 0.10691432] | 0 | beta = log(or)/sd_pgs |
| PPM019549 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.34953 [1.93904652, 2.84689917] β: 0.85421 [0.66219637, 1.04623039] |
AUROC: 0.72497 [0.67810544, 0.77184412] | R²: 0.10858 [0.06368116, 0.1638136] | 0 | beta = log(or)/sd_pgs |
| PPM019550 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.03998 [1.95464119, 2.1290527] β: 0.71294 [0.67020664, 0.75567714] |
AUROC: 0.69081 [0.68023489, 0.70138671] | R²: 0.11235 [0.100658, 0.12536432] | 0 | beta = log(or)/sd_pgs |
| PPM019365 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | β: 0.50696 [0.46857737, 0.54535222] OR: 1.66024 [1.59771962, 1.72521592] |
AUROC: 0.64155 [0.63100072, 0.65209011] | R²: 0.05592 [0.04878852, 0.06462078] | 0 | beta = log(or)/sd_pgs |
| PPM019366 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.77072 [1.74154078, 1.80038299] β: 0.57138 [0.55477023, 0.58799941] |
AUROC: 0.65624 [0.65188392, 0.66059213] | R²: 0.06923 [0.06509505, 0.07276728] | 0 | beta = log(or)/sd_pgs |
| PPM019367 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.60503 [1.39429381, 1.84761448] β: 0.47314 [0.33238806, 0.61389534] |
AUROC: 0.62871 [0.58989471, 0.66752285] | R²: 0.0394 [0.01850853, 0.06709891] | 0 | beta = log(or)/sd_pgs |
| PPM019368 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.74575 [1.66147743, 1.8343018] β: 0.55719 [0.50770723, 0.60666392] |
AUROC: 0.64976 [0.63666034, 0.66286316] | R²: 0.06621 [0.05482, 0.07762809] | 0 | beta = log(or)/sd_pgs |
| PPM019369 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.46589 [1.26693944, 1.69608562] β: 0.38246 [0.2366041, 0.52832302] |
AUROC: 0.60655 [0.56457528, 0.64853134] | R²: 0.02531 [0.00997384, 0.04844316] | 0 | beta = log(or)/sd_pgs |
| PPM019370 | PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.80882 [1.74205374, 1.87814873] β: 0.59268 [0.55506473, 0.63028658] |
AUROC: 0.65979 [0.65003927, 0.66954015] | R²: 0.07392 [0.06512011, 0.08357077] | 0 | beta = log(or)/sd_pgs |
| PPM019509 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.84253 [1.76511474, 1.9233483] β: 0.61114 [0.5682157, 0.65406757] |
AUROC: 0.66712 [0.65580582, 0.67842704] | R²: 0.08368 [0.07334262, 0.09443435] | 0 | beta = log(or)/sd_pgs |
| PPM019510 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.11238 [2.07329005, 2.15220653] β: 0.74782 [0.72913674, 0.76649361] |
AUROC: 0.69944 [0.69492796, 0.7039464] | R²: 0.12024 [0.1150319, 0.12575818] | 0 | beta = log(or)/sd_pgs |
| PPM019511 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.18207 [1.79180061, 2.65733751] β: 0.78027 [0.58322104, 0.97732469] |
AUROC: 0.71782 [0.66712303, 0.76852111] | R²: 0.09364 [0.05088803, 0.14629713] | 0 | beta = log(or)/sd_pgs |
| PPM019512 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93239 [1.8472515, 2.02145706] β: 0.65876 [0.61369886, 0.70381857] |
AUROC: 0.67779 [0.66648658, 0.68909316] | R²: 0.0943 [0.0823039, 0.10674354] | 0 | beta = log(or)/sd_pgs |
| PPM019513 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.29829 [1.90607316, 2.77121128] β: 0.83216 [0.64504519, 1.01928451] |
AUROC: 0.727 [0.68076039, 0.77324327] | R²: 0.10782 [0.06568955, 0.16319521] | 0 | beta = log(or)/sd_pgs |
| PPM019514 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.05028 [1.96459765, 2.13969686] β: 0.71798 [0.67528746, 0.76066416] |
AUROC: 0.69166 [0.68106518, 0.70224548] | R²: 0.11435 [0.10241705, 0.12708645] | 0 | beta = log(or)/sd_pgs |
| PPM019413 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.61464 [1.55394223, 1.67770259] β: 0.47911 [0.44079507, 0.51742535] |
AUROC: 0.6334 [0.62282373, 0.64397359] | R²: 0.05009 [0.04317505, 0.05809181] | 0 | beta = log(or)/sd_pgs |
| PPM019414 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.72899 [1.70061022, 1.75784976] β: 0.54754 [0.53098714, 0.56409133] |
AUROC: 0.64996 [0.64560075, 0.65432486] | R²: 0.06387 [0.05988493, 0.0675063] | 0 | beta = log(or)/sd_pgs |
| PPM019415 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.58283 [1.37520299, 1.8218099] β: 0.45922 [0.31860135, 0.59983046] |
AUROC: 0.62693 [0.58820997, 0.66564469] | R²: 0.03717 [0.01784551, 0.06382176] | 0 | beta = log(or)/sd_pgs |
| PPM019416 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.7155 [1.6331199, 1.80203152] β: 0.5397 [0.49049223, 0.58891465] |
AUROC: 0.64563 [0.63247965, 0.65878399] | R²: 0.06273 [0.05191156, 0.07305575] | 0 | beta = log(or)/sd_pgs |
| PPM019417 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.42423 [1.23268451, 1.64552911] β: 0.35363 [0.20919432, 0.49806198] |
AUROC: 0.59717 [0.55485917, 0.63948019] | R²: 0.02202 [0.00748612, 0.04464707] | 0 | beta = log(or)/sd_pgs |
| PPM019418 | PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.75979 [1.69513119, 1.82691975] β: 0.5652 [0.52776014, 0.60263135] |
AUROC: 0.65299 [0.64321086, 0.66276462] | R²: 0.06765 [0.05919841, 0.07667134] | 0 | beta = log(or)/sd_pgs |
| PPM019557 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.85139 [1.77385839, 1.93231376] β: 0.61594 [0.57315705, 0.65871813] |
AUROC: 0.66576 [0.65440883, 0.6771033] | R²: 0.0856 [0.07431455, 0.09691892] | 0 | beta = log(or)/sd_pgs |
| PPM019558 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.08323 [2.04484796, 2.12232796] β: 0.73392 [0.71532344, 0.75251358] |
AUROC: 0.69557 [0.69102783, 0.70012184] | R²: 0.11662 [0.11151327, 0.1224519] | 0 | beta = log(or)/sd_pgs |
| PPM019559 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.14725 [1.76035627, 2.61917044] β: 0.76419 [0.56551621, 0.96285764] |
AUROC: 0.71264 [0.66340362, 0.76188569] | R²: 0.08821 [0.04783816, 0.13908427] | 0 | beta = log(or)/sd_pgs |
| PPM019560 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88479 [1.80187082, 1.97153535] β: 0.63382 [0.58882547, 0.67881261] |
AUROC: 0.67112 [0.65977263, 0.68247009] | R²: 0.08725 [0.07619297, 0.09947738] | 0 | beta = log(or)/sd_pgs |
| PPM019561 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.22812 [1.85142042, 2.6814579] β: 0.80116 [0.61595314, 0.98636064] |
AUROC: 0.71617 [0.66691669, 0.76542647] | R²: 0.10162 [0.06080214, 0.16049942] | 0 | beta = log(or)/sd_pgs |
| PPM019562 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.98362 [1.9013261, 2.06946831] β: 0.68492 [0.64255159, 0.72729172] |
AUROC: 0.68358 [0.67275618, 0.69440469] | R²: 0.10516 [0.09308417, 0.11828841] | 0 | beta = log(or)/sd_pgs |
| PPM019407 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.64103 [1.57912878, 1.70535148] β: 0.49532 [0.45687329, 0.53377123] |
AUROC: 0.63737 [0.62675736, 0.64797822] | R²: 0.0532 [0.04622562, 0.06191163] | 0 | beta = log(or)/sd_pgs |
| PPM019408 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.7432 [1.71450629, 1.77238361] β: 0.55573 [0.53912516, 0.57232531] |
AUROC: 0.65242 [0.6480568, 0.65678307] | R²: 0.06545 [0.06174367, 0.06888215] | 0 | beta = log(or)/sd_pgs |
| PPM019409 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.56536 [1.35914439, 1.80285464] β: 0.44811 [0.30685538, 0.58937132] |
AUROC: 0.62314 [0.58448319, 0.66179346] | R²: 0.03515 [0.01639285, 0.06168013] | 0 | beta = log(or)/sd_pgs |
| PPM019410 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.72445 [1.64139537, 1.81169954] β: 0.54491 [0.49554672, 0.59426538] |
AUROC: 0.64679 [0.63364992, 0.65993923] | R²: 0.06355 [0.05288965, 0.07449614] | 0 | beta = log(or)/sd_pgs |
| PPM019411 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.51041 [1.305849, 1.74702266] β: 0.41238 [0.2668534, 0.557913] |
AUROC: 0.61087 [0.57033984, 0.65140365] | R²: 0.02956 [0.01317004, 0.05393655] | 0 | beta = log(or)/sd_pgs |
| PPM019412 | PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.78417 [1.71851145, 1.85232925] β: 0.57895 [0.54145848, 0.6164439] |
AUROC: 0.65585 [0.64609462, 0.66560523] | R²: 0.07087 [0.06226027, 0.0800237] | 0 | beta = log(or)/sd_pgs |
| PPM019551 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.85969 [1.78202022, 1.94075024] β: 0.62041 [0.57774767, 0.66307462] |
AUROC: 0.66695 [0.65563544, 0.67826496] | R²: 0.08735 [0.07633175, 0.0992353] | 0 | beta = log(or)/sd_pgs |
| PPM019552 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.07288 [2.03493661, 2.11152358] β: 0.72894 [0.71046467, 0.74740976] |
AUROC: 0.69577 [0.69123757, 0.70029742] | R²: 0.11667 [0.11154524, 0.12247006] | 0 | beta = log(or)/sd_pgs |
| PPM019553 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.03055 [1.66481796, 2.4766266] β: 0.70831 [0.50971579, 0.90689739] |
AUROC: 0.69826 [0.64746513, 0.7490511] | R²: 0.07586 [0.03742202, 0.12418827] | 0 | beta = log(or)/sd_pgs |
| PPM019554 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | β: 0.64165 [0.59666245, 0.68664195] OR: 1.89962 [1.81604752, 1.98703176] |
AUROC: 0.67416 [0.66287108, 0.68544793] | R²: 0.08958 [0.07836312, 0.10195549] | 0 | beta = log(or)/sd_pgs |
| PPM019555 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.24918 [1.87123091, 2.70346002] β: 0.81056 [0.62659645, 0.99453244] |
AUROC: 0.71358 [0.66350006, 0.76366431] | R²: 0.10571 [0.05891518, 0.1658404] | 0 | beta = log(or)/sd_pgs |
| PPM019556 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.99361 [1.91126828, 2.07950655] β: 0.68995 [0.64776704, 0.73213063] |
AUROC: 0.68577 [0.6750112, 0.69652488] | R²: 0.10775 [0.0952096, 0.12071823] | 0 | beta = log(or)/sd_pgs |
| PPM019419 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | β: 0.48736 [0.44905474, 0.52567252] OR: 1.62802 [1.56683043, 1.69159609] |
AUROC: 0.63532 [0.62467241, 0.64596639] | R²: 0.05189 [0.04462939, 0.06050746] | 0 | beta = log(or)/sd_pgs |
| PPM019420 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.73797 [1.70945914, 1.76696055] β: 0.55272 [0.53617703, 0.56926087] |
AUROC: 0.65207 [0.64770258, 0.65644351] | R²: 0.06524 [0.06134318, 0.06889406] | 0 | beta = log(or)/sd_pgs |
| PPM019421 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.57454 [1.3683506, 1.81179039] β: 0.45396 [0.31360607, 0.59431552] |
AUROC: 0.62734 [0.58839198, 0.66629096] | R²: 0.0365 [0.01640351, 0.06192232] | 0 | beta = log(or)/sd_pgs |
| PPM019422 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.72094 [1.6384216, 1.80760485] β: 0.54287 [0.49373334, 0.59200268] |
AUROC: 0.64671 [0.63347915, 0.65993367] | R²: 0.06366 [0.05229169, 0.07516806] | 0 | beta = log(or)/sd_pgs |
| PPM019423 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.51133 [1.30438605, 1.7511135] β: 0.41299 [0.26573247, 0.56025187] |
AUROC: 0.61379 [0.57261519, 0.65495499] | R²: 0.029 [0.01275949, 0.05212183] | 0 | beta = log(or)/sd_pgs |
| PPM019424 | PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.77492 [1.70965861, 1.84266319] β: 0.57375 [0.5362937, 0.61121191] |
AUROC: 0.65535 [0.64554283, 0.66515647] | R²: 0.06966 [0.06127445, 0.07856851] | 0 | beta = log(or)/sd_pgs |
| PPM019569 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.80595 [1.73048314, 1.8847033] β: 0.59109 [0.54840064, 0.63377041] |
AUROC: 0.6624 [0.65109537, 0.67370194] | R²: 0.07916 [0.06887128, 0.08999476] | 0 | beta = log(or)/sd_pgs |
| PPM019570 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.05454 [2.01691586, 2.09287461] β: 0.72005 [0.70156954, 0.73853853] |
AUROC: 0.69351 [0.6889787, 0.69804346] | R²: 0.11337 [0.10797044, 0.11887705] | 0 | beta = log(or)/sd_pgs |
| PPM019571 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.12708 [1.74969815, 2.58584538] β: 0.75475 [0.55944329, 0.95005249] |
AUROC: 0.70896 [0.65720843, 0.76072108] | R²: 0.08902 [0.04599459, 0.13892936] | 0 | beta = log(or)/sd_pgs |
| PPM019572 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.87036 [1.78869769, 1.9557568] β: 0.62613 [0.58148781, 0.67077723] |
AUROC: 0.6708 [0.65946402, 0.6821401] | R²: 0.08647 [0.07503424, 0.09847291] | 0 | beta = log(or)/sd_pgs |
| PPM019573 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.10264 [1.75170999, 2.52386924] β: 0.74319 [0.56059245, 0.92579314] |
AUROC: 0.70361 [0.65513648, 0.75208618] | R²: 0.08919 [0.05003056, 0.14377367] | 0 | beta = log(or)/sd_pgs |
| PPM019574 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.9751 [1.89295623, 2.06080819] β: 0.68062 [0.63813975, 0.72309823] |
AUROC: 0.68255 [0.67175657, 0.6933417] | R²: 0.10323 [0.09195074, 0.11628312] | 0 | beta = log(or)/sd_pgs |
| PPM019563 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.79229 [1.71735502, 1.87049062] β: 0.58349 [0.54078533, 0.62620076] |
AUROC: 0.65988 [0.64852879, 0.6712255] | R²: 0.07703 [0.06661609, 0.0880941] | 0 | beta = log(or)/sd_pgs |
| PPM019564 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.0553 [2.01766754, 2.09363347] β: 0.72042 [0.70194216, 0.73890106] |
AUROC: 0.69363 [0.68909737, 0.69815964] | R²: 0.11358 [0.10818829, 0.11891045] | 0 | beta = log(or)/sd_pgs |
| PPM019566 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88631 [1.80402119, 1.97234441] β: 0.63462 [0.59001817, 0.67922289] |
AUROC: 0.67266 [0.66141319, 0.68391119] | R²: 0.08914 [0.07744616, 0.10184036] | 0 | beta = log(or)/sd_pgs |
| PPM019567 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.13119 [1.7764108, 2.5568319] β: 0.75668 [0.57459492, 0.93876895] |
AUROC: 0.7097 [0.66045876, 0.75894676] | R²: 0.09337 [0.05345622, 0.14637157] | 0 | beta = log(or)/sd_pgs |
| PPM019568 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.97586 [1.89392638, 2.06134031] β: 0.681 [0.63865212, 0.72335641] |
AUROC: 0.68272 [0.67193914, 0.69350427] | R²: 0.10396 [0.09215189, 0.11637443] | 0 | beta = log(or)/sd_pgs |
| PPM019565 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.15033 [1.76929402, 2.61342601] β: 0.76562 [0.57058061, 0.96066201] |
AUROC: 0.71858 [0.66846898, 0.76868259] | R²: 0.09202 [0.05146716, 0.14494702] | 0 | beta = log(or)/sd_pgs |
| PPM019371 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.50345 [1.44736806, 1.56169867] β: 0.40776 [0.36974678, 0.44577412] |
AUROC: 0.61483 [0.6041949, 0.62546154] | R²: 0.03687 [0.03036813, 0.04440322] | 0 | beta = log(or)/sd_pgs |
| PPM019372 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.5159 [1.49147674, 1.54071414] β: 0.41601 [0.39976673, 0.43224604] |
AUROC: 0.61664 [0.61218514, 0.62110289] | R²: 0.03779 [0.03485119, 0.0407422] | 0 | beta = log(or)/sd_pgs |
| PPM019373 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.41368 [1.22998344, 1.62480429] β: 0.34619 [0.20700071, 0.48538737] |
AUROC: 0.59685 [0.55878634, 0.63490483] | R²: 0.02157 [0.0084806, 0.0408865] | 0 | beta = log(or)/sd_pgs |
| PPM019374 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.51726 [1.4458611, 1.59218042] β: 0.4169 [0.36870506, 0.46510441] |
AUROC: 0.61419 [0.60043482, 0.62795106] | R²: 0.03874 [0.02972293, 0.04762759] | 0 | beta = log(or)/sd_pgs |
| PPM019375 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.36644 [1.18199147, 1.57966055] β: 0.31221 [0.1672007, 0.45720998] |
AUROC: 0.58936 [0.54856639, 0.63014506] | R²: 0.01701 [0.00515533, 0.0361295] | 0 | beta = log(or)/sd_pgs |
| PPM019376 | PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.52553 [1.47054481, 1.58257468] β: 0.42234 [0.38563295, 0.45905307] |
AUROC: 0.61809 [0.60795567, 0.62822808] | R²: 0.03875 [0.03244269, 0.04550058] | 0 | beta = log(or)/sd_pgs |
| PPM019515 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.59583 [1.52885526, 1.6657401] β: 0.46739 [0.42451926, 0.51026953] |
AUROC: 0.62793 [0.61636768, 0.63949484] | R²: 0.04886 [0.0404352, 0.05732086] | 0 | beta = log(or)/sd_pgs |
| PPM019516 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.7257 [1.69478953, 1.7571791] β: 0.54563 [0.52755856, 0.56370974] |
AUROC: 0.65061 [0.64587451, 0.65533965] | R²: 0.06617 [0.06206093, 0.07052172] | 0 | beta = log(or)/sd_pgs |
| PPM019517 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.56915 [1.28114247, 1.92191081] β: 0.45054 [0.24775224, 0.65331991] |
AUROC: 0.63143 [0.57812692, 0.68474053] | R²: 0.02944 [0.00956735, 0.06119207] | 0 | beta = log(or)/sd_pgs |
| PPM019518 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.64521 [1.57424498, 1.71937474] β: 0.49787 [0.45377578, 0.5419607] |
AUROC: 0.637 [0.62528706, 0.64870674] | R²: 0.0552 [0.04605743, 0.06529161] | 0 | beta = log(or)/sd_pgs |
| PPM019519 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | β: 0.65945 [0.46590265, 0.85299521] OR: 1.93373 [1.59345187, 2.34666509] |
AUROC: 0.67403 [0.62336814, 0.72468515] | R²: 0.06214 [0.02869604, 0.10462456] | 0 | beta = log(or)/sd_pgs |
| PPM019520 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.75123 [1.67930969, 1.8262382] β: 0.56032 [0.51838281, 0.60225822] |
AUROC: 0.65399 [0.64288674, 0.66509836] | R²: 0.0708 [0.06025191, 0.08141476] | 0 | beta = log(or)/sd_pgs |
| PPM019377 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.51371 [1.45690938, 1.57273254] β: 0.41457 [0.37631733, 0.45281458] |
AUROC: 0.61677 [0.60614744, 0.62739669] | R²: 0.03765 [0.03122797, 0.04458387] | 0 | beta = log(or)/sd_pgs |
| PPM019378 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.57309 [1.54753963, 1.59906233] β: 0.45304 [0.43666633, 0.46941741] |
AUROC: 0.62593 [0.62148932, 0.63037613] | R²: 0.04421 [0.04108768, 0.04733518] | 0 | beta = log(or)/sd_pgs |
| PPM019379 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.48885 [1.29381926, 1.7132878] β: 0.39801 [0.25759851, 0.53841421] |
AUROC: 0.61392 [0.57666682, 0.65116657] | R²: 0.02805 [0.01127913, 0.04970286] | 0 | beta = log(or)/sd_pgs |
| PPM019380 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.54351 [1.46962869, 1.62111114] β: 0.43406 [0.38500977, 0.4831118] |
AUROC: 0.61643 [0.60273161, 0.63013007] | R²: 0.04054 [0.03169724, 0.04959805] | 0 | beta = log(or)/sd_pgs |
| PPM019381 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | β: 0.30458 [0.1594086, 0.44974616] OR: 1.35605 [1.17281707, 1.56791414] |
AUROC: 0.58631 [0.54480747, 0.62781198] | R²: 0.01615 [0.00465348, 0.03568609] | 0 | beta = log(or)/sd_pgs |
| PPM019382 | PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.58738 [1.52948202, 1.64746461] β: 0.46208 [0.42492913, 0.49923751] |
AUROC: 0.62786 [0.61789935, 0.63782848] | R²: 0.04538 [0.0390985, 0.05265595] | 0 | beta = log(or)/sd_pgs |
| PPM019521 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.65268 [1.5832893, 1.72511914] β: 0.5024 [0.45950452, 0.54529611] |
AUROC: 0.63839 [0.62689394, 0.64987964] | R²: 0.05647 [0.04798058, 0.06559575] | 0 | beta = log(or)/sd_pgs |
| PPM019522 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.82864 [1.7955911, 1.86229749] β: 0.60357 [0.58533427, 0.62181093] |
AUROC: 0.6649 [0.66024355, 0.66955943] | R²: 0.08013 [0.07594604, 0.0849066] | 0 | beta = log(or)/sd_pgs |
| PPM019523 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.6915 [1.38133728, 2.07131408] β: 0.52562 [0.32305207, 0.72818323] |
AUROC: 0.63946 [0.58058365, 0.69834094] | R²: 0.04017 [0.01277226, 0.08063675] | 0 | beta = log(or)/sd_pgs |
| PPM019524 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.73299 [1.65753964, 1.81186867] β: 0.54985 [0.50533436, 0.59435873] |
AUROC: 0.65124 [0.6397176, 0.66276176] | R²: 0.06647 [0.05674221, 0.07746767] | 0 | beta = log(or)/sd_pgs |
| PPM019526 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.81235 [1.73744769, 1.89047452] β: 0.59462 [0.55241719, 0.63682787] |
AUROC: 0.66197 [0.65090246, 0.67303245] | R²: 0.07892 [0.06819253, 0.09030102] | 0 | beta = log(or)/sd_pgs |
| PPM019525 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.09235 [1.73026328, 2.53021198] β: 0.73829 [0.54827358, 0.92830309] |
AUROC: 0.69188 [0.63818733, 0.74557944] | R²: 0.08168 [0.04043084, 0.13345443] | 0 | beta = log(or)/sd_pgs |
| PPM019395 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.59437 [1.53276253, 1.65844649] β: 0.46648 [0.42707168, 0.50588132] |
AUROC: 0.62805 [0.61730846, 0.63879374] | R²: 0.04474 [0.03764085, 0.05255667] | 0 | beta = log(or)/sd_pgs |
| PPM019396 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.66993 [1.64183933, 1.69850558] β: 0.51278 [0.49581716, 0.52974879] |
AUROC: 0.63827 [0.63378595, 0.64274622] | R²: 0.05278 [0.04931446, 0.05616794] | 0 | beta = log(or)/sd_pgs |
| PPM019397 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.51618 [1.31170795, 1.75251743] β: 0.41619 [0.27133007, 0.56105328] |
AUROC: 0.61353 [0.5733705, 0.65369542] | R²: 0.02871 [0.01250794, 0.05342829] | 0 | beta = log(or)/sd_pgs |
| PPM019398 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.73541 [1.65197692, 1.82304779] β: 0.55124 [0.5019727, 0.60050971] |
AUROC: 0.65009 [0.63697565, 0.66320694] | R²: 0.06532 [0.05353864, 0.07670765] | 0 | beta = log(or)/sd_pgs |
| PPM019399 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.41849 [1.2278941, 1.63866418] β: 0.34959 [0.20530059, 0.49388139] |
AUROC: 0.60107 [0.56006001, 0.6420884] | R²: 0.02154 [0.00783799, 0.0429191] | 0 | beta = log(or)/sd_pgs |
| PPM019400 | PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.75895 [1.69468766, 1.82564559] β: 0.56472 [0.52749845, 0.60193367] |
AUROC: 0.65397 [0.64416994, 0.6637611] | R²: 0.06832 [0.06011876, 0.07710225] | 0 | beta = log(or)/sd_pgs |
| PPM019539 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.83755 [1.76079665, 1.91764763] β: 0.60843 [0.56576635, 0.65109924] |
AUROC: 0.66652 [0.65523959, 0.67779057] | R²: 0.08398 [0.07344274, 0.09506364] | 0 | beta = log(or)/sd_pgs |
| PPM019540 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.10912 [2.07031069, 2.14865068] β: 0.74627 [0.72769869, 0.76484005] |
AUROC: 0.70032 [0.69582741, 0.70480679] | R²: 0.12127 [0.11622782, 0.12684792] | 0 | beta = log(or)/sd_pgs |
| PPM019541 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.09532 [1.71819723, 2.55521892] β: 0.73971 [0.54127562, 0.9381379] |
AUROC: 0.70813 [0.65766064, 0.75860174] | R²: 0.08266 [0.04385125, 0.13403974] | 0 | beta = log(or)/sd_pgs |
| PPM019542 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.94637 [1.86071817, 2.03596439] β: 0.66597 [0.62096253, 0.71096961] |
AUROC: 0.68099 [0.66968894, 0.69228485] | R²: 0.09676 [0.08473465, 0.10933361] | 0 | beta = log(or)/sd_pgs |
| PPM019543 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.33868 [1.93329423, 2.82907628] β: 0.84959 [0.65922541, 1.03995025] |
AUROC: 0.72874 [0.68089354, 0.77659441] | R²: 0.10918 [0.06519807, 0.16739921] | 0 | beta = log(or)/sd_pgs |
| PPM019544 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.05644 [1.97084383, 2.14575861] β: 0.72098 [0.67846179, 0.76349315] |
AUROC: 0.6931 [0.68251948, 0.70367807] | R²: 0.1164 [0.10387553, 0.12958633] | 0 | beta = log(or)/sd_pgs |
| PPM019383 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011215| European Ancestry| 130,758 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.68728 [1.62374245, 1.75330376] β: 0.52312 [0.48473364, 0.56150187] |
AUROC: 0.64492 [0.63436542, 0.65546756] | R²: 0.05957 [0.05207671, 0.0683119] | 0 | beta = log(or)/sd_pgs |
| PPM019384 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011227| European Ancestry| 217,530 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.79574 [1.76611997, 1.82586546] β: 0.58542 [0.56878504, 0.6020541] |
AUROC: 0.66012 [0.65578171, 0.66445565] | R²: 0.07267 [0.06845349, 0.07630969] | 0 | beta = log(or)/sd_pgs |
| PPM019385 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011238| South Asian Ancestry| 24,319 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.65971 [1.44271166, 1.90933646] β: 0.50664 [0.36652444, 0.64675578] |
AUROC: 0.64011 [0.60165094, 0.67856339] | R²: 0.0456 [0.02415111, 0.07590576] | 0 | beta = log(or)/sd_pgs |
| PPM019386 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011254| European Ancestry| 35,377 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.77954 [1.69371921, 1.86971028] β: 0.57636 [0.52692683, 0.62578349] |
AUROC: 0.65472 [0.6415564, 0.66787483] | R²: 0.07113 [0.05912593, 0.08267581] | 0 | beta = log(or)/sd_pgs |
| PPM019387 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011282| South Asian Ancestry| 4,350 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.54652 [1.33583678, 1.79042912] β: 0.43601 [0.28955789, 0.58245532] |
AUROC: 0.61895 [0.57716253, 0.6607321] | R²: 0.03271 [0.01452627, 0.05810203] | 0 | beta = log(or)/sd_pgs |
| PPM019388 | PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PSS011268| European Ancestry| 48,968 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Breast cancer | OR: 1.82572 [1.75833364, 1.89568002] β: 0.60197 [0.56436656, 0.63957762] |
AUROC: 0.6625 [0.65279453, 0.67221102] | R²: 0.0764 [0.06786928, 0.08556093] | 0 | beta = log(or)/sd_pgs |
| PPM019533 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88737 [1.80789009, 1.97034824] β: 0.63519 [0.59216047, 0.6782103] |
AUROC: 0.6718 [0.66057034, 0.68302823] | R²: 0.09007 [0.07870731, 0.10123858] | 0 | beta = log(or)/sd_pgs |
| PPM019534 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.16613 [2.12587867, 2.20714003] β: 0.77294 [0.75418521, 0.79169757] |
AUROC: 0.70492 [0.70043717, 0.70939503] | R²: 0.12803 [0.12275071, 0.13385339] | 0 | beta = log(or)/sd_pgs |
| PPM019535 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.17738 [1.78364146, 2.65802706] β: 0.77812 [0.57865704, 0.97758414] |
AUROC: 0.71302 [0.66145726, 0.76459247] | R²: 0.09073 [0.04829108, 0.14750786] | 0 | beta = log(or)/sd_pgs |
| PPM019536 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.96184 [1.87524209, 2.05242919] β: 0.67388 [0.62873777, 0.71902406] |
AUROC: 0.68192 [0.67063949, 0.69320216] | R²: 0.09847 [0.08648881, 0.11141801] | 0 | beta = log(or)/sd_pgs |
| PPM019537 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.33409 [1.93362624, 2.81750157] β: 0.84762 [0.65939712, 1.03585052] |
AUROC: 0.73073 [0.68290478, 0.77855694] | R²: 0.11103 [0.06711153, 0.17090094] | 0 | beta = log(or)/sd_pgs |
| PPM019538 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.07191 [1.98501238, 2.16261171] β: 0.72847 [0.68562515, 0.77131661] |
AUROC: 0.69359 [0.68298073, 0.70420632] | R²: 0.11691 [0.10474566, 0.12968023] | 0 | beta = log(or)/sd_pgs |
| PPM020095 | PGS004164 (PRS16_LC) |
PSS011294| East Asian Ancestry| 55,266 individuals |
PGP000518 | Wei X et al. Int J Cancer (2023) |
Reported Trait: Lung cancer in never smokers | HR: 1.28 [1.17, 1.4] | — | — | age, education, BMI, COPD history, personal history of cancer, family history of cancer, and the first 10 principal components of ancestry | — |
| PPM020096 | PGS004165 (PRS21_LC) |
PSS011294| East Asian Ancestry| 55,266 individuals |
PGP000518 | Wei X et al. Int J Cancer (2023) |
Reported Trait: Lung cancer in never smokers | HR: 1.29 [1.18, 1.41] | — | — | age, education, BMI, COPD history, personal history of cancer, family history of cancer, and the first 10 principal components of ancestry | — |
| PPM020097 | PGS004165 (PRS21_LC) |
PSS011294| East Asian Ancestry| 55,266 individuals |
PGP000518 | Wei X et al. Int J Cancer (2023) |
Reported Trait: Incident lung cancer in never smokers | — | — | Hazard ratio (HR, high vs low risk): 2.09 [1.56, 2.8] | age, first 10 principal components of ancestry, MI, education, COPD history, personal history of cancer and family history of cancer | — |
| PPM020099 | PGS004166 (bc_1) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64831 | — | year of birth | — |
| PPM020100 | PGS004167 (bc_2) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64213 | — | year of birth | — |
| PPM020101 | PGS004168 (bc_3) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64699 | — | year of birth | — |
| PPM020102 | PGS004169 (bc_4) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64504 | — | year of birth | — |
| PPM020103 | PGS004170 (bc_5) |
PSS011296| European Ancestry| 45,334 individuals |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Reported Trait: Breast cancer | — | AUROC: 0.64455 | — | year of birth | — |
| PPM020292 | PGS004240 (PRS89_CRC) |
PSS011326| Multi-ancestry (including European)| 3,809 individuals |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Reported Trait: Colorectal cancer | — | — | Hazard ratio (HR, high vs low PRS tertile): 2.51 [2.04, 3.09] | Age, sex, red meat intake, BMI, family history of CRC, smoking status, alcohol intake, townsend deprivation index, race, education (College or University degree, vocational qualifications, optional national exams at ages 17 to 18 years, national exams at age 16 years, none of the above, unknown), other common diseases (hypertension, heart diseases, diabetes) | — |
| PPM020293 | PGS004240 (PRS89_CRC) |
PSS011327| Multi-ancestry (including European)| 125,021 individuals |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Reported Trait: Colorectal cancer | — | — | Hazard ratio (HR, high vs low PRS tertile): 2.48 [2.11, 2.91] | Age, sex, red meat intake, BMI, family history of CRC, smoking status, alcohol intake, townsend deprivation index, race, education (College or University degree, vocational qualifications, optional national exams at ages 17 to 18 years, national exams at age 16 years, none of the above, unknown), other common diseases (hypertension, heart diseases, diabetes) | — |
| PPM020294 | PGS004240 (PRS89_CRC) |
PSS011327| Multi-ancestry (including European)| 125,021 individuals |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Reported Trait: Colorectal cancer x Saturated fatty acids interaction | HR: 1.14 [1.11, 1.18] | — | — | Age, sex, race, BMI, family history, red meat intake, smoking status, alcohol intake, townsend deprivation index, education level, other common diseases (hypertension, heart diseases, diabetes) | — |
| PPM020295 | PGS004240 (PRS89_CRC) |
PSS011326| Multi-ancestry (including European)| 3,809 individuals |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Reported Trait: Colorectal cancer x Saturated fatty acids interaction | HR: 1.17 [1.12, 1.22] | — | — | Age, sex, race, BMI, family history, red meat intake, smoking status, alcohol intake, townsend deprivation index, education level, other common diseases (hypertension, heart diseases, diabetes) | — |
| PPM020296 | PGS004240 (PRS89_CRC) |
PSS011327| Multi-ancestry (including European)| 125,021 individuals |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Reported Trait: Colorectal cancer (with saturated fatty acid and clinical risk factors) | — | AUROC: 0.734 [0.72, 0.749] | — | Age, sex, race, BMI, family history, red meat intake, smoking status, alcohol intake, townsend deprivation index, education level, other common diseases (hypertension, heart diseases, diabetes) | — |
| PPM020297 | PGS004240 (PRS89_CRC) |
PSS011326| Multi-ancestry (including European)| 3,809 individuals |
PGP000541 | Fan L et al. Int J Cancer (2023) |
Reported Trait: Colorectal cancer (with saturated fatty acid and clinical risk factors) | — | AUROC: 0.662 [0.64, 0.683] | — | Age, sex, race, BMI, family history, red meat intake, smoking status, alcohol intake, townsend deprivation index, education level, other common diseases (hypertension, heart diseases, diabetes) | — |
| PPM020298 | PGS004241 (PRS12_bladder) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Bladder cancer | HR: 1.41 [1.09, 1.83] | — | — | first 10 genetic principal components | — |
| PPM020308 | PGS004241 (PRS12_bladder) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Bladder cancer | HR: 1.28 [1.12, 1.48] | — | — | first 10 genetic principal components | — |
| PPM020299 | PGS004242 (PRS306_breast) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Breast cancer | HR: 1.58 [1.53, 1.64] | — | — | first 10 genetic principal components | — |
| PPM020300 | PGS004243 (PRS67_colorectum) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Colorectal cancer | HR: 1.49 [1.39, 1.61] | — | — | first 10 genetic principal components | — |
| PPM020309 | PGS004243 (PRS67_colorectum) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Colorectal cancer | HR: 1.51 [1.42, 1.61] | — | — | first 10 genetic principal components | — |
| PPM020301 | PGS004244 (PRS16_endometrium) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Endometrial cancer | HR: 1.25 [1.14, 1.36] | — | — | first 10 genetic principal components | — |
| PPM020302 | PGS004245 (PRS12_kidney) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Kidney cancer | HR: 1.22 [1.02, 1.45] | — | — | first 10 genetic principal components | — |
| PPM020310 | PGS004245 (PRS12_kidney) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Kidney cancer | HR: 1.25 [1.1, 1.41] | — | — | first 10 genetic principal components | — |
| PPM020311 | PGS004246 (PRS43_lung) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Lung cancer | HR: 1.2 [1.11, 1.3] | — | — | first 10 genetic principal components | — |
| PPM020303 | PGS004246 (PRS43_lung) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Lung cancer | HR: 1.18 [1.08, 1.28] | — | — | first 10 genetic principal components | — |
| PPM020312 | PGS004247 (PRS65_melanoma) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Melanoma | HR: 1.71 [1.55, 1.89] | — | — | first 10 genetic principal components | — |
| PPM020304 | PGS004247 (PRS65_melanoma) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Melanoma | HR: 1.78 [1.62, 1.96] | — | — | first 10 genetic principal components | — |
| PPM020306 | PGS004249 (PRS25_ovary) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Ovarian cancer | HR: 1.16 [1.03, 1.31] | — | — | first 10 genetic principal components | — |
| PPM020307 | PGS004250 (PRS19_pancreas) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Pancreatic cancer | HR: 1.37 [1.16, 1.61] | — | — | first 10 genetic principal components | — |
| PPM020314 | PGS004250 (PRS19_pancreas) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Pancreatic cancer | HR: 1.39 [1.2, 1.61] | — | — | first 10 genetic principal components | — |
| PPM020315 | PGS004251 (PRS125_prostate) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Prostate cancer | HR: 1.78 [1.72, 1.85] | — | — | first 10 genetic principal components | — |
| PPM020363 | PGS004295 (GenoBoost_breast_cancer_0) |
PSS011338| European Ancestry| 36,380 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.64123 | Covariate-adjusted pseudo-R2: 0.02653 AUPRC: 0.64123 |
age, sex, PC1-10 | — |
| PPM020364 | PGS004296 (GenoBoost_breast_cancer_1) |
PSS011338| European Ancestry| 36,380 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.64037 | Covariate-adjusted pseudo-R2: 0.02541 AUPRC: 0.64037 |
age, sex, PC1-10 | — |
| PPM020365 | PGS004297 (GenoBoost_breast_cancer_2) |
PSS011338| European Ancestry| 36,380 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.64119 | Covariate-adjusted pseudo-R2: 0.02635 AUPRC: 0.64119 |
age, sex, PC1-10 | — |
| PPM020366 | PGS004298 (GenoBoost_breast_cancer_3) |
PSS011338| European Ancestry| 36,380 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.64169 | Covariate-adjusted pseudo-R2: 0.02726 AUPRC: 0.64169 |
age, sex, PC1-10 | — |
| PPM020367 | PGS004299 (GenoBoost_breast_cancer_4) |
PSS011338| European Ancestry| 36,380 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.63627 | Covariate-adjusted pseudo-R2: 0.02431 AUPRC: 0.63627 |
age, sex, PC1-10 | — |
| PPM020368 | PGS004300 (GenoBoost_colorectal_cancer_0) |
PSS011340| European Ancestry| 67,428 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Colorectal cancer | — | AUROC: 0.66861 | Covariate-adjusted pseudo-R2: 0.00382 AUPRC: 0.66861 |
age, sex, PC1-10 | — |
| PPM020369 | PGS004301 (GenoBoost_colorectal_cancer_1) |
PSS011340| European Ancestry| 67,428 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Colorectal cancer | — | AUROC: 0.66747 | Covariate-adjusted pseudo-R2: 0.0036 AUPRC: 0.66747 |
age, sex, PC1-10 | — |
| PPM020370 | PGS004302 (GenoBoost_colorectal_cancer_2) |
PSS011340| European Ancestry| 67,428 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Colorectal cancer | — | AUROC: 0.66658 | Covariate-adjusted pseudo-R2: 0.00253 AUPRC: 0.66658 |
age, sex, PC1-10 | — |
| PPM020371 | PGS004303 (GenoBoost_colorectal_cancer_3) |
PSS011340| European Ancestry| 67,428 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Colorectal cancer | — | AUROC: 0.66945 | Covariate-adjusted pseudo-R2: 0.00423 AUPRC: 0.66945 |
age, sex, PC1-10 | — |
| PPM020372 | PGS004304 (GenoBoost_colorectal_cancer_4) |
PSS011340| European Ancestry| 67,428 individuals |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Reported Trait: Colorectal cancer | — | AUROC: 0.66807 | Covariate-adjusted pseudo-R2: 0.00325 AUPRC: 0.66807 |
age, sex, PC1-10 | — |
| PPM020419 | PGS004320 (PRS16_UGI) |
PSS011353| European Ancestry| 415,589 individuals |
PGP000551 | Liu W et al. Nutrients (2023) |
Reported Trait: Upper gastrointestinal cancer with unfavourable diet | — | — | Hazard ratio (HR, unfavourable diet and PRS in top quintile vs favourable diet with PRS in bottom quintile): 1.6 [1.2, 2.13] | age at recruitment, sex, assessment center (10 regions), ethnicity, Townsend deprivation index, education, BMI, glycosylated hemoglobin (HbA1c), smoking status, alcohol intake frequency, physical activity, multimorbidity, family history of cancer, and the first 10 principal components of ancestry | — |
| PPM020438 | PGS004325 (GRS19_LC) |
PSS011362| European Ancestry| 308,490 individuals |
PGP000559 | Wang Y et al. Front Physiol (2023) |
Reported Trait: Lung carcinogenesis (in smokers) | — | — | Hazard ratio (HR, highest PRS quintile and heavy smokers vs lowest PRS quintile and never smokers): 4.63 [3.0, 7.13] | Education, sex, genotype array, and the first ten important components | — |
| PPM020439 | PGS004325 (GRS19_LC) |
PSS011362| European Ancestry| 308,490 individuals |
PGP000559 | Wang Y et al. Front Physiol (2023) |
Reported Trait: Lung carcinogenesis | — | — | Hazard ratio (HR, highest vs lowest PRS quintiles): 1.58 [1.21, 2.08] | Education, sex, genotype array, the first ten primary components, quit time for smokers only, and pack-years for smokers | — |
| PPM020556 | PGS004441 (disease.breast_cancer.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: Breast cancer | OR: 1.22014 | — | — | — | — |
| PPM020557 | PGS004442 (disease.C34.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: C34 (Malignant neoplasm of bronchus and lung) | OR: 1.16807 | — | — | — | — |
| PPM020560 | PGS004445 (disease.D12.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: D12 (Benign neoplasm of colon, rectum, anus and anal canal) | OR: 1.19821 | — | — | — | — |
| PPM020626 | PGS004511 (meta.breast_cancer.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: Breast cancer | OR: 1.22647 | — | — | — | — |
| PPM020627 | PGS004512 (meta.C34.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: C34 (Malignant neoplasm of bronchus and lung) | OR: 1.31649 | — | — | — | — |
| PPM020630 | PGS004515 (meta.D12.score) |
PSS011364| European Ancestry| 56,192 individuals |
PGP000561 | Jung H et al. Commun Biol (2024) |
Reported Trait: D12 (Benign neoplasm of colon, rectum, anus and anal canal) | OR: 1.20806 | — | — | — | — |
| PPM020694 | PGS004579 (BRCA_PRSCS) |
PSS011365| European Ancestry| 190,879 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Breast cancer | OR: 1.76 [1.73, 1.79] | — | — | — | — |
| PPM020695 | PGS004580 (CRC_PRSCS) |
PSS011366| European Ancestry| 342,499 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Colorectal cancer | OR: 1.5 [1.46, 1.55] | — | — | — | — |
| PPM020696 | PGS004581 (PRCA_PRSCS) |
PSS011367| European Ancestry| 151,620 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Prostate cancer | OR: 2.13 [2.08, 2.17] | — | — | — | — |
| PPM020702 | PGS004586 (PPS_CRC) |
PSS011374| East Asian Ancestry| 543 individuals |
PGP000564 | Xin J et al. Nat Commun (2024) |
Reported Trait: Overall survival of colorectal cancer | HR: 1.9 [1.61, 2.24] | AUROC: 0.649 | — | sex, age, smoking status, drinking status and top 10 principal components | — |
| PPM020701 | PGS004586 (PPS_CRC) |
PSS011373| European Ancestry| 470 individuals |
PGP000564 | Xin J et al. Nat Commun (2024) |
Reported Trait: Overall survival of colorectal cancer | HR: 1.99 [1.57, 2.52] | AUROC: 0.652 | — | sex, age, stage and top 10 principal components | — |
| PPM020703 | PGS004586 (PPS_CRC) |
PSS011372| European Ancestry| 713 individuals |
PGP000564 | Xin J et al. Nat Commun (2024) |
Reported Trait: Overall survival of colorectal cancer | HR: 1.8 [1.49, 2.17] | AUROC: 0.658 | — | sex, age, smoking status, drinking status, research center, arm, stage, grade and top 10 principal components | — |
| PPM020722 | PGS004592 (PRS_KC) |
PSS011383| European Ancestry| 998 individuals |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Reported Trait: Keratinocyte cancer | OR: 1.51 [1.3, 1.76] | AUROC: 0.74 | R²: 0.231 | Age, sex, self-reported skin tanning ability, clinical grade of neck elastosis, genotyping batch, first 2 PCs | — |
| PPM020723 | PGS004592 (PRS_KC) |
PSS011383| European Ancestry| 998 individuals |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Reported Trait: Keratinocyte cancer | — | — | Odds ratio (OR, top PRS quintile vs bottom PRS quintile): 3.45 [2.18, 5.5] | Age, sex, self-reported skin tanning ability, clinical grade of neck elastosis, genotyping batch, first 2 PCs | — |
| PPM020753 | PGS004599 (PRS102_Pca) |
PSS011391| East Asian Ancestry| 3,166 individuals |
PGP000577 | Ruan X et al. J Clin Med (2023) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, high vs low PRS quintile): 3.63 [2.61, 5.0] | Age, family history, PSA, %fPSA, 10 PCs | — |
| PPM020754 | PGS004599 (PRS102_Pca) |
PSS011391| East Asian Ancestry| 3,166 individuals |
PGP000577 | Ruan X et al. J Clin Med (2023) |
Reported Trait: Prostate cancer | — | AUROC: 0.904 [0.887, 0.921] | — | Age, familiy history, log(prostate volume), log(prostate health index) | — |
| PPM020757 | PGS004601 (PRS17_Pca) |
PSS011394| East Asian Ancestry| 2,628 individuals |
PGP000579 | Wu Y et al. Clin Genet (2023) |
Reported Trait: Prostate cancer in males undergoing prostate biopsy | — | — | p (PRS in cases vs controls): 5.56e-17 | — | — |
| PPM020758 | PGS004601 (PRS17_Pca) |
PSS011393| East Asian Ancestry| 2,425 individuals |
PGP000579 | Wu Y et al. Clin Genet (2023) |
Reported Trait: Primary prostate cancer | — | — | p (PRS in cases vs controls): 3.31e-23 | — | — |
| PPM020786 | PGS004611 (RORP_PRS) |
PSS011411| Multi-ancestry (including European)| 10,196 individuals |
PGP000590 | Shieh Y et al. NPJ Precis Oncol (2023) |
Reported Trait: Breast cancer-specific survival | HR: 1.13 [1.06, 1.21] | — | — | 10 PCs | — |
| PPM020872 | PGS004687 (bladder_cancer) |
PSS011431| European Ancestry| 40,771 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Bladder cancer | — | AUROC: 0.5582 | — | — | — |
| PPM020873 | PGS004688 (breast_cancer) |
PSS011432| European Ancestry| 21,249 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Breast cancer | — | AUROC: 0.665 | — | — | — |
| PPM020874 | PGS004689 (colorectal_cancer) |
PSS011433| European Ancestry| 40,648 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Colorectal cancer | — | AUROC: 0.556 | — | — | — |
| PPM020875 | PGS004690 (kidney_cancer) |
PSS011434| European Ancestry| 40,841 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Kidney cancer | — | AUROC: 0.5644 | — | — | — |
| PPM020876 | PGS004691 (lung_cancer) |
PSS011435| European Ancestry| 40,850 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Lung cancer | — | AUROC: 0.6178 | — | — | — |
| PPM020877 | PGS004692 (ovarian_cancer) |
PSS011436| European Ancestry| 22,025 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Ovarian cancer | — | AUROC: 0.5298 | — | — | — |
| PPM020878 | PGS004693 (pancreatic_cancer) |
PSS011437| European Ancestry| 40,877 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Pancreatic cancer | — | AUROC: 0.5426 | — | — | — |
| PPM020879 | PGS004694 (prostate_cancer) |
PSS011438| European Ancestry| 18,514 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Prostate cancer | — | AUROC: 0.6894 | — | — | — |
| PPM020962 | PGS004737 (breast_cancer_PRSmix_eur) |
PSS011486| European Ancestry| 5,680 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Breast cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.038 [0.028, 0.048] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM020963 | PGS004738 (breast_cancer_PRSmixPlus_eur) |
PSS011486| European Ancestry| 5,680 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Breast cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.038 [0.028, 0.048] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM021040 | PGS004815 (prostate_cancer_PRSmix_eur) |
PSS011469| European Ancestry| 3,782 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Prostate cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.112 [0.093, 0.131] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM021041 | PGS004816 (prostate_cancer_PRSmixPlus_eur) |
PSS011469| European Ancestry| 3,782 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Prostate cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.112 [0.093, 0.131] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM021091 | PGS004860 (Genome-wide-PRS) |
PSS011520| European Ancestry| 24,012 individuals |
PGP000607 | Boumtje V et al. EBioMedicine (2024) |
Reported Trait: Incident lung cancer | OR: 1.33 | AUROC: 0.893 [0.887, 0.898] | R²: 0.49 | Sex, age,BMI, smocking status(ever or never smoker), and the first 10 ancestry-based PCA | — |
| PPM021102 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 18.2 [9.36, 35.4] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
| PPM021103 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 3.19 [2.51, 4.05] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
| PPM021104 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 3.84 [3.12, 4.72] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
| PPM021105 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 5.67 [3.84, 8.38] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
| PPM021101 | PGS004865 (PRS105_BC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 16.2 [8.1, 32.5] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
| PPM021113 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 15.04 [6.06, 37.34] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
| PPM021114 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 21.24 [9.84, 45.84] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
| PPM021115 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 4.17 [3.06, 5.68] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
| PPM021116 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 4.86 [3.71, 6.37] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
| PPM021117 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 6.51 [4.0, 10.6] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
| PPM021118 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BARD1 carriers younger than 40 years | OR: 1.94 [1.02, 3.68] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BARD1 variant carriers vs non-carriers |
| PPM021119 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRIP1 carriers younger than 40 years | OR: 2.73 [1.65, 4.54] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRIP1 variant carriers vs non-carriers |
| PPM021120 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CDH1 carriers younger than 40 years | OR: 17.98 [3.8, 85.06] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CDH1 variant carriers vs non-carriers |
| PPM021121 | PGS004866 (PRS105_ERposBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among NF1 carriers younger than 40 years | OR: 2.34 [0.75, 7.31] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in NF1 variant carriers vs non-carriers |
| PPM021106 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 61.05 [25.31, 147.28] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
| PPM021107 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 13.16 [4.29, 35.2] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
| PPM021108 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 1.78 [0.92, 3.46] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
| PPM021109 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 1.79 [1.02, 3.14] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
| PPM021110 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 11.95 [6.41, 22.3] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
| PPM021111 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BARD1 carriers younger than 40 years | OR: 4.42 [1.9, 10.3] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BARD1 variant carriers vs non-carriers |
| PPM021112 | PGS004867 (PRS105_ERnegBC) |
PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRIP1 carriers younger than 40 years | OR: 2.45 [1.0, 5.97] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRIP1 variant carriers vs non-carriers |
| PPM021136 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011557| European Ancestry| 36,886 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.63 [1.55, 1.71] | C-index: 0.63 [0.61, 0.64] | — | PCs 1-10 | — |
| PPM021137 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011556| European Ancestry| 17,370 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.48 [1.43, 1.54] | C-index: 0.63 [0.62, 0.65] | — | PCs 1-10 | — |
| PPM021138 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011554| European Ancestry| 24,387 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.63 [1.42, 1.88] | — | — | PCs 1-10 | — |
| PPM021139 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011555| European Ancestry| 7,018 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.42 [1.3, 1.55] | C-index: 0.61 [0.59, 0.64] | — | PCs 1-10 | — |
| PPM021140 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011553| European Ancestry| 230,276 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.61 [1.59, 1.64] | C-index: 0.64 [0.63, 0.64] | — | PCs 1-10 | — |
| PPM021141 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011552| European Ancestry| 130,985 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.59 [1.53, 1.65] | C-index: 0.63 [0.62, 0.64] | — | PCs 1-10 | — |
| PPM021134 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011559| European Ancestry| 242,571 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.67 [1.64, 1.7] | — | — | PCs 1-10 | — |
| PPM021135 | PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PSS011558| European Ancestry| 21,171 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Breast Cancer | HR: 1.55 [1.49, 1.63] | C-index: 0.62 [0.61, 0.63] | — | PCs 1-10 | — |
| PPM021157 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011627| European Ancestry| 204,761 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.96 [1.92, 1.99] | — | — | PCs 1-10 | — |
| PPM021158 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011626| European Ancestry| 17,270 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.66 [1.59, 1.73] | C-index: 0.65 [0.64, 0.66] | — | PCs 1-10 | — |
| PPM021159 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011625| European Ancestry| 32,747 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.85 [1.77, 1.93] | C-index: 0.67 [0.65, 0.68] | — | PCs 1-10 | — |
| PPM021160 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011624| European Ancestry| 12,058 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.86 [1.74, 2.0] | C-index: 0.68 [0.66, 0.7] | — | PCs 1-10 | — |
| PPM021161 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011622| European Ancestry| 19,798 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 2.12 [1.69, 2.66] | — | — | PCs 1-10 | — |
| PPM021163 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011621| European Ancestry| 181,814 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.98 [1.94, 2.01] | C-index: 0.69 [0.69, 0.7] | — | PCs 1-10 | — |
| PPM021164 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011620| European Ancestry| 68,883 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.79 [1.72, 1.87] | C-index: 0.67 [0.65, 0.68] | — | PCs 1-10 | — |
| PPM021162 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011623| European Ancestry| 7,018 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.61 [1.42, 1.83] | C-index: 0.66 [0.62, 0.7] | — | PCs 1-10 | — |
| PPM021181 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011657| European Ancestry| 38,448 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 0.9 [0.89, 0.91] | C-index: 0.53 [0.53, 0.54] | — | PCs 1-10 | — |
| PPM021182 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011656| European Ancestry| 69,715 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 1.13 [1.11, 1.15] | C-index: 0.54 [0.53, 0.54] | — | PCs 1-10 | — |
| PPM021183 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011655| European Ancestry| 29,427 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 1.06 [1.04, 1.08] | C-index: 0.54 [0.53, 0.55] | — | PCs 1-10 | — |
| PPM021184 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011653| European Ancestry| 44,177 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 1.15 [1.08, 1.23] | — | — | PCs 1-10 | — |
| PPM021185 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011654| European Ancestry| 7,018 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 1.1 [1.05, 1.14] | C-index: 0.55 [0.53, 0.56] | — | PCs 1-10 | — |
| PPM021187 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011651| European Ancestry| 199,868 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 1.15 [1.13, 1.16] | C-index: 0.54 [0.53, 0.55] | — | PCs 1-10 | — |
| PPM021186 | PGS004875 (INTERVENE_MegaPRS_AllCancers) |
PSS011652| European Ancestry| 412,090 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Cancer | HR: 1.17 [1.16, 1.17] | C-index: 0.54 [0.54, 0.55] | — | PCs 1-10 | — |
| PPM021216 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011566| European Ancestry| 38,448 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.28 [1.21, 1.35] | C-index: 0.57 [0.56, 0.59] | — | PCs 1-10 | — |
| PPM021217 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011565| European Ancestry| 69,715 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.34 [1.27, 1.41] | C-index: 0.58 [0.57, 0.6] | — | PCs 1-10 | — |
| PPM021218 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011564| European Ancestry| 29,427 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.44 [1.38, 1.5] | C-index: 0.6 [0.59, 0.62] | — | PCs 1-10 | — |
| PPM021220 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011563| European Ancestry| 7,018 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.59 [1.41, 1.79] | C-index: 0.64 [0.61, 0.68] | — | PCs 1-10 | — |
| PPM021221 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011561| European Ancestry| 407,920 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.54 [1.5, 1.58] | C-index: 0.62 [0.61, 0.63] | — | PCs 1-10 | — |
| PPM021222 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011560| European Ancestry| 199,868 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.44 [1.37, 1.51] | C-index: 0.61 [0.59, 0.63] | — | PCs 1-10 | — |
| PPM021219 | PGS004880 (INTERVENE_MegaPRS_Colorectal_cancer) |
PSS011562| European Ancestry| 44,186 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Colorectal Cancer | HR: 1.37 [1.12, 1.68] | — | — | PCs 1-10 | — |
| PPM021245 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011607| European Ancestry| 38,448 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.13 [1.07, 1.19] | C-index: 0.54 [0.52, 0.56] | — | PCs 1-10 | — |
| PPM021246 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011606| European Ancestry| 69,715 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.32 [1.24, 1.4] | C-index: 0.59 [0.57, 0.61] | — | PCs 1-10 | — |
| PPM021247 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011605| European Ancestry| 29,427 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.26 [1.2, 1.33] | C-index: 0.6 [0.58, 0.62] | — | PCs 1-10 | — |
| PPM021248 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011603| European Ancestry| 44,187 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.43 [1.06, 1.93] | — | — | PCs 1-10 | — |
| PPM021249 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011604| European Ancestry| 7,018 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.21 [1.03, 1.41] | C-index: 0.62 [0.57, 0.67] | — | PCs 1-10 | — |
| PPM021250 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011602| European Ancestry| 277,400 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.24 [1.2, 1.28] | C-index: 0.62 [0.61, 0.63] | — | PCs 1-10 | — |
| PPM021251 | PGS004884 (INTERVENE_MegaPRS_Lung_cancer) |
PSS011601| European Ancestry| 199,868 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident lung cancer | HR: 1.08 [1.01, 1.16] | C-index: 0.57 [0.54, 0.59] | — | PCs 1-10 | — |
| PPM021270 | PGS004890 (CC-GWAS_PRS) |
PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer compared to luminal-like breast cancer | — | — | Odds ratio (OR, high vs low tertile): 2.62 [1.44, 4.75] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
| PPM021271 | PGS004891 (TNBC_PRS25) |
PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer | — | — | Odds ratio (OR, high vs low tertile): 1.54 [0.92, 2.59] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
| PPM021272 | PGS004892 (TNBC_PRS41) |
PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer | — | — | Odds ratio (OR, high vs low tertile): 1.53 [0.92, 2.55] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
| PPM021273 | PGS004893 (overall.hybrid.prs) |
PSS011673| African Ancestry| 5,821 individuals |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Reported Trait: Breast cancer | OR: 1.34 [1.27, 1.42] | AUROC: 0.581 [0.566, 0.597] | — | age, consortium/study, and top 10 principal components | — |
| PPM021274 | PGS004894 (ERpos.prs) |
PSS011673| African Ancestry| 5,821 individuals |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Reported Trait: Estrogen receptor positive breast cancer | OR: 1.49 [1.39, 1.6] | AUROC: 0.608 [0.588, 0.627] | — | age, consortium/study, and top 10 principal components | — |
| PPM021275 | PGS004895 (ERneg.prs) |
PSS011673| African Ancestry| 5,821 individuals |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Reported Trait: Estrogen receptor negative breast cancer | OR: 1.31 [1.21, 1.43] | AUROC: 0.576 [0.553, 0.598] | — | age, consortium/study, and top 10 principal components | — |
| PPM021341 | PGS004904 (PRS127_CRC) |
PSS011697| European Ancestry| 113,256 individuals |
PGP000636 | Jiang F et al. Int J Cancer (2023) |
Reported Trait: Incident and prevelant early-onset colorectal cancer | OR: 2.29 [1.98, 2.64] | — | — | Age, sex, education, family history, type 1 diabetes, 5 PCs | — |
| PPM021342 | PGS004904 (PRS127_CRC) |
PSS011697| European Ancestry| 113,256 individuals |
PGP000636 | Jiang F et al. Int J Cancer (2023) |
Reported Trait: Incident early-onset colorectal cancer | OR: 2.51 [1.77, 3.56] | — | — | Age, sex, education, family history, type 1 diabetes, 5 PCs | — |
| PPM021343 | PGS004904 (PRS127_CRC) |
PSS011697| European Ancestry| 113,256 individuals |
PGP000636 | Jiang F et al. Int J Cancer (2023) |
Reported Trait: Incident and prevelant early-onset colorectal adenoma | OR: 1.59 [1.48, 1.71] | — | — | Age, sex, education, family history, type 1 diabetes, 5 PCs | — |
| PPM021344 | PGS004904 (PRS127_CRC) |
PSS011697| European Ancestry| 113,256 individuals |
PGP000636 | Jiang F et al. Int J Cancer (2023) |
Reported Trait: Incident early-onset colorectal adenoma | OR: 1.57 [1.39, 1.77] | — | — | Age, sex, education, family history, type 1 diabetes, 5 PCs | — |
| PPM021361 | PGS004908 (PRS107_KC) |
PSS011702| European Ancestry| 324,805 individuals |
PGP000640 | Purdue MP et al. Nat Genet (2024) |
Reported Trait: Kidney cancer | OR: 1.5 [1.43, 1.58] | AUROC: 0.74 [0.72, 0.75] | — | Age, sex, PCs, BMI, smoking, hypertension | — |
| PPM021362 | PGS004908 (PRS107_KC) |
PSS011702| European Ancestry| 324,805 individuals |
PGP000640 | Purdue MP et al. Nat Genet (2024) |
Reported Trait: Clear cell renal cell carcinoma | OR: 1.69 [1.57, 1.81] | AUROC: 0.74 [0.72, 0.76] | — | Age, sex, PCs, BMI, smoking, hypertension | — |
| PPM021368 | PGS004912 (PRS183) |
PSS011706| East Asian Ancestry| 2,344 individuals |
PGP000643 | Tian J et al. Genome Med (2024) |
Reported Trait: Colorectal advanced neoplasm | OR: 1.61 [1.33, 1.94] | AUROC: 0.591 | — | age, sex, family history, principal components, genotype platform | — |
| PPM021369 | PGS004912 (PRS183) |
PSS011706| East Asian Ancestry| 2,344 individuals |
PGP000643 | Tian J et al. Genome Med (2024) |
Reported Trait: Colorectal non-advanced adenoma | OR: 1.25 [1.14, 1.38] | AUROC: 0.556 | — | age, sex, family history, principal components, genotype platform | — |
| PPM021370 | PGS004912 (PRS183) |
PSS011705| European Ancestry| 24,322 individuals |
PGP000643 | Tian J et al. Genome Med (2024) |
Reported Trait: Colorectal advanced neoplasm | OR: 1.34 [1.28, 1.4] | AUROC: 0.582 | — | age, sex, family history, principal components, genotype platform | — |
| PPM021371 | PGS004912 (PRS183) |
PSS011705| European Ancestry| 24,322 individuals |
PGP000643 | Tian J et al. Genome Med (2024) |
Reported Trait: Colorectal non-advanced adenoma | OR: 1.19 [1.15, 1.23] | AUROC: 0.546 | — | age, sex, family history, principal components, genotype platform | — |
| PPM021752 | PGS004945 (PRS87_CRC) |
PSS011779| European Ancestry| 306,857 individuals |
PGP000671 | Gao P et al. Int J Cancer (2023) |
Reported Trait: Incident colorectal cancer | — | — | Hazard ratio (HR, top vs bottom PGS tertile): 2.35 [2.11, 2.6] | Age, sex, ethnic, college or university degree, Townsend deprivation index, alcohol drinking, smoking status, BMI, protein diet, regular physical activity, sleep duration, hyperlipidemia, hypertension, T2D, triglycerides, total cholesterol, glucose, eGFR, genotyping array, 10 PCs | — |
| PPM021769 | PGS004954 (PRS26_TC) |
PSS011791| Multi-ancestry (including European)| 73,346 individuals |
PGP000676 | Pozdeyev N et al. J Clin Endocrinol Metab (2024) |
Reported Trait: Thyroid cancer | — | AUROC: 0.7 | — | Age, sex, genotyping batch, 10 PCs | — |
| PPM021775 | PGS004955 (PRS23) |
PSS011794| European Ancestry| 406,880 individuals |
PGP000678 | Zhu M et al. Int J Epidemiol (2023) |
Reported Trait: Incident lung cancer | HR: 1.24 [1.19, 1.29] | — | — | Age, sex, smoking status, BMI, highest education level, family history of cancer, personal medical history (previous cancer diagnoses and chronic obstructive pulmonary disease), the forced expiratory volume in 1 second, 10 PCs | — |
| PPM022170 | PGS005086 (PGS64518_OC) |
PSS011825| East Asian Ancestry| 61,457 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.12 [1.05, 1.2] | — | — | — | — |
| PPM022166 | PGS005086 (PGS64518_OC) |
PSS011826| European Ancestry| 245,377 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.46 [1.37, 1.54] | AUROC: 0.607 [0.59, 0.623] | — | — | — |
| PPM022167 | PGS005087 (PGS5957_OC) |
PSS011826| European Ancestry| 245,377 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.45 | AUROC: 0.603 | — | — | — |
| PPM022171 | PGS005087 (PGS5957_OC) |
PSS011825| East Asian Ancestry| 61,457 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.14 | — | — | — | — |
| PPM022168 | PGS005088 (PGS3448_OC) |
PSS011826| European Ancestry| 245,377 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.45 | AUROC: 0.604 | — | — | — |
| PPM022172 | PGS005088 (PGS3448_OC) |
PSS011825| East Asian Ancestry| 61,457 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.14 | — | — | — | — |
| PPM022169 | PGS005089 (PGS400_OC) |
PSS011826| European Ancestry| 245,377 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.43 [1.35, 1.52] | AUROC: 0.603 | — | — | — |
| PPM022173 | PGS005089 (PGS400_OC) |
PSS011825| East Asian Ancestry| 61,457 individuals |
PGP000680 | Barnes DR et al. medRxiv (2024) |Pre |
Reported Trait: Epithelial ovarian cancer | OR: 1.13 | — | — | — | — |
| PPM022284 | PGS005104 (PRSAFR) |
PSS011899| African Ancestry| 7,096 individuals |
PGP000694 | Jia G et al. Nat Genet (2024) |
Reported Trait: Breast cancer | OR: 1.42 [1.33, 1.51] | AUROC: 0.6 [0.58, 0.62] | — | Age, study, genotyping array, 5 PCs | — |
| PPM022286 | PGS005105 (PRSAFR_ER+) |
PSS011901| African Ancestry| 5,844 individuals |
PGP000694 | Jia G et al. Nat Genet (2024) |
Reported Trait: ER-positive breast cancer | OR: 1.36 [1.26, 1.47] | AUROC: 0.6 [0.58, 0.63] | — | — | — |
| PPM022288 | PGS005106 (PRSAFR_ER−) |
PSS011900| African Ancestry| 4,814 individuals |
PGP000694 | Jia G et al. Nat Genet (2024) |
Reported Trait: ER-negative breast cancer | OR: 1.67 [1.49, 1.87] | AUROC: 0.62 [0.59, 0.66] | — | — | — |
| PPM022397 | PGS005160 (PRS-ESC) |
PSS011937| East Asian Ancestry| 100,219 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Esophageal Cancer | HR: 1.26 [1.16, 1.38] β: 0.246 |
C-index: 0.559 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022398 | PGS005161 (PRS-GC) |
PSS011938| East Asian Ancestry| 100,219 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Stomach Cancer | HR: 1.27 [1.18, 1.38] β: 0.239 |
C-index: 0.572 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022399 | PGS005162 (PRS-CRC) |
PSS011936| East Asian Ancestry| 100,219 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Colorectal Cancer | HR: 1.54 [1.43, 1.66] β: 0.432 |
C-index: 0.612 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022401 | PGS005163 (PRS-LC) |
PSS011939| East Asian Ancestry| 100,219 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Lung Cancer | HR: 1.22 [1.16, 1.28] β: 0.199 |
C-index: 0.55 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022402 | PGS005164 (PRS-BC) |
PSS011942| East Asian Ancestry| 57,359 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Breast Cancer | HR: 1.42 [1.3, 1.55] β: 0.344 |
C-index: 0.596 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022403 | PGS005165 (PRS-CC) |
PSS011943| East Asian Ancestry| 57,359 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Cervical Cancer | HR: 1.2 [1.06, 1.36] β: 0.182 |
C-index: 0.566 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022404 | PGS005166 (PRS-OC) |
PSS011944| East Asian Ancestry| 57,359 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Ovarian Cancer | HR: 1.25 [1.02, 1.52] β: 0.223 |
C-index: 0.579 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022405 | PGS005167 (PRS-PC) |
PSS011941| East Asian Ancestry| 42,860 individuals |
PGP000711 | Zhu M et al. PLoS Med (2025) |
Reported Trait: Prostate Cancer | HR: 1.75 [1.43, 2.15] β: 0.565 |
C-index: 0.658 | — | Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components | The HR and C-index values were derived from Cox proportional hazards regression models. |
| PPM022451 | PGS005169 (PRS25_LUAD) |
PSS011947| East Asian Ancestry| 2,048 individuals |
PGP000713 | Blechter B et al. JAMA Netw Open (2023) |
Reported Trait: Lung adenocarcinoma | OR: 1.6 [1.46, 1.75] | — | — | — | — |
| PPM022452 | PGS005169 (PRS25_LUAD) |
PSS011947| East Asian Ancestry| 2,048 individuals |
PGP000713 | Blechter B et al. JAMA Netw Open (2023) |
Reported Trait: Lung adenocarcinoma x Environmental Tobacco Smoke interaction | — | — | p-value (p, Environmental Tobacco Smoke at home and at work and high PRS vs Environmental Tobacco Smoke never and low PRS): 0.00065 | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000001 | All breast cancer | — | [
|
— | European | — | 33 cohorts
|
iCOGS |
| PSS000002 | ER-negative breast cancer | — | [
|
— | European | — | 33 cohorts
|
iCOGS |
| PSS000003 | ER-positive breast cancer | — | [
|
— | European | — | 33 cohorts
|
iCOGS |
| PSS011431 | — | — | [
|
— | European | — | UKB | — |
| PSS011432 | — | — | [
|
— | European | — | UKB | — |
| PSS011433 | — | — | [
|
— | European | — | UKB | — |
| PSS011434 | — | — | [
|
— | European | — | UKB | — |
| PSS011435 | — | — | [
|
— | European | — | UKB | — |
| PSS000004 | Invasive breast cancer-affected | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS000005 | ER-positive breast cancer cases | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS000006 | ER-negative breast cancer cases | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS000007 | Incident registry-confirmed invasive breast cancers developed | — | [ ,
0.0 % Male samples |
— | European | — | UKB | Prospective Test Set (UKB) |
| PSS011436 | — | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS011437 | — | — | [
|
— | European | — | UKB | — |
| PSS011438 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS011444 | Participants were classified according to the most advanced finding at colonoscopy (CRC, AA, non-advanced adenoma, other or none of above). Fecal hemoglobin concentrations were measured using Ridascreen Haemoglobin which is based on an enzyme immunoassay (participants recruited until December 2008), and FOB Gold which is based on a latex agglutination assay (participants recruited from December 2008 on). In both groups of participants, fully automated FIT analyses were conducted, blinded with respect to colonoscopy results, using Tecan Freedom Evolyzer (Ridascreen Haemoglobin) and Abbott Architect c8000 (FOB Gold), respectively. | — | [ ,
51.4 % Male samples |
Mean = 61.8 years | European, Not reported | — | BLITZ | — |
| PSS011445 | Participants were classified according to the most advanced finding at colonoscopy (CRC, AA, non-advanced adenoma, other or none of above). Fecal hemoglobin concentrations were measured using Ridascreen Haemoglobin which is based on an enzyme immunoassay (participants recruited until December 2008), and FOB Gold which is based on a latex agglutination assay (participants recruited from December 2008 on). In both groups of participants, fully automated FIT analyses were conducted, blinded with respect to colonoscopy results, using Tecan Freedom Evolyzer (Ridascreen Haemoglobin) and Abbott Architect c8000 (FOB Gold), respectively. | — | [ ,
53.5 % Male samples |
Mean = 63.1 years | European, Not reported | — | BLITZ | — |
| PSS000014 | Breast cancer ascertainment was based on self-report in an interview with a trained nurse, ICD-9 codes (174 or 174.9) or ICD-10 codes (C50.X) in hospitalization records, or a breast cancer diagnosis reported to the national registry before the date of enrollment. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | UKB Phase 2 |
| PSS009520 | — | — | [ ,
100.0 % Male samples |
— | European (Estonian) |
— | EB | — |
| PSS009272 | — | — | 18,722 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009273 | — | — | 19,990 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009274 | — | — | 10,197 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009275 | — | — | 8,501 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009277 | — | — | 19,893 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009278 | — | — | 19,895 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009279 | — | — | 19,923 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009280 | — | — | 19,539 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS000038 | Cases were ascertained by linkage to the California Cancer Registry and defined as pathologically-confirmed diagnoses of invasive breast cancers with positive/elevated ER expression on immunohistochemical staining. ER-negative cases and those with unavailable ER status were excluded. Excluded women self-identified as premenopausal, perimenopausal, or postmenopausal as a direct result of surgery or medical treatments, such as chemotherapy. Women on hormonal therapy or selective estrogen receptor modulators at the time of blood draw were also excluded. | — | [ ,
0.0 % Male samples |
— | East Asian | — | CPMCBHC | Nested case-control study from the CPMC Breast Health Cohort. |
| PSS000039 | Cases were ascertained by linkage to the California Cancer Registry and defined as pathologically-confirmed diagnoses of invasive breast cancers with positive/elevated ER expression on immunohistochemical staining. ER-negative cases and those with unavailable ER status were excluded. Excluded women self-identified as premenopausal, perimenopausal, or postmenopausal as a direct result of surgery or medical treatments, such as chemotherapy. Women on hormonal therapy or selective estrogen receptor modulators at the time of blood draw were also excluded. | — | [ ,
0.0 % Male samples |
— | European | — | CPMCBHC | Nested case-control study from the CPMC Breast Health Cohort. |
| PSS000040 | Cases were ascertained by linkage to the California Cancer Registry and defined as pathologically-confirmed diagnoses of invasive breast cancers with positive/elevated ER expression on immunohistochemical staining. ER-negative cases and those with unavailable ER status were excluded. Excluded women self-identified as premenopausal, perimenopausal, or postmenopausal as a direct result of surgery or medical treatments, such as chemotherapy. Women on hormonal therapy or selective estrogen receptor modulators at the time of blood draw were also excluded. | — | [ ,
0.0 % Male samples |
— | East Asian, European, Hispanic or Latin American | — | CPMCBHC | Nested case-control study from the CPMC Breast Health Cohort. |
| PSS000041 | For each cohort core data on disease status, age at diagnosis (age at observation or questionnaire for controls), family history of PrCa, and clinical factors for cases (for example, PSA at diagnosis and Gleason score) was extracted | — | [ ,
100.0 % Male samples |
— | European | — | 42 cohorts
|
These samples (OncoArray) were also used in the GWAS meta-analysis |
| PSS011469 | — | — | 3,782 individuals | — | European | — | AllofUs | — |
| PSS011486 | — | — | 5,680 individuals | — | European | — | AllofUs | — |
| PSS003602 | All individuals were childhood cancer survivors. Of the 6,414 childhood cancer survivors, 1,374 had received neck radiotherapy (neck-RT) as a form of treatment. Cases were individuals who developed subsequent thyroid cancer (STC). Cases of STC were ascertained by self-report questionnaires and subsequently confirmed by pathology reports. 73 of the 121 STC cases had received neck-RT as a form of childhood cancer treatment, whilst 48 had not. Of the controls, 1,301 had received neck-RT as a form of childhood cancer treatment. | Median = 36.5 years | [ ,
47.7 % Male samples |
— | European | — | NR | — |
| PSS003603 | All individuals were childhood cancer survivors. Of the 2,370 childhood cancer survivors, 476 had received neck radiotherapy (neck-RT) as a form of treatment. Cases were individuals who developed subsequent thyroid cancer (STC). Cases of STC were clinically ascertained. 47 of the 65 STC cases had received neck-RT as a form of childhood cancer treatment, whilst 18 had not. | Median = 36.6 years IQR = [30.3, 44.1] years |
[ ,
53.4 % Male samples |
— | European | — | SJCRH | — |
| PSS011520 | Lung cancer diagnosis was confirmed by pathological examination using resected specimens. | — | [ ,
45.72 % Male samples |
Mean = 59.65 years | European (French cancadian) |
— | CARTaGENE, LORD | CARTaGENE data application number 890519 |
| PSS011527 | — | — | 245 individuals | — | European | — | TCGA | — |
| PSS011527 | — | — | 30 individuals | — | Asian unspecified | — | TCGA | — |
| PSS011527 | — | — | 13 individuals | — | African American or Afro-Caribbean | — | TCGA | — |
| PSS011527 | — | — | 71 individuals | — | Not reported | — | TCGA | — |
| PSS000533 | Any Cancer PheCode | — | [
|
— | European | — | MGI | — |
| PSS000535 | PheCode:145; ICD9CM:140.0, 140.1, 140.3, 140.4, 140.5, 140.6, 140.8, 140.9, 141.0, 141.1, 141.2, 141.3, 141.4, 141.5, 141.6, 141.8, 141.9, 142.0, 142.1, 142.2, 142.8, 142.9, 143.0, 143.1, 143.8, 143.9, 144.0, 144.1, 144.8, 144.9, 145.0, 145.1, 145.2, 145.3, 145.4, 145.5, 145.6, 145.8, 145.9, 230.0, V10.01; ICD10CM:C00, C00.0, C00.1, C00.2, C00.3, C00.4, C00.5, C00.6, C00.8, C00.9, C01, C02, C02.0, C02.1, C02.2, C02.3, C02.4, C02.8, C02.9, C03, C03.0, C03.1, C03.9, C04, C04.0, C04.1, C04.8, C04.9, C05, C05.0, C05.1, C05.2, C05.8, C05.9, C06, C06.0, C06.1, C06.2, C06.8, C06.80, C06.89, C06.9, C07, C08, C08.0, C08.1, C08.9, D00.0, D00.00, D00.01, D00.02, D00.03, D00.04, D00.05, D00.06, D00.07, D00.08 | — | [
|
— | European | — | MGI | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | ProtecT | — |
| PSS000537 | PheCode:150; ICD9CM:150.0, 150.1, 150.2, 150.3, 150.4, 150.5, 150.8, 150.9, 230.1, V10.03; ICD10CM:C15, C15.3, C15.4, C15.5, C15.8, C15.9, D00.1 | — | [
|
— | European | — | MGI | — |
| PSS000538 | PheCode:153.2; ICD9CM:153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9, 159.0, 209.10, 209.11, 209.12, 209.13, 209.14, 209.15, 209.16, 230.3, V10.05; ICD10CM:C18, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C26.0, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.029, D01.0 | — | [
|
— | European | — | MGI | — |
| PSS000539 | PheCode:153.3; ICD9CM:154.0, 154.1, 154.2, 154.3, 209.17, 230.4, 230.5, 230.6, 796.70, 796.71, 796.72, 796.73, 796.74, 796.76, V10.06; ICD10CM:C19, C20, C21.0, C21.1, C7A.026, D01.1, D01.2, D01.3, R85.610, R85.611, R85.612, R85.613, R85.614, R85.619 | — | [
|
— | European | — | MGI | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | SEARCH | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 60.0] years | European | — | UKGPCS | — |
| PSS000069 | Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. | Median = 13.0 years | [ ,
100.0 % Male samples |
Range = [55.0, 71.0] years | European (Finnish) |
— | ERSPC | — |
| PSS000536 | PheCode:149.4; ICD9CM:161.0, 161.1, 161.2, 161.3, 161.8, 161.9, 231.0, V10.21; ICD10CM:C32, C32.0, C32.1, C32.2, C32.3, C32.8, C32.9, D02.0 | — | [
|
— | European | — | MGI | — |
| PSS000070 | BRCA1 mutation carriers were followed until breast or ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last observation whichever occurred first. | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 40 |
| PSS000071 | BRCA2 mutation carriers were followed until breast or ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last observation whichever occurred first. | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 43 |
| PSS000072 | BRCA1 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 50 |
| PSS000073 | BRCA2 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 57 |
| PSS000548 | PheCode:172; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, 173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, 232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9, V10.82, V10.83; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9, D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
| PSS000540 | PheCode:153; ICD9CM:153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9, 154.0, 154.1, 154.2, 154.3, 154.8, 159.0, 209.10, 209.11, 209.12, 209.13, 209.14, 209.15, 209.16, 209.17, 230.3, 230.4, 230.5, 230.6, 796.70, 796.71, 796.72, 796.73, 796.74, 796.76, V10.05, V10.06; ICD10CM:C18, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20, C21.0, C21.1, C21.2, C21.8, C26.0, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, D01.0, D01.1, D01.2, D01.3, R85.610, R85.611, R85.612, R85.613, R85.614, R85.619 | — | [
|
— | European | — | MGI | — |
| PSS000541 | PheCode:165.1; ICD9CM:162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 209.21, 231.2, V10.11; ICD10CM:C33, C34, C34.0, C34.00, C34.01, C34.02, C34.1, C34.10, C34.11, C34.12, C34.2, C34.3, C34.30, C34.31, C34.32, C34.8, C34.80, C34.81, C34.82, C34.9, C34.90, C34.91, C34.92, C7A.090, D02.2, D02.20, D02.21, D02.22 | — | [
|
— | European | — | MGI | — |
| PSS000542 | PheCode:165; ICD9CM:162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 163.0, 163.1, 163.8, 163.9, 165.0, 165.8, 165.9, 209.21, 231.1, 231.2, 231.8, 231.9, V10.11, V10.12, V10.20, V10.29; ICD10CM:C33, C34, C34.0, C34.00, C34.01, C34.02, C34.1, C34.10, C34.11, C34.12, C34.2, C34.3, C34.30, C34.31, C34.32, C34.8, C34.80, C34.81, C34.82, C34.9, C34.90, C34.91, C34.92, C38.4, C39, C39.0, C39.9, C45.0, C7A.090, D02.1, D02.2, D02.20, D02.21, D02.22, D02.3, D02.4 | — | [
|
— | European | — | MGI | — |
| PSS000074 | Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000075 | Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000076 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000077 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000547 | PheCode:172.3; ICD9CM:232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9; ICD10CM:D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
| PSS000549 | PheCode:174.1; ICD9CM:174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233.0, V10.3; ICD10CM:C50, C50.0, C50.01, C50.011, C50.012, C50.019, C50.02, C50.021, C50.022, C50.029, C50.1, C50.11, C50.111, C50.112, C50.119, C50.12, C50.121, C50.122, C50.129, C50.2, C50.21, C50.211, C50.212, C50.219, C50.22, C50.221, C50.222, C50.229, C50.3, C50.31, C50.311, C50.312, C50.319, C50.32, C50.321, C50.322, C50.329, C50.4, C50.41, C50.411, C50.412, C50.419, C50.42, C50.421, C50.422, C50.429, C50.5, C50.51, C50.511, C50.512, C50.519, C50.52, C50.521, C50.522, C50.529, C50.6, C50.61, C50.611, C50.612, C50.619, C50.62, C50.621, C50.622, C50.629, C50.8, C50.81, C50.811, C50.812, C50.819, C50.82, C50.821, C50.822, C50.829, C50.9, C50.91, C50.911, C50.912, C50.919, C50.92, C50.921, C50.922, C50.929, D05, D05.0, D05.00, D05.01, D05.02, D05.1, D05.10, D05.11, D05.12, D05.8, D05.80, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92 | — | [
|
— | European | — | MGI | — |
| PSS000552 | PheCode:185; ICD9CM:185, 233.4, V10.46; ICD10CM:C61, D07.5 | — | [
|
— | European | — | MGI | — |
| PSS000078 | — | — | [ ,
0.0 % Male samples |
— | East Asian | — | 11 cohorts
|
— |
| PSS000079 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | SGWAS | SGWAS (Stage 1). Smaller set of the larger test set from this study. |
| PSS000553 | PheCode:187.2; ICD9CM:186.0, 186.9, V10.47; ICD10CM:C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92 | — | [
|
— | European | — | MGI | — |
| PSS000080 | Questionnaires were mailed to women biennially to collect information on breast cancer risk factors, including age at menarche, age at first birth, parity, family history of breast cancer, height, weight, physical activity, menopausal status, age at menopause, and HT use. Incident breast cancer cases up to 1 June 2010 were also identified through biennial questionnaires. Diagnoses were confirmed with the participants (or next of kin), and permission was obtained to collect relevant medical or pathology reports. Analysis was restricted to invasive breast cancer. | Mean = 26.54 years | [ ,
0.0 % Male samples |
Mean = 53.7 years Sd = 8.0 years Range = [34.0, 70.0] years |
European, NR | — | NHS, NHS2 | Performance metrics are reported for the "All women" results of Table 2 |
| PSS000081 | Questionnaires were mailed to women biennially to collect information on breast cancer risk factors, including age at menarche, age at first birth, parity, family history of breast cancer, height, weight, physical activity, menopausal status, age at menopause, and HT use. Incident breast cancer cases up to 1 June 2010 were also identified through biennial questionnaires. Diagnoses were confirmed with the participants (or next of kin), and permission was obtained to collect relevant medical or pathology reports. Analysis was restricted to invasive breast cancer. | Mean = 23.08 years | [ ,
0.0 % Male samples |
Mean = 53.7 years Sd = 8.0 years Range = [34.0, 70.0] years |
European, NR | — | NHS, NHS2 | Performance metrics are reported for the "All women" results of Table 3 |
| PSS000555 | PheCode:189.2; ICD9CM:188.0, 188.1, 188.2, 188.3, 188.4, 188.5, 188.6, 188.7, 188.8, 188.9, 233.7, 236.7, 239.4, V10.51; ICD10CM:C67, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0, D41.4, D49.4 | — | [
|
— | European | — | MGI | — |
| PSS000556 | PheCode:190; ICD9CM:190.0, 190.1, 190.2, 190.3, 190.4, 190.5, 190.6, 190.7, 190.8, 190.9, 234.0, V10.84; ICD10CM:C69, C69.0, C69.00, C69.01, C69.02, C69.1, C69.10, C69.11, C69.12, C69.2, C69.20, C69.21, C69.22, C69.3, C69.30, C69.31, C69.32, C69.4, C69.40, C69.41, C69.42, C69.5, C69.50, C69.51, C69.52, C69.6, C69.60, C69.61, C69.62, C69.8, C69.80, C69.81, C69.82, C69.9, C69.90, C69.91, C69.92, D09.2, D09.20, D09.21, D09.22 | — | [
|
— | European | — | MGI | — |
| PSS000082 | A family-based cohort including 323 breast cancer cases and 262 unaffected relatives from 101 families. Unaffected relatives derived from 49 out of 101 families. | — | [ ,
0.0 % Male samples |
Mean (Cases) = 51.0 years Sd (Cases) = 11.0 years |
European | — | NR | — |
| PSS000558 | PheCode:193; ICD9CM:193, V10.87; ICD10CM:C73 | — | [
|
— | European | — | MGI | — |
| PSS000568 | PheCode:172.21; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
| PSS000569 | PheCode:172.22; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
| PSS000570 | PheCode:174.1; ICD9:233.0; ICD10:C50.0, C50.1, C50.2, C50.3, C50.4, C50.5, C50.6, C50.8, C50.9, D05.1, D05.7, D05.9, Z85.3 | — | [
|
— | European | — | UKB | — |
| PSS000571 | PheCode:182; ICD9:179, 182, 182.0, 182.1, 182.8, 233.2; ICD10:C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55, D07.0 | — | [
|
— | European | — | UKB | — |
| PSS000563 | PheCode:204.4; ICD9CM:203.00, 203.01, 203.02, 203.80, 203.81, 203.82; ICD10CM:C88.2, C88.3, C88.9, C90.0, C90.00, C90.01, C90.02, C90.2, C90.20, C90.21, C90.22, C90.30, C90.31, C90.32 | — | [
|
— | European | — | MGI | — |
| PSS000573 | PheCode:185; ICD9:185, 233.4; ICD10:C61, D07.5 | — | [
|
— | European | — | UKB | — |
| PSS000565 | PheCode:157; ICD9:157, 157.0, 157.1, 157.2, 157.3, 157.4, 157.8, 157.9; ICD10:C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9 | — | [
|
— | European | — | UKB | — |
| PSS000086 | — | — | [
|
— | East Asian | — | 8 cohorts
|
— |
| PSS000576 | PheCode:189.2; ICD9:233.7, 236.7, 239.4; ICD10:C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0, D41.4 | — | [
|
— | European | — | UKB | — |
| PSS000087 | — | — | [
|
— | European | — | 8 cohorts
|
— |
| PSS000575 | PheCode:189.11; ICD9:189.0; ICD10:C64 | — | [
|
— | European | — | UKB | — |
| PSS000578 | PheCode:191.1; ICD9:192, 192.0, 192.1, 192.2, 192.3, 192.8, 192.9; ICD10:C70.0, C70.1, C70.9, C71.0, C71.1, C71.2, C71.3, C71.4, C71.5, C71.6, C71.7, C71.8, C71.9, C72.0, C72.1, C72.2, C72.3, C72.4, C72.5, C72.8, C72.9 | — | [
|
— | European | — | UKB | — |
| PSS000579 | PheCode:193; ICD9:193; ICD10:C73 | — | [
|
— | European | — | UKB | — |
| PSS000574 | PheCode:187.2; ICD9:186, 186.0, 186.9; ICD10:C62.0, C62.1, C62.9 | — | [
|
— | European | — | UKB | — |
| PSS011535 | Cases are individuals who were incident diagnosed with invasive breast cancer. | Mean = 10.0 years | [ ,
0.0 % Male samples |
— | Not reported | — | MMHS | — |
| PSS011536 | Cases are individuals who were diagnosed with invasive breast cancer. They were free from cancer at the beginning of the study. | Mean = 10.0 years | [ ,
0.0 % Male samples |
— | Not reported | — | NHS | — |
| PSS000582 | PheCode:204.4; ICD9:203, 203.0, 203.8; ICD10:C88.1, C88.3, C88.9, C90.0, C90.2 | — | [
|
— | European | — | UKB | — |
| PSS000577 | PheCode:191.11; ICD9:191, 191.0, 191.1, 191.2, 191.3, 191.4, 191.5, 191.6, 191.7, 191.8, 191.9; ICD10:C71.0, C71.1, C71.2, C71.3, C71.4, C71.5, C71.6, C71.7, C71.8, C71.9 | — | [
|
— | European | — | UKB | — |
| PSS007618 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007619 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007620 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS011552 | — | — | [
|
— | European | — | EB | — |
| PSS011553 | — | — | [
|
— | European | — | FinnGen | — |
| PSS011554 | — | — | [
|
— | European | — | G&H | — |
| PSS000595 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | CAUG | — |
| PSS000596 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS011557 | — | — | [
|
— | European | — | HUNT | — |
| PSS011556 | — | — | [
|
— | European | — | GEL | — |
| PSS011555 | — | — | [
|
— | European | — | GS:SFHS | — |
| PSS011559 | — | — | [
|
— | European | — | UKB | — |
| PSS011558 | — | — | [
|
— | European | — | MGBB | — |
| PSS011561 | — | — | [
|
— | European | — | FinnGen | — |
| PSS000597 | In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. Cases Diagnosed within 10 years of blood collection. | Mean = 10.0 years | [ ,
28.1 % Male samples |
— | European | — | HPFS, NHS, PHS, WHI | Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample) |
| PSS000598 | In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. | — | [ ,
33.4 % Male samples |
— | European | — | HPFS, NHS, PHS, WHI | Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample) |
| PSS011565 | — | — | [
|
— | European | — | HUNT | — |
| PSS011566 | — | — | [
|
— | European | — | MGBB | — |
| PSS011564 | — | — | [
|
— | European | — | GEL | — |
| PSS011563 | — | — | [
|
— | European | — | GS:SFHS | — |
| PSS011560 | — | — | [
|
— | European | — | EB | — |
| PSS011562 | — | — | [
|
— | European | — | G&H | — |
| PSS000105 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years IQR = [55.0, 63.0] years |
European | — | ProtecT | — |
| PSS000105 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis) | — | [ ,
100.0 % Male samples |
Mean = 64.3 years IQR = [60.2, 67.5] years |
European | — | ProtecT | — |
| PSS000106 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years IQR = [55.0, 63.0] years |
European | — | ProtecT | — |
| PSS000106 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer. | — | [ ,
100.0 % Male samples |
Mean = 63.4 years IQR = [59.0, 67.5] years |
European | — | ProtecT | — |
| PSS000107 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years IQR = [55.0, 63.0] years |
European | — | ProtecT | — |
| PSS003581 | All individuals were BRCA1 carriers. BRCA1 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 28 cohorts
|
Additional controls were obtained from UCHICAGO |
| PSS003582 | All individuals were BRCA2 carriers. BRCA2 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 35 cohorts
|
Additional controls were obtained from UCHICAGO |
| PSS003583 | All individuals were BRCA1 carriers. BRCA1 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with prostate cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 31 cohorts
|
Additional cases and controls were obtained from UCHICAGO |
| PSS003584 | All individuals were BRCA2 carriers. BRCA2 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with prostate cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 36 cohorts
|
Additional cases and controls were obtained from UCHICAGO |
| PSS000107 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases) | — | [ ,
100.0 % Male samples |
— | European | — | ProtecT | — |
| PSS000108 | Adjudicated endpoint determined from medical notes by an outcome review committee | Mean = 11.1 years IQR = [10.0, 12.0] years |
[ ,
0.0 % Male samples |
Mean = 63.0 years Range = [50.0, 74.0] years |
European | — | UKCTOCS | — |
| PSS000108 | Adjudicated endpoint determined from medical notes by an outcome review committee | Mean = 11.1 years IQR = [10.0, 12.0] years |
[ ,
0.0 % Male samples |
Mean = 63.0 years Range = [50.0, 74.0] years |
European | — | UKCTOCS | — |
| PSS000109 | Participants were followed-up for cancer events mainly through linkage with official death certificates, chronic disease registries, and the Chinese national health insurance system. | Median = 10.44 years | [ ,
42.93 % Male samples |
Mean = 53.67 years Se = 10.98 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011602 | — | — | [
|
— | European | — | FinnGen | — |
| PSS011603 | — | — | [
|
— | European | — | G&H | — |
| PSS011604 | — | — | [
|
— | European | — | GS:SFHS | — |
| PSS011605 | — | — | [
|
— | European | — | GEL | — |
| PSS011606 | — | — | [
|
— | European | — | HUNT | — |
| PSS011607 | — | — | [
|
— | European | — | MGBB | — |
| PSS011601 | — | — | [
|
— | European | — | EB | — |
| PSS003595 | Cases were individuals with invasive breast cancer. Of the 585 cases, 475 were individuals with prevalent invasive breast cancer whilst 110 were individuals with incident invasive breast cancer. Incident invasive breast cancer was adjudicated by an expert panel using histopathology, metastasis imaging or other clinical evidence. Histopathology was available for 103 of the 110 individuals with incident invasive breast cancer. Of the 103 individuals, 74 had incident invasive estrogren receptor postivie/progesterone receptor positive breast cancer. Age at diagnosis of prevalent invasive breast cancer was self-reported as before or after 50 years. Of the 475 individuals with prevalent invasive breast cancer 60 had been diagnosed before the age of 50, whilst the remaining 415 had been diagnosed at age 50 or over. | Median = 4.7 years IQR = [3.65, 5.75] years |
[ ,
0.0 % Male samples |
Mean = 75.1 years | European | — | ASPREE | — |
| PSS003598 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 59.6 years Sd = 16.5 years |
African unspecified | — | eMERGE | — |
| PSS003599 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 66.1 years Sd = 17.7 years |
European | — | eMERGE | — |
| PSS003600 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 59.9 years Sd = 19.4 years |
Hispanic or Latin American | — | eMERGE | — |
| PSS007616 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007617 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007621 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007622 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007623 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007624 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007625 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007626 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007627 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007628 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007629 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007630 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007631 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007632 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007633 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007634 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007635 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007636 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007637 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007638 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007639 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007640 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009528 | — | — | [ ,
100.0 % Male samples |
— | European | Norwegian | HUNT | — |
| PSS009532 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | MGBB | — |
| PSS007643 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007644 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007645 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009536 | — | — | [ ,
100.0 % Male samples |
— | European | — | MGBB | — |
| PSS009519 | — | — | [ ,
0.0 % Male samples |
— | European (Estonian) |
— | EB | — |
| PSS009535 | — | — | [ ,
0.0 % Male samples |
— | European | — | MGBB | — |
| PSS009531 | — | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | MGBB | — |
| PSS009540 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS007651 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007652 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007653 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007654 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007655 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007656 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007657 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007658 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007659 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007660 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009544 | — | — | [ ,
100.0 % Male samples |
— | European | British | UKB | — |
| PSS009548 | — | — | [ ,
100.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS009543 | — | — | [ ,
0.0 % Male samples |
— | European | British | UKB | — |
| PSS009547 | — | — | [ ,
0.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS011657 | — | — | [
|
— | European | — | MGBB | — |
| PSS009523 | — | — | [ ,
0.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS009524 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS007664 | Cases were individuals with (incident) invasive colorectal cancer diagnosed after a baseline assessment. Colorectal cancer was identified using linkedc cancer registry data using ICD-9 (1530–1539, 1540–1541), ICD-10 (C18–C20) codes or self-reported disease). | — | [ ,
45.85 % Male samples |
— | European | — | UKB | — |
| PSS009527 | — | — | [ ,
0.0 % Male samples |
— | European | Norwegian | HUNT | — |
| PSS007670 | Cases were individuals who had been diagnosed with breast cancer. | — | [ ,
0.0 % Male samples |
— | European (Greek-Cypriot) |
— | NR | Cases and controls were obtained from the MASTOS study. |
| PSS009566 | — | — | [
|
Maximum = 50.0 years | European | — | 9 cohorts
|
CRCGEN, Kentucky, LCCS |
| PSS011672 | The molecular intrinsic subtypes of breast cancer were determined following the strategy of Giovanni's work using the PAM50 classifier in the TCGA-BRCA. Basal-like and luminal-like breast cancer were determined by PAM50. | — | [
|
— | European | — | TCGA | — |
| PSS011672 | Triple-negative breast cancer (TNBC) was defined as ER negative, PR negative and HER2 negative. The luminal breast cancer was defined as ER and/or PR positive. | — | [
|
— | African American or Afro-Caribbean | — | AABCG | — |
| PSS011673 | — | — | [
|
Mean = 52.7 years Sd = 12.7 years |
African American or Afro-Caribbean (African American, African, and African Barbadian) |
— | AABC, AMBER, BCAC, GBHS, ROOT | — |
| PSS007942 | — | — | 1,719 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS007943 | — | — | 1,810 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS011677 | Cases include women that developed breast cancer. All women were below the age of 70. | Median = 10.0 years Range = [0.03, 10.0] years |
[ ,
0.0 % Male samples |
Mean = 59.92 years | European (Dutch) |
— | RS | — |
| PSS011678 | Cases include women that developed breast cancer. Within the cases there were 290 invasive breast cancer cases and 34 in situ breast cancer cases. | Median = 12.4 years Range = [0.03, 24.43] years |
[ ,
0.0 % Male samples |
Mean = 66.05 years | European (Dutch) |
— | RS | — |
| PSS007944 | — | — | 1,143 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS011620 | — | — | [
|
— | European | — | EB | — |
| PSS011621 | — | — | [
|
— | European | — | FinnGen | — |
| PSS000110 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 29010 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS000111 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 26000 | — | [ ,
0.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS000112 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27010 | — | [ ,
0.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS000113 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 21041 - 21049, 21051, 21052, and 21060 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS000114 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27020 | — | [ ,
0.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS000115 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 29020 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS007946 | — | — | 1,803 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS000117 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 22030 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS011622 | — | — | [
|
— | European | — | G&H | — |
| PSS011623 | — | — | [
|
— | European | — | GS:SFHS | — |
| PSS000120 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 20010, 20020, 20030, 20040, 20050, 20060, 20070, 20080, 20090, and 20100 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS000121 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27040 | — | [ ,
0.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS000122 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 21100 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS000123 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28010 | — | [ ,
100.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS011624 | — | — | [
|
— | European | — | GEL | — |
| PSS000125 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28020 | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS000126 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 32010 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
| PSS011693 | — | — | [
|
— | African unspecified | — | CCSS, SJLIFE | — |
| PSS011694 | — | — | [
|
— | European | — | CCSS, SJLIFE | — |
| PSS011695 | — | — | 718 individuals, 49.4 % Male samples |
— | African unspecified | — | CCSS, SJLIFE | — |
| PSS011696 | — | — | 9,895 individuals, 49.8 % Male samples |
— | European | — | CCSS, SJLIFE | — |
| PSS009539 | — | — | [ ,
0.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS011625 | — | — | [
|
— | European | — | HUNT | — |
| PSS011697 | — | — | 113,256 individuals | — | European | — | UKB | — |
| PSS011626 | — | — | [
|
— | European | — | MGBB | — |
| PSS011627 | — | — | [
|
— | European | — | UKB | — |
| PSS011702 | — | — | [
|
— | European | — | UKB | — |
| PSS011705 | — | — | [ ,
55.6 % Male samples |
Mean = 62.07 years Sd = 5.21 years |
European | — | PLCO | — |
| PSS011706 | — | — | [ ,
46.72 % Male samples |
Mean = 57.59 years Sd = 8.47 years |
East Asian (Chinese) |
— | ZJCRC | — |
| PSS011707 | Cases are those of incident breast cancer. In UK Biobank, cancer diagnoses were ascertained through linkage to national cancer registries in England, Wales, and Scotland. Invasive breast cancer was coded using the 10th Revision of the International Classification of Diseases. Death was ascertained via linkage to death registries. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS011708 | Cases are those of incident breast cancer. In UK Biobank, cancer diagnoses were ascertained through linkage to national cancer registries in England, Wales, and Scotland. Invasive breast cancer was coded using the 10th Revision of the International Classification of Diseases. Death was ascertained via linkage to death registries. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS011712 | — | — | [ ,
43.5 % Male samples |
— | African unspecified | — | INHALE | — |
| PSS011713 | — | — | [ ,
47.2 % Male samples |
— | European | — | INHALE | — |
| PSS009592 | — | — | [ ,
0.0 % Male samples |
— | Not reported | — | TCGA | — |
| PSS009593 | — | — | [
|
— | Not reported | — | TCGA | — |
| PSS009594 | — | — | [ ,
100.0 % Male samples |
— | Not reported | — | TCGA | — |
| PSS007697 | — | — | [
|
— | European | — | CanPath | — |
| PSS009595 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. | Median = 109.0 months | [ ,
52.0 % Male samples |
Mean = 61.3 years | Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — |
| PSS009596 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. | — | [
|
— | Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — |
| PSS009597 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. | — | [
|
Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — | |
| PSS009598 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. | — | [
|
— | Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — |
| PSS009599 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. | — | [
|
Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — | |
| PSS009600 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. LSDM is defined in cases as type 2 diabetes diagnosed more than 24 months before PDAC diagnosis. Defined in controls as type 2 diabetes diagnosed more than 24 months before date of death or date of last follow up. | — | [
|
— | Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — |
| PSS009601 | PDAC cases were considered incident if diagnosed after study entry or without a date of diagnosis if identified by mortality alone. NODM is defined in cases as type 2 diabetes diagnosed within 24 months before or after diagnosis of PDAC. Defined in controls as type 2 diabetes diagnosed 24 months before death or last follow up. | — | [
|
— | Not reported | European, African American or Afro-Caribbean, South Asian, East Asian, African unspecified | UKB | — |
| PSS007717 | — | — | [
|
— | European | — | UKB | — |
| PSS007718 | — | — | [
|
— | European | — | UKB | — |
| PSS009609 | — | — | [ ,
0.0 % Male samples |
Range = [0.0, 50.0] years | European | — | NHS2, UKB | GS |
| PSS009610 | — | — | [ ,
0.0 % Male samples |
Range = [50.0, 100.0] years | European | — | 9 cohorts
|
GS |
| PSS009611 | — | — | 302,425 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | MCCS | — |
| PSS009612 | — | — | 840,867 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | EPIC | — |
| PSS009613 | — | — | 408,679 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | EPIC | — |
| PSS009614 | — | — | 188,453 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | KARMA | — |
| PSS009615 | — | — | 1,401,091 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | EPIC, PROCAS, UKB | — |
| PSS009616 | — | — | 5,328,392 individuals, 0.0 % Male samples |
Range = [50.0, 70.0] years | European | — | 7 cohorts
|
GS |
| PSS007724 | — | — | 2,362 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007725 | — | — | 2,483 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007726 | — | — | 1,482 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007727 | — | — | 844 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007728 | — | — | 2,471 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007729 | — | — | 2,477 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS007730 | — | — | 2,453 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS009617 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Korean) |
— | NR | — |
| PSS009619 | — | — | [ ,
44.1 % Male samples |
Mean = 56.3 years Sd = 8.0 years |
European | — | UKB | — |
| PSS011651 | — | — | [
|
— | European | — | EB | — |
| PSS011652 | — | — | [
|
— | European | — | FinnGen | — |
| PSS011653 | — | — | [
|
— | European | — | G&H | — |
| PSS011654 | — | — | [
|
— | European | — | GS:SFHS | — |
| PSS009632 | — | — | [ ,
100.0 % Male samples |
— | European | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | Asian unspecified | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | European | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS000207 | PheCode 172 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
| PSS000208 | Squamous cell carcinoma: ICD9-173.02,173.12,173.22,173.32,173.42,173.52,173.62,173.72,173.82,173.92 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
| PSS000209 | Basal cell carcinoma: ICD9-173.01,173.11,173.21,173.31,173.41,173.51,173.61,173.71,173.81,173.91 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | Sub-Saharan African (Ghanaian) |
— | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS000211 | PheCode 172 | — | [ ,
45.9 % Male samples |
Mean = 57.7 years Sd = 8.1 years |
European | White British Subset | UKB | — |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | Hispanic or Latin American | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS000840 | Cases: clinically diagnosed or screen-detected prostate cancer. Controls: free of cancer | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
| PSS000841 | Cases: clinically diagnosed with prostate cancer. Controls: free of cancer. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
| PSS000843 | Cases: screen-detected prostate cancer. Controls: free of cancer. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC | — |
| PSS000842 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
| PSS009636 | — | — | [
|
— | European | — | NR | International Multiple Myeloma rESEarch (IMMEnSE) consortium |
| PSS011656 | — | — | [
|
— | European | — | HUNT | — |
| PSS000218 | Phenotypic information was self-reported by the individual through an online, interactive health history tool | — | [ ,
0.0 % Male samples |
— | European | — | CG | Samples are individuals whose healthcare provider had ordered a Color Genomics multi-gene panel test |
| PSS000220 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR | Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000221 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | African unspecified | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000222 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | Asian unspecified | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000223 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | European | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000224 | Age at death due to prostate cancer. | — | [ ,
100.0 % Male samples |
Mean = 70.0 years IQR = [63.0, 76.0] years |
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR | Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS011753 | — | — | [ ,
100.0 % Male samples |
— | European | — | AHS | — |
| PSS011754 | — | — | [ ,
100.0 % Male samples |
— | European | — | AHS | — |
| PSS009645 | — | — | [
|
— | Not reported | — | DACHS | — |
| PSS009648 | — | — | [ ,
100.0 % Male samples |
— | European | — | MDC | — |
| PSS009649 | — | — | [ ,
100.0 % Male samples |
— | European | — | VIP | — |
| PSS009650 | — | — | [ ,
100.0 % Male samples |
— | European | — | NR | — |
| PSS000853 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Bladder cancer =(ICD-9 = 188 or ICD-10 = C67). | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000854 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Breast cancer=(ICD-9 = 174 or ICD-10 = C50). | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000855 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Colorectal Cancer=(ICD-9 = 153, 154.1 or ICD-10 = C18, C20) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000856 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Kidney Cancer=(ICD-9 = 189.0 or ICD-10 = C64) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000857 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Lung cancer=(ICD-9 = 162.2–162.9 or ICD-10 = C34). | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000858 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Ovarian cancer=(ICD-9 = 183.0 or ICD-10 = C56; ICD-O: 8441, 8460, 8462, 8380, 8381, 8470, 8471, 8472, 8473, 8480, 8310, 8140, 8260, 8440, 8450, 9000, 8000, and 8010) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000859 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Pancreatic Cancer=(ICD-9 = 157 or ICD-10 = C25) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS000860 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Prostate=(ICD-9 = 185 or ICD-10 = C61) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS009652 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | NR | — |
| PSS009659 | multiple myeloma (ICD-9 = 203 or ICD-10 = C90.0) | — | 290 individuals | — | European | — | UKB | — |
| PSS009660 | endometrial cancer (ICD-9 = 182 or ICD-10 = C54) | — | 629 individuals | — | European | — | UKB | — |
| PSS009661 | esophageal cancer (ICD-9 = 150 or ICD-10 = C15) | — | 406 individuals | — | European | — | UKB | — |
| PSS009662 | gastric cancer (ICD- 9 = 151 or ICD-10 = C16) | — | 272 individuals | — | European | — | UKB | — |
| PSS000871 | Basal cell carcinoma cases were determined by a baseline survey containing 34 questions regarding personal history of skin cancer(including skin cancer type, age at diagnosis, body location, prescribed treatments and information regarding cancer recurrence) | — | [ ,
38.9 % Male samples |
European | — | 23andMe | — | |
| PSS000873 | Squamous cell carcinoma cases were determined by a baseline survey containing 34 questions regarding personal history of skin cancer(including skin cancer type, age at diagnosis, body location, prescribed treatments and information regarding cancer recurrence) | — | [ ,
38.9 % Male samples |
European | — | 23andMe | — | |
| PSS000874 | Clinically significant cancer were any of: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis or distant metastasis. | — | [ ,
100.0 % Male samples |
— | African unspecified | — | 18 cohorts
|
PRACTICAL consortium |
| PSS000893 | Participants were 50 years of age or older. Cases included individuals with colorectal cancer. For cases, reference age was defined as the age of diagnosis of first primary CRC. For controls, reference age was defined as the age at selection. | — | [
|
Range = [50.0, 100.0] years | European | — | RPGEH | — |
| PSS000894 | Participants were under 50 years of age. Cases included individuals with colorectal cancer. For cases, reference age was defined as the age of diagnosis of first primary CRC. For controls, reference age was defined as the age at selection. | — | [
|
Range = [0.0, 50.0] years | European | — | RPGEH | — |
| PSS000251 | Colorectal adenocarcinoma located in the distal colon confirmed by medical records, pathology reports, or death certificate | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000252 | Colorectal adenocarcinoma located in the distal colon confirmed by medical records, pathology reports, or death certificate | — | [ ,
100.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000253 | Colorectal adenocarcinoma located in the proximal colon confirmed by medical records, pathology reports, or death certificate | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000254 | Colorectal adenocarcinoma located in the proximal colon confirmed by medical records, pathology reports, or death certificate | — | [ ,
100.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000255 | Colorectal adenocarcinoma located in the rectum confirmed by medical records, pathology reports, or death certificate | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000256 | Colorectal adenocarcinoma located in the rectum confirmed by medical records, pathology reports, or death certificate | — | [ ,
100.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000257 | Colorectal adenocarcinoma confirmed by medical records, pathology reports, or death certificate | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000258 | Colorectal adenocarcinoma confirmed by medical records, pathology reports, or death certificate | — | [ ,
100.0 % Male samples |
— | European | — | 6 cohorts
|
Training and test split not relevant to PGS |
| PSS000896 | Participants were under 50 years of age with no family history of colorectal cancer. Cases included individuals with colorectal cancer. For cases, reference age was defined as the age of diagnosis of first primary CRC. For controls, reference age was defined as the age at selection. | — | [
|
Range = [0.0, 50.0] years | European | — | RPGEH | — |
| PSS000259 | — | — | [ ,
57.21 % Male samples |
Range = [25.0, 90.0] years | European (Spanish) |
— | MCC-Spain | — |
| PSS000897 | Participants were 50 years of age or older with a history of colorectal cancer. Cases included individuals with colorectal cancer. For cases, reference age was defined as the age of diagnosis of first primary CRC. For controls, reference age was defined as the age at selection. | — | [
|
Range = [50.0, 100.0] years | European | — | RPGEH | — |
| PSS011779 | — | — | 306,857 individuals | — | European | — | UKB | — |
| PSS011791 | — | — | 73,346 individuals | — | African American or Afro-Caribbean, Asian unspecified, European, Native American, Not reported | — | CCPM | — |
| PSS011793 | — | — | [
|
— | East Asian (Chinese) |
— | CKB | — |
| PSS011794 | — | — | [
|
— | European | — | UKB | — |
| PSS000912 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [ ,
46.28 % Male samples |
— | European | — | UKB | — |
| PSS000913 | — | — | 167,955 individuals | — | European | — | UKB | — |
| PSS000914 | — | — | 67,186 individuals | — | European | — | UKB | — |
| PSS000915 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000916 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000917 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000260 | — | — | [ ,
0.0 % Male samples |
Mean (Cases) = 68.8 years Sd (Cases) = 9.7 years |
European | — | 14 cohorts
|
— |
| PSS000261 | — | — | [ ,
100.0 % Male samples |
Mean (Cases) = 67.8 years Sd (Cases) = 9.7 years |
European | — | 14 cohorts
|
— |
| PSS000262 | Excluding participants with prevalent cancer at recruitment colorectal cancer was defined as ICD codes: C18 (except C18.1, Appendix), C19 and C20 | — | [ ,
45.0 % Male samples |
Mean = 57.0 years IQR = [50.0, 63.0] years |
European | — | UKB | Follow-up time = 1,751,445 person years |
| PSS000263 | Excluding participants with prevalent cancer at recruitment colorectal cancer was defined as ICD codes: C18 (except C18.1, Appendix), C19 and C20 | — | [ ,
46.0 % Male samples |
Mean = 57.0 years IQR = [50.0, 63.0] years |
European | — | UKB | Follow-up time = 1,388,191 person years |
| PSS000921 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000920 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000919 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000918 | Cases are individuals with a lung cancer diagnosis. Lung cancer diagnosis was obtained through record linkage with death and cancer registries with the follow‐up time up to date of death, lung cancer diagnosis, or March 31, 2016 (in England and Wales) and Oct 31, 2015 (in Scotland) per censor date defined by UKB. To minimize the possibility of including lung cancer metastasis, we excluded lung cancer that occurred within 5 years of different primary cancer. | — | [
|
— | European | — | UKB | — |
| PSS000924 | Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 39,445 individuals had a family history of prostate cancer (≥1 first degree relative affected). | — | [ ,
100.0 % Male samples |
Mean = 66.0 years IQR = [60.0, 71.0] years |
European, NR | — | 60 cohorts
|
— |
| PSS000925 | Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. | — | [ ,
100.0 % Male samples |
Mean = 66.0 years IQR = [60.0, 71.0] years |
European, NR | — | 60 cohorts
|
— |
| PSS000925 | Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. | — | [ ,
100.0 % Male samples |
Mean = 68.0 years IQR = [62.0, 74.0] years |
Asian unspecified, NR | — | 60 cohorts
|
— |
| PSS000925 | Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. | — | [ ,
100.0 % Male samples |
Mean = 62.0 years IQR = [56.0, 68.0] years |
African unspecified, NR | — | 60 cohorts
|
— |
| PSS000923 | Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 1028 individuals had a family history of prostate cancer (≥1 first degree relative affected). | — | [ ,
100.0 % Male samples |
Mean = 68.0 years IQR = [62.0, 74.0] years |
Asian unspecified, NR | — | 60 cohorts
|
— |
| PSS000922 | Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 5557 individuals had a family history of prostate cancer (≥1 first degree relative affected). | — | [ ,
100.0 % Male samples |
Mean = 62.0 years IQR = [56.0, 68.0] years |
African unspecified, NR | — | 60 cohorts
|
— |
| PSS007945 | — | — | 575 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS000926 | Cases included individuals with any type of prostate cancer (PCa). For any clinically significant PCa, cases were defined as individuals with any of the following: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis, or distant metastasis. | — | [ ,
100.0 % Male samples |
— | European | — | ProtecT, UKGPCS | — |
| PSS007947 | — | — | 1,801 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS007948 | — | — | 1,801 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS007949 | — | — | 1,787 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS010980 | — | — | 4,797 individuals | — | European | — | NR | GCAT |
| PSS000268 | Unselected participants of the German screening colonoscopy program are recruited by gastroenterology practices in southern Germany in this multicenter study.Colonoscopy and histology reports are collected and information from these reports is extracted independently in a standardized way by two trained investigators, who are blinded with respect to questionnaire and genotype data and who resolve discrepancies by consensus after further review and discussion. Based on colonoscopy reports, participants are categorized with respect to the most advanced lesion: CRC, advanced adenoma (AA), non-advanced adenoma (NAA), hyperplastic polyp, or undefined polyp. Advanced adenomas are defined as adenomas ≥1 cm or adenomas with cellular or structural atypia. | — | [ ,
61.74 % Male samples |
Range = [50.0, 79.0] years | European | — | BLITZ | — |
| PSS000269 | Unselected participants of the German screening colonoscopy program are recruited by gastroenterology practices in southern Germany in this multicenter study.Colonoscopy and histology reports are collected and information from these reports is extracted independently in a standardized way by two trained investigators, who are blinded with respect to questionnaire and genotype data and who resolve discrepancies by consensus after further review and discussion. Based on colonoscopy reports, participants are categorized with respect to the most advanced lesion: CRC, advanced adenoma (AA), non-advanced adenoma (NAA), hyperplastic polyp, or undefined polyp. Advanced adenomas are defined as adenomas ≥1 cm or adenomas with cellular or structural atypia. | — | [ ,
60.48 % Male samples |
Range = [50.0, 79.0] years | European | — | BLITZ | — |
| PSS011825 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Japanese) |
— | BBJ | — |
| PSS000271 | — | — | [ ,
40.85 % Male samples |
Mean (Cases) = 58.34 years Sd (Cases) = 12.85 years |
East Asian (Han Chinese) |
— | NCRCC | — |
| PSS011826 | — | — | [ ,
0.0 % Male samples |
— | European (British) |
— | UKB | — |
| PSS010985 | — | — | 738 individuals | Mean = 59.35 years | European | — | TCGA | — |
| PSS010986 | — | — | 327 individuals | Mean = 69.11 years | European | — | TCGA | — |
| PSS010988 | — | — | 470 individuals | Mean = 67.3 years | European | — | TCGA | — |
| PSS010989 | — | — | 372 individuals | Mean = 64.72 years | European | — | TCGA | — |
| PSS010991 | — | — | 501 individuals | Mean = 60.09 years | European | — | TCGA | — |
| PSS010992 | — | — | 408 individuals | Mean = 61.67 years | European | — | TCGA | — |
| PSS000953 | In set 1 (1034 cases), prostate cancer cases were identified by linking with the cancer registries in Hawaii and California. In set 2 (1192 cases) cases were indiviuals with prostate cancer determined by cancer diagnosis, enrollment in prostate cancer studies at University of Texas M.D. Ancerson Cancer Centre or by biposy confirmation. | — | [ ,
100.0 % Male samples |
— | Hispanic or Latin American | — | LAAPC, MDA, MEC, SABOR | — |
| PSS010994 | — | — | 692 individuals | Mean = 60.99 years | European | — | TCGA | — |
| PSS010995 | — | — | 448 individuals | Mean = 58.23 years | European | — | TCGA | — |
| PSS010996 | — | — | 360 individuals | Mean = 48.04 years | European | — | TCGA | — |
| PSS011005 | — | — | [
|
— | African American or Afro-Caribbean (Black) |
— | OCAC | — |
| PSS011005 | — | — | [
|
— | European | — | OCAC | — |
| PSS011835 | — | Median = 10.7 years | [ ,
0.0 % Male samples |
— | East Asian (Chinese) |
— | TPMI | — |
| PSS011836 | — | Median = 10.0 years | [ ,
100.0 % Male samples |
— | East Asian (Chinese) |
— | TPMI | — |
| PSS011005 | — | — | [
|
— | Not reported | — | OCAC | — |
| PSS011015 | — | Median = 16.9 years | [ ,
0.0 % Male samples |
Mean = 53.8 years Sd = 7.8 years |
East Asian (Japanese) |
— | JPHC | — |
| PSS000974 | Cases are individuals with breast cancer. 1380 of these are male breast cancer cases and 1671 are female breast cancer cases | — | [ ,
48.07 % Male samples |
— | European | — | B58C, COH, UK-BCN-MBCS, UKBGS | Additional male breast cancer cases were recruited from the University of Leeds, the University of Cambridge. |
| PSS000975 | Cases were defined as having a biopsy-confirmed prostate cancer documented by a pathology report or at least two prostate cancer-related billing codes any time before or within 6 months of the date of blood collection. | — | [ ,
100.0 % Male samples |
— | African unspecified | — | MGBB | Formerly known as Partners healthcare Biobank (PHB) |
| PSS000976 | Cases were defined as having a biopsy-confirmed prostate cancer documented by a pathology report or at least two prostate cancer-related billing codes any time before or within 6 months of the date of blood collection. | — | [ ,
100.0 % Male samples |
— | European | — | MGBB | Formerly known as Partners healthcare Biobank (PHB) |
| PSS000272 | Primary tumor samples from TCGA | — | [
|
Mean = 69.0 years Sd = 10.0 years |
European | — | TCGA | — |
| PSS000272 | — | — | [
|
— | European | — | eMERGE | — |
| PSS000273 | Primary tumor samples from TCGA | — | [ ,
0.0 % Male samples |
Mean = 60.0 years Sd = 13.0 years |
European | — | TCGA | — |
| PSS000273 | — | — | [ ,
0.0 % Male samples |
— | European | — | eMERGE | — |
| PSS000274 | Primary tumor samples from TCGA | — | [
|
Mean = 68.0 years Sd = 13.0 years |
European | — | TCGA | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | European | — | CG | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | African unspecified | — | CG | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | CG | — |
| PSS000979 | Cases were individuals with breast cancer based on self-reporting at the time of enrollment. Out of the total 19,264 individuals, 845 individuals were carriers of a hereditary breast and ovarian cancer (HBOC) variant. Of the 845 individuals, 174 had breast cancer. | — | [ ,
0.0 % Male samples |
— | Not reported | — | CG | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | Asian unspecified | — | UKB | — |
| PSS000980 | Cases were individuals with breast cancer based on self-reporting at the base line (Data code: 1002), primary diagnoses (ICD-10) from hospitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,C509,D05,D050,D051,D057,D059,D486,Z853), primary diagnoses (ICD-9) from hospitalization records (Data codes: 174,174,1740,1743,1744,1745,1748,1749,2330,2383,2393), secondary disgnoses (ICD-10) from hopsitalization records (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508,D05,D050,D051,D057,D 059,D486,Z853), secondary diagnoses (ICD-9) from hopsitalization records (Data codes: 174,1749,2330,V103), cancer registry data specifying the type of cancer (ICD-10) from the cancer registry (Data codes: C50,C500,C501,C502,C503,C504,C506,C508,C509,D050,D051,D057,D059,174,175,1740,1741,1742,1743,1744,1745,1746,1748,1749,2330,2383), primary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) and secondary cause of death (ICD-10) from the death registry (Data codes: C50,C500,C501,C502,C503,C504,C505,C506,C508) . Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. Of the total number of cases and controls, 115 were carriers of a pathogenic or likely pathogenic variant. | — | [ ,
0.0 % Male samples |
— | Not reported | — | UKB | — |
| PSS000274 | — | — | [
|
— | European | — | eMERGE | — |
| PSS000276 | — | — | [
|
— | European | — | eMERGE | — |
| PSS000276 | Primary tumor samples from TCGA | — | [
|
Mean = 67.0 years Sd = 9.0 years |
European | — | TCGA | — |
| PSS000278 | — | — | [ ,
0.0 % Male samples |
— | European | — | eMERGE | — |
| PSS000278 | Primary tumor samples from TCGA | — | [ ,
0.0 % Male samples |
Mean = 60.0 years Sd = 12.0 years |
European | — | TCGA | — |
| PSS000279 | — | — | [
|
— | European | — | eMERGE | — |
| PSS000983 | Cases were individuals with malignant prostate cancer. All individuals (cases and controls) were carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants in ATM, BRCA2, CHEK2, and HOXB13 genes. | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS000279 | Primary tumor samples from TCGA | — | [
|
Mean = 66.0 years Sd = 11.0 years |
European | — | TCGA | — |
| PSS000280 | — | — | [ ,
100.0 % Male samples |
— | European | — | eMERGE | — |
| PSS000280 | Primary tumor samples from TCGA | — | [ ,
100.0 % Male samples |
Mean = 62.0 years Sd = 7.0 years |
European | — | TCGA | — |
| PSS000281 | — | — | [
|
— | European | — | eMERGE | — |
| PSS000281 | Primary tumor samples from TCGA | — | [
|
Mean = 62.0 years Sd = 12.0 years |
European | — | TCGA | — |
| PSS000282 | — | — | [
|
— | European | — | eMERGE | — |
| PSS000282 | Primary tumor samples from TCGA | — | [
|
Mean = 49.0 years Sd = 16.0 years |
European | — | TCGA | — |
| PSS000982 | Cases were individuals with cutaneous melanoma. Of the 628 cases, 528 were prevalent melanoma, whilst 98 were incident melanoma cases. Endpoints used were primary invasive cutaneous melanoma and metastatic melanoma with unknown primary location occurring during the trial (incident). Metastatic recurrence was excluded. Incident melanomas were confirmed by expert panel using histopathology, imaging of metastasis or other clinical evidence. If a participant had two events during the trial, the time of the first event was used. Prevalent melanomas occurring pre-trial were self-reported by participants but not confirmed by review of medical records and assumed to be invasive. Age at diagnosis for self-reported melanomas was reported as either before or after 50 years. | Median = 4.7 years | [ ,
45.0 % Male samples |
Mean = 75.0 years Sd = 4.23 years |
European | — | ASPREE | — |
| PSS000981 | Cases were individuals with colorectal cancer based on self-reporting at the baseline (Coding IDs: 10,221,023), primary cause of death (ICD-10) from the death registry (Coding IDsC180,C182,C183,C184,C185,C186,C187,C188,C189), secondary cause of death (ICD-10) from the death registry (Coding IDs: C180,C182,C183,C184,C185,C186,C187,C188,C189), type of cancer (ICD-10) from the cancer registry (Coding IDs: C18,C180,C181,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375, 153,154,1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1 548,2303,2304), primary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), primary diagnoses (ICD-9) from hopsitalization records (Coding IDs: 153,154,1530,1532,1533,1534,1536,1537,1539,1540,1541), secondary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), secondary diagnoses (ICD-9) from hospitialization records (Coding IDs: 153,153,154,1532,1533,1541). Of the total number of cases and controls, 76 were carriers of a pathogenic or likely pathogenic variant in any of the following genes: MLH1, MSH2, MSH6 and PMS2. | — | [
|
— | European | — | UKB | — |
| PSS011030 | — | — | [ ,
100.0 % Male samples |
— | European | — | EB | — |
| PSS011031 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | MADCaP | — |
| PSS011032 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | MGBB | — |
| PSS011033 | — | — | [ ,
100.0 % Male samples |
— | European | — | MGBB | — |
| PSS000981 | Cases were individuals with colorectal cancer based on self-reporting at the baseline (Coding IDs: 10,221,023), primary cause of death (ICD-10) from the death registry (Coding IDsC180,C182,C183,C184,C185,C186,C187,C188,C189), secondary cause of death (ICD-10) from the death registry (Coding IDs: C180,C182,C183,C184,C185,C186,C187,C188,C189), type of cancer (ICD-10) from the cancer registry (Coding IDs: C18,C180,C181,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375, 153,154,1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1 548,2303,2304), primary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), primary diagnoses (ICD-9) from hopsitalization records (Coding IDs: 153,154,1530,1532,1533,1534,1536,1537,1539,1540,1541), secondary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), secondary diagnoses (ICD-9) from hospitialization records (Coding IDs: 153,153,154,1532,1533,1541). Of the total number of cases and controls, 76 were carriers of a pathogenic or likely pathogenic variant in any of the following genes: MLH1, MSH2, MSH6 and PMS2. | — | [
|
— | African unspecified | — | UKB | — |
| PSS011035 | — | — | [ ,
100.0 % Male samples |
— | European | — | MGI | — |
| PSS011034 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | MGI | — |
| PSS000981 | Cases were individuals with colorectal cancer based on self-reporting at the baseline (Coding IDs: 10,221,023), primary cause of death (ICD-10) from the death registry (Coding IDsC180,C182,C183,C184,C185,C186,C187,C188,C189), secondary cause of death (ICD-10) from the death registry (Coding IDs: C180,C182,C183,C184,C185,C186,C187,C188,C189), type of cancer (ICD-10) from the cancer registry (Coding IDs: C18,C180,C181,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375, 153,154,1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1 548,2303,2304), primary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), primary diagnoses (ICD-9) from hopsitalization records (Coding IDs: 153,154,1530,1532,1533,1534,1536,1537,1539,1540,1541), secondary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), secondary diagnoses (ICD-9) from hospitialization records (Coding IDs: 153,153,154,1532,1533,1541). Of the total number of cases and controls, 76 were carriers of a pathogenic or likely pathogenic variant in any of the following genes: MLH1, MSH2, MSH6 and PMS2. | — | [
|
— | Asian unspecified | — | UKB | — |
| PSS000981 | Cases were individuals with colorectal cancer based on self-reporting at the baseline (Coding IDs: 10,221,023), primary cause of death (ICD-10) from the death registry (Coding IDsC180,C182,C183,C184,C185,C186,C187,C188,C189), secondary cause of death (ICD-10) from the death registry (Coding IDs: C180,C182,C183,C184,C185,C186,C187,C188,C189), type of cancer (ICD-10) from the cancer registry (Coding IDs: C18,C180,C181,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375, 153,154,1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1 548,2303,2304), primary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), primary diagnoses (ICD-9) from hopsitalization records (Coding IDs: 153,154,1530,1532,1533,1534,1536,1537,1539,1540,1541), secondary diagnoses (ICD-10) from hospitalization records (Coding IDs: C18,C180,C182,C183,C184,C185,C186,C187,C188,C189,C19,C20,D010,D011,D012,D374,D375), secondary diagnoses (ICD-9) from hospitialization records (Coding IDs: 153,153,154,1532,1533,1541). Of the total number of cases and controls, 76 were carriers of a pathogenic or likely pathogenic variant in any of the following genes: MLH1, MSH2, MSH6 and PMS2. | — | [
|
— | Not reported | — | UKB | — |
| PSS008154 | — | — | 6,010 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008155 | — | — | 6,328 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008156 | — | — | 2,782 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008157 | — | — | 3,182 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008159 | — | — | 6,301 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008160 | — | — | 6,310 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008161 | — | — | 6,305 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS008162 | — | — | 6,171 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS011899 | — | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | AABCG | — |
| PSS011900 | — | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | AABCG | — |
| PSS011901 | — | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | AABCG | — |
| PSS011904 | — | Median = 6.2 years IQR = [3.7, 10.9] years |
3,110 individuals, 100.0 % Male samples |
Median = 56.6 years IQR = [51.4, 61.5] years |
European, African unspecified | — | BioVU | No prostate cancer and prostate specific antigen level < 4 mg/mL at baseline |
| PSS011057 | — | — | [ ,
65.5 % Male samples |
Mean = 61.6 years Range = [20.0, 90.0] years |
African American or Afro-Caribbean (African American) |
— | GERA | — |
| PSS011058 | — | — | [ ,
42.1 % Male samples |
Mean = 55.8 years Range = [20.0, 90.0] years |
East Asian | — | GERA | — |
| PSS011059 | — | — | [ ,
41.6 % Male samples |
Mean = 62.3 years Range = [20.0, 90.0] years |
European | — | GERA | — |
| PSS011060 | — | — | [ ,
38.7 % Male samples |
Mean = 55.0 years Range = [20.0, 90.0] years |
Hispanic or Latin American | — | GERA | — |
| PSS011061 | The colorectal cancer case subjects were defined as those who had at least two ICD9/10 codes for CRC. Control sub- jects had zero ICD9/10 codes for CRC. Participants with a single ICD9/10 code for CRC were excluded from analysis. | — | [
|
— | European | — | eMERGE | — |
| PSS011062 | — | — | [ ,
50.5 % Male samples |
Mean = 64.5 years | Asian unspecified | — | GERA, MG-JPN | — |
| PSS011063 | — | — | [ ,
44.0 % Male samples |
Mean = 61.33 years | African American or Afro-Caribbean | — | GERA, MG-AA, eMERGE | — |
| PSS011064 | — | — | [ ,
47.5 % Male samples |
Mean = 64.0 years | Hispanic or Latin American | — | GERA, HCCS | — |
| PSS011065 | — | — | [ ,
52.75 % Male samples |
Mean = 65.75 years | European | — | BCC, CPSII, GERA, eMERGE | — |
| PSS011069 | — | — | 495 individuals, 0.0 % Male samples |
Median = 53.0 years IQR = [48.0, 59.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS011070 | — | — | 332 individuals, 0.0 % Male samples |
Median = 58.0 years IQR = [52.0, 64.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS011071 | — | — | 409 individuals, 100.0 % Male samples |
Median = 59.0 years IQR = [52.0, 65.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS011072 | — | — | 181 individuals, 0.0 % Male samples |
Median = 59.0 years IQR = [55.0, 64.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS011073 | — | — | 381 individuals, 100.0 % Male samples |
Median = 60.0 years IQR = [55.0, 64.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS011074 | — | — | 308 individuals, 100.0 % Male samples |
Median = 59.0 years IQR = [54.0, 64.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS000995 | Cases are women with breast cancer. Of the 4414 breast cancer cases, 2470 were ER-positive and 1372 were ER-negative. | — | [ ,
0.0 % Male samples |
— | African American or Afro-Caribbean | — | 10 cohorts
|
All cohorts part of African American Breast Cancer (AABC) consortium and/or The African American Breast Cancer Epidemiology and Risk (AMBER)consortium. |
| PSS000995 | Cases are women with breast cancer. Of the 3928 breast cancer cases, 1533 were ER-positive and 987 were ER-negative. | — | [ ,
0.0 % Male samples |
Mean = 47.71 years | African American or Afro-Caribbean, Sub-Saharan African, African unspecified | — | 15 cohorts
|
All cohorts part of The GAME-ON OncoArray Consortium or The GWAS of Breast Cancer in the African Diaspora Consortium (ROOT) |
| PSS000995 | Cases are women with breast cancer. Of the 899 breast cancer cases, 296 were ER-positive and 277 were ER-negative. | — | [ ,
0.0 % Male samples |
— | Sub-Saharan African | — | GBHS | — |
| PSS010092 | — | — | [
|
— | European | — | CORSA | — |
| PSS010093 | — | — | [
|
— | East Asian (Chinese) |
— | NR | JSCRC |
| PSS009907 | — | — | [ ,
0.0 % Male samples |
— | European | — | NR | UKB |
| PSS010094 | — | — | 355,543 individuals | — | European | — | UKB | — |
| PSS011931 | — | — | 499 individuals, 0.0 % Male samples |
— | African unspecified | — | HNP | — |
| PSS011931 | — | — | 3,728 individuals, 0.0 % Male samples |
— | Hispanic or Latin American | — | HNP | — |
| PSS011931 | — | — | 832 individuals, 0.0 % Male samples |
— | East Asian | — | HNP | — |
| PSS011931 | — | — | 19,484 individuals, 0.0 % Male samples |
— | European | — | HNP | — |
| PSS011931 | — | — | 929 individuals, 0.0 % Male samples |
— | Not reported | — | HNP | — |
| PSS011931 | — | — | 119 individuals, 0.0 % Male samples |
— | South East Asian | — | HNP | — |
| PSS009913 | — | — | [
|
— | European | — | PANSCAN | — |
| PSS009918 | — | — | 5,306 individuals, 51.9 % Male samples |
Mean = 62.1 years | European | — | BLITZ | — |
| PSS009919 | — | — | 2,559 individuals, 0.0 % Male samples |
Mean = 54.0 years Sd = 8.4 years |
Not reported | — | NR | AMDTSS |
| PSS009923 | — | — | [
|
— | East Asian (Chinese) |
— | NR | — |
| PSS009924 | — | — | [
|
— | East Asian (Korean) |
— | NR | — |
| PSS009925 | — | — | 295 individuals, 0.0 % Male samples |
— | Not reported | — | IARC | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | European | White | UKB | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | African unspecified | Black | UKB | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | Asian unspecified | — | UKB | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | Not reported | — | UKB | — |
| PSS011940 | ICD-10: C25 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
42.8 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011937 | ICD-10: C15 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
42.8 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011938 | ICD-10: C16 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
42.8 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011936 | ICD-10: C18-20 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
42.8 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011939 | ICD-10: C33-34 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
42.8 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011942 | ICD-10: C50 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
0.0 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011943 | ICD-10: C53 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
0.0 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011944 | ICD-10: C56 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
0.0 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011941 | ICD-10: C61 | Median = 11.33 years Range = [10.18, 12.26] years |
[ ,
100.0 % Male samples |
Mean = 53.69 years Sd = 11.01 years |
East Asian (Chinese) |
— | CKB | — |
| PSS011947 | — | — | [ ,
0.0 % Male samples |
— | East Asian (Han Chinese) |
— | GELAC | — |
| PSS009932 | MetS is defined as having any three or more of five MetS components, including central obesity, hypertension, dyslipidemia, hypertriglyceridemia, and hyperglyce- mia, according to the National Cholesterol Education Programme Adult Treatment Panel III criteria (NCEP- ATP III) | — | [
|
— | European | — | UKB | — |
| PSS011949 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | LAAPC, MEC | — |
| PSS011949 | — | — | [ ,
100.0 % Male samples |
— | Sub-Saharan African | — | CA UG Study | — |
| PSS009939 | — | — | 39,444 individuals | — | European (Finnish) |
— | FinnGen | — |
| PSS009945 | Patients in the symptomatic cohort that were diagnosed with prostate cancer within 2 years of the index date were treated as cases. Patients with no record of a prostate cancer diagnosis within 2 years of the index date were considered controls | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS001010 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
| PSS001011 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS001012 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS001013 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
| PSS001014 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS000341 | Cases were ascertained using ICD-10 C73 (PTC, FTC, cancer/carcinoma, and rare nonmedullary) | — | [ ,
46.41 % Male samples |
— | European | — | deCODE | — |
| PSS000342 | Histologically confirmed papillary or follicular thyroid carcinoma (PTC) patients (including traditional PTC and follicular variant PTC) | — | [ ,
26.08 % Male samples |
— | European | — | NR | — |
| PSS000343 | Cases were ascertained using ICD-10 C73 (PTC, FTC, cancer/carcinoma, and rare nonmedullary) | — | [ ,
45.97 % Male samples |
— | European | — | UKB | — |
| PSS001015 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
| PSS001017 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. 207 of the cases were in non-smokers and 1334 were in smokers. | — | [
|
— | European | — | UKB | — |
| PSS001020 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
| PSS001021 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |
| PSS001022 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
| PSS001023 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS001024 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS001025 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
| PSS008378 | — | — | 1,123 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008379 | — | — | 1,200 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008380 | — | — | 467 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008381 | — | — | 664 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008382 | — | — | 1,195 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008383 | — | — | 1,197 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS008384 | — | — | 1,178 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS000359 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (4) HER2-enriched-like (ER- and PR-, HER2+) | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000360 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (1) luminal A-like (ER+ and/or PR+, HER2-, grade 1 & 2); | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000361 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (2) luminal B/HER2-negative-like (ER+ and/or PR+, HER2-, grade 3) | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000362 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (3) luminal B-like (ER+ and/or PR+, HER2+); | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS000363 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (5) triple-negative ( ER-, PR-, HER2-). | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
| PSS009955 | — | — | 3,008 individuals | — | African American or Afro-Caribbean (African American) |
— | AAPC | — |
| PSS009956 | — | — | 1,190 individuals | — | East Asian (Chinese) |
— | NR | ChinaPCa |
| PSS009957 | — | — | 104,586 individuals | — | European | — | UKB | — |
| PSS009959 | — | — | [
|
— | African unspecified | — | MADCaP | — |
| PSS009964 | — | — | 10,120 individuals, 100.0 % Male samples |
Median = 65.3 years | European, Not reported | 99% European | HPFS | — |
| PSS001030 | Cases included individuals with polyps. Of the 5331 cases, 2952 had conventional adenomas (CAs), 1585 had serrated polyps (SAs) and 794 had sychronous CAs and SPs. CAs were defined as tubular, tubulovillous and villous adenomas and adenomas with high-grade dysplasia. Advanced CAs were defined by at least one CA ≥10 mm in diameter or with advanced histology (tubulovillous/villous histological features or high-grade/severe dysplasia) or ≥3 CAs regardless of histology or size. SPs were defined as hyperplastic polyps and mixed/serrated adenomas. Individuals at high risk of malignancy were defined as having SPs located in the proximal colon or with a size of ≥10 mm. Mixed/serrated ademonas were defined as both mixed polyps (those with both adenomatous and hyperplastic changes in histology) and polyps with any serrated diagnosis (e.g. serrated adenomas, serrated polyps and SSA/Ps). If a participant had both CAs and SPs in an endoscopy, each type of the polyps were recorded separately, and considered the patient as a synchronous SP and CA case. | — | [ ,
30.0 % Male samples |
Mean = 63.2 years Sd = 10.0 years |
European | — | HPFS, NHS, NHS2 | — |
| PSS001031 | Exclusion criteria for healthy controls included subjects with polyposis, adenomas, and diseases related to or causing a predisposition for cancer. Cases included subjects with colorectal cancer, confirmed by endoscopic and histological examinations. | — | [ ,
51.39 % Male samples |
— | East Asian (Han-Chinese) |
— | NR | Subects obtained from First Hospital of China Medical University (CMU) |
| PSS001032 | Exclusion criteria for healthy controls included subjects with polyposis, adenomas, and diseases related to or causing a predisposition for cancer. Cases included subjects with colorectal cancer, confirmed by endoscopic and histological examinations. | — | [ ,
53.86 % Male samples |
— | East Asian (Han-Chinese) |
— | NR | Subjects obtained from Fudan University Shanghai Cancer Center (FUSCC) |
| PSS001033 | Exclusion criteria for healthy controls included subjects with polyposis, adenomas, and diseases related to or causing a predisposition for cancer. Cases included subjects with colorectal cancer, confirmed by endoscopic and histological examinations. | — | [ ,
53.72 % Male samples |
— | East Asian (Han-Chinese) |
— | NR | Subjects obtained from Sun Yat-Sen University Cancer Center (SYSUCC) |
| PSS009966 | — | 30,472 individuals, 100.0 % Male samples |
Median = 61.0 years | African unspecified | — | NR | — | |
| PSS009967 | — | 13,985 individuals, 100.0 % Male samples |
Median = 61.0 years | East Asian | — | NR | — | |
| PSS009968 | — | 888,086 individuals, 100.0 % Male samples |
Median = 65.0 years | European | — | NR | — | |
| PSS009969 | — | 81,109 individuals, 100.0 % Male samples |
Median = 61.0 years | Hispanic or Latin American | — | NR | — | |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | European | — | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean (African American) |
— | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | Native American (Native Hawaiian) |
— | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Japanese) |
— | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | Hispanic or Latin American (Latino) |
— | MEC | — |
| PSS009971 | — | — | 30,716 individuals | — | European | — | MGBB | — |
| PSS009971 | — | — | 1,807 individuals | — | African unspecified (Black) |
— | MGBB | — |